<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006870.pub3" GROUP_ID="VASC" ID="548606122300502828" MERGED_FROM="" MODIFIED="2015-04-21 13:54:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-04-21 13:54:29 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0603" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-04-21 13:54:29 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Statins for acute coronary syndrome</TITLE>
<CONTACT>
<PERSON ID="68AD23FB82E26AA2014441B6F5EFDC5D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Matthias</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Briel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>matthias.briel@usb.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Basel Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel (USB)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-04-21 13:52:50 +0100" MODIFIED_BY="Nicole Martin">
<PERSON ID="49439188344021232020091102154825" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Noah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vale</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>noahvale@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Family Medicine</DEPARTMENT>
<ORGANISATION>St Mary's Hospital, McGill University</ORGANISATION>
<ADDRESS_1>377 Rue Jean Brilliant</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1M5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 514 734 2679</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15780" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alain</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Nordmann</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ANordmann@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Hebelstrasse 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 76 470 34 13</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 265 31 09</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6339E40282E26AA20003EB8A7EDA5BD2" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Gregory</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Schwartz</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Cardiology Section</POSITION>
<EMAIL_1>gregory.schwartz@va.gov</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>VA Medical Center and University of Colorado</ORGANISATION>
<ADDRESS_1>1055 Clermont St</ADDRESS_1>
<ADDRESS_2/>
<CITY>Denver</CITY>
<ZIP/>
<REGION>Colorado</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 303 393 2826</PHONE_1>
<PHONE_2/>
<FAX_1>+1 303 393 5054</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6342EEF382E26AA20003EB8A2DD4C1C0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>de Lemos</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>james.delemos@utsouthwestern.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiology/Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Texas Southwestern Medical School</ORGANISATION>
<ADDRESS_1>5909 Harry Hines Blvd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dallas</CITY>
<ZIP/>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 21 4645 7528</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6348CC7982E26AA20003EB8A2EEE9062" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Furio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Colivicchi</LAST_NAME>
<SUFFIX/>
<POSITION>Director Cardiology Division</POSITION>
<EMAIL_1>furcol@rdn.it</EMAIL_1>
<EMAIL_2>f.colivicchi@sanfilipponeri.roma.it</EMAIL_2>
<URL/>
<MOBILE_PHONE>+39.338.949.3664</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Cardiovascular Department</DEPARTMENT>
<ORGANISATION>S. Filippo Neri Hospital</ORGANISATION>
<ADDRESS_1>330 Viale Gorgia da Leontini</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 3306 2794</PHONE_1>
<PHONE_2>+39.06.3306.2429</PHONE_2>
<FAX_1>+39.3306.2489</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="79EC6B3682E26AA2007D5B6E629B4768" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Frank</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>den Hartog</LAST_NAME>
<SUFFIX/>
<POSITION>Cardiologist</POSITION>
<EMAIL_1>hartogf@zgv.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiology Department</DEPARTMENT>
<ORGANISATION>Gelderse Vallei Hospital</ORGANISATION>
<ADDRESS_1>postbus 9025</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ede</CITY>
<ZIP>6710 HN</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+00 31 31 434343</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19341227809797058404100629163027" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Petr</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ostadal</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ostadal@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Cardiology</DEPARTMENT>
<ORGANISATION>Na Homolce Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Prague</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CZ">Czech Republic</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="63879393941207708126100629162915" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Stella</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Macin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>macinucic@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>54-379154578149</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Coronary Intensive Care Unit</DEPARTMENT>
<ORGANISATION>Instituto de Cardiologia</ORGANISATION>
<ADDRESS_1>Juana F Cabrel</ADDRESS_1>
<ADDRESS_2/>
<CITY>Corrientes</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10262993496297962554100629162736" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anho</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Liem</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>anho@zeelandnet.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Cardiology</DEPARTMENT>
<ORGANISATION>Franciscus Gasthuis Rotterdam</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Rotterdam</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="51580278102891815738100629162512" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Edward</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Mills</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>Edward.Mills@uottawa.ca</EMAIL_1>
<EMAIL_2>emills@sfu.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>451 Smyth Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8M5</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 718 317 8530</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="35051308698117391978100629163200" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Neera</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bhatnagar</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bhatnag@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main Street West</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18834" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Heiner</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Bucher</LAST_NAME>
<SUFFIX>MD MPH</SUFFIX>
<POSITION/>
<EMAIL_1>hbucher@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Basel Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel (USB)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="68AD23FB82E26AA2014441B6F5EFDC5D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Matthias</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Briel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>matthias.briel@usb.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Basel Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel (USB)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-04-21 13:52:50 +0100" MODIFIED_BY="Nicole Martin">
<UP_TO_DATE>
<DATE DAY="12" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-21 13:54:29 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-04-21 13:54:29 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>No further evidence is expected to change the conclusion of this review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-21 13:53:06 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-04-21 13:53:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>The updated search found no new studies, so the review conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-21 13:53:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>Search updated on 12 April 2013: no further eligible studies identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-27 08:27:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>Addition of a 'Summary of findings' (SoF) table. Previous tables erroneously published as SoF tables were moved to the 'Additional tables' section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Santésuisse</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Gottfried and Julia Bangerter-Rhyner-Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-07-11 15:05:39 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-06-27 09:31:30 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-07-12 12:01:26 +0100" MODIFIED_BY="Joey Kwong">Statins for acute coronary syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-27 09:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Long-term therapy with statins (for at least one year) has been shown to reduce the risk of heart attack, stroke, and all-cause mortality in patients with and without established coronary heart disease. The early period following an acute coronary syndrome is a critical stage of coronary heart disease, with a high risk of recurrent events and death. We aimed to determine if early initiation of statins improves patient-relevant outcomes within the first four months following an acute coronary syndrome. This review is an update of a review previously published in 2011 that included 18 studies, enrolling 14,303 patients. The update of this review did not identify any new studies for inclusion. We did not find a significant risk reduction for all-cause mortality, heart attack, or stroke within the first four months. We had some concerns about risk of bias and imprecision of the results. The risk of unstable angina was reduced by about 25% at four months following acute coronary syndrome. Serious side effects from early treatment with statins were rare (0.1%), and serious muscle toxicity was mostly observed with simvastatin 80 mg.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-27 08:28:53 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-06-27 08:28:01 +0100" MODIFIED_BY="[Empty name]">
<P>The early period following the onset of acute coronary syndrome (ACS) represents a critical stage of coronary heart disease, with a high risk of recurrent events and deaths. The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear. This is an update of a review previously published in 2011.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects, both harms and benefits, of early administered statins in patients with ACS, in terms of mortality and cardiovascular events.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-27 08:28:31 +0100" MODIFIED_BY="[Empty name]">
<P>We updated the searches of CENTRAL (2013, Issue 3), MEDLINE (Ovid) (1946 to April Week 1 2013), EMBASE (Ovid) (1947 to 2013 Week 14), and CINAHL (EBSCO) (1938 to 2013) on 12 April 2013. We applied no language restrictions. We supplemented the search by contacting experts in the field, by reviewing the reference lists of reviews and editorials on the topic, and by searching trial registries.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-27 08:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) comparing statins with placebo or usual care, with initiation of statin therapy within 14 days following the onset of ACS, follow-up of at least 30 days, and reporting at least one clinical outcome.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed risk of bias and extracted data. We calculated risk ratios (RRs) for all outcomes in the treatment and control groups and pooled data using random-effects models.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Eighteen studies (14,303 patients) compared early statin treatment versus placebo or no treatment in patients with ACS. The new search did not identify any new studies for inclusion. There were some concerns about risk of bias and imprecision of summary estimates. Based on moderate quality evidence, early statin therapy did not decrease the combined primary outcome of death, non-fatal myocardial infarction, and stroke at one month (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.80 to 1.08) or four months (RR 0.93, 95% CI 0.81 to 1.06) of follow-up when compared to placebo or no treatment. There were no statistically significant risk reductions from statins for total death, total myocardial infarction, total stroke, cardiovascular death, revascularization procedures, and acute heart failure at one month or at four months, although there were favorable trends related to statin use for each of these endpoints. Moderate quality evidence suggests that the incidence of unstable angina was significantly reduced at four months following ACS (RR 0.76, 95% CI 0.59 to 0.96). There were nine individuals with myopathy (elevated creatinine kinase levels more than 10 times the upper limit of normal) in statin-treated patients (0.13%) versus one (0.015%) in the control groups. Serious muscle toxicity was mostly limited to patients treated with simvastatin 80 mg.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Based on moderate quality evidence, due to concerns about risk of bias and imprecision, initiation of statin therapy within 14 days following ACS does not reduce death, myocardial infarction, or stroke up to four months, but reduces the occurrence of unstable angina at four months following ACS. Serious side effects were rare.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-11 15:04:55 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-06-27 08:40:47 +0100" MODIFIED_BY="[Empty name]">
<P>Coronary heart disease accounts for 20% of overall mortality in the United States (<LINK REF="REF-AHA-2007" TYPE="REFERENCE">AHA 2007</LINK>). Large trials and meta-analyses have shown that HMG CoA reductase inhibitors (statins) effectively reduce low-density lipoprotein (LDL) cholesterol and clinical endpoints such as cardiovascular events and overall mortality in a large spectrum of patients at varying risk of cardiovascular disease (<LINK REF="REF-_x0034_S-1994" TYPE="REFERENCE">4S 1994</LINK>; <LINK REF="REF-HPS-2002" TYPE="REFERENCE">HPS 2002</LINK>; <LINK REF="REF-Shepherd-1995" TYPE="REFERENCE">Shepherd 1995</LINK>; <LINK REF="REF-Studer-2005" TYPE="REFERENCE">Studer 2005</LINK>). A limitation of most of the trials in secondary prophylaxis after acute myocardial infarction or unstable angina is, however, that statins have been started three or more months after an acute event. Acute coronary syndrome (ACS) is defined as a broad spectrum of manifestations that are due to insufficient coronary blood supply. These include ST-segment elevation myocardial infarction, non-ST-segment elevation ACS with or without myocardial cell necrosis (unstable angina and/or non-ST-segment elevation myocardial infarction), and ST-segment depression (non-Q-wave) myocardial infarction. The early period following an ACS represents a critical stage of coronary heart disease with a high risk of recurrent events and death due to vessel occlusions from vulnerable coronary plaques (<LINK REF="REF-Wood-1998" TYPE="REFERENCE">Wood 1998</LINK>). Therefore, strategies to stabilize vulnerable coronary plaques during this high-risk period are paramount.</P>
<P>Experimental data indicate that statins may have early beneficial effects by improving the endothelial function of arteries (<LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>), decreasing platelet aggregability and thrombus formation (<LINK REF="REF-Rosenson-1998" TYPE="REFERENCE">Rosenson 1998</LINK>), and reducing vascular inflammation (<LINK REF="REF-Ridker-1998" TYPE="REFERENCE">Ridker 1998</LINK>). Each of these mechanisms plays an important role in ACS and they are targets for existing or new drugs in the management of the ACS (<LINK REF="REF-Kumar-2009" TYPE="REFERENCE">Kumar 2009</LINK>). Statins may exert these additional effects beyond their cholesterol-lowering effect, which makes them amenable to supplementary therapy of ACS (<LINK REF="REF-Sposito-2002" TYPE="REFERENCE">Sposito 2002</LINK>).</P>
<P>There is controversial evidence from observational studies that statin therapy prior to or at hospital discharge is associated with reducing short-term mortality among patients after an ACS (<LINK REF="REF-Aronow-2001" TYPE="REFERENCE">Aronow 2001</LINK>; <LINK REF="REF-Fonarow-2005" TYPE="REFERENCE">Fonarow 2005</LINK>; <LINK REF="REF-Newby-2002" TYPE="REFERENCE">Newby 2002</LINK>; <LINK REF="REF-Spencer-2004" TYPE="REFERENCE">Spencer 2004</LINK>; <LINK REF="REF-Stenestrand-2001" TYPE="REFERENCE">Stenestrand 2001</LINK>). Evidence from randomized controlled trials (RCTs) focusing on patients with an ACS indicates that statins may reduce combined endpoints that include recurrent angina, re-angioplasty, and re-hospitalization (<LINK REF="REF-Cannon-2004b" TYPE="REFERENCE">Cannon 2004b</LINK>; <LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="REF-Serruys-2002" TYPE="REFERENCE">Serruys 2002</LINK>). These endpoints, however, may be less reliable because they depend to a greater extent on clinical judgement and local practices. Therefore information on 'harder' clinical endpoints, such as definite myocardial infarction, stroke, and coronary heart disease-specific mortality, is important.</P>
<IMPORTANCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review previously published in 2011. Morrissey et al have questioned the Level of Evidence: 1A recommendation of the current American College of Cardiology/American Heart Association (ACC/AHA) guidelines that statin therapy should be initiated in patients before hospital discharge after an episode of ACS regardless of the baseline LDL level because of a mismatch with the underlying evidence (<LINK REF="REF-Morrissey-2009" TYPE="REFERENCE">Morrissey 2009</LINK>). Two previous meta-analyses on the topic suggested that early treatment with statins does not reduce death, myocardial infarction, or stroke up to four months following an ACS (<LINK REF="REF-Briel-2006a" TYPE="REFERENCE">Briel 2006a</LINK>; <LINK REF="REF-Hulten-2006" TYPE="REFERENCE">Hulten 2006</LINK>). Hulten et al used slightly different eligibility criteria (e.g. they allowed for head to head comparisons of statins to be included), did not contact investigators of primary trials for unpublished data, and pooled hazard ratios instead of risk ratios (<LINK REF="REF-Hulten-2006" TYPE="REFERENCE">Hulten 2006</LINK>). They concluded that early statin therapy reduces the combined endpoint of death, recurrent ischemia, and recurrent myocardial infarction at six months of treatment and thereafter.</P>
<P>The purpose of the present study is to comprehensively update previous systematic reviews and meta-analyses of RCTs evaluating the effects of early use of statins on relevant clinical endpoints of cardiovascular morbidity and overall mortality during the early stages at one and four months following the onset of ACS (<LINK REF="REF-Briel-2006a" TYPE="REFERENCE">Briel 2006a</LINK>; <LINK REF="REF-Vale-2011" TYPE="REFERENCE">Vale 2011</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-01-11 09:09:29 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects, both harms and benefits, of early administered statins in patients with ACS, in terms of mortality and cardiovascular events.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-10 14:57:49 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-07-10 14:57:49 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-06-27 08:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>We include randomized controlled trials (RCTs) comparing statin to placebo or no treatment in patients with an ACS (myocardial infarction or unstable angina). We excluded trials comparing two different statins without a placebo or no treatment control. We only considered trials with at least 30 days of follow-up of participants after an ACS, reporting at least one clinical outcome.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-27 08:42:24 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with recent ACS, regardless of prior lipid levels and prior lipid-modifying treatment or diet. ACS is defined as a broad spectrum of manifestations that are due to insufficient coronary blood supply. These include ST-segment elevation myocardial infarction, non-ST-segment elevation ACS with or without myocardial cell necrosis (unstable angina and/or non-ST-segment elevation myocardial infarction), and ST-segment depression (non-Q-wave) myocardial infarction. We included patients regardless of previous ACS, percutaneous coronary interventions including stents, or co-morbidities such as atrial fibrillation with or without antithrombotic treatment.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Initiation of statin therapy (HMG-CoA reductase inhibitors such as pravastatin, simvastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) administered orally at any dosage within 14 days following the onset of an acute coronary syndrome. We only considered trials using cerivastatin for sensitivity analysis since this compound was withdrawn from the market in 2001 (<LINK REF="REF-Staffa-2002" TYPE="REFERENCE">Staffa 2002</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-07-10 14:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the following clinical outcomes at one month, four months (range three to six months), and 12 months of follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and death from all causes</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Death from all causes</LI>
<LI>Death from cardiovascular causes</LI>
<LI>Fatal and non-fatal myocardial infarction or reinfarction</LI>
<LI>Fatal and non-fatal stroke</LI>
<LI>Revascularization procedures (bypass grafts, angioplasty with or without stenting)</LI>
<LI>Unstable angina (recurrent myocardial ischemia requiring emergency hospitalization)</LI>
<LI>Acute (new or worsening) heart failure</LI>
<LI>Adverse events (rhabdomyolysis, creatinine kinase levels more than 10 times the upper limit of normal values, and liver aminotransferase levels more than three times the upper limit of normal values)</LI>
<LI>Patient-perceived quality of life</LI>
</UL>
<P>We considered outcomes and adverse events irrespective of their putative relation to the treatment. To maximize the statistical power of our primary analysis and to recognize the event hierarchy of fatal and non-fatal events (occurrence of death precludes any other clinical events), we chose a combined primary endpoint to test the most patient-relevant 'hard' outcomes: death, myocardial infarction, and stroke. Each of the components is highly patient-relevant and about equally frequent (<LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>).</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-27 08:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>To identify relevant trials we updated the searches from February 2010 by re-running the searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 3), MEDLINE (Ovid, 1946 to April Week 1 2013), EMBASE Classic and EMBASE (Ovid, 1947 to 2013 Week 14), and CINAHL (EBSCO, 1938 to 12 April 2013) on 12 April 2013.</P>
<P>We did not impose any language restrictions. In addition, we searched previous systematic reviews (<LINK REF="REF-Briel-2006a" TYPE="REFERENCE">Briel 2006a</LINK>; <LINK REF="REF-Hulten-2006" TYPE="REFERENCE">Hulten 2006</LINK>), reference lists of identified articles, recently published editorials and narrative reviews on the topic, and trial registries (ISRCTN trials registry: <A HREF="http://isrctn.org/">isrctn.org/</A>; US National Institute of Health Clinical Trials Registry: 
<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov/</A>) for further eligible trials. We contacted specialists in the field for any unpublished studies.</P>
<P>The detailed electronic search strategies developed by NB and MB for MEDLINE, EMBASE, CENTRAL, and CINAHL, which include filters for finding RCTs (modified from <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>), are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We updated the electronic searches with the help of the Cochrane Heart Group (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We have added some search terms and updated the RCT filter for MEDLINE and EMBASE (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-10 14:55:04 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two authors (NV and AJN) independently assessed trial eligibility using a predefined form. We resolved disagreement by discussion and consensus. We excluded double reports. We applied no language restrictions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two authors (NV and AJN) independently assessed the risk of bias in the selected trials according to the Cochrane 'Risk of bias' tool (six domains).</P>
<P>We ranked the risk of selection bias with respect to allocation concealment as:</P>
<UL>
<LI>low risk (i.e. central randomization; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque, sealed envelopes; or other description regarding the methods used that warrants a judgement of adequate allocation concealment)</LI>
<LI>unclear risk (i.e. unreported)</LI>
<LI>high risk (for instance, alternation or reference to case record numbers or to dates of birth)</LI>
</UL>
<P>We resolved disagreements by discussion and consensus. We used our 'Risk of bias' assessment of included trials to explore heterogeneity among trials and to perform subgroup analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>Two authors (NV and AJN) independently extracted trial data in duplicate using predefined forms. We extracted data on patients' characteristics (age, gender, diabetes, hypertension, current smoker, prior myocardial infarction, lipid values at baseline, myocardial infarction as the index event, concomitant treatment for the index event (fibrinolysis, percutaneous coronary intervention), statin regimen (type of statin, daily dosage, starting time, duration), control group therapy (placebo or conventional treatment), follow-up duration, and measured outcomes for both study groups (proportion of patients with the outcome) at one, four, and 12 months following the onset of the ACS. We resolved any disagreement between authors by discussion and consensus.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We calculated risk ratios with 95% confidence intervals for all outcomes in the treatment and control groups and pooled them by conducting a random-effects model meta-analysis (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We also calculated Peto odds ratios (fixed-effect model), which are suggested for rare events (<LINK REF="REF-Deeks-1998" TYPE="REFERENCE">Deeks 1998</LINK>). We investigated the presence of publication bias by means of funnel plots (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). We tested for heterogeneity with the Cochran Q test and measured inconsistency (I<SUP>2 </SUP>statistic: the percentage of total variance across studies that is due to heterogeneity rather than chance) of treatment effects across the primary and secondary outcomes (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We did not include studies without events in either group in the analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We examined treatment effects according to 'Risk of bias' components (concealed treatment allocation, blinding of patients and caregivers, blinded outcome assessment) for the combined primary outcome death, myocardial infarction, and stroke, for death from all causes, and for unstable angina. We also assessed the effect of time to initiation of statins on the combined primary outcome, and the type of statin on the combined primary outcome. We also conducted a sensitivity analysis by including unpublished data from a trial using cerivastatin on death from all causes, total myocardial infarction, total stroke, and unstable angina (<LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-11 15:04:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-07-11 15:04:25 +0100" MODIFIED_BY="[Empty name]">
<P>The combined search of CENTRAL, MEDLINE, EMBASE, and CINAHL identified 2324 potentially relevant articles, of which we excluded all but 63 because it was clear from the abstract that they were not eligible (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Full-text assessment of the 63 potentially relevant articles resulted in the further exclusion of 39 studies (39 articles) because they were not randomized trials, had a follow-up of less than one month, treatment was given for less than one month, they were head-to-head comparisons of statins, statin therapy was initiated beyond 14 days following the onset of ACS, or no or unclear clinical outcome data were reported. In an update of the electronic search on 12 April 2013 we identified another 2268 potentially relevant articles (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). After title and abstract screening we checked 24 full texts but found no new eligible studies for inclusion.</P>
<P>For information on the excluded studies please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Included in the meta-analysis were 19 RCTs (24 references). One trial using cerivastatin was prematurely stopped because the drug was withdrawn from the market (<LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>). We excluded data from the 4.5-month follow-up of this trial from the primary analysis, but included the data in a sensitivity analysis. The remaining 18 RCTs enrolled a total of 14,303 patients (7172 treatment, 7131 control). We found no evidence of ongoing eligible trials. Authors of included primary trials contributed additional data relevant for the purpose of this analysis. We were unable to contact the investigators from three trials (<LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-Sakamoto-2005" TYPE="STUDY">Sakamoto 2005</LINK>; <LINK REF="STD-Shal_x0027_nev-2007" TYPE="STUDY">Shal'nev 2007</LINK>).</P>
<P>Seventeen of the 19 included trials investigated four different statins: pravastatin (seven trials; <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>; <LINK REF="STD-OACIS_x002d_LIPID-2008" TYPE="STUDY">OACIS-LIPID 2008</LINK>; <LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>; <LINK REF="STD-PAIS-2001" TYPE="STUDY">PAIS 2001</LINK>; <LINK REF="STD-PTT-2002" TYPE="STUDY">PTT 2002</LINK>; <LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>), atorvastatin (four trials; <LINK REF="STD-Colivicchi-2002" TYPE="STUDY">Colivicchi 2002</LINK>; <LINK REF="STD-ESTABLISH-2004" TYPE="STUDY">ESTABLISH 2004</LINK>; <LINK REF="STD-Macin-2005" TYPE="STUDY">Macin 2005</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>), fluvastatin (three trials; <LINK REF="STD-FACS-2010" TYPE="STUDY">FACS 2010</LINK>; <LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>), and simvastatin (three trials; <LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-Ren-2009" TYPE="STUDY">Ren 2009</LINK>; <LINK REF="STD-Shal_x0027_nev-2007" TYPE="STUDY">Shal'nev 2007</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). One trial allowed any statin to be used in the intervention group (<LINK REF="STD-Sakamoto-2005" TYPE="STUDY">Sakamoto 2005</LINK>).</P>
<P>In accordance with our eligibility criteria, we only included the subgroup of patients with unstable angina from the Lescol Intervention Prevention Study (<LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>). In the A-to-Z trial we only used data from the placebo comparison during the first four months of follow-up (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>).</P>
<P>Of the 19 included trials, four were international, multicenter trials (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>), three were conducted in Japan (<LINK REF="STD-ESTABLISH-2004" TYPE="STUDY">ESTABLISH 2004</LINK>; <LINK REF="STD-OACIS_x002d_LIPID-2008" TYPE="STUDY">OACIS-LIPID 2008</LINK>; <LINK REF="STD-Sakamoto-2005" TYPE="STUDY">Sakamoto 2005</LINK>), two in the Netherlands (<LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-PAIS-2001" TYPE="STUDY">PAIS 2001</LINK>), and one each were conducted in Germany (<LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>), Belgium (<LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>), Argentina (<LINK REF="STD-Macin-2005" TYPE="STUDY">Macin 2005</LINK>), Australia (<LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>), Turkey (<LINK REF="STD-PTT-2002" TYPE="STUDY">PTT 2002</LINK>), Canada (<LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>), China (<LINK REF="STD-Ren-2009" TYPE="STUDY">Ren 2009</LINK>), the Czech Republic and Slovakia (<LINK REF="STD-FACS-2010" TYPE="STUDY">FACS 2010</LINK>), and Russia (<LINK REF="STD-Shal_x0027_nev-2007" TYPE="STUDY">Shal'nev 2007</LINK>). The earliest included trial started recruitment in April 1996 (<LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>), with the latest concluding in July 2006 (<LINK REF="STD-Ren-2009" TYPE="STUDY">Ren 2009</LINK>). However, six trials did not specify the recruitment dates (<LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>; <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>; <LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>; <LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>; <LINK REF="STD-Shal_x0027_nev-2007" TYPE="STUDY">Shal'nev 2007</LINK>). Eleven trials were reported to be industry-sponsored (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>; <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>; <LINK REF="STD-PAIS-2001" TYPE="STUDY">PAIS 2001</LINK>; <LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>; <LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>; <LINK REF="STD-FACS-2010" TYPE="STUDY">FACS 2010</LINK>). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Study population</HEADING>
<P>The reported mean age of participants in the trials ranged from 53 to 69 years (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). All trials enrolled mostly men (range among trials, 59% to 88%). There was considerable variation in the proportion of cardiovascular risk factors and participants with a myocardial infarction prior to the index event (range, 0% to 85%). Due to different trial protocols the proportion of participants with co-interventions for the index event such as fibrinolytic therapy or percutaneous coronary interventions (PCI) varied widely among trials (range, 0% to 100%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Lipid-lowering effects</HEADING>
<P>The average weighted mean baseline LDL cholesterol level of included participants was 120 mg/dL (3.1 mmol/L) (range, 78 to 178 mg/dL (2.0 to 4.6 mmol/L)) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Mean reduction of LDL cholesterol ranged from -15% to -53% and of total cholesterol from -9% to -37%, with higher reductions in trials using higher drug doses and/or more potent drugs. The effects on HDL cholesterol and triglycerides were less pronounced and inconsistent among trials (range of average change for HDL cholesterol, -9.5% to +13%; and for triglycerides, -28% to +10%).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-11 15:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of bias varied among studies (see 'Risk of bias' summary, 
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Concealed allocation of participants was reported only for three trials (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>). Eight trials were reported to have assessed clinical outcomes in a blinded fashion (<LINK REF="STD-Colivicchi-2002" TYPE="STUDY">Colivicchi 2002</LINK>; <LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="STD-OACIS_x002d_LIPID-2008" TYPE="STUDY">OACIS-LIPID 2008</LINK>; <LINK REF="STD-Sakamoto-2005" TYPE="STUDY">Sakamoto 2005</LINK>; <LINK REF="STD-Ren-2009" TYPE="STUDY">Ren 2009</LINK>), and 11 trials reported blinding of caregivers and patients (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-FACS-2010" TYPE="STUDY">FACS 2010</LINK>; <LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-Macin-2005" TYPE="STUDY">Macin 2005</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>; <LINK REF="STD-PAIS-2001" TYPE="STUDY">PAIS 2001</LINK>; <LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>; <LINK REF="STD-Ren-2009" TYPE="STUDY">Ren 2009</LINK>). Loss to follow-up was under 2% in all but three studies (<LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>: 8%, <LINK REF="STD-Sakamoto-2005" TYPE="STUDY">Sakamoto 2005</LINK>: 16%, <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>: 19%). One trial was stopped early for benefit (<LINK REF="STD-Colivicchi-2002" TYPE="STUDY">Colivicchi 2002</LINK>), with potential overestimation of treatment effects (Bassler 2010).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Statins versus placebo or no treatment</HEADING>
<P>Analyses for publication bias indicated no evidence for such bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Since there were only minimal differences in the estimates when calculating risk ratios or Peto odds ratios (fixed-effect model), we reported outcomes as risk ratios (RR) only.</P>
<SUBSECTION>
<HEADING LEVEL="4">Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and death from all causes</HEADING>
<P>There was no significant difference in the primary combined outcome with early statin treatment in comparison to placebo or no treatment at one month (RR 0.93, 95% confidence interval (CI) 0.80 to 1.08; 13 studies, 13,484 patients) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), four months (RR 0.93, 95% CI 0.81 to 1.06; 11 studies, 9625 participants) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), or 12 months (RR 0.80, 95% CI 0.58 to 1.11; six studies, 2080 participants) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). We found no evidence of relevant heterogeneity among trials at any follow-up time points (I² = 0%).</P>
<P>In sensitivity analyses, summary estimates of the primary endpoint at four months suggested smaller risk reductions for trials with higher methodological quality compared to trials that lacked a respective quality component. In trials with concealed allocation the summary RR for statins compared to control was 0.96 (95% CI 0.79 to 1.16; three studies, 8407 participants) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). For trials without concealed allocation the RR was 0.70 (95% CI 0.44 to 1.14; eight studies, 1218 participants) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). For trials with blinded outcome assessment the summary RR was 0.94 (95% CI 0.82 to 1.08; five studies, 9028 participants) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). For trials without blinded outcome assessment the RR was 0.60 (95% CI 0.30 to 1.22; six studies, 597 participants) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). For trials with blinding of patients and caregivers the summary RR was 0.95 (95% CI 0.82 to 1.09; seven studies, 9271 participants; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). For trials without blinding of patients and caregivers the RR was 0.46 (95% CI 0.21 to 1.00; four studies, 354 participants) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>We did not find different treatment effects for trials with initiation of statin therapy within three days versus up to 14 days (<LINK REF="CMP-005.14" TYPE="ANALYSIS">Analysis 5.14</LINK>), or for trials using different types of statins (<LINK REF="CMP-005.15" TYPE="ANALYSIS">Analysis 5.15</LINK>). Overall, we found moderate quality evidence that early statins provide no relevant risk reduction for the combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total deaths within the first four months following acute coronary syndrome (ACS) (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death from all causes</HEADING>
<P>We found no statistically significant difference in death from all causes with early statin therapy compared to placebo or usual care at one month (RR 0.78, 95% CI 0.59 to 1.03; 13 studies, 13,155 patients) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), four months (RR 0.90, 95% CI 0.70 to 1.14; 12 studies, 9733 participants) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), or 12 months (RR 0.68, 95% CI 0.39 to 1.20; six studies, 2080 participants) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). We found no evidence of relevant heterogeneity among trials at any follow-up time points (I² = 0%).</P>
<P>In sensitivity analyses, summary estimates of the primary endpoint at four months suggested smaller risk reductions for trials with higher methodological quality compared to trials that lacked a respective quality component. For trials with concealed allocation the RR for statins compared to control was 0.94 (95% CI 0.72 to 1.21; three studies, 8407 participants) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). For trials without concealed allocation the RR was 0.64 (95% CI 0.31 to 1.31; nine studies, 1326 participants) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). For trials with blinded outcome assessment the summary RR was 0.91 (95% CI 0.71 to 1.17; five studies, 9028 participants) (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>). For trials without blinded outcome assessment the RR was 0.77 (95% CI 0.31 to 1.90; seven studies, 705 participants) (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>). For trials with blinding of patients and caregivers the summary RR was 0.93 (95% CI 0.72 to 1.19; seven studies, 9271 participants) (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). For trials without blinding of patients and caregivers the RR was 0.55 (95% CI 0.21 to 1.44; five studies, 462 participants) (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). When we additionally included 4.5-month data from 3605 patients with ACS from the PRINCESS study in a sensitivity analysis (Prevention of Ischemic Events by Early Treatment of Cerivastatin Study, <LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>), the summary RR for all-cause mortality was 0.95 (95% CI 0.78 to 1.17) (<LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>).</P>
<P>Overall, we found moderate quality evidence that early statins provide no relevant risk reduction for the combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total deaths within the first four months following ACS (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death from cardiovascular causes</HEADING>
<P>There was no statistically significant difference in deaths from cardiovascular causes with early statin treatment in comparison to placebo or no treatment at one month (RR 0.80, 95% CI 0.60 to 1.07; 10 studies, 12,387 participants) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), four months (RR 0.84, 95% CI 0.64 to 1.09; eight studies, 9273 participants) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), or 12 months (RR 0.55, 95% CI 0.28 to 1.09; five studies, 1954 participants) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). We found no evidence of relevant heterogeneity among trials at any follow-up time points (I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fatal and non-fatal myocardial infarction or reinfarction</HEADING>
<P>We found no statistically significant difference in fatal and non-fatal myocardial infarctions with early statin treatment in comparison to placebo or usual care at one month (RR 0.98, 95% CI 0.82 to 1.16; 12 studies, 13,074 participants) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), four months (RR 0.91, 95% CI 0.77 to 1.06; 10 studies, 9537 participants) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), or 12 months (RR 0.94, 95% CI 0.61 to 1.45; five studies, 1954 participants) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). We found no evidence of relevant heterogeneity among trials at any follow-up time points (I² = 0%).</P>
<P>In a sensitivity analysis we included 4.5-month data from 3605 patients with ACS from the PRINCESS study and found a summary RR for fatal and non-fatal myocardial infarctions of 0.90 (95% CI 0.78 to 1.03) (<LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>).</P>
<P>Due to some concerns about risk of bias and imprecision of results we rated the quality of the available evidence that early statins provide no relevant risk reduction for fatal and non-fatal myocardial infarction within the first four months following ACS as moderate (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fatal and non-fatal stroke</HEADING>
<P>There was no statistically significant difference in fatal and non-fatal strokes with early statin treatment in comparison to placebo or usual care at one month (RR 0.78, 95% CI 0.47 to 1.29; seven studies, 12,147 participants) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), four months (RR 0.72, 95% CI 0.45 to 1.16; seven studies, 8536 participants) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), or 12 months (RR 0.38, 95% CI 0.13 to 1.10; four studies, 1130 participants) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). We found no evidence of relevant heterogeneity among trials at all follow-up time points (I² = 0%).</P>
<P>In a sensitivity analysis we included 4.5-month data from 3605 patients with ACS from the PRINCESS study and found a summary RR for fatal and non-fatal strokes of 0.79 (95% CI 0.52 to 1.18) (<LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Revascularization procedures</HEADING>
<P>There was no statistically significant difference for revascularization procedures (bypass grafts, angioplasty) with early statin treatment compared to placebo or usual care at one month (RR 1.00, 95% CI 0.86 to 1.16; 10 studies, 9668 participants) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), or four months (RR 0.92, 95% CI 0.78 to 1.08; nine studies, 9474 participants) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). However, at 12 months we found a reduced risk of revascularization procedures with early statins (RR 0.70, 95% CI 0.52 to 0.93; five studies, 1999 participants) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). The heterogeneity among treatment effects was low at one month (I² = 0%) and four months (I² = 21%), but moderate at 12 months (I² = 50%). This may be due to differences in settings and definitions of the endpoint of revascularization procedures among trials (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unstable angina</HEADING>
<P>The RR for unstable angina with early statin therapy compared to placebo or no treatment at one month was 0.89 (95% CI 0.76 to 1.05; 10 studies, 12,181 participants) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), at four months the RR was 0.76 (95% CI 0.59 to 0.96; nine studies, 8770 participants) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>), and at 12 months the RR was 0.61 (95% CI 0.33 to 1.12; four studies, 1130 participants) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). The heterogeneity among treatment effects was low at one month (I² = 0%), but we found moderate heterogeneity at four months (I² = 33%) and at 12 months (I² = 35%). This may be due to differences in the definition of the endpoint of unstable angina among trials (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>In sensitivity analyses, summary estimates for unstable angina at four months suggested smaller risk reductions for trials with higher methodological quality compared to trials that lacked a respective quality component. In trials with concealed allocation the summary RR for statins compared to control was 0.79 (95% CI 0.64 to 0.97; two studies, 7583 participants) (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>). For trials without concealed allocation the RR was 0.68 (95% CI 0.44 to 1.04; seven studies, 1187 participants) (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>). For trials with blinded outcome assessment the summary RR was 0.81 (95% CI 0.66 to 0.99; four studies, 8204 participants) (<LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>). For trials without blinded outcome assessment the RR was 0.59 (95% CI 0.35 to 1.00; five studies, 566 participants) (<LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>). For trials with blinding of patients and caregivers the summary RR was 0.85 (95% CI 0.64 to 1.14; five studies, 8378 participants) (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>). For trials without blinding of patients and caregivers the RR was 0.51 (95% CI 0.34 to 0.79; four studies, 392 participants) (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>).</P>
<P>When we additionally included 4.5-month data from 3605 patients with ACS from the PRINCESS study in a sensitivity analysis (<LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>), the summary RR for unstable angina was 0.78 (95% CI 0.65 to 0.95) (<LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>).</P>
<P>Overall, we found moderate quality evidence that early statin therapy leads to a relevant risk reduction of unstable angina within the first four months following ACS (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acute heart failure</HEADING>
<P>There was no statistically significant difference for acute (new or worsening) heart failure with early statin treatment compared to placebo or no treatment at one month (RR 0.85, 95% CI 0.63 to 1.14; five studies, 11,141 participants) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), four months (RR 0.86, 95% CI 0.65 to 1.15; two studies, 7583 participants) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>), or at 12 months (RR 0.09, 95% CI 0.01 to 1.64; one study, 353 participants) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). The heterogeneity among treatment effects was low at one month (I² = 0%) and four months (I² = 0%); at 12 months there was only one study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Among all included trials, only three incidents of rhabdomyolysis were reported in patients treated with statins (0.04%); all occurred in the A-to-Z trial (RR 6.90, 95% CI 0.36 to 133.47; 4497 participants) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). There were nine individuals with myopathy (elevated creatinine kinase levels more than 10 times the upper limit of normal) in the statin groups versus one in the control groups (0.13% versus 0.015%); the summary RR for myopathy was significantly higher with statins than with control (RR 4.69, 95% CI 1.01 to 21.67; three studies, 4677 participants) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). All nine cases occurred beyond the first month of statin treatment and seven of the nine patients were treated with high-dose simvastatin (80 mg/day). None of the nine patients died. The risk of elevated liver aminotransferase levels (ALT more than three times the upper limit of normal) was significantly higher in the early statin groups than the control groups (RR 2.49, 95% CI 1.16 to 5.32; five studies, 11,914 participants) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). The heterogeneity in the effects on elevated liver aminotransferase levels was moderate (I² = 48%). This may be due to differences in trial settings and included patients (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Due to serious concerns about the imprecision of the rhabdomyolysis results, we rated the available evidence as low quality (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient-perceived quality of life</HEADING>
<P>None of the included trials reported patient-perceived quality of life.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-27 09:38:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Key findings</HEADING>
<P>This systematic review of randomized controlled trials in over 14,000 patients with acute coronary syndrome (ACS) investigated whether early statin therapy compared to placebo or no treatment improves patient-relevant outcomes shortly after ACS. The results of our meta-analysis did not show a statistically significant reduction of the composite primary endpoint (death, myocardial infarction, or stroke) for patients treated early with statins at one month, four months, and 12 months following ACS. There was, however, a non-significant trend towards risk reduction and this trend increased with time. There were non-significant trends towards risk reductions for the secondary outcomes of total death, total myocardial infarction, total stroke, cardiovascular death, and acute heart failure at one month, four months, and 12 months following ACS. The only significant relative risk reductions were in unstable angina at four months (estimated relative risk reduction of 24%) and revascularization procedures at 12 months (estimated relative risk reduction of 30%) following ACS. There were few data available from included trials at 12 months. However, the vulnerable coronary situation following ACS usually stabilizes within three to four months and other studies have already shown significant risk reductions for hard clinical outcomes such as myocardial infarction, stroke, or death in patients with stable coronary heart disease (<LINK REF="REF-_x0034_S-1994" TYPE="REFERENCE">4S 1994</LINK>; <LINK REF="REF-Briel-2004" TYPE="REFERENCE">Briel 2004</LINK>; <LINK REF="REF-LIPID-Study-Group-1998" TYPE="REFERENCE">LIPID Study Group 1998</LINK>; <LINK REF="REF-Studer-2005" TYPE="REFERENCE">Studer 2005</LINK>). Our results at 12 months are compatible with these findings.</P>
<P>In terms of adverse events we found that the risk of elevated liver aminotransferase levels (ALT more than three times the upper limit of normal) was significantly higher in the early statin groups than the control groups, but serious events such as myopathy or rhabdomyolysis were rare (three reported incidents of rhabdomyolysis in patients treated early with simvastatin 80 mg (0.04%) and nine individuals with myopathy (elevated creatinine kinase levels more than 10 times the upper limit of normal) in statin-treated patients (0.13%); seven of these nine individuals took simvastatin 80 mg).</P>
<P>Overall we rated the quality of evidence for all outcomes as moderate due to some concerns about risk of bias and imprecision of results (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), except for rhabdomyolysis for which we only found low quality evidence due to serious concerns about imprecision of results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why should effects on unstable angina be stronger than effects on myocardial infarction?</HEADING>
<P>One could argue that statins might ameliorate coronary vascular endothelial function, but that doing so does not directly influence atherothrombosis. One might also posit that there actually are concordant effects on all of these endpoints (trends are all in a favorable direction with statins), but that the composite sample size and duration of observation in this group of trials are inadequate to ascertain an effect with sufficiently low type I error rate. Another important point is the biomarker methods used for ascertainment of myocardial infarction in many of these studies. In the late 1990s or even early 2000s, many sites continued to use CK-MB or even total CK as the biomarker to detect myocardial injury. Multicenter trials generally do not specify one biomarker to define myocardial injury in endpoint events. Thus many endpoint events that would be associated with a small rise in troponin and today be categorized as acute myocardial infarction according to the current International Definition of Myocardial Infarction (<LINK REF="REF-Thygesen-2007" TYPE="REFERENCE">Thygesen 2007</LINK>), were likely to have been considered biomarker-negative and categorized as unstable angina using the older and less sensitive biomarker methods prevalent during the conduct of the trials in question. Therefore, one might reasonably expect that had contemporary diagnostic criteria and methods been applied to the events in these trials, there might have been more events categorized as acute myocardial infarction (and fewer as unstable angina), affording greater power to detect an effect of early statin therapy on acute myocardial infarction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Strengths and weaknesses</HEADING>
<P>We have conducted an extensive literature search to retrieve all relevant eligible trials and collaborated with the investigators of the primary trials. This collaboration with experts in the field should minimize potential publication bias. In addition, formal testing indicated little evidence for such bias. In searching trial registries we found no evidence of ongoing eligible trials, which means that the trials gathered in this review may constitute the totality of the available evidence on the topic.</P>
<P>We were unable to include one small trial with 151 randomized individuals because the original investigators failed to clarify outcome events (<LINK REF="STD-Pedersen-2000" TYPE="STUDY">Pedersen 2000</LINK>). Two other trials including 3468 patients had a follow-up of only one month (<LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>) and 1.5 months (<LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>). As a consequence, the power of our analysis at four months was compromised.</P>
<P>It may well be that early use of statins in ACS is associated with a beneficial effect on hard clinical outcomes such as total mortality, myocardial infarction, and stroke in the short term; summary estimates for all efficacy outcomes show a trend towards risk reduction with early statin therapy, but this meta-analysis may lack the power to detect a significant risk reduction for hard outcomes. However, our sensitivity analyses indicated even smaller treatment effects when restricting the analysis to trials of adequate methodological quality, or when we additionally included secondary endpoint data from a large, prematurely terminated trial using cerivastatin in 3605 patients (<LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>). To rule out effects of 10% risk reduction or less on our combined primary endpoint (death, myocardial infarction, and stroke), more than 34,000 patients with ACS would need to be randomized (<LINK REF="REF-Lachin-2000" TYPE="REFERENCE">Lachin 2000</LINK>).</P>
<P>As expected, statins lowered low-density lipoprotein (LDL) cholesterol levels more efficiently than placebo or usual care, and there were larger reductions in LDL cholesterol in trials using higher doses of statins. However, available data precluded adequate exploration of an association between clinical outcomes and the lipid-lowering potency of different statin types and doses. It remains an open question whether potent statins at top doses provide clinical benefit that is not achieved with lower-intensity statin therapy, since the only individual trials that have shown significant clinical benefit of statins in the early period following ACS are those that compared atorvastatin 80 mg with placebo (<LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>) or pravastatin 40 mg (<LINK REF="REF-Cannon-2004b" TYPE="REFERENCE">Cannon 2004b</LINK>). The possibility that high-intensity, but not moderate-intensity statin therapy is beneficial in the early period after ACS is supported by data from a meta-analysis of five randomized controlled trials that compared high-intensity with moderate-intensity statin treatment in a total of 39,612 patients with coronary heart disease (<LINK REF="REF-Baigent-2010" TYPE="REFERENCE">Baigent 2010</LINK>). Two of the five trials (A-to-Z (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>) and PROVE-IT (<LINK REF="REF-Cannon-2004b" TYPE="REFERENCE">Cannon 2004b</LINK>)) included only ACS patients; two other included trials (SEARCH (<LINK REF="REF-Armitage-2010" TYPE="REFERENCE">Armitage 2010</LINK>) and IDEAL (<LINK REF="STD-Pedersen-2005" TYPE="STUDY">Pedersen 2005</LINK>)) included some patients with recent ACS. The risk ratio (RR) for major vascular events among those treated with a high-intensity regimen was 0.85 (95% confidence interval (CI) 0.82 to 0.89). In part, this finding led to the recent recommendation in the 2013 AHA/ACC Guideline for the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults that most patients with established coronary heart disease should be treated with an intensive statin regimen (<LINK REF="REF-Stone-2013" TYPE="REFERENCE">Stone 2013</LINK>).</P>
<P>Finally, this systematic review cannot address the benefit of the use of early statins in patients with ACS undergoing early percutaneous coronary intervention (PCI) of culprit lesions, since only a minority of patients in the included trials underwent PCI. Finally, as only one trial specified that it was unfunded (<LINK REF="STD-PTT-2002" TYPE="STUDY">PTT 2002</LINK>), and 11 trials specified direct industry sponsorship (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>; <LINK REF="STD-FACS-2010" TYPE="STUDY">FACS 2010</LINK>; <LINK REF="STD-FLORIDA-2002" TYPE="STUDY">FLORIDA 2002</LINK>; <LINK REF="STD-L_x002d_CAD-2000" TYPE="STUDY">L-CAD 2000</LINK>; <LINK REF="STD-LAMIL-1997" TYPE="STUDY">LAMIL 1997</LINK>; <LINK REF="STD-LIPS-2002" TYPE="STUDY">LIPS 2002</LINK>; <LINK REF="STD-MIRACL-2001" TYPE="STUDY">MIRACL 2001</LINK>; <LINK REF="STD-PACT-2004" TYPE="STUDY">PACT 2004</LINK>; <LINK REF="STD-PAIS-2001" TYPE="STUDY">PAIS 2001</LINK>; <LINK REF="STD-PRINCESS-2004" TYPE="STUDY">PRINCESS 2004</LINK>; <LINK REF="STD-RECIFE-1999" TYPE="STUDY">RECIFE 1999</LINK>), the reader should be cautioned of a potential bias of interpretation of trial results (<LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Comparison with other studies</HEADING>
<P>Our findings contrast with results from published observational studies on the topic that suggest a lower risk of mortality with early statin therapy within one month following ACS (odds ratios as low as 0.4) (<LINK REF="REF-Aronow-2001" TYPE="REFERENCE">Aronow 2001</LINK>; <LINK REF="REF-Fonarow-2005" TYPE="REFERENCE">Fonarow 2005</LINK>; <LINK REF="REF-Spencer-2004" TYPE="REFERENCE">Spencer 2004</LINK>; <LINK REF="REF-Stenestrand-2001" TYPE="REFERENCE">Stenestrand 2001</LINK>). Results from these observational studies, however, may be prone to bias due to survivor treatment selection (<LINK REF="REF-Glesby-1996" TYPE="REFERENCE">Glesby 1996</LINK>), competing medical issues (<LINK REF="REF-Redelmeier-1998" TYPE="REFERENCE">Redelmeier 1998</LINK>), or differences in unknown confounders between comparison groups (<LINK REF="REF-Laupacis-2004" TYPE="REFERENCE">Laupacis 2004</LINK>). Another large observational study that found no benefit of early statin initiation in a propensity and covariate-adjusted analysis might have better captured potentially important confounders (<LINK REF="REF-Newby-2002" TYPE="REFERENCE">Newby 2002</LINK>). Our meta-analysis of randomized controlled trials demonstrates that observational studies with insufficient control of confounders greatly overestimate the magnitude of effect from early statin therapy in ACS.</P>
<P>On first sight, our findings might appear to contrast with results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial that randomized patients with ACS to atorvastatin 80 mg/day or pravastatin 40 mg/day (<LINK REF="STD-Cannon-2004a" TYPE="STUDY">Cannon 2004a</LINK>). In fact, however, there is no obvious discordance. In PROVE-IT, Kaplan-Meier curves of the primary composite endpoint appear to diverge as early as 30 days after ACS in favor of patients treated with atorvastatin, but the difference did not reach statistical significance until six months. It is important to note that the primary composite endpoint of PROVE-IT comprised not only death, myocardial infarction, and stroke, but also recurrent unstable angina requiring re-hospitalization and revascularization. If the more limited composite of death, myocardial infarction, and stroke is considered, there was no significant difference between the two treatment arms of PROVE-IT. Unstable angina and revascularization were the most frequent events in PROVE-IT and appeared to have driven the primary composite endpoint. Similarly, our meta-analysis indicates that statins reduce the risk of unstable angina following ACS at four months. Although endpoints such as unstable angina depend at least in part on clinicians' judgment or action, and therefore may be less reliable (<LINK REF="REF-Freemantle-2003" TYPE="REFERENCE">Freemantle 2003</LINK>), our finding of a risk reduction for unstable angina of 19% (95% CI 1% to 34%) at four months in trials with blinded outcome assessment supports the validity of this result.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-27 09:38:38 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-27 09:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Statins impact lipid profiles within days (<LINK REF="STD-Correia-2002" TYPE="STUDY">Correia 2002</LINK>), and in vitro studies show immediate inhibition of smooth muscle cell proliferation and stimulation of re-endothelialization by statins (<LINK REF="REF-Walter-2004" TYPE="REFERENCE">Walter 2004</LINK>). These effects seem to translate into a reduction of unstable angina pectoris at four months following ACS, but not to the same extent into a reduction of death, myocardial infarction, or stroke.</P>
<P>In our meta-analysis we considered only endpoint events that occurred during the period of randomized treatment. It is likely that the beneficial effects of statins are cumulative. In most of the landmark trials of statins in patients with chronic coronary heart disease a benefit of treatment was not evident until one to two years after randomization (<LINK REF="REF-_x0034_S-1994" TYPE="REFERENCE">4S 1994</LINK>; <LINK REF="REF-LIPID-Study-Group-1998" TYPE="REFERENCE">LIPID Study Group 1998</LINK>). Similarly, there appeared to be a delayed benefit of more intensive statin treatment, compared to less intensive statin treatment, in the late phase of the A-to-Z trial (<LINK REF="STD-de-Lemos-2004" TYPE="STUDY">de Lemos 2004</LINK>). Therefore, some of the benefit of statin treatment in the period up to four months after ACS may only become manifest after four months.</P>
<P>This systematic review confirms that early treatment with statins in ACS can, in general, be considered safe and that the highest approved doses of potent statins may be considered in this context (<LINK REF="REF-Stone-2013" TYPE="REFERENCE">Stone 2013</LINK>). However, physicians and patients should pay close attention to muscle-related symptoms, especially when maximum available doses - in particular of simvastatin 80 mg - are administered (<LINK REF="REF-Ara-2009" TYPE="REFERENCE">Ara 2009</LINK>), or when clinical risk factors for statin myopathy are present (e.g. advanced age, low body mass, impaired renal function).</P>
<P>There are concerns that when administered in clinical practice, long-term adherence to statins among patients with recent onset of ACS is poor (<LINK REF="REF-Jackevicius-2002" TYPE="REFERENCE">Jackevicius 2002</LINK>). Evidence from a small randomized trial and from observational studies suggests better adherence to statins when therapy is started in hospital shortly after an acute event (<LINK REF="REF-Nordmann-2000" TYPE="REFERENCE">Nordmann 2000</LINK>; <LINK REF="REF-Smith-2005" TYPE="REFERENCE">Smith 2005</LINK>).</P>
<P>In summary, initiation of statin therapy within 14 days following ACS produces favorable trends but does not significantly reduce death, myocardial infarction, or stroke up to four months after the index event. Early initiation of statin therapy does significantly reduce the occurrence of unstable angina at four months following ACS. Serious muscle toxicity was more common with early statin therapy than with placebo, but was rare and mostly limited to treatment with simvastatin 80 mg.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>A pooled analysis using individual patient data from eligible trials would be useful since it allows for pooled time-to-event analyses, powerful subgroup analyses, and multivariable regression analyses to clarify further the timing and mechanism by which statins confer cardiovascular benefits.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-13 16:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>We are grateful to Peter L Thompson, MD, Michael A Blazing, MD, Gerrit-Anne van Es, PhD, Meral Kayikcioglu, MD, Hans-Richard Arntz, MD, Nic JGM Veeger, MSc, Jocelyn Dupuis, MD PhD, Shinya Okazaki, MD, R Scott Wright, MD, and the Cochrane Heart Group.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-07-11 15:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Vale declared no interests.</P>
<P>Dr Nordmann declared no interests.</P>
<P>Dr Schwartz has received honoraria and grant support from Pfizer.</P>
<P>Dr de Lemos has received honoraria from Merck, Pfizer, Merck/Schering, and Bristol-Myers Squibb and grant support from Merck and Pfizer. He has also received consulting fees from Astra Zeneca for participation in an endpoint review committee for a product unrelated to the current manuscript. </P>
<P>Dr Colivicchi declared no interests.</P>
<P>Dr den Hartog declared no interests.</P>
<P>Dr Ostadal has received honoraria from Pfizer, Merck, and AstraZeneca and grant support from Novartis.</P>
<P>Dr Macin declared no interests.</P>
<P>Dr Liem has received honoraria from Merck/Schering and Astra Zeneca.</P>
<P>Dr. Mills has received grant support or consulting honoraria from Pfizer, Merck, Janssen, Astra Zeneca, Novartis, and Boehringer Ingelheim.</P>
<P>Mrs Bhatnagar declared no interests.</P>
<P>Dr Bucher has received grant support from Merck and Bristol-Myers Squibb.</P>
<P>Dr Briel declared no interests.</P>
<P>None of the support or honoraria above were related to research or drugs that are subject of the current meta-analysis. There was no pharmaceutical industry support for this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>NV: carried out study selection, quality assessment, and data extraction; drafted the review text.<BR/>AJN: carried out study selection, quality assessment and data extraction; drafted the review text.<BR/>GGS, JAdL, FC, PO, SMM, AL, EM, FdH, HCB: participated in collection of additional data and critically reviewed the manuscript for important intellectual content.<BR/>MB: conceived and designed the review; carried out part of the study selection, quality assessment, and data extraction; drafted the review text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-01-17 16:51:09 +0000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-05-17 20:28:22 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-10 16:50:38 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-07-10 16:14:06 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-07-10 16:14:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Colivicchi-2002" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Colivicchi 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colivicchi F, Guido V, Tubaro M, Ammirati F, Montefoschi N, Varveri A, et al</AU>
<TI>Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction</TI>
<SO>American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>8</NO>
<PG>872&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-de-Lemos-2004" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="de Lemos 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al</AU>
<TI>Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>11</NO>
<PG>1307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-ESTABLISH-2004" MODIFIED="2011-04-08 10:59:29 +0100" MODIFIED_BY="[Empty name]" NAME="ESTABLISH 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-04-08 10:59:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al</AU>
<TI>Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>9</NO>
<PG>1061-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-FACS-2010" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="FACS 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ostadal P, Alan D, Hajek P, Vejvoda J, Mates M, Blasko P, et al</AU>
<TI>Fluvastatin in the therapy of acute coronary syndrome: rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)</TI>
<SO>Current Controlled Trials in Cardiovascular Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>1</NO>
<PG>4</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:00:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-08 11:00:27 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISRCTN 81331696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100526&lt;br&gt;IS - 1745-6215 (Electronic)&lt;br&gt;IS - 1745-6215 (Linking)&lt;br&gt;LA - ENG&lt;br&gt;PT - JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, et al</AU>
<TI>Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)</TI>
<SO>Trials</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>1</NO>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-FLORIDA-2002" MODIFIED="2011-04-08 11:01:33 +0100" MODIFIED_BY="[Empty name]" NAME="FLORIDA 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-08 11:01:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liem AH, van Boven AJ, Veeger NJGM, Withagen AJ, Robles de Medina RM, Tijssen JGP, et al</AU>
<TI>Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial</TI>
<SO>European Heart Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>24</NO>
<PG>1931-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-LAMIL-1997" MODIFIED="2011-04-11 10:23:19 +0100" MODIFIED_BY="Joey Kwong" NAME="LAMIL 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-08 11:02:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kesteloot H, Claeys G, Blanckaert N, Lesaffre E</AU>
<TI>Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin</TI>
<SO>Acta Cardiologica</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>2</NO>
<PG>107&#8211;16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-30 15:15:14 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-L_x002d_CAD-2000" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="L-CAD 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al</AU>
<TI>Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)</TI>
<SO>American Journal of Cardiology</SO>
<YR>2000</YR>
<VL>86</VL>
<NO>12</NO>
<PG>1293&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-LIPS-2002" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="LIPS 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al</AU>
<TI>Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>24</NO>
<PG>3215</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Macin-2005" MODIFIED="2011-04-08 11:04:27 +0100" MODIFIED_BY="[Empty name]" NAME="Macin 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:04:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, et al</AU>
<TI>Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>3</NO>
<PG>451&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MIRACL-2001" MODIFIED="2011-04-08 11:04:49 +0100" MODIFIED_BY="[Empty name]" NAME="MIRACL 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-08 11:04:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al</AU>
<TI>Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>13</NO>
<PG>1711</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-OACIS_x002d_LIPID-2008" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="OACIS-LIPID 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, et al</AU>
<TI>Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID study</TI>
<SO>Circulation</SO>
<YR>2008</YR>
<VL>72</VL>
<NO>1</NO>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PACT-2004" MODIFIED="2011-04-08 11:06:33 +0100" MODIFIED_BY="[Empty name]" NAME="PACT 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-04-08 11:06:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ</AU>
<TI>Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>148</VL>
<NO>1</NO>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PAIS-2001" MODIFIED="2011-04-08 11:07:13 +0100" MODIFIED_BY="[Empty name]" NAME="PAIS 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-08 11:07:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>den Hartog FR, van Kalmthout PM, van Loenhout TT, Schaafsma HJ, Rila H, Verheugt FW</AU>
<TI>Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>5</NO>
<PG>300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-PRINCESS-2004" MODIFIED="2014-07-10 16:14:06 +0100" MODIFIED_BY="[Empty name]" NAME="PRINCESS 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-04-08 11:07:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>LaBlanche JM, Wright RS, Jukema JW, Charbonneau F, Creplet J, Eldar M, et al</AU>
<TI>Reductions in early recurrent coronary ischemia from early administration of statin therapy upon admission for myocardial infarction: results of the PRINCESS trial</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>17</NO>
<PG>2339</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-10 16:14:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wright RS</AU>
<TI>PRINCESS: Prevention of ischaemic events by early treatment of cerivastatin after acute myocardial infarction</TI>
<SO>Hotline session III, European Society of Cardiology</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PTT-2002" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="PTT 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-08 11:09:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kayikçio&#287;lu M, Can L, Kültürsay H, Payzin S, Turko&#287;lu C</AU>
<TI>Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty</TI>
<SO>Acta Cardiologica</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>4</NO>
<PG>295</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-08 11:09:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;UI - 22705835&lt;br&gt;DA - 20030624&lt;br&gt;IS - 0167-5273&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:09:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kayikcioglu M, Can L, Evrengul H, Payzin S, Kultursay H</AU>
<TI>The effect of statin therapy on ventricular late potentials in acute myocardial infarction</TI>
<SO>International Journal of Cardiology</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>1</NO>
<PG>63-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-08 11:10:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kayikcioglu M, Turkoglu C, Kltrsay H, Evrengul H, Can L</AU>
<TI>The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>I-303. Abstract 1586</PG>
<IDENTIFIERS MODIFIED="2009-12-15 10:38:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kayikcioglu M, Turkoglu C, Kultursay H, Harum H, Can L</AU>
<TI>Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin turkish trial (PTT)</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>1-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-11-08 21:22:54 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-RECIFE-1999" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="RECIFE 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dupuis J, Tardif JC, Cernacek P, Theroux P</AU>
<TI>Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>25</NO>
<PG>3227</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2009" MODIFIED="2011-04-08 11:11:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:11:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren HZ, Ma LL, Wang LX</AU>
<TI>Effect of simvastatin on plasma interleukin-6 in patients with unstable angina</TI>
<SO>Clinical and Investigative Medicine. Médecine Clinique et Experimentale</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>4</NO>
<PG>E280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Sakamoto-2005" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Sakamoto 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al</AU>
<TI>Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese</TI>
<SO>American Journal of Cardiology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>8</NO>
<PG>1165&#8211;71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shal_x0027_nev-2007" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Shal'nev 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shal'nev VI</AU>
<TI>The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome</TI>
<SO>Klinicheskaia Meditsina</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>11</NO>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akasaka-2012" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Akasaka 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;br&gt;ESC Congress 2012 Munchen Germany. Conference Start: 20120825 Conference End: 20120829. Conference Publication: (var.pagings)&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akasaka T, Komukai K, Ishibashi K, Tanimoto T, Matsuo Y, Ino Y, et al</AU>
<TI>Effect of intensive vs. moderate lipid-lowering therapy with atorvastatin on the stabilization of atherosclerosis in acute coronary syndromes: serial optical coherence tomography analysis</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33</VL>
<PG>355</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barderas-2009" MODIFIED="2011-04-08 11:14:36 +0100" MODIFIED_BY="[Empty name]" NAME="Barderas 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:14:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barderas MG, Tunón J, Dardé VM, De la Cuesta F, Jiménez-Nácher JJ, Tarin N, et al</AU>
<TI>Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome</TI>
<SO>Proteomics</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>7</NO>
<PG>1982-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bermejo-2006" MODIFIED="2011-04-08 11:15:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bermejo 2006" NOTES="&lt;p&gt;Not a clinical trial&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:15:02 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:15:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bermejo J, Segovia J, Alfonso F</AU>
<TI>Summary of the Clinical Studies Reported in the Scientific Sessions in the American Heart Association 2005 (Dallas, Texas, USA, 13&#8211;16 November 2005)</TI>
<SO>Revista Espanola de Cardiologia (Internet)</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>2</NO>
<PG>143&#8211;53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cannon-2004a" MODIFIED="2011-04-08 12:10:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cannon 2004a" YEAR="2004">
<REFERENCE MODIFIED="2011-04-08 11:15:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20040408&lt;br&gt;IS - 1533-4406&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Anticholesteremic Agents)&lt;br&gt;RN - 0 (Heptanoic Acids)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;RN - 0 (Lipoproteins, HDL Cholesterol)&lt;br&gt;RN - 0 (Lipoproteins, LDL Cholesterol)&lt;br&gt;RN - 0 (Pyrroles)&lt;br&gt;RN - 110862-48-1 (atorvastatin)&lt;br&gt;RN - 81093-37-0 (Pravastatin)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:15:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al</AU>
<TI>Intensive versus moderate lipid lowering with statins after acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>15</NO>
<PG>1495-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chi-2007" MODIFIED="2011-04-08 11:15:48 +0100" MODIFIED_BY="[Empty name]" NAME="Chi 2007" NOTES="&lt;p&gt;Treatment initiated within 14 days of event&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:15:48 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2007">
<REFERENCE MODIFIED="2011-04-08 11:15:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chi H, Wang S, Chen J, Zhang J</AU>
<TI>Long-term effects of simvastatin on protection against atrial fibrillation in patients with acute myocardial infarction</TI>
<SO>Journal of Geriatric Cardiology</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>3</NO>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiodini-2007" MODIFIED="2011-04-08 11:16:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chiodini 2007" NOTES="&lt;p&gt;Treatment initiated within 14 days of event&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:16:28 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2007">
<REFERENCE MODIFIED="2011-04-08 11:16:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiodini BD, Franzosi MG, Barlera S, Signorini S, Lewis CM, D'Orazio A, et al</AU>
<TI>Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study</TI>
<SO>European Heart Journal</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>16</NO>
<PG>1977-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chyrchel-2011" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Chyrchel 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Chyrchel, Michal Dudek, Dariusz Rzeszutko, Lukasz Dziewierz, Artur Chyrchel, Bernadeta Rakowski, Tomasz Dubiel, Jacek S&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chyrchel M, Dudek D, Rzeszutko L, Dziewierz A, Chyrchel B, Rakowski T, et al</AU>
<TI>Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome</TI>
<SO>Cardiovascular Revascularization Medicine</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>2-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colivicchi-2010" MODIFIED="2011-04-08 11:17:28 +0100" MODIFIED_BY="[Empty name]" NAME="Colivicchi 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-04-08 11:17:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20100517&lt;br&gt;IS - 1473-4877 (Electronic)&lt;br&gt;IS - 0300-7995 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:17:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colivicchi F, Tubaro M, Mocini D, Genovesi EA, Strano S, Melina G, et al</AU>
<TI>Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>1277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colivicchi-2010a" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Colivicchi 2010a" YEAR="2010">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Colivicchi, Furio Tubaro, Marco Mocini, David Genovesi Ebert, Alberto Strano, Stefano Melina, Giovanni Uguccioni, Massimo Santini, Massimo&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, et al</AU>
<TI>Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2010</YR>
<VL>26</VL>
<PG>1277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colivicchi-2011" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Colivicchi 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;br&gt;42 Congresso Nazionale di Cardiologia dell'ANMCO Fortezza da Basso Italy. Conference Start: 20110511 Conference End: 20110514. Conference Publication: (var.pagings). 12 (5 SUPPL&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colivicchi F, Colaiaco C, Golia E, Tubaro M, Aiello A, Aspromonte N, et al</AU>
<TI>Full-dose atorvastatin reduces hospitalizations for heart failure after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease</TI>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>15S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Correia-2002" MODIFIED="2011-04-08 11:18:03 +0100" MODIFIED_BY="[Empty name]" NAME="Correia 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-08 11:18:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;UI - 22101870&lt;br&gt;DA - 20020710&lt;br&gt;IS - 0002-9149&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Anticholesteremic Agents)&lt;br&gt;RN - 0 (Heptanoic Acids)&lt;br&gt;RN - 0 (Lipids)&lt;br&gt;RN - 0 (Pyrroles)&lt;br&gt;RN - 0 (Triglycerides)&lt;br&gt;RN - 110862-48-1 (atorvastatin)&lt;br&gt;RN - 57-88-5 (Cholesterol)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:18:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correia LC, Sposito AC, Passos LC, Lima JC, Braga JC, Rocha MS, et al</AU>
<TI>Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction</TI>
<SO>American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>2</NO>
<PG>162-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Winter-2005" MODIFIED="2011-04-08 11:18:31 +0100" MODIFIED_BY="[Empty name]" NAME="de Winter 2005" NOTES="&lt;p&gt;Unrelated topic&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:18:31 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:18:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Winter RJ, Windhausen F, Cornel JH, Dunselman PHJM, Janus CL, Bendermacher PEF, et al</AU>
<TI>Early invasive versus selectively invasive management for acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>11</NO>
<PG>1095</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dohi-2010" MODIFIED="2014-04-08 14:06:01 +0100" MODIFIED_BY="[Empty name]" NAME="Dohi 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-08 14:06:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Dohi, Tomotaka Miyauchi, Katsumi Okazaki, Shinya Yokoyama, Takayuki Yanagisawa, Naotake Tamura, Hiroshi Kojima, Takahiko Yokoyama, Ken Kurata, Takeshi Daida, Hiroyuki&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:06:01 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, et al</AU>
<TI>Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study</TI>
<SO>Atherosclerosis</SO>
<YR>2010</YR>
<VL>210</VL>
<PG>497-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FLAME-2006" MODIFIED="2011-04-08 11:18:56 +0100" MODIFIED_BY="[Empty name]" NAME="FLAME 2006" NOTES="&lt;p&gt;Head to head comparison of statins (simvastatin 20mg vs simvastatin 40mg)&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:18:56 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:18:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wojakowski W, Maslankiewicz K, Ochala A, Pyrlik A, Ciosek J, Wieja P, et al</AU>
<TI>Early treatment with simvastatin in myocardial infarction to reduce the levels of multiple inflammatory markers in 6-month follow-up. FLAME randomized clinical trial</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>114</VL>
<PG>II_650-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-14 13:02:44 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-2010" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ge 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Ge, JunBo Kim, Young-Jo Jang, Yang-Soo Zhu, JunRen Marschner, Ian C Lam, William&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge J, Kim YJ, Jang YS, Zhu J, Marschner IC, Lam W</AU>
<TI>Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes</TI>
<SO>Journal of Cardiology</SO>
<YR>2010</YR>
<VL>55</VL>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-G_x00f3_mez_x002d_Doblas-2006" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Gómez-Doblas 2006" NOTES="&lt;p&gt;Follow-up less than 30 days.&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gómez-Doblas JJ, Jimenez-Navarro MF, Garcia-Pinilla JM, Rodriguez-Bailon I, Robledo J, Cabrera F, et al</AU>
<TI>Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium)</TI>
<TO>Influencia del tratamiento temprano con estatinas en la función endotelial tras el infarto de miocardio en pacientes con valores normales de colesterol. Estudio VAATOPE</TO>
<SO>Medicina Clinica</SO>
<YR>2006</YR>
<VL>126</VL>
<NO>9</NO>
<PG>325&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-G_x00f3_mez_x002d_Hern_x00e1_ndez-2008" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Gómez-Hernández 2008" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2008">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gómez-Hernández A, Sánchez-Galán E, Ortego M, Martin-Ventura JL, Blanco-Colio LM, Tarin-Vicente N, et al</AU>
<TI>Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome</TI>
<SO>American Journal of Cardiology</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guazzi-2007" MODIFIED="2011-04-08 11:19:28 +0100" MODIFIED_BY="[Empty name]" NAME="Guazzi 2007" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:19:28 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2007">
<REFERENCE MODIFIED="2011-04-08 11:19:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guazzi M, Tumminello G, Reina G, Vicenzi M, Guazzi MD</AU>
<TI>Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>6</NO>
<PG>454&#8211;62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2009" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hall 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Hall, Alistair S Jackson, Beryl M Farrin, Amanda J Efthymiou, Maria Barth, Julian H Copeland, Joanne Bailey, Kristian M Romaine, Simon P R Balmforth, Anthony J McCormack, Terry Whitehead, Andrew Flather, Marcus D Nixon, Jane SPACE ROCKET Trial Group Murray G Shepherd J Packard CJ Flather MD Brady AJ McCormack T Palmer CR Lindsay I Grizzard N Marran J Brown J Worthy G Fountain J Lindop E Babalis D Booth J Foley C Breen R Armstrong E Tooze P Platts M Carter A Zezulka A Doherty S Purvis J McCorkell G Trouton T Hunter B Saeed BT Nicholson A Aggarwal R Banks T Wright L Lindsay S Akeroyd L Hesmondhalgh V Grant S Longley J Robson RH Graham A Smyllie J Armitage S Patel N Large J Purcell IF Jones SJ Forsyth H Slaughter J Vallance BD Young J Moreland G Appleby MA Atkinson J Welsh C Clarke C Baig MW Liu A Stancliffe D Pell A Anderson J Batin PD Beevers J Bottomley D Durkin B Brooksby P Moore B Findlay I Dougall JC Adgey J Tomlin AJ Sapsford R Bown A Keeling PJ Chapple T Hughes D Passmore J Pounsberry J Rodaway M Davis JA Machin J Trent RJ Bull L Wilkinson F Lee HS Coppinger T Dunne L Waywell C Chung G Buckley C Gibbons D Pye M Hairsine B&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, et al</AU>
<TI>A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial</TI>
<SO>European Journal of Cardiovascular Prevention &amp; Rehabilitation</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>712-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2011" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="He 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;He, Xian-Zhi Zhou, Sheng-Hua Wan, Xin-Hong Wang, Hai-Yu Zhong, Qing-Hua Xue, Jian-Fang&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He XZ, Zhou SH, Wan XH, Wang HY, Zhong QH, Xue JF</AU>
<TI>The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome</TI>
<SO>Clinical Cardiology</SO>
<YR>2011</YR>
<VL>34</VL>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiro-2009" MODIFIED="2011-04-08 11:21:51 +0100" MODIFIED_BY="[Empty name]" NAME="Hiro 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:21:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al</AU>
<TI>Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>4</NO>
<PG>293&#8211;302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiro-2009a" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Hiro 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20090717&lt;br&gt;IS - 1558-3597 (Electronic)&lt;br&gt;IS - 0735-1097 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Heptanoic Acids)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;RN - 0 (Pyrroles)&lt;br&gt;RN - 0 (Quinolines)&lt;br&gt;RN - A0JWA85V8F (atorvastatin)&lt;br&gt;RN - M5681Q5F9P (pitavastatin)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al</AU>
<TI>Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>4</NO>
<PG>293-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiro-2010" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hiro 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Hiro, Takafumi Kimura, Takeshi Morimoto, Takeshi Miyauchi, Katsumi Nakagawa, Yoshihisa Yamagishi, Masakazu Ozaki, Yukio Kimura, Kazuo Saito, Satoshi Yamaguchi, Tetsu Daida, Hiroyuki Matsuzaki, Masunori JAPAN-ACS Investigators Ito T Takashima H Sato T Watarai M Kazatani Y Hiramatsu S Hishida H Saku K Miura S Iwata A Watanabe S Noda T Tanaka R Ono K Dote K Kato M Sasaki S Ueda K Inoue I Kawagoe T Kamiya H Daida H Miyauchi K Suwa S Nakazato Y Tanimoto K Nanto S Sera F Nobuyoshi M Yasumoto H Mitsudo K Fuku Y Kimura T Nakagawa Y Nonogi H Otsuka Y Kokubu N Iida H Nakayama M Minagoe S Nakajima H Sonoda M Kouya T Miyamoto N Suzuki Y Taguchi S Ujihira T Saitou H Itoh A Yunoki K Honda T Nakao K Yamada N Meguro T Takizawa K Ogawa H Iwami T Ishiwata S Fujimoto Y Hayashi Y Toyofuku M Otsuka M Hirata Y Ando J Akasaka T Kubo T Kitabata H Matsuzaki M Hiro T Fujii T Okamura T Yamada J Hashimoto G Fujimura T Ichimiya S Kanashiro M Watanabe J Fukui S Ohashi T Kurebayashi N Hibi K Comment in: Circ J. 2010 Jun;74(6):1073-4; PMID: 20472962&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al</AU>
<TI>Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial)</TI>
<SO>Circulation Journal</SO>
<YR>2010</YR>
<VL>74</VL>
<PG>1165-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Kanadasi-2006" MODIFIED="2011-04-11 09:46:22 +0100" MODIFIED_BY="Joey Kwong" NAME="Kanadasi 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:22:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanada&#351;&#305; M, Çayl&#305; M, Demirta&#351; M, Inal T, Demir M, Koç M, et al</AU>
<TI>The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol</TI>
<SO>Heart and Vessels</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>5</NO>
<PG>291&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kashima-2009" MODIFIED="2011-04-08 11:22:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kashima 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:22:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kashima Y, Izawa A, Aizawa K, Koshikawa M, Kasai H, Tomita T, et al</AU>
<TI>Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study</TI>
<SO>Journal of Cardiology</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>1</NO>
<PG>76&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuznetsova-2010" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kuznetsova 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;Russian&lt;br&gt;Kuznetsova, M A Vaulin, N A Masenko, V P Gratsianskii, N A Russian&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuznetsova MA, Vaulin NA, Masenko VP, Gratsianskii NA</AU>
<TI>Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation</TI>
<SO>Kardiologiia</SO>
<YR>2010</YR>
<VL>50</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lablanche-2008" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lablanche 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lablanche JM, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, et al</AU>
<TI>Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design</TI>
<SO>Archives of Cardiovascular Diseases</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>6</NO>
<PG>399&#8211;406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LAVA-2005" MODIFIED="2011-04-08 11:23:23 +0100" MODIFIED_BY="[Empty name]" NAME="LAVA 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:23:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wojakowski W, Michalowska A, Majka M, Maslankiewicz K, Wyderka R, Krol M, et al</AU>
<TI>Early treatment with fluvastatin enhances the mobilization of CD34+, CD117+, CXCR4+, C-met+ stem cells into peripheral blood in patients with acute myocardial infarction: LAVA trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>Suppl A, February</NO>
<PG>A197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemos-2005" MODIFIED="2011-04-08 11:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lemos 2005" NOTES="&lt;p&gt;Treatment initiated within 14 days of event&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:23:52 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:23:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemos PA, de Feyter PJ, Serruys PW, Saia F, Arampatzis CA, Disco C, et al</AU>
<TI>Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>98</VL>
<NO>3</NO>
<PG>479&#8211;86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leone-2008" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Leone 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone AM, Rutella S, Giannico MB, Perfetti M, Zaccone V, Brugaletta S, et al</AU>
<TI>Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2008</YR>
<VL>130</VL>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" MODIFIED="2011-04-08 11:24:01 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2005" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:24:01 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:24:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JJ, Fang CH</AU>
<TI>Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina</TI>
<SO>Clinical Chemistry</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>9</NO>
<PG>1735</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2011-04-08 11:25:22 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006" NOTES="&lt;p&gt;Follow-up less than 30 days.&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:25:22 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:25:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JJ, Li YS, Fang CH, Hui RT, Yang YJ, Cheng JL, et al</AU>
<TI>Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>92</VL>
<NO>4</NO>
<PG>529</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2012" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lim 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;rzh&lt;br&gt;research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0207277. PMID: 22356794&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim SY, Bae EH, Choi JS, Kim CS, Park JW, Ma SK, et al</AU>
<TI>Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction</TI>
<SO>American Journal of Cardiology</SO>
<YR>2012</YR>
<VL>109</VL>
<PG>1425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Link-2006" MODIFIED="2010-01-31 16:06:34 +0000" MODIFIED_BY="[Empty name]" NAME="Link 2006" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2010-01-31 16:06:34 +0000" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2010-01-31 16:05:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Link A, Ayadhi T, Bohm M, Nickenig G</AU>
<TI>Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>24</NO>
<PG>2945</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Link-2006a" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Link 2006a" YEAR="2006">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Link A, Ayadhi T, Bohm M, Nickenig G</AU>
<TI>Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>2945-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Link-2011" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Link 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Link, Andreas Selejan, Simina Hewera, Lisa Walter, Felix Nickenig, Georg Bohm, Michael&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Link A, Selejan S, Hewera L, Walter F, Nickenig G, Bohm M</AU>
<TI>Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes</TI>
<SO>Clinical Research in Cardiology</SO>
<YR>2011</YR>
<VL>100</VL>
<PG>147-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Liu, Peng Jiang, Jie Li, Jianping Hong, Tao Zhang, Yan Yu, Ronghui Jia, Jia Huo, Yong&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu P, Jiang J, Li J, Hong T, Zhang Y, Yu R, et al</AU>
<TI>Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design</TI>
<SO>Catheterization &amp; Cardiovascular Interventions</SO>
<YR>2012</YR>
<VL>79</VL>
<PG>967-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miyauchi-2006" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Miyauchi 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al</AU>
<TI>Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design</TI>
<SO>Circulation Journal</SO>
<YR>2006</YR>
<VL>70</VL>
<PG>1624-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteiro-2008" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Monteiro 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monteiro CMC, Oliveira L, Izar MCO, Santos AO, Povoa RMS, Fischer SM, et al</AU>
<TI>Early effects of lipid lowering treatment in subjects with metabolic syndrome and acute coronary syndromes</TI>
<SO>International Journal of Atherosclerosis</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-2008" MODIFIED="2010-01-31 16:06:38 +0000" MODIFIED_BY="[Empty name]" NAME="Nakamura 2008" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2010-01-31 16:06:38 +0000" NOTES_MODIFIED_BY="[Empty name]" YEAR="2008">
<REFERENCE MODIFIED="2010-01-31 16:05:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura T, Obata J, Kitta Y, Takano H, Kobayashi T, Fujioka D, et al</AU>
<TI>Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>4</NO>
<PG>365</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakaya-2005" MODIFIED="2011-04-08 11:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Nakaya 2005" NOTES="&lt;p&gt;No randomization&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:25:59 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:25:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, Yamazaki T, et al</AU>
<TI>Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>1</NO>
<PG>67&#8211;73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ordulu-2008" MODIFIED="2011-04-08 11:26:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ordulu 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-04-08 11:26:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ordulu E, Erdogan O</AU>
<TI>Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes</TI>
<SO>International Journal of Cardiology</SO>
<YR>2008</YR>
<VL>128</VL>
<NO>2</NO>
<PG>282&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ostadal-2003" MODIFIED="2011-04-08 11:27:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ostadal 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-08 11:27:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20030704&lt;br&gt;IS - 0300-8177&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;RN - 0 (Interleukin-6)&lt;br&gt;RN - 0 (Interleukin-8)&lt;br&gt;RN - 0 (Pyridines)&lt;br&gt;RN - 0 (cerivastatin)&lt;br&gt;RN - 9007-41-4 (C-Reactive Protein)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:27:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, et al</AU>
<TI>The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction</TI>
<SO>Molecular and Cellular Biochemistry</SO>
<YR>2003</YR>
<VL>246</VL>
<NO>1-2</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patti-2007" MODIFIED="2011-04-08 11:28:07 +0100" MODIFIED_BY="[Empty name]" NAME="Patti 2007" NOTES="&lt;p&gt;Treatment not given for more than 30 days&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:28:07 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2007">
<REFERENCE MODIFIED="2011-04-08 11:28:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al</AU>
<TI>Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>12</NO>
<PG>1272&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEACE-2005" MODIFIED="2011-04-08 11:28:33 +0100" MODIFIED_BY="[Empty name]" NAME="PEACE 2005" NOTES="&lt;p&gt;Head to head comparison of statins (pravastatin 20mg vs simvastatin 40mg)&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:28:33 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:28:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Min Z, Zhao M, Jia SQ</AU>
<TI>Pravastatin early use in acute coronary evaluation (PEACE) trial</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>95</VL>
<NO>Suppl 8, April</NO>
<PG>74A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-2000" MODIFIED="2011-04-08 11:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Pedersen 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-04-08 11:30:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20001211&lt;br&gt;IS - 0149-2918&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Anticholesteremic Agents)&lt;br&gt;RN - 79902-63-9 (Simvastatin)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:30:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen TR, Jahnsen KE, Vatn S, Semb AG, Kontny F, Zalmai A, et al</AU>
<TI>Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>8</NO>
<PG>949-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-2005" MODIFIED="2011-04-08 11:31:11 +0100" MODIFIED_BY="[Empty name]" NAME="Pedersen 2005" NOTES="&lt;p&gt;Treatment initiated within 14 days of event&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:31:11 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:31:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al</AU>
<TI>High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>19</NO>
<PG>2437</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitt-2008" MODIFIED="2011-04-08 11:31:32 +0100" MODIFIED_BY="[Empty name]" NAME="Pitt 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-04-08 11:31:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitt B, Loscalzo J, Ycas J, Raichlen JS</AU>
<TI>Lipid levels after acute coronary syndromes</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>15</NO>
<PG>1440-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitt-2012" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Pitt 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;English&lt;br&gt;Pitt, Bertram Loscalzo, Joseph Monyak, John Miller, Elinor Raichlen, Joel&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J</AU>
<TI>Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study)</TI>
<SO>American Journal of Cardiology</SO>
<YR>2012</YR>
<VL>109</VL>
<PG>1239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Post-2012" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Post 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Post S, Post MC, Van Den Branden BJ, Eefting FD, Goumans MJ, Stella PR, et al</AU>
<TI>Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2012</YR>
<VL>80</VL>
<PG>756-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakata-2005" MODIFIED="2011-04-08 11:34:19 +0100" MODIFIED_BY="[Empty name]" NAME="Sakata 2005" NOTES="&lt;p&gt;Not a clinical trial.&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:34:19 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2005">
<REFERENCE MODIFIED="2011-04-08 11:34:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakata Y, Sato H, Kinjo K, Fujii K, Kodama K, Tanouchi J, et al</AU>
<TI>Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction</TI>
<SO>Heart Drug</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>4</NO>
<PG>193&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-2007" MODIFIED="2011-04-08 11:34:49 +0100" MODIFIED_BY="[Empty name]" NAME="Shah 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-04-08 11:34:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, et al</AU>
<TI>Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions</TI>
<SO>Experimental and Clinical Cardiology</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>2</NO>
<PG>91-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefanadi-2009" MODIFIED="2011-04-08 11:35:30 +0100" MODIFIED_BY="[Empty name]" NAME="Stefanadi 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:35:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefanadi E, Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Vavuranakis E, et al</AU>
<TI>Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation</TI>
<SO>International Journal of Cardiology</SO>
<YR>2009</YR>
<VL>133</VL>
<NO>2</NO>
<PG>266-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suh-2011" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Suh 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;rzh&lt;br&gt;research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0207277. PMID: 21890083&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suh SY, Rha SW, Ahn TH, Shin EK, Choi CU, Oh DJ, et al</AU>
<TI>Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS])</TI>
<SO>American Journal of Cardiology</SO>
<YR>2011</YR>
<VL>108</VL>
<PG>1530-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teshima-2009" MODIFIED="2011-04-08 11:36:01 +0100" MODIFIED_BY="[Empty name]" NAME="Teshima 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:36:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, et al</AU>
<TI>Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction</TI>
<SO>Journal of Cardiology</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>1</NO>
<PG>58-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tousoulis-2006" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tousoulis 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Kotsopoulou M, Tsioufis C, et al</AU>
<TI>The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>109</VL>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tousoulis-2006a" MODIFIED="2011-04-08 11:36:51 +0100" MODIFIED_BY="[Empty name]" NAME="Tousoulis 2006a" NOTES="&lt;p&gt;Did not assess clinical outcomes.&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:36:51 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:36:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Kotsopoulou M, Tsioufis C, et al</AU>
<TI>The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>109</VL>
<NO>1</NO>
<PG>48&#8211;52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tousoulis-2006b" MODIFIED="2011-04-08 11:36:46 +0100" MODIFIED_BY="[Empty name]" NAME="Tousoulis 2006b" NOTES="&lt;p&gt;Treatment initiated within 14 days of event&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:36:46 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2011-04-08 11:36:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C</AU>
<TI>Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina</TI>
<SO>International Journal of Cardiology</SO>
<YR>2006</YR>
<VL>106</VL>
<NO>3</NO>
<PG>333&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xin_x002d_wei-2009" MODIFIED="2011-04-08 11:37:16 +0100" MODIFIED_BY="[Empty name]" NAME="Xin-wei 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:37:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xin-wei JIA, Xiang-hua FU, Jing Z, Xin-shun GU, Wei-ze FAN, Wei-li WU, et al</AU>
<TI>Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome</TI>
<SO>Chinese Medical Journal</SO>
<YR>2009</YR>
<VL>122</VL>
<NO>6</NO>
<PG>659&#8211;64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yun-2009" MODIFIED="2011-04-08 11:38:13 +0100" MODIFIED_BY="[Empty name]" NAME="Yun 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:38:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al</AU>
<TI>The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome</TI>
<SO>International Journal of Cardiology</SO>
<YR>2009</YR>
<VL>137</VL>
<NO>3</NO>
<PG>246-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2013" MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-04-08 14:02:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Embase&lt;br&gt;English&lt;br&gt;Boston Scientific [United States] iLab Ultrasound Imaing system: Boston Scientific [United States]&lt;/p&gt;" NOTES_MODIFIED="2014-04-08 14:02:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Wang H, Liu S, Gong P, Lin J, Lu J, et al</AU>
<TI>Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2013</YR>
<VL>18</VL>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2009" MODIFIED="2011-04-08 11:38:51 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-08 11:38:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Z, Geng J, Ge ZM, Wang W, Zhang Y, Kang WQ</AU>
<TI>Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina</TI>
<SO>Clinical and Experimental Pharmacology &amp; Physiology</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>5-6</NO>
<PG>554-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2009" MODIFIED="2014-06-26 16:36:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-26 16:36:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70104955 English Journal: Conference Abstract&lt;/p&gt;" NOTES_MODIFIED="2014-06-26 16:36:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng XY, Liu L, Yang DG</AU>
<TI>Early effect of atorvastatin, alone and in combination with probucol, on endothelial dysfunction in patients with acute coronary syndrome</TI>
<SO>Atherosclerosis Supplements</SO>
<YR>2009</YR>
<VL>Conference</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2009a" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MEDLINE&lt;br&gt;Chinese&lt;br&gt;Zheng, Xiao-yan Liu, Ling Zhao, Shui-ping Chinese&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng XY, Liu L, Zhao SP</AU>
<TI>Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome</TI>
<SO>Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]</SO>
<YR>2009</YR>
<VL>37</VL>
<PG>900-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-10 16:50:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-10 16:50:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-_x0034_S-1994" MODIFIED="2011-04-08 11:39:17 +0100" MODIFIED_BY="[Empty name]" NAME="4S 1994" NOTES="&lt;p&gt;UI - 95057659&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:39:17 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Scandinavian Simvastatin Survival Study Group</AU>
<TI>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8934</NO>
<PG>1383-9</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:39:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-AHA-2007" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="AHA 2007" TYPE="OTHER">
<AU>American Heart Association</AU>
<TI>Heart disease and stroke statistics - 2007 update</TI>
<SO>Available at www.americanheart.org/statistics</SO>
<YR>2006 (accessed August 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2003" MODIFIED="2011-04-08 11:40:47 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen B, Chen W, Gluud C, Kjaergard LL</AU>
<TI>Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>7</NO>
<PG>921-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ara-2009" MODIFIED="2011-04-08 11:41:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ara 2009" NOTES="&lt;p&gt;DA - 20090716&lt;br&gt;IS - 1366-5278 (Print)&lt;br&gt;IS - 1366-5278 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Antilipemic Agents)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:41:08 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ara R, Pandor A, Stevens J, Rees A, Rafia R</AU>
<TI>Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>34</NO>
<PG>1-118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-2010" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Armitage 2010" NOTES="&lt;p&gt;DA - 20101115&lt;br&gt;IS - 1474-547X (Electronic)&lt;br&gt;IS - 0140-6736 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Anticholesteremic Agents)&lt;br&gt;RN - 0 (Cholesterol, HDL)&lt;br&gt;RN - 0 (Cholesterol, LDL)&lt;br&gt;RN - 0 (Triglycerides)&lt;br&gt;RN - AGG2FN16EV (Simvastatin)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al</AU>
<TI>Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9753</NO>
<PG>1658-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aronow-2001" MODIFIED="2014-07-10 16:16:33 +0100" MODIFIED_BY="[Empty name]" NAME="Aronow 2001" NOTES="&lt;p&gt;UI - 21198542&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:16:33 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al</AU>
<TI>Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9262</NO>
<PG>1063-8</PG>
<IDENTIFIERS MODIFIED="2014-07-10 16:16:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Baigent-2010" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Baigent 2010" NOTES="&lt;p&gt;DA - 20101115&lt;br&gt;IS - 1474-547X (Electronic)&lt;br&gt;IS - 0140-6736 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Meta-Analysis&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Cholesterol, LDL)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al</AU>
<TI>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9753</NO>
<PG>1670-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Briel-2004" MODIFIED="2011-04-08 11:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="Briel 2004" NOTES="&lt;p&gt;DA - 20041006&lt;br&gt;IS - 0002-9343&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Meta-Analysis&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Antilipemic Agents)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:42:00 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Briel M, Studer M, Glass TR, Bucher HC</AU>
<TI>Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<NO>8</NO>
<PG>596-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cannon-2004b" MODIFIED="2014-07-10 16:16:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cannon 2004b" NOTES="&lt;p&gt;DA - 20040408&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:16:59 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al</AU>
<TI>Intensive versus moderate lipid lowering with statins after acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>15</NO>
<PG>1495-504</PG>
<IDENTIFIERS MODIFIED="2014-07-10 16:16:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-1998" NAME="Deeks 1998" TYPE="CONFERENCE_PROC">
<AU>Deeks J, Bradburn M, Localio R, Berlin J</AU>
<TI>Much ado about nothing: statistical methods for meta-analysis with rare events</TI>
<SO>6th Cochrane Colloquium, Baltimore, MD, USA</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fonarow-2005" NAME="Fonarow 2005" NOTES="&lt;p&gt;DA - 20050829&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al</AU>
<TI>Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>96</VL>
<NO>5</NO>
<PG>611-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="680"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2003" MODIFIED="2011-04-08 11:43:05 +0100" MODIFIED_BY="[Empty name]" NAME="Freemantle 2003" NOTES="&lt;p&gt;DA - 20030521&lt;br&gt;IS - 0098-7484&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:43:05 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C</AU>
<TI>Composite outcomes in randomized trials: greater precision but with greater uncertainty?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2554-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glesby-1996" MODIFIED="2011-04-08 11:43:29 +0100" MODIFIED_BY="[Empty name]" NAME="Glesby 1996" NOTES="&lt;p&gt;DA - 19960618&lt;br&gt;IS - 0003-4819&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;PT - Review, Tutorial&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;br&gt;SB - X&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:43:29 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Glesby MJ, Hoover DR</AU>
<TI>Survivor treatment selection bias in observational studies: examples from the AIDS literature</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<NO>11</NO>
<PG>999-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" NOTES="&lt;p&gt;DA - 20020711&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="533"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;UI - 22837839&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="411"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-HPS-2002" NAME="HPS 2002" NOTES="&lt;p&gt;UI - 22110872&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>The Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9326</NO>
<PG>7-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hulten-2006" NAME="Hulten 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hulten E, Jackson JL, Douglas K, George S, Villines TC</AU>
<TI>The effect of early, intensive statin therapy on acute coronary syndrome. A meta-analysis of randomized controlled trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>1814-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackevicius-2002" MODIFIED="2011-04-08 11:44:18 +0100" MODIFIED_BY="[Empty name]" NAME="Jackevicius 2002" NOTES="&lt;p&gt;DA - 20020722&lt;br&gt;IS - 0098-7484 (Print)&lt;br&gt;IS - 0098-7484 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Antilipemic Agents)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:44:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jackevicius CA, Mamdani M, Tu JV</AU>
<TI>Adherence with statin therapy in elderly patients with and without acute coronary syndromes</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>4</NO>
<PG>462-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2009" MODIFIED="2011-04-08 11:45:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2009" NOTES="&lt;p&gt;DA - 20091002&lt;br&gt;IS - 1942-5546 (Electronic)&lt;br&gt;IS - 0025-6196 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Biological Markers)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:45:10 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Cannon CP</AU>
<TI>Acute coronary syndromes: diagnosis and management, part I</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2009</YR>
<VL>84</VL>
<NO>10</NO>
<PG>917-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachin-2000" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lachin 2000" TYPE="BOOK_SECTION">
<AU>Lachin JM</AU>
<TI>Sample size, power, and efficiency</TI>
<SO>Biostatistical Methods</SO>
<YR>2000</YR>
<PG>61-86</PG>
<EN>1st</EN>
<ED>Lachin JM</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-2004" MODIFIED="2011-04-08 11:46:34 +0100" MODIFIED_BY="[Empty name]" NAME="Laupacis 2004" NOTES="&lt;p&gt;DA - 20040602&lt;br&gt;IS - 1539-3704&lt;br&gt;LA - eng&lt;br&gt;PT - Comment&lt;br&gt;PT - Editorial&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:46:34 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Mamdani M</AU>
<TI>Observational studies of treatment effectiveness: some cautions</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>11</NO>
<PG>923-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LIPID-Study-Group-1998" MODIFIED="2011-04-08 11:47:01 +0100" MODIFIED_BY="[Empty name]" NAME="LIPID Study Group 1998" NOTES="&lt;p&gt;DA - 19981105&lt;br&gt;IS - 0028-4793 (Print)&lt;br&gt;IS - 0028-4793 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;RN - 0 (Anticholesteremic Agents)&lt;br&gt;RN - 0 (Lipids)&lt;br&gt;RN - 81093-37-0 (Pravastatin)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:47:01 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>LIPID Study Group</AU>
<TI>Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>19</NO>
<PG>1349-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2005" MODIFIED="2011-04-08 11:47:15 +0100" MODIFIED_BY="[Empty name]" NAME="Montori 2005" NOTES="&lt;p&gt;DA - 20050311&lt;br&gt;IS - 1468-5833 (Electronic)&lt;br&gt;IS - 0959-535X (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Review&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:47:15 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al</AU>
<TI>Validity of composite end points in clinical trials</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7491</NO>
<PG>594-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrissey-2009" MODIFIED="2011-04-08 11:47:38 +0100" MODIFIED_BY="[Empty name]" NAME="Morrissey 2009" NOTES="&lt;p&gt;DA - 20091002&lt;br&gt;IS - 1558-3597 (Electronic)&lt;br&gt;IS - 0735-1097 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;RN - 0 (Cholesterol, LDL)&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:47:38 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Morrissey RP, Diamond GA, Kaul S</AU>
<TI>Statins in acute coronary syndromes: do the guideline recommendations match the evidence?</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>15</NO>
<PG>1425-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newby-2002" NAME="Newby 2002" NOTES="&lt;p&gt;UI - 22065685&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, et al</AU>
<TI>Early statin initiation and outcomes in patients with acute coronary syndromes</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>23</NO>
<PG>3087-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="349"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nordmann-2000" MODIFIED="2011-04-08 11:48:14 +0100" MODIFIED_BY="[Empty name]" NAME="Nordmann 2000" NOTES="&lt;p&gt;DA - 20001212&lt;br&gt;IS - 0953-6205 (Print)&lt;br&gt;LA - ENG&lt;br&gt;PT - JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:48:14 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Nordmann A, Blattmann L, Gallino A, Khetari R, Martina B, Muller P, et al</AU>
<TI>Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>6</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redelmeier-1998" MODIFIED="2011-04-08 11:48:39 +0100" MODIFIED_BY="[Empty name]" NAME="Redelmeier 1998" NOTES="&lt;p&gt;DA - 19980521&lt;br&gt;IS - 0028-4793&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:48:39 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Redelmeier DA, Tan SH, Booth GL</AU>
<TI>The treatment of unrelated disorders in patients with chronic medical diseases</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>21</NO>
<PG>1516-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ridker-1998" MODIFIED="2011-04-08 11:52:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ridker 1998" NOTES="&lt;p&gt;UI - 98409017&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:52:08 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al</AU>
<TI>Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>9</NO>
<PG>839-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="34"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rosenson-1998" NAME="Rosenson 1998" NOTES="&lt;p&gt;UI - 98273996&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rosenson RS, Tangney CC</AU>
<TI>Antiatherothrombotic properties of statins: implications for cardiovascular event reduction</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<NO>20</NO>
<PG>1643-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Serruys-2002" MODIFIED="2011-04-08 11:53:10 +0100" MODIFIED_BY="[Empty name]" NAME="Serruys 2002" NOTES="&lt;p&gt;UI - 22072453&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:53:10 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al</AU>
<TI>Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>24</NO>
<PG>3215-22</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:53:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Shepherd-1995" MODIFIED="2011-04-08 11:53:30 +0100" MODIFIED_BY="[Empty name]" NAME="Shepherd 1995" NOTES="&lt;p&gt;UI - 96036646&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:53:30 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al</AU>
<TI>Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>20</NO>
<PG>1301-7</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:53:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2005" MODIFIED="2011-04-08 11:53:56 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2005" NOTES="&lt;p&gt;DA - 20050502&lt;br&gt;IS - 1097-6744 (Electronic)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:53:56 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E</AU>
<TI>Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>3</NO>
<PG>444-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-2004" MODIFIED="2011-04-08 11:54:25 +0100" MODIFIED_BY="[Empty name]" NAME="Spencer 2004" NOTES="&lt;p&gt;DA - 20040602&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:54:25 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al</AU>
<TI>Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>11</NO>
<PG>857-66</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:54:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sposito-2002" MODIFIED="2011-04-08 11:54:40 +0100" MODIFIED_BY="[Empty name]" NAME="Sposito 2002" NOTES="&lt;p&gt;DA - 20021014&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:54:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sposito AC, Chapman MJ</AU>
<TI>Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit</TI>
<SO>Arteriosclerosis, Thrombosis &amp; Vascular Biology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1524-34</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:54:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Staffa-2002" MODIFIED="2011-04-08 11:54:51 +0100" MODIFIED_BY="[Empty name]" NAME="Staffa 2002" NOTES="&lt;p&gt;UI - 21833855&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:54:51 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Staffa JA, Chang J, Green L</AU>
<TI>Cerivastatin and reports of fatal rhabdomyolysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>7</NO>
<PG>539-40</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:54:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stenestrand-2001" MODIFIED="2011-04-08 11:55:01 +0100" MODIFIED_BY="[Empty name]" NAME="Stenestrand 2001" NOTES="&lt;p&gt;UI - 21136990&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:55:01 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Stenestrand U, Wallentin L</AU>
<TI>Early statin treatment following acute myocardial infarction and 1-year survival</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>4</NO>
<PG>430-6</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:55:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" NOTES="&lt;p&gt;DA - 20010713&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M, Smith GD</AU>
<TI>Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7304</NO>
<PG>101-5</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:55:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stone-2013" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Stone 2013" NOTES="&lt;p&gt;DA - 20131113&lt;br&gt;IS - 1524-4539 (Electronic)&lt;br&gt;IS - 0009-7322 (Linking)&lt;br&gt;LA - ENG&lt;br&gt;PT - JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2014-06-27 08:21:50 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al</AU>
<TI>2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</TI>
<SO>Circulation</SO>
<YR>2013 Nov 7 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2014-06-26 16:52:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-26 16:52:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jacc.2013.11.002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Studer-2005" MODIFIED="2011-04-08 11:55:27 +0100" MODIFIED_BY="[Empty name]" NAME="Studer 2005" NOTES="&lt;p&gt;DA - 20050412&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:55:27 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC</AU>
<TI>Effect of different antilipidemic agents and diets on mortality: a systematic review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>7</NO>
<PG>725-30</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:55:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thygesen-2007" MODIFIED="2011-04-08 11:56:13 +0100" MODIFIED_BY="[Empty name]" NAME="Thygesen 2007" NOTES="&lt;p&gt;DA - 20071022&lt;br&gt;IS - 0195-668X (Print)&lt;br&gt;IS - 0195-668X (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;RN - 0 (Biological Markers)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:56:13 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Thygesen K, Alpert JS, White HD</AU>
<TI>Universal definition of myocardial infarction</TI>
<SO>European Heart Journal</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>20</NO>
<PG>2525-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walter-2004" MODIFIED="2011-04-08 11:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="Walter 2004" NOTES="&lt;p&gt;DA - 20040217&lt;br&gt;IS - 1381-6128&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;PT - Review, Tutorial&lt;br&gt;RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:57:05 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Walter DH</AU>
<TI>Insights into early and rapid effects of statin therapy after coronary interventions</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>369-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-1998" MODIFIED="2011-04-08 11:57:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 1998" NOTES="&lt;p&gt;UI - 99038428&lt;/p&gt;" NOTES_MODIFIED="2011-04-08 11:57:23 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K, et al</AU>
<TI>Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention</TI>
<SO>European Heart Journal</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>10</NO>
<PG>1434-503</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:57:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Briel-2006a" MODIFIED="2011-05-06 15:18:48 +0100" MODIFIED_BY="Joey Kwong" NAME="Briel 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Briel M, Schwartz GG, Thompson PL, DeLemos JA, Blazing MA, van Es GA, et al</AU>
<TI>Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes. A meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>2046-56</PG>
<IDENTIFIERS MODIFIED="2011-05-06 15:18:48 +0100" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<REFERENCE ID="REF-Briel-2006b" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Briel 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Briel M, Schwartz GG, Bucher HC, Nordmann AJ</AU>
<TI>5012 Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a systematic review and collaborative meta-analysis of randomized trials</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>Suppl 1</NO>
<PG>856</PG>
<IDENTIFIERS MODIFIED="2011-04-08 11:59:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Briel-2011" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Briel 2011" TYPE="OTHER">
<AU>Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, et al</AU>
<TI>Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients</TI>
<SO>International Journal of Cardiology</SO>
<YR>2011 Feb 3 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vale-2011" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Vale 2011" TYPE="COCHRANE_REVIEW">
<AU>Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, et al</AU>
<TI>Statins for acute coronary syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2014-05-22 16:30:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-22 16:30:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006870.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-10 15:48:38 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-07-10 15:48:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Source" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Daily intervention" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Control">
<INCLUDED_CHAR MODIFIED="2014-07-10 15:31:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colivicchi-2002">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Italy</P>
<P>
<B>Patient recruitment</B>: January 1999 to July 2001</P>
<P>
<B>Blinding</B>: outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 12 months</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-10 15:31:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 40, control 41</P>
<P>
<B>Mean age (SD) in years</B>: statin 69 (14), control 68 (14)</P>
<P>
<B>Men, n (%)</B>: statin 23 (58%), control 24 (59%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 22 (55%), control 24 (58%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 35 (87%), control 37 (90%)</P>
<P>
<B>Current smoker, n (%)</B>: unspecified</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 34 (85%), control 35 (85%)</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: unspecified</LI>
<LI>Unstable angina: unspecified</LI>
<LI>Fibrinolysis therapy: none</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: (1) angiographic evidence of severe and diffuse coronary artery disease, that was not amenable to direct revascularization by coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, as determined by a cardiac surgeon and an interventional cardiologist during the index admission; (2) objective evidence of symptomatic reversible myocardial ischemia (0.1 mV ST-segment depression on the electrocardiogram) at a low exercise workload while receiving medical treatment (2 antianginal medications at maximal tolerated doses), as assessed by treadmill ergometry (Bruce's protocol) before discharge; and (3) left ventricular ejection fraction 35%</P>
<P>
<B>Exclusion criteria</B>: presence of congestive heart failure, the need for continuous use of intravenous antianginal medications, and the presence of any major concurrent illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:12 +0100" MODIFIED_BY="[Empty name]">
<P>Atorvastatin 80 mg initiated on average 12 days of onset of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of cardiovascular death, non-fatal MI, readmission for ACS (requiring new electrocardiographic changes or cardiac marker elevation), and stroke</P>
<P>
<B>Secondary</B>: individual components of the primary endpoint</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-02-26 09:54:13 +0000" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>Adherence to the National Cholesterol Education Program Guidelines</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 13:54:24 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care including lipid-lowering therapy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:35:47 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1, 3, 6, and 12 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Lemos-2004">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 322 centers in 41 countries</P>
<P>
<B>Patient recruitment</B>: December 1999 to January 2003</P>
<P>
<B>Blinding</B>: patients, caregivers, and outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 4 months for comparison simvastatin 40/80 mg versus placebo</P>
<P>
<B>Lost to follow-up</B>: 44 (1%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 2265, control 2232</P>
<P>
<B>Mean age (SD) in years</B>: statin 60 (11), control 61 (11)</P>
<P>
<B>Men, n (%)</B>: statin 1716 (76%), control 1680 (75%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 529 (23%), control 530 (24%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 1131 (50%), control 1105 (50%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 926 (41%), control 915 (41%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 409 (18%), control 355 (16%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 1956 (86%), control 1919 (86%)</LI>
<LI>Unstable angina: statin 309 (14%), control 313 (14%)</LI>
<LI>Fibrinolysis therapy: statin 483 (21%), control 472 (21%)</LI>
<LI>Percutaneous coronary intervention (PCI): statin 979 (43%), control 979 (44%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: patients with ACS, between the ages of 21 and 80 years with either non-ST-elevation ACS; total cholesterol of 250 mg/dL (6.48 mmol/L) or lower; stabilized for at least 12 consecutive hours within 5 days after symptom onset, and meeting at least one of the following high-risk characteristics: age older than 70 years, diabetes mellitus, prior history of coronary artery disease, peripheral arterial disease, or stroke; elevation of serum creatine kinase-MB or troponin levels; recurrent angina with ST-segment changes; electrocardiographic evidence of ischemia on a pre-discharge stress test; or multivessel coronary artery disease determined by coronary angiography</P>
<P>
<B>Exclusion criteria</B>: on statins at time of randomization, coronary artery bypass graft surgery planned, or PCI planned within the following 2 weeks; ALT level higher than 20% above the upper limit of normal; an increased risk of myopathy due to renal impairment (serum creatinine level &gt; 2.0 mg/dL) or concomitant therapy with agents known to enhance myopathy risk, such as fibrates, cyclosporine, macrolide antibiotics, azole antifungals, amiodarone, or verapamil; or a prior history of non exercise-related elevations in creatine kinase level or nontraumatic rhabdomyolysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Simvastatin 40 mg initiated within 5 days of onset of ACS and then titrated to 80 mg at 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of cardiovascular death, non-fatal MI, readmission for ACS (requiring new electrocardiographic changes or cardiac marker elevation), and stroke</P>
<P>
<B>Secondary</B>: individual components of the primary endpoint, revascularization due to documented ischemia, death from any cause, new-onset congestive heart failure (requiring admission or initiation of heart failure medications), and cardiovascular rehospitalization</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-26 13:36:04 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by Merck</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:36:05 +0100" MODIFIED_BY="[Empty name]">
<P>All patients were encouraged to adopt an American Heart Association Step I diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 14:15:48 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:36:07 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data for the review at 1 and 4 months of follow-up provided by original investigators. After 4 months the control group received simvastatin 20 mg</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ESTABLISH-2004">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Japan</P>
<P>
<B>Patient recruitment</B>: November 2001 to August 2003</P>
<P>
<B>Blinding</B>: statistician</P>
<P>
<B>Intention-to-treat</B>: unspecified</P>
<P>
<B>Follow-up period</B>: 6 months</P>
<P>
<B>Lost to follow-up</B>: 1 (1%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 35, control 35</P>
<P>
<B>Mean age (SD) in years</B>: statin 61 (10), control 63 (11)</P>
<P>
<B>Men, n (%)</B>: statin 30 (86%), control 30 (86%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 12 (34%), control 11 (31%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 19 (54%), control 19 (54%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 24 (69%), control 19 (54%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 5 (14%), control 5 (14%)</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: statin 22 (63%), control 26 (74%)</LI>
<LI>Unstable angina: statin 13 (37%), control 9 (26%)</LI>
<LI>Fibrinolysis therapy: statin 7 (20%), control 3 (9%)</LI>
<LI>Percutaneous coronary intervention (PCI): statin 35 (100%), control 35 (100%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: ACS with significant stenosis on initial coronary angiography and received PCI. ACS was defined as high-risk unstable angina, non&#8211;ST-elevated myocardial infarction (MI) or ST-elevated MI. MI was diagnosed by the rise (2 times) in serum creatine phosphokinase and positivity for troponin T</P>
<P>
<B>Exclusion criteria</B>: failed PCI, diseased bypass graft, recommended CABG, cardiogenic shock, and administration of lipid-lowering drugs (statin, clofibrate, probucol or analog, nicotinic acid, or other prohibited drug) before enrollment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:19 +0100" MODIFIED_BY="[Empty name]">
<P>Atorvastatin 20 mg initiated within 14 days of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: % change in plaque volume</P>
<P>
<B>Secondary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), and unstable angina</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-02-26 10:15:43 +0000" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Aspirin 100 mg daily, ticlopidine 100 mg twice daily</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-02-26 10:17:22 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care including lipid-lowering diet</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1, 4 and 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:34:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FACS-2010">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 5 centers in Czech Republic and Slovakia</P>
<P>
<B>Patient recruitment</B>: November 2003 to February 2006</P>
<P>
<B>Blinding</B>: participants, caregivers</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 12 months</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 78, control 78</P>
<P>
<B>Mean age (SD) in years</B>: statin 61 (12), control 63 (11)</P>
<P>
<B>Men, n (%)</B>: statin 55 (71%), control 51 (65%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 14 (18%), control 16 (21%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 40 (51%), control 40 (51%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 33 (42%), control 39 (50%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 4 (5%), control 8 (10%)</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: statin &gt; 47 (60%), control &gt; 54 (69%)</LI>
<LI>Unstable angina: statin &lt; 31 (40%), control &lt; 24 (31%)</LI>
<LI>Fibrinolysis therapy: none</LI>
<LI>Percutaneous coronary intervention (PCI): statin 68 (87%), control 71 (91%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: ST elevation ACS must have resting chest pain less than 12 hours before admission and either &#8805; 1 mm ST-segment elevation in 2 or more continuous leads or new left bundle branch block on ECG. Those with non-ST elevation ACS must have resting chest pain during the previous 48 hours and either &#8805; 1 mm ST segment depression or negative T waves in 2 or more continuous leads</P>
<P>
<B>Exclusion criteria</B>: &lt; 18 years of age or if they have concomitant active liver disease or persistent elevation of transaminases (&gt; 3 times the upper limit of normal), a history of lipid-lowering therapy less than 30 days before the index event or a known allergy to fluvastatin or to any additives present in the drug. Other exclusions include inability to ingest oral medication, unwillingness to be followed for the duration of the study, muscle disease (e.g. myositis), and creatine kinase &#8805; 5 times the upper limit of normal due to conditions other than myocardial infarction. Women of childbearing potential who are pregnant, nursing or who are not using effective contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fluvastatin 80 mg within 1 hour of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-10 15:34:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: levels of C-reactive protein and IL-6</P>
<P>
<B>Secondary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-22 14:31:51 +0000" MODIFIED_BY="[Empty name]">
<P>Medication and Clinical Monitoring by Novartis Pharma CR, Laboratory investigations by grant from Czech Ministry of Health</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-02-26 10:28:03 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-22 14:30:04 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1, 3, and 12 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:35:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FLORIDA-2002">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 28 centers in The Netherlands</P>
<P>
<B>Patient recruitment</B>: July 1997 to May 1999</P>
<P>
<B>Blinding</B>: patients, caregivers, and outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: unspecified</P>
<P>
<B>Follow-up period</B>: 12 months</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-10 15:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 265, control 275</P>
<P>
<B>Mean age (SD) in years</B>: statin 61 (12), control 60 (11)</P>
<P>
<B>Men, n (%)</B>: statin 214 (81%), control 234 (85%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 29 (11%), control 31 (11%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 67 (25%), control 65 (24%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 140 (53%), control 139 (51%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 31 (12%), control 31 (11%)</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: statin 265 (100%), control 275 (100%)</LI>
<LI>Unstable angina: none</LI>
<LI>Fibrinolysis therapy: statin 137 (52%), control 133 (48%)</LI>
<LI>Percutaneous coronary intervention (PCI): statin 8 (3%), control 10 (4%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: new or markedly increased chest pain lasting longer than 30 minutes, or a new pathological Q wave of 0.04 s duration, or 25% of the corresponding R wave amplitude, both in at least 2 contiguous leads</P>
<P>
<B>Exclusion criteria</B>: age &lt; 18 years, use of lipid-lowering agents within the previous 3 months, a high triglyceride level of &gt; 4.5 mmol/l, known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (New York Heart Association class IV), a scheduled percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and co-medication that influences the ST-segment (digoxin, quinidine or tricyclic antidepressants), atrial fibrillation, Wolff-Parkinson-White syndrome, complete left bundle-branch block, known pre-existent ST-segment deviations before the qualifying MI, left ventricular hypertrophy with a pattern of strain or presence of a permanent pacemaker</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fluvastatin 80 mg within 14 days of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), unstable angina requiring emergency hospitalization</P>
<P>
<B>Secondary</B>: ischemia on the ambulatory ECG (without taking clinical events into account), change in ischemic burden, the time to a major clinical event and the 12-month change in lipid profile</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-08 22:19:54 +0000" MODIFIED_BY="[Empty name]">
<P>Unrestricted Grant from AstraZeneca, The Netherlands</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>At discretion of attending cardiologist for starting standard medication including aspirin, beta-blocking agents, and/or ACE-inhibitors</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-08 22:10:02 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1, 4, 6, and 12 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x002d_CAD-2000">
<CHAR_METHODS MODIFIED="2014-06-26 13:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Germany</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: none</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 24 months</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 70, control 56</P>
<P>
<B>Mean age (SD) in years</B>: statin 55 (10), control 59 (11)</P>
<P>
<B>Men, n (%)</B>: statin 57 (81%), control 44 (79%)</P>
<P>
<B>Diabetes, n (%)</B>: none</P>
<P>
<B>Hypertension, n (%)</B>: statin 22 (31%), control 18 (32%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 49 (70%), control 36 (64%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 45 (64%), control 39 (70%)</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: statin 32 (46%), control 23 (41%)</LI>
<LI>Unstable angina: statin 38 (54%), control 33 (59%)</LI>
<LI>Fibrinolysis therapy: unspecified</LI>
<LI>Percutaneous coronary intervention (PCI): statin 58 (83%), control 50 (89%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: total cholesterol of &gt; 200 to &lt; 400 mg/dL and low-density lipoprotein (LDL) cholesterol of &gt; 130 to &lt; 300 mg/dL (after exclusion of secondary forms of hyperlipidemia) with an acute myocardial infarction (defined by new Q waves and increase of enzymes of &gt; 3-fold the normal value) and/or who underwent emergency percutaneous transluminal coronary balloon angioplasty due to severe or unstable angina pectoris (defined by clinical symptoms and electrocardiographic (ECG) alterations</P>
<P>
<B>Exclusion criteria</B>: &gt; 75 years old, diabetics (fasting blood glucose &gt; 125 mg/dL), patients with post-coronary artery bypass graft, known malignant disease, serious kidney or liver dysfunction (creatinine &gt; 1.5 mg/dL, alanine aminotransferase and aspartate aminotransferase &gt; 2 times normal value), or women of child-bearing age not using a reliable contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 20 to 40 mg (8 of 70 individuals received additionally cholestyramine or nicotinic acid) within 1 to 11 days of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke</P>
<P>
<B>Secondary</B>: non-fatal myocardial infarction, coronary balloon angioplasty or bypass grafting, stroke, new onset of occlusive peripheral vascular disease, cardiovascular death, and all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-02-26 11:11:21 +0000" MODIFIED_BY="[Empty name]">
<P>Bristol-Myers Squibb Company, Munich, Germany</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-01 16:11:42 +0000" MODIFIED_BY="[Empty name]">
<P>All patients received dietary counseling per the standards of the European Atherosclerosis Society</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Usual care (including lipid-lowering therapy)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1, 4, 6,12, and 24 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:41:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LAMIL-1997">
<CHAR_METHODS MODIFIED="2014-06-26 17:16:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 10 centers in Belgium</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: participants and caregivers, but not outcome assessors</P>
<P>
<B>Intention-to-treat</B>: not reported</P>
<P>
<B>Follow-up period</B>: 3 months</P>
<P>
<B>Lost to follow-up</B>: 14 (20%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-10 15:41:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 36, control 33</P>
<P>
<B>Mean age (SD) in years</B>: unspecified</P>
<P>
<B>Men, n (%)</B>: unspecified</P>
<P>
<B>Diabetes, n (%)</B>: unspecified</P>
<P>
<B>Hypertension, n (%)</B>: unspecified</P>
<P>
<B>Current smoker, n (%)</B>: unspecified</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: unspecified</P>
<P>
<B>Index event, n (%)</B>: 
</P>
<UL>
<LI>Myocardial infarction: statin 36 (100%), control 33 (100%)</LI>
<LI>Unstable angina: none</LI>
<LI>Fibrinolysis therapy: unspecified</LI>
<LI>Percutaneous coronary intervention (PCI): unspecified</LI>
</UL>
<P>
<B>Inclusion criteria</B>: definite cases of acute MI using ECG and enzymatic criteria</P>
<P>
<B>Exclusion criteria</B>: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 10 to 20 mg 3 days after ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: lipid profile</P>
<P>
<B>Secondary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, and revascularization procedures (CABG/PCI)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Bristol-Myers-Squibb Pharmaceutical Company who also played a role in co-ordinating the study</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>None specified, no other lipid-lowering drugs allowed</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-08 21:04:46 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:37:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LIPS-2002">
<CHAR_METHODS MODIFIED="2014-06-26 17:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 57 centers in 10 countries</P>
<P>
<B>Patient recruitment</B>: April 1996 to October 1998</P>
<P>
<B>Blinding</B>: patients, caregivers, and outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: median of 3.9 years</P>
<P>
<B>Lost to follow-up</B>: 0 up to 12 months of follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 417, control 407 (these individuals just represent the subgroup of patients with unstable angina; the LIPS trial originally included another 853 individuals with stable angina)</P>
<P>
<B>Mean age (SD) in years</B>: statin 61 (10), control 60 (10)</P>
<P>
<B>Men, n (%)</B>: statin 344 (83%), control 336 (83%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 65 (16%), control 34 (8%)</P>
<P>
<B>Hypertension, n (%)</B>: statin not available, control not available</P>
<P>
<B>Current smoker, n (%)</B>: statin not available, control not available</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 184 (44%), control 172 (42%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 0, control 0</LI>
<LI>Unstable angina: statin 417 (100%), control 407 (100%)</LI>
<LI>Fibrinolysis therapy: statin 0, control 0</LI>
<LI>Percutaneous coronary intervention (PCI): statin 417 (100%), control 407 (100%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: patients with unstable angina, who had successfully undergone their first PCI of 1 or more lesions in the native coronary arteries. Successful PCI was defined as a reduction of the stenosis diameter to less than 50% in the target lesion without evidence of myocardial necrosis, need for repeat PCI or CABG, or death before hospital discharge. Any type of PCI was allowed and included balloon angioplasty with or without stent placement, rotational or directional atherectomy, laser ablation, transluminal extraction catheter, or cutting balloon. Patients further needed to have a total cholesterol level between 135 and 270 mg/dL (3.5 to 7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) before the index procedure. The upper total cholesterol limit for eligibility was 212 mg/dL (5.5 mmol/L) for patients whose baseline lipids were measured from blood drawn 24 hours to 4 weeks following MI and 232 mg/dL (6.0 mmol/L) for patients with type 1 or 2 diabetes mellitus</P>
<P>
<B>Exclusion criteria</B>: sustained systolic blood pressure of more than 180 mmHg and diastolic blood pressure of more than 100 mmHg despite medical therapy, left ventricular ejection fraction of less than 30%, a history of previous PCI or CABG, severe valvular disease, idiopathic cardiomyopathy or congenital heart disease, severe renal dysfunction (defined as serum creatinine level &gt; 1.8 mg/dL, obesity (defined as a body mass index &gt; 35 kg/m<SUP>2</SUP>), and the presence of malignant or other disease with a life expectancy of less than 4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>Fluvastatin 80 mg initiated at a median of 2 days after the index PCI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-10 15:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: development of a major adverse cardiac event (MACE), defined as cardiac death (any death unless an unequivocal noncardiac cause could be established); non-fatal MI (appearance of pathological Q waves that were absent at baseline or a total creatine kinase level &gt; 2 times the upper limit of normal (ULN) with presence of CK isoenzyme MB higher than the ULN); or a re-intervention procedure (CABG, repeat PCI, or PCI for a new lesion). Angiographic assessments without interventions were not included</P>
<P>
<B>Secondary</B>: MACE, excluding re-intervention procedures (surgical or PCI) occurring in the first 6 months of follow-up for lesions treated at the index procedure, cardiac mortality, non-cardiac mortality, all-cause mortality, combined cardiac mortality and MI, and combined all-cause mortality and MI</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by Novartis Pharma AG who also provided the fluvastatin and matching placebo</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>Dietary and lifestyle counseling</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-08 22:02:23 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data for the subgroup of patients with unstable angina at 1, 4, and 12 months of follow-up were provided by original investigators</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macin-2005">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Argentina</P>
<P>
<B>Patient recruitment</B>: December 1999 to November 2000</P>
<P>
<B>Blinding</B>: patients and caregivers, but not outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: unspecified</P>
<P>
<B>Follow-up period</B>: 1 month</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 44, control 46</P>
<P>
<B>Mean age (SD) in years</B>: statin 59 (13), control 61 (12)</P>
<P>
<B>Men, n (%)</B>: statin 34 (77%), control 33 (72%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 10 (23%), control 11 (24%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 29 (66%), control 31 (67%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 18 (41%), control 19 (41%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 5 (11%), control 7(15%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 23 (52%), control 31 (67%)</LI>
<LI>Unstable angina: statin 21 (48%), control 15 (33%)</LI>
<LI>Fibrinolysis therapy: statin 7 (16%), control 8 (17%)</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: &gt; 21 years old who fulfilled both of the following criteria: ACS within 48 hours of onset and CRP levels &#8805; 1.4 mg/dl within 24 hours. Acute coronary syndrome was diagnosed in the presence of ischemic chest pain at rest lasting &#8805; 20 minutes and at least 1 of the following: new or presumably new ST-segment deviations on electrocardiogram (electrocardiographic evidence of ST-segment elevation or depression), enzyme abnormalities (creatine kinase&#8211;MB above upper limit of reference in &#8805; 2 samples obtained with an interval of &gt; 6 hours), and/or troponin T &#8805; 0.02 ng/mL</P>
<P>
<B>Exclusion criteria</B>: (1) use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor or another lipid-lowering agent at any time during the preceding 1 month; (2) history of active liver disease; (3) untreated endocrine disorder; (4) history of systemic inflammatory disease or cancer; (5) known hypersensitivity to statins; (6) patients judged to be unlikely to comply with the study drug regimen or study process; (7) known infectious disease in the last 30 days; (8) unwilling to provide written informed consent; and (9) cardiogenic shock or acute pulmonary edema</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Atorvastatin 40 mg within 96 hours of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-10 15:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: C-reactive protein levels</P>
<P>
<B>Secondary</B>: lipid profile, acute phase reactants, composite of death, non-fatal MI, and non-fatal stroke, death from any cause, fatal MI, non-fatal MI and unstable angina</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Unspecified. Laboratorio Elea Sacifya provided active drug and placebo</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-07-10 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received dietary counseling to promote compliance with National Cholesterol Education Program (NCEP) diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 14:42:17 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MIRACL-2001">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 122 centers in Europe, North America, South Africa, Australasia</P>
<P>
<B>Patient recruitment</B>: May 1997 to September 1999</P>
<P>
<B>Blinding</B>: patients, caregivers, and outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 4 month</P>
<P>
<B>Lost to follow-up</B>: 9 (0.4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 1538, control 1548</P>
<P>
<B>Mean age (SD) in years</B>: statin 65 (12), control 65 (12)</P>
<P>
<B>Men, n (%)</B>: statin 992 (64%), control 1020 (66%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 342 (22%), control 373 (24%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 843 (55%), control 846 (55%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 429 (28%), control 430 (28%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 382 (25%), control 392 (25%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 812 (53%), control 843 (55%)</LI>
<LI>Unstable angina: statin 726 (47%), control 705 (45%)</LI>
<LI>Fibrinolysis therapy: statin 109 (7%), control 139 (9%)</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: 18 years or older with chest pain or discomfort of at least 15 minutes' duration that occurred at rest or with minimal exertion within the 24-hour period preceding hospitalization and represented a change from their usual anginal pattern</P>
<P>
<B>Exclusion criteria</B>: serum total cholesterol level at screening exceeded 270 mg/dL (7 mmol/L) (sites in Poland and South Africa used levels of 310 mg/dL (8 mmol/L)), coronary revascularization was planned or anticipated at the time of screening, evidence of Q-wave acute MI within the preceding 4 weeks; coronary artery bypass surgery within the preceding 3 months; percutaneous coronary intervention within the preceding 6 months; left bundle-branch block or paced ventricular rhythm; severe congestive heart failure (New York Heart Association class IIIb or IV); concurrent treatment with other lipid-regulating agents (except niacin at doses of 500 mg/d), vitamin E (except at doses #400 IU/d), or drugs associated with rhabdomyolysis in combination with statins; severe anemia; renal failure requiring dialysis; hepatic dysfunction (alanine aminotransferase greater than 2 times ULN); insulin-dependent diabetes; pregnancy or lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-26 11:26:56 +0000" MODIFIED_BY="[Empty name]">
<P>Atorvastatin 80 mg daily, starting at a mean of 3 days after onset of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke</P>
<P>
<B>Secondary</B>: death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), unstable angina requiring emergency hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Grant from Pfizer Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>All participants received instruction and counseling to promote compliance with NCEP step 1 diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-10-26 12:25:36 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 4 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:45:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 14 centers in Japan</P>
<P>
<B>Patient recruitment</B>: May 2000 to December 2003</P>
<P>
<B>Blinding</B>: outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 9 months</P>
<P>
<B>Lost to follow-up</B>: 5 (1%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-10 15:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 176, control 177</P>
<P>
<B>Mean age (SD) in years</B>: statin 64 (10), control 63 (11)</P>
<P>
<B>Men, n (%)</B>: statin 129 (73%), control 142 (80%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 52 (30%), control 59 (34%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 81 (46%), control 87 (49%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 98 (56%), control 105 (59%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 16 (9%), control 19 (10%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: unspecified</LI>
<LI>Unstable angina: unspecified</LI>
<LI>Fibrinolysis therapy: unspecified</LI>
<LI>Percutaneous coronary intervention (PCI): statin 161 (91%), control 161 (91)%</LI>
</UL>
<P>
<B>Inclusion criteria</B>: (1) clinical history of central chest pressure, pain, or tightness lasting for 30 minutes or more, (2) typical electrocardiographic changes (i.e. ST-segment elevation &gt; 0.1 mV in at least 1 standard or 2 precordial leads, ST-segment depression &gt; 0.1 mV in at least 2 leads, abnormal Q wave, or T wave inversion in at least 2 leads), and (3) an increase in the serum creatine kinase activity more than twice the normal laboratory value. All patients presenting within 1 week after the onset of acute MI were registered prospectively</P>
<P>
<B>Exclusion criteria</B>: concurrent therapy with any statins or had a history of side effects associated with any statin. Evidence of life-threatening arrhythmia, severe chronic congestive heart failure (New York Heart Association class III&#8211;IV), hepatic dysfunction, renal failure, cerebrovascular disease, poorly controlled diabetes, pregnancy, lactation, age &lt; 20 years, and unable to take medication or absence of written informed consent. Patients whom the doctors consider inappropriate for any other reason were also not included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:35 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 10 mg initiated on average within 7 days after onset of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-26 13:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: combination of death, non-fatal myocardial infarction, unstable angina, revascularization and non-fatal stroke, and re-hospitalization because of other cardiovascular diseases</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-26 13:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Tokyo, Japan and from Japan Arteriosclerosis Prevention Fund, Tokyo, Japan</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-07-10 15:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received instructions and counseling to promote compliance with the National Cholesterol Education Program (NCEP) Step I diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 15:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:38:05 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 9 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:46:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PACT-2004">
<CHAR_METHODS MODIFIED="2014-06-27 09:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 6 centers in Australia</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: patients and caregivers, but not outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 1 month</P>
<P>
<B>Lost to follow-up</B>: 85 (2%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-10 15:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 1710, control 1698</P>
<P>
<B>Mean age (SD) in years</B>: statin 62 (12), control 61 (12)</P>
<P>
<B>Men, n (%)</B>: statin 1308 (76%), control 1285 (76%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 244 (14%), control 234 (14%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 700 (41%), control 714 (42%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 608 (36%), control 575 (34%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 236 (14%), control 197 (12%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 1109 (65%), control 1111 (65%)</LI>
<LI>Unstable angina: statin 601 (35%), control 587 (35%)</LI>
<LI>Fibrinolysis therapy: statin 651 (38%), control 671 (40%)</LI>
<LI>Percutaneous coronary intervention (PCI): statin 414 (24%), control 406 (24%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: 24 hours of the onset of symptoms if they had electrocardiographic changes suggestive of an acute MI or unstable angina</P>
<P>
<B>Exclusion criteria</B>: taking statin therapy before their event (other lipid-lowering therapies were permitted), participation in any other clinical trial or the taking of an investigational drug within the previous 30 days, planned coronary revascularization or cardiac transplantation, severe renal or hepatic disease or other severe disease, drug- or alcohol-related problems, gastrointestinal disease or a history of gastrointestinal surgery that might affect drug absorption, and known hypersensitivity or previous serious adverse reactions to statin therapy Women of child-bearing potential</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 20 to 40 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, unstable angina requiring emergency hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-08 21:57:13 +0000" MODIFIED_BY="[Empty name]">
<P>Bristol-Myers Squibb, Australia</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-02-26 15:47:22 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-08 21:59:11 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:38:15 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 month; trial stopped early due to recruitment difficulties</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PAIS-2001">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in The Netherlands</P>
<P>
<B>Patient recruitment</B>: April 1997 to- January 1998</P>
<P>
<B>Blinding</B>: patients and caregivers, but not outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 3 months</P>
<P>
<B>Lost to follow-up</B>: 2 (2%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 50, control 49</P>
<P>
<B>Mean age (SD) in years</B>: statin 64 (1), control 63 (2)</P>
<P>
<B>Men, n (%)</B>: statin 35 (70%), control 37 (76%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 8 (16%), control 5 (10%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 12 (24%), control 16 (33%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 17 (34%), control 17 (35%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 14 (28%), control 12 (25%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 35 (70%), control 31 (63%)</LI>
<LI>Unstable angina: statin 15 (30%), control 18 (37%)</LI>
<LI>Fibrinolysis therapy: statin 17 (34%), control 14 (29%)</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: men aged 18 to 80 or postmenopausal women with serum total cholesterol levels &gt; 5.2 mmol/l and LDL cholesterol levels &gt; 3.5 mmol/l; signs of either UA or acute MI (defined as ST segment elevations &#8805; 1 mm in 2 leads or T-wave inversion)</P>
<P>
<B>Exclusion criteria</B>: history of hypersensitivity to statins, severe congestive heart failure, cardiomyopathy, significant liver disease, significant gastrointestinal disease or abdominal surgery that might adversely influence drug absorption, substance or alcohol abuse, history or present use of any other lipid-lowering or investigational agent, uncontrolled diabetes, thyroid disease, severe renal impairment, dysproteinemia, primary muscle disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 40 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), "recurrent angina pectoris"</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-01 14:16:23 +0000" MODIFIED_BY="[Empty name]">
<P>Funded by Bristol-Myers Squibb, Woerden, The Netherlands</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>"Dispensed educational materials on appropriate dietary modification"</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-08 21:19:57 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:38:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRINCESS-2004">
<CHAR_METHODS MODIFIED="2014-06-26 17:16:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 280 centers in 8 countries</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: patients, caregivers, and outcome adjudicators</P>
<P>
<B>Intention-to-treat</B>: yes</P>
<P>
<B>Follow-up period</B>: 4.5 months (44% of the participants completed the 4.5 months of follow-up at trial termination)</P>
<P>
<B>Lost to follow-up</B>: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 1795, control 1810</P>
<P>
<B>Mean age (SD) in years</B>: not available</P>
<P>
<B>Men, n (%)</B>: not available</P>
<P>
<B>Diabetes, n (%)</B>: not available</P>
<P>
<B>Hypertension, n (%)</B>: not available</P>
<P>
<B>Current smoker, n (%)</B>: not available</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: not available</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: not available</LI>
<LI>Unstable angina: not available</LI>
<LI>Fibrinolysis therapy: not available</LI>
<LI>Percutaneous coronary intervention (PCI): not available</LI>
</UL>
<P>
<B>Inclusion criteria</B>: patients with ACS (myocardial infarction or unstable angina), no lower LDL cholesterol limit</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-17 10:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>Cerivastatin 0.4 mg initiated within 2 days of onset of ACS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina or heart failure</P>
<P>
<B>Secondary</B>: recurrent coronary ischemia including ischemic coronary revascularization, fatal and non-fatal reinfarction and unstable angina, all-cause mortality, myocardial infarction, and stroke</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-17 10:54:05 +0000" MODIFIED_BY="[Empty name]">
<P>Funded by Bayer</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-17 10:42:35 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-12-17 10:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo (after 3 months the control group received cerivastatin 0.4 mg)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>The trial was prematurely interrupted on 8 August 2001 when Bayer withdrew cerivastatin from the worldwide market. Outcome data on mortality from any cause, fatal and non-fatal myocardial infarction, and fatal and non-fatal stroke at 4.5 months of follow-up were provided by the original investigators</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PTT-2002">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Turkey</P>
<P>
<B>Patient recruitment</B>: June 1997 to September 1998</P>
<P>
<B>Blinding</B>: none</P>
<P>
<B>Intention-to-treat</B>: unclear</P>
<P>
<B>Follow-up period</B>: 6 months</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 79, control 85</P>
<P>
<B>Mean age (SD) in years</B>: statin 53 (11), control 52 (10)</P>
<P>
<B>Men, n (%)</B>: statin 65 (82%), control 69 (81%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 14 (18%), control 13 (15%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 16 (20%), control 21 (25%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 63 (80%), control 66 (78%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin none, control none</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 79 (100%), control 85 (100%)</LI>
<LI>Unstable angina: none</LI>
<LI>Fibrinolysis therapy: statin 79 (100%), control 85 (100%)</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: patients receiving fibrinolysis therapy within 6 hours of ST-segment elevated acute MI</P>
<P>
<B>Exclusion criteria</B>: contraindications for thrombolytic therapy, age &gt; 75 years, history of myocardial infarction, previous percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, congestive heart failure, secondary hyperlipidemia, uncontrolled hypertension or diabetes mellitus, liver disease, thyroid dysfunction, use of anticoagulant drugs other than aspirin, use of steroids or hormone replacement therapy, women of childbearing potential and patients with physical or psychosocial disorders that could interfere with protocol adherence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 40 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), "recurrent angina pectoris"</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-26 13:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>Not funded</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received fibrinolysis therapy, intravenous nitrates, heparin infusions, a AHA step II diet and a daily 100 mg aspirin</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-03-01 14:21:52 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 6 months. Note: only a subgroup of 77 patients (40 intervention, 37 control, those who received additional coronary angioplasty) were followed up for 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RECIFE-1999">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Canada</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: participants and caregivers, but not outcome assessors</P>
<P>
<B>Intention-to-treat</B>: unclear</P>
<P>
<B>Follow-up period</B>: 6 weeks</P>
<P>
<B>Lost to follow-up</B>: 0 for clinical events</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 30, control 30</P>
<P>
<B>Mean age (SD) in years</B>: statin 55 (2), control 56 (2)</P>
<P>
<B>Men, n (%)</B>: statin 26 (93%), control 22 (81%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 1 (4%), control 0 (0%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 5 (18%), control 8 (29%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 14 (50%), control 17 (63%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 1 (4%), control 2 (7%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 11 (39%), control 12 (44%)</LI>
<LI>Unstable angina: statin 19 (61%), control 18 (66%)</LI>
<LI>Fibrinolysis therapy: none</LI>
<LI>Percutaneous coronary intervention (PCI): statin 16 (57%), control 17 (63%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: diagnosis of acute myocardial infarction or unstable angina and admission total serum cholesterol ?5.2 mmol/L or LDL cholesterol ?3.4 mmol/L and serum triglycerides ?4.5 mmol/L</P>
<P>
<B>Exclusion criteria</B>: presence of heart failure with an ejection fraction of &lt; 40%, administration of lipid-lowering agents in the preceding 8 weeks, renal failure with serum creatinine level &gt; 200 mmol/L, and patients requiring coronary artery bypass surgery, premenopausal women, postmenopausal women on hormone replacement therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:40 +0100" MODIFIED_BY="[Empty name]">
<P>Pravastatin 40 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: brachial artery flow</P>
<P>
<B>Secondary</B>: composite of death, non-fatal MI, and non-fatal stroke, death from any cause, cardiovascular death, fatal MI, non-fatal MI, total stroke, revascularization procedures (CABG/PCI), unstable angina requiring emergency hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-01 14:41:36 +0000" MODIFIED_BY="[Empty name]">
<P>Funded by Bristol-Myers Squibb, Canada</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:39:09 +0100" MODIFIED_BY="[Empty name]">
<P>American Heart Association step 2 diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-01 16:36:55 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:39:11 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1.5 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2009">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in China</P>
<P>
<B>Patient recruitment</B>: March 2004 to July 2006</P>
<P>
<B>Blinding</B>: probable blinding of participants and caregivers; blinding of outcome assessors not reported</P>
<P>
<B>Intention-to-treat</B>: unclear</P>
<P>
<B>Follow-up period</B>: 4 weeks</P>
<P>
<B>Lost to follow-up</B>: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-26 14:33:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 43, control 43</P>
<P>
<B>Mean age (SD) in years</B>: statin 58 (11), control 59 (10)</P>
<P>
<B>Men, n (%)</B>: statin 27 (63%), control 30 (70%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 12 (28%), control 10 (23%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 21 (49%), control 18 (42%)</P>
<P>
<B>Current smoker, n (%)</B>: not available</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 1 (4%), control 2 (7%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: none</LI>
<LI>Unstable angina: statin 43 (100%), control 43 (100%)</LI>
<LI>Fibrinolysis therapy: none</LI>
<LI>Percutaneous coronary intervention (PCI): none</LI>
</UL>
<P>
<B>Inclusion criteria</B>: newly diagnosed unstable angina, age &gt; 18 years, ischemic symptoms &lt; 72 h, absence of cardiogenic shock, and not previously treated with statin</P>
<P>
<B>Exclusion criteria</B>: severe renal dysfunction, primary cardiomyopathy or COPD, taking inflammatory drugs other than aspirin, elevated cardiac markers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:34:35 +0100" MODIFIED_BY="[Empty name]">
<P>Simvastatin 40 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: plasma IL-6</P>
<P>
<B>Secondary</B>: death from any cause, cardiovascular death, fatal MI, non-fatal MI, heart failure, revascularization procedures (CABG/PCI)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-06-26 13:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-02-25 15:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-02-25 15:51:22 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-10 15:24:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakamoto-2005">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: multi-center randomized controlled trial</P>
<P>
<B>Setting</B>: 28 centers in Japan</P>
<P>
<B>Patient recruitment</B>: February 2002 to September 2004</P>
<P>
<B>Blinding</B>: no blinding of participants or caregivers, but blinding of outcome assessors</P>
<P>
<B>Intention-to-treat</B>: unclear</P>
<P>
<B>Follow-up period</B>: 24 months</P>
<P>
<B>Lost to follow-up</B>: 35 (7%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 241, control 245</P>
<P>
<B>Mean age (SD) in years</B>: statin 63 (11), control 65 (12)</P>
<P>
<B>Men, n (%)</B>: statin 190 (80%), control 193 (79%)</P>
<P>
<B>Diabetes, n (%)</B>: statin 83 (35%), control 61 (25%)</P>
<P>
<B>Hypertension, n (%)</B>: statin 149 (63%), control 142 (58%)</P>
<P>
<B>Current smoker, n (%)</B>: statin 131 (55%), control 130 (53%)</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: statin 10 (4%), control 15 (6%)</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: statin 241 (100%), control 245 (100%)</LI>
<LI>Unstable angina: none</LI>
<LI>Fibrinolysis therapy: statin 45 (19%), control 50 (20%)</LI>
<LI>Percutaneous coronary intervention (PCI): statin 215 (91%), control 220 (90%)</LI>
</UL>
<P>
<B>Inclusion criteria</B>: qualifying AMI (increased creatinine phosphokinase-MB and/or total creatinine phosphokinase level &#8805; 2 times the upper limit of normal) and prolonged chest pain (&gt; 30 minutes), objective evidence of myocardial ischemia based on dynamic or interval ST- or T-wave changes in &#8805; 2 contiguous electrocardiographic leads (&#8805; 0.1 mV ST elevation, &#8805; 0.05 mV flat or downsloping ST depression at the J point and 80 ms after the J point, or &#8805; 0.3 mV T-wave inversion), or new left bundle branch block; serum total cholesterol levels were required to be 180 to 240 mg/dL on admission</P>
<P>
<B>Exclusion criteria</B>: &lt; 18 years of age, use of lipid-lowering agents within the previous 3 months,known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (Killip's class III or IV), a scheduled PCI or coronary artery bypass grafting (CABG), previous PCI (within 6 months) or CABG (within 3 months), and the presence of malignant disease or allergy to statins</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Any statin (pravastatin, atorvastatin, &#64258;uvastatin, simvastatin, or pitavastatin)</P>
<P>Note: statin and dose at discretion of treating physician and could be switched or adjusted at any time but prohibited from using any other lipid-lowering agent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-10 15:24:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: combination of cardiovascular death, non-fatal MI, recurrent symptomatic myocardial ischemia with objective evidence that required emergency rehospitalization, congestive heart failure that required emergency rehospitalization, and non-fatal stroke</P>
<P>
<B>Secondary</B>: CABG, PCI for a new lesion, and repeat PCI procedures for restenosis of infarct-related or non-infarct-related lesions</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-01 15:25:50 +0000" MODIFIED_BY="[Empty name]">
<P>Funded by the Japan Heart Foundation and the Ministry of Health, Labour and Welfare, Tokyo, Japan</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-06-26 13:39:40 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received instruction and counseling to promote compliance with the Japan Atherosclerosis Society Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases Step I diet</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 14:35:25 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care excluding statins</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 1 and 24 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shal_x0027_nev-2007">
<CHAR_METHODS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: single-center randomized controlled trial</P>
<P>
<B>Setting</B>: 1 center in Russia</P>
<P>
<B>Patient recruitment</B>: unspecified</P>
<P>
<B>Blinding</B>: none</P>
<P>
<B>Intention-to-treat</B>: unclear</P>
<P>
<B>Follow-up period</B>: 6 months</P>
<P>
<B>Lost to follow-up</B>: 2 (2%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-26 14:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized</B>: statin 55, control 53</P>
<P>
<B>Mean age (SD) in years</B>: not available</P>
<P>
<B>Men, n (%)</B>: not available</P>
<P>
<B>Diabetes, n (%)</B>: not available</P>
<P>
<B>Hypertension, n (%)</B>: not available</P>
<P>
<B>Current smoker, n (%)</B>: not available</P>
<P>
<B>Prior myocardial infarction, n (%)</B>: not available</P>
<P>
<B>Index event, n (%)</B>:</P>
<UL>
<LI>Myocardial infarction: not available</LI>
<LI>Unstable angina: not available</LI>
<LI>Fibrinolysis therapy: not available</LI>
<LI>Percutaneous coronary intervention (PCI): not available</LI>
</UL>
<P>
<B>Inclusion criteria</B>: patients with acute coronary syndrome (myocardial infarction or unstable angina)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-26 13:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>Simvastatin 40 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary</B>: total death, unstable angina (hospitalized and non-hospitalized), MI (acute and in later follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-09 15:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>Unspecified</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-22 14:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>Unspecified</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2009-11-09 15:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>Usual care</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-06-26 13:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data available at 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACE: angiotensin-converting enzyme<BR/>ACS: acute coronary syndrome<BR/>AHA: American Heart Association<BR/>ALT: aminotransferase<BR/>CABG: coronary artery bypass grafting<BR/>COPD: chronic obstructive pulmonary disease</P>
<P>CRP: C-reactive protein<BR/>d: day<BR/>ECG: electrocardiogram<BR/>IL-6: interleukin-6<BR/>LDL: low-density lipoprotein</P>
<P>MACE: major adverse cardiac event<BR/>MI: myocardial infarction</P>
<P>NCEP: National Cholesterol Education Program<BR/>PCI: percutaneous coronary intervention</P>
<P>UA: unstable angina<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akasaka-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 20 mg versus atorvastatin 5 mg); no clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:31:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barderas-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:31:36 +0000" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:37:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bermejo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:37:51 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cannon-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus pravastatin 40 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not initiated within 14 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiodini-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not initiated within 14 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chyrchel-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Only 7 days of statin treatment and follow-up; no clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colivicchi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of high-dose (80 mg/d) versus low-dose (20 mg/d) atorvastatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colivicchi-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:47 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus atorvastatin 20 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colivicchi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus atorvastatin 20 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Correia-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up less than 30 days (only 5 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Winter-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dohi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Extended follow-up of the already included ESTABLISH trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FLAME-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:49 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (simvastatin 20 mg versus simvastatin 40 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Statin versus placebo only for pretreatment of PCI; after PCI both groups received statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guazzi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-G_x00f3_mez_x002d_Doblas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up less than 30 days (only 8 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:30:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-G_x00f3_mez_x002d_Hern_x00e1_ndez-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (simvastatin versus rosuvastatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 40 mg versus atorvastatin 10 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiro-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (pitavastatin versus atorvastatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiro-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (pitavastatin versus atorvastatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiro-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (pitavastatin versus atorvastatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:36:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanadasi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:36:46 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kashima-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Protocol for a head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuznetsova-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin versus rosuvastatin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:33:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lablanche-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:33:14 +0000" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LAVA-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported; fluvastatin 80 mg within 12 hours versus 4 to 5 days following ACS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemos-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not initiated within 14 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leone-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:52 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus atorvastatin 20 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:31:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:31:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up less than 30 days (only 14 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:14:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:32:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Link-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:32:02 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:14:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Link-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:14:50 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:15:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Link-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:15:04 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:52 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus "usual care statin dose")</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miyauchi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (pitavastatin versus atorvastatin); design and rationale paper for Hiro T et al</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:17:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monteiro-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:17:04 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 20:32:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakamura-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 20:32:13 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakaya-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:33:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ordulu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:33:16 +0000" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ostadal-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up less than 30 days (only 1 day)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not given for 30 days (only twice)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PEACE-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:53 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (pravastatin 20 mg versus pravastatin 40 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedersen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data not available per treatment group for the comparison simvastatin 40 mg versus usual care</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedersen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not initiated within 14 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-19 16:17:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pitt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-19 16:17:07 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:18:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pitt-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Post-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Only statin versus placebo for pretreatment of PCI; no clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:38:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakata-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:38:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shah-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statin combinations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:33:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stefanadi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:33:57 +0000" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:19:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:38:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teshima-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-08 14:19:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tousoulis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-08 14:19:29 +0100" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 10:38:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tousoulis-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 10:38:50 +0000" MODIFIED_BY="[Empty name]">
<P>No clinical outcomes assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tousoulis-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment not initiated within 14 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xin_x002d_wei-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>High versus low-dose statin therapy in pre-PCI in ACS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yun-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>Only pre-procedural comparison (rosuvastatin versus no statin); after PCI all patients received rosuvastatin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-26 14:36:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-26 14:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins (atorvastatin 80 mg versus atorvastatin 20 mg)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-25 15:34:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-25 15:34:27 +0000" MODIFIED_BY="[Empty name]">
<P>Head to head comparison of statins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Atorvastatin versus atorvastatin plus probucol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Atorvastatin versus atorvastatin plus probucol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACS: acute coronary syndrome<BR/>PCI: percutaneous coronary intervention</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-06-26 13:44:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:44:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>Computer-generated random list but no explicit specification on blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:05:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>Minimization method of randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:33:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Block randomization - method of sequence generation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:35:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Randomization sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:36:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>Stratified randomization - sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:36:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:40:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Block randomization - sequence generation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>Stratified randomization - sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>Sequence generation unspecified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-17 16:32:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>Block randomization using blinded allocation tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-26 13:39:48 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-11 09:49:09 +0100" MODIFIED_BY="Joey Kwong" RESULT="UNKNOWN" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Adequate. Coded medication containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>Central randomization stratified by study center</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>Adequate. Central randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:15:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>No blinding of participants or caregivers but outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:15:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Reported blinding of participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Reported blinding of participants, caregivers, and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:16:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>Reported blinding of participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Blinded patients, caregivers, and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:16:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>Reported blinding of participants, caregivers, and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Blinded participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>No blinding of participants or caregivers, but blinded outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:16:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>Reported blinding of participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>Reported blinding of participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>Blinded patients, caregivers, and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or clinical outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Reported blinding of participants and caregivers, but not outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Blinding of participants and caregivers probable; blinding of clinical outcome assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:17:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>No blinding of participants or caregivers, but blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>No blinding of participants, caregivers, or outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-26 17:15:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>Blinded patients, caregivers, and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:35:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>Complete follow-up of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>1 patient was lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Complete follow-up of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Complete patient follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>Complete patient follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>It remains unclear how many patients were lost to follow-up for clinical events; 14 patients (20%) were not available for a follow-up lipid profile</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Complete patient follow-up within first 12 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:37:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>0.4% of patients lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Complete patient follow-up for clinical events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:38:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>1% of participants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:38:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>2% of participants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>2% of patients lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:38:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>No full publication available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>Complete follow-up for clinical outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Complete follow-up for clinical events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Complete follow-up for clinical events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>"Follow-up information was sought for all patients who were withdrawn early from the study." 35 patients (7%) dropped out (unclear if followed up or not)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>2% of participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-26 13:36:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>1% of patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-26 13:39:50 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:35:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided; study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>Author contact failed; no protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided; study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>Author contact partially established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>Author contact failed; no study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>Author contact failed; no study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>Author contact established; data on relevant outcomes provided; study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:35:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colivicchi-2002">
<DESCRIPTION>
<P>Stopped early for benefit after 5th interim analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ESTABLISH-2004">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FACS-2010">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-27 08:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FLORIDA-2002">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x002d_CAD-2000">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; no stopping early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-LAMIL-1997">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LIPS-2002">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MIRACL-2001">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:37:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Macin-2005">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-OACIS_x002d_LIPID-2008">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PACT-2004">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PAIS-2001">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PRINCESS-2004">
<DESCRIPTION>
<P>Adherence to intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PTT-2002">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RECIFE-1999">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2009">
<DESCRIPTION>
<P>Adherence to the intention-to-treat principle not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sakamoto-2005">
<DESCRIPTION>
<P>Adherence to intention-to-treat not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:39:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shal_x0027_nev-2007">
<DESCRIPTION>
<P>Adherence to intention-to-treat not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-26 13:36:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Lemos-2004">
<DESCRIPTION>
<P>Adhered to the intention-to-treat principle; not stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-06-27 09:45:34 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-06-27 09:45:34 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-06-26 14:41:08 +0100" MODIFIED_BY="[Empty name]">Statins compared to control at 4 months (3 to 6 months) for acute coronary syndrome</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Statins compared to control at 4 months (3 to 6 months) for acute coronary syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population</B>: patients with acute coronary syndrome<BR/>
<B>Settings</B>: inpatients, developed countries<BR/>
<B>Intervention</B>: statins<BR/>
<B>Comparison</B>: control at 4 months (3 to 6 months)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control at 4 months (3 to 6 months)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Statins</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(65 to 85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.81 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>9625<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death from all causes</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(20 to 32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.9 </B>
<BR/>(0.7 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>9733<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Fatal and non-fatal myocardial infarction or reinfarction</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
<BR/>(50 to 69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.77 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>9537<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Fatal and non-fatal stroke</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(4 to 11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.45 to 1.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>8536<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Unstable angina</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>63 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
<BR/>(37 to 60)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.59 to 0.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>8770<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acute heart failure</B>
<BR/>Follow-up: mean 4 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(17 to 30)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.65 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>7583<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Rhabdomyolysis</B>
<BR/>Follow-up: mean 4 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 6.9 </B>
<BR/>(0.36 to 133.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4497<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The basis of the assumed risk is the average risk of control group patients.<BR/>
<SUP>2</SUP>The largest studies had allocation concealment and used blinding for patients, caregivers, and outcome assessors; however for many studies allocation concealment remained unclear and almost half were open-label. Sensitivity analyses with high quality studies did not change the point estimate.<BR/>
<SUP>3</SUP>The CI includes effects suggesting benefit as well as no benefit, therefore we decided to downgrade by one level when considering this imprecision together with some concerns about risk of bias.<BR/>
<SUP>4</SUP>There is moderate heterogeneity among studies included in the analysis of unstable angina at four months (I² = 33%). The subgroup analysis for trials with blinded outcome assessment (because of possible subjective component for diagnosis of unstable angina) was still statistically significant, but the estimated risk reduction was smaller. Overall we decided to downgrade by one level when considering the heterogeneity and remaining concerns about the risk of bias.<BR/>
<SUP>5</SUP>The CI includes the possibility of both harms or benefits and there are only three events of rhabdomyolysis in total; therefore we decided to downgrade by two levels for imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-07-10 16:12:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-07-10 15:59:54 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary intervention; NA, not available. See Table 1 footnote for expansions of trial names.&lt;/p&gt;&lt;p&gt;* These 824 individuals are the subgroup of patients with unstable angina in the LIPS [Lescol Intervention Prevention Study]-trial&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 15:59:54 +0100" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-06-29 03:41:41 +0100" MODIFIED_BY="Joey Kwong">Baseline characteristics of included patients</TITLE>
<TABLE COLS="21" ROWS="20">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Trial (reference)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Randomized individuals, n</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Mean age, years (SD)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Men, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Diabetes, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Hypertension, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Current smoker, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Prior MI, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>MI as index event, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Fibrinolysis for index event, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>PCI for index event, n (%)</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LAMIL 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RECIFE 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 (93)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (81)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (29)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (39)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (44)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (57)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (63)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-CAD 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>57 (81)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44 (79)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (32)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49 (70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (64)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 (64)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32 (46)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58 (83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50 (89)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PAIS 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37 (76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (16)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (33)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (34)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (35)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (34)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (29)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PTT 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (82)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69 (81)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13 (15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66 (78)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PACT 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1710</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1698</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1308 (76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1285 (76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>244 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>234 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>700 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>714 (42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>608 (36)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>575 (34)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>236 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>197 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1109 (65)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1111 (65)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>651 (38)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>671 (40)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>414 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>406 (24)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LIPS 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>417*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>407*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>344 (83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>336 (83)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (16)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 (8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>184 (44)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>172 (42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>417 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>407 (100)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLORIDA 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>265</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>275</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>214 (81)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>234 (85)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>140 (53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>139 (51)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>265 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>275 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>137 (52)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>133 (48)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MIRACL 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1538</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1548</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>992 (64)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1020 (66)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>342 (22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>373 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>843 (55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>846 (55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>429 (28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>430 (28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>382 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>392 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>812 (53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>843 (55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>109 (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>137 (9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Colivicchi 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 (58)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (88)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37 (90)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 (85)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (85)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ESTABLISH 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (34)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (69)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 (74)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 (100)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A-to-Z 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2265</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2232</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1716 (76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1680 (75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>529 (23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>530 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1131 (50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1105 (50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>926 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>915 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>409 (18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>355 (16)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1956 (86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1919 (86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>483 (21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>472 (21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>979 (43)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>979 (44)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakamoto 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>237</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>244</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>190 (80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>193 (79)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>83 (35)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>149 (63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>142 (58)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>131 (55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130 (53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15 (6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>208 (88)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>219 (90)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 (19)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50 (20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>215 (91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>220 (90)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Macin 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59 (13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 (77)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33 (72)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 (65.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (67.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 (52)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (67)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (15.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (17.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sato 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>176</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>177</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>129 (73)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>142 (80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52 (30)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59 (34)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81 (46)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>87 (49)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>98 (56)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105 (59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>161 (91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>161 (91)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Shal'nev 2007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACS 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (71)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51 (65)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (51)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (51)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33 (42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; 47 (60)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; 54 (69)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68 (87)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71 (91)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ren 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58 (11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59 (10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (63)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (49)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* These individuals make up the subgroup of patients with unstable angina (n=824).</P>
<P>MI: myocardial infarction<BR/>NA: not applicable<BR/>PCI: percutaneous coronary intervention<BR/>SD: standard deviation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-07-10 16:03:12 +0100" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;Abbreviations: ACS, acute coronary syndrome; LAMIL, Lipid Acute Myocardial Infarction Lowering; RECIFE, REduction of Cholesterol in Ischemia and Function of the Endothelium; L-CAD, Lipid-Coronary Artery Disease; PAIS, Pravastatin in Acute Ischemic Syndromes; PTT, Pravastatin Turkish Trial; PACT, Pravastatin in Acute Coronary Treatment; LIPS, Lescol Intervention Prevention Study; FLORIDA, FLuvastatin On RIsk Diminishment after Acute myocardial infarction; MIRACL, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering.&lt;/p&gt;&lt;p&gt;* 8 of 70 individuals received additionally cholestyramine or nicotinic acid.&lt;/p&gt;&lt;p&gt;&amp;#134; Individuals in the control group were allowed conventional medical treatment including lipid-lowering therapy.&lt;/p&gt;&lt;p&gt;&amp;#135; All 164 individuals were followed-up for 1 month, a subgroup of 77 (40/37) individuals with additional coronary angioplasty were followed-up for 6 months.&lt;/p&gt;&lt;p&gt;&amp;#167; These 824 individuals represent just the subgroup with unstable angina; the LIPS [Lescol Intervention Prevention Study]-trial originally included another 853 individuals with stable angina.&lt;/p&gt;&lt;p&gt;|| After 4 months individuals in the control group received simvastatin 20mg.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:03:12 +0100" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-06-26 15:41:59 +0100" MODIFIED_BY="[Empty name]">General characteristics of included trials</TITLE>
<TABLE COLS="8" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Source</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Daily<BR/>intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. of<BR/>individuals<BR/>randomized</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Mean initiation<BR/>of statin<BR/>after onset<BR/>of ACS, days</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Duration of<BR/>follow-up<BR/>available, months</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. (%) of<BR/>individuals<BR/>followed up</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Reported concealed<BR/>allocation/masked<BR/>patients/caregiver/<BR/>assessor</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LAMIL 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>10 to 20 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (80)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RECIFE 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (92)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-CAD 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>20 to 40 mg*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 4, and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/no/no/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PAIS 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>99</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97 (98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PTT 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>164&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 6&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>164 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/no/no/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PACT 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin</P>
<P>20 to 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3408</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3323 (98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LIPS 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin</P>
<P>80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>824§</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 4, and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>824 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLORIDA 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin</P>
<P>80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>540</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 4, and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>540 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/yes/yes/yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MIRACL 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin</P>
<P>80 mg    </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3086</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3075 (99.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes/yes/yes/yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Colivicchi 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin</P>
<P>80 mg    </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 3, and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/no/no/yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ESTABLISH 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin</P>
<P>20 mg    </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 4, and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69 (99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/no/no/no</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A-to-Z 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin</P>
<P>40 to 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4497</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 4||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4453 (99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes/yes/yes/yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakamoto 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any statin**</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>486</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>407 (84)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/No/No/Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Macin 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>90</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89 (99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/Yes/Yes/No</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sato 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 10 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>353</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>348 (99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/No/No/Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Shal'nev 2007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>110</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>108 (98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/No/No/No</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACS 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1, 3, and 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/Yes/Yes/No</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ren 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>86</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>86 (100)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No/Yes/Yes/Yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* 8 of 70 individuals received additionally cholestyramine or nicotinic acid.</P>
<P>&#8224; Individuals in the control group were allowed conventional medical treatment including lipid-lowering therapy.</P>
<P>&#8225; All 164 individuals were followed-up for 1 month, a subgroup of 77 (40/37) individuals with additional coronary angioplasty were followed-up for 6 months.</P>
<P>§ These 824 individuals represent just the subgroup with unstable angina; the LIPS [Lescol Intervention Prevention Study]-trial originally included another 853 individuals with stable angina.</P>
<P>|| After 4 months individuals in the control group received simvastatin 20mg.</P>
<P>ACS: acute coronary syndrome</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2014-07-10 16:06:40 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;Abbreviations: NA, not available; LDL, low density lipoprotein; HDL, high density lipoprotein. See Table 1 footnote for expansions of trial names.&lt;/p&gt;&lt;p&gt;* Lipid values in individual trials were measured at different time points during follow-up; we report those closest to the 4 months follow-up date.&lt;/p&gt;&lt;p&gt;** Baseline lipid levels were defined as the average (mean) before treatment in intervention and control groups. The percentage of change for each trial was calculated as the difference in the mean change in lipid levels from baseline to follow-up in the intervention and the control groups. To convert from mg/dL to mmol/L, multiply by 0.02586 for cholesterol and by 0.01129 for triglycerides.&lt;/p&gt;&lt;p&gt;&amp;#8225; Individuals in the control group were allowed conventional medical treatment including lipid-lowering therapy.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:06:40 +0100" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-06-29 03:41:50 +0100" MODIFIED_BY="Joey Kwong">Lipid values at baseline and changes during follow-up</TITLE>
<TABLE COLS="7" ROWS="20">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Trial (reference)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intervention</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Follow-up*</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Total cholesterol</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>LDL cholesterol</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>HDL cholesterol</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Triglycerides</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" COLSPAN="4" VALIGN="BOTTOM">
<P>Baseline mean, mg/dL</P>
<P>(% mean change in difference between treatment and control groups)&#8224;</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LAMIL 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 10 to 20 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>228 (-13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>158 (-23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (+5.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RECIFE 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.5 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>247 (-21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>164 (-27)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42 (+13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>194 (-21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-CAD 2000&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 20 to 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>237 (-24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>178 (-25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32 (-6.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>142 (±0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PAIS 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>255 (-23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>176 (-24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43 (+9.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>199 (-13)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PTT 2002&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>230 (-12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>133 (-25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (+3.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>214 (-5.8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PACT 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 20 to 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>219 (NA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LIPS 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.5 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>201 (-28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>131 (-39)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (-2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>155 (-21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLORIDA 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>207 (-22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>137 (-31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 (+3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>146 (-22)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MIRACL 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.5 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>206 (-37)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>124 (-53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47 (±0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>183 (-28)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Colivicchi 2002&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>220 (-9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>131 (-15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (+1.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>167 (-13)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ESTABLISH 2004&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin 20 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191 (-28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>124 (-41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44 (-8.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>109 (+4.9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A-to-Z 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin 40 to 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>184 (-33)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>112 (-49)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (+2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>149 (-22)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakamoto 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any statin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>207 (-12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>134 (-23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47 (+2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>135 (-5.2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Macin 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Atorvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>194 (-19)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>124 (-30)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37 (+11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>189 (+0.8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sato 2008&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pravastatin 10 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>220 (NA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49 (NA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>117 (NA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>148 (NA)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Shal'nev 2007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>212 (-29)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>131 (-46)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49 (-9.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>146 (-15)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACS 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluvastatin 80 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>212 (-26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>135 (-31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47 (-4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>162 (+10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ren 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simvastatin 40 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>228 (-23%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>139 (-31)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (+9.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Lipid values in individual trials were measured at different time points during follow-up; we report those closest to the 4 months follow-up date.</P>
<P>&#8224; Baseline lipid levels were defined as the average (mean) before treatment in intervention and control groups. The percentage of change for each trial was calculated as the difference in the mean change in lipid levels from baseline to follow-up in the intervention and the control groups. To convert from mg/dL to mmol/L, multiply by 0.02586 for cholesterol and by 0.01129 for triglycerides.</P>
<P>&#8225; Individuals in the control group were allowed conventional medical treatment including lipid-lowering therapy.</P>
<P>HDL: high-density lipoprotein<BR/>LDL: low-density lipoprotein<BR/>NA: not applicable</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2014-07-10 16:12:37 +0100" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;Abbreviations: MI, myocardial infarction; CABG, coronary artery bypass grafts; PCI, percutaneous coronary interventions; NA, not available. See Table 1 footnote for expansions of trial names.&lt;/p&gt;&lt;p&gt;* Combined primary endpoint; unique patients.&lt;/p&gt;&lt;p&gt;&amp;#8224; Patients with &amp;#8220;recurrent angina pectoris&amp;#8221;.&lt;/p&gt;&lt;p&gt;&amp;#8225; All 164 individuals were followed-up for 1 month, a subgroup of 77 individuals with additional coronary angioplasty were followed-up for 6 months.&lt;/p&gt;&lt;p&gt;&amp;#167; These 824 individuals represent just the subgroup with unstable angina; the LIPS [Lescol Intervention Prevention Study]-trial originally included another 853 individuals with stable angina.&lt;/p&gt;&lt;p&gt;|| Fatal strokes only; non-fatal strokes were not recorded.&lt;/p&gt;&lt;p&gt;&amp;#182; Patients with &amp;#8220;recurrent ischemia necessitating hospitalization&amp;#8221;.&lt;/p&gt;&lt;p&gt;# Patients with &amp;#8220;recurrent symptomatic myocardial ischemia with objective evidence and emergency hospitalization&amp;#8221;.&lt;/p&gt;&lt;p&gt;** Individuals enrolled into the trial were not amenable for direct revascularization by coronary artery bypass grafting or percutaneous coronary intervention.&lt;/p&gt;&lt;p&gt;&amp;#8224;&amp;#8224; Revascularization procedures had to be urgent, occur more than 14 days after randomization, and were not allowed to be planned prior to enrollment.&lt;/p&gt;&lt;p&gt;&amp;#8225;&amp;#8225; Patients with &amp;#8220;readmission for acute coronary syndrome&amp;#8221;.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&amp;#167;&amp;#167; Patients with &amp;#8220;new onset congestive heart failure requiring admission or initiation of heart failure medications&amp;#8221;.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:12:37 +0100" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-06-26 15:53:18 +0100" MODIFIED_BY="[Empty name]">Clinical endpoints in trials of early statin therapy versus control in acute coronary syndromes</TITLE>
<TABLE COLS="25" ROWS="41">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Trial (reference)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Total death, MI, stroke, n (%) *</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Total death, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Cardiovascular death, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>Total MI, n (%)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Total stroke, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Revascularization (CABG/PCI), n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Unstable angina, n (%)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM">
<P>Adverse events, n (%)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>Acute heart failure</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="BOTTOM">
<P>QOL</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Rhabdomyolysis</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>CK &gt; 10x ULN</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>ALT &gt; 3x ULN</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statin</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LAMIL 1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (8.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (9.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (8.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (9.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (3.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RECIFE 1999</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-CAD 2000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (3.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (16.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (8.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (21.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (8.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (17.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PAIS 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (6.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (8.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (32.0) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (22.4) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (8.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (8.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (8.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (22.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (18.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (48.0) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (42.9) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PTT 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (16.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (10.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (8.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (5.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (8.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (15.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15 (17.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (13.9) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25 (29.4) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (18.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (8.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (8.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (16.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (27.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (43.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (30.0) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (59.4) &#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PACT 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>86 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96 (5.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 (1.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 (2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67 (3.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70 (4.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (0.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>123 (7.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126 (7.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (0.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (1.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LIPS 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>77 (18.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>87 (21.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78 (18.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88 (21.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (1.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) ||</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>79 (18.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88 (21.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLORIDA 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (1.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (6.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (4.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.3) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (1.8) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (3.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (3.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (11.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32 (11.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (4.2) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (3.3) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (5.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (4.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (3.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (13.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41 (14.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (5.3) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 (5.1) ¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 (10.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 (10.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (7.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (5.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (1.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 (17.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51 (18.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (6.0)¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (6.5)¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MIRACL 2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101 (6.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96 (6.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32 (2.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (1.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21 (1.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80 (5.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67 (4.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (0.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>162 (10.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>147 (9.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 (4.7) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>87 (5.6) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>162 (10.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>183 (11.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64 (4.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68 (4.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51 (3.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (3.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>118 (7.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>131 (8.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>254 (16.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>250 (16.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>95 (6.2) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130 (8.4) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Colivicchi 2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.4) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)##</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (12.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (22.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (17.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (5.0) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.3) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)##</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (17.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13 (31.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (7.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (9.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (9.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (12.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (24.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (4.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0) **</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (5.0) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (14.6) #</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.5)##</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ESTABLISH 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (22.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (22.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A-to-Z 2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>99 (4.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105 (4.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 (0.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 (0.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>86 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>98 (4.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (0.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (0.8) &#8224;&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (1.0) &#8224;&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (1.2) &#8225;&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (1.3) &#8225;&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.04)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.04)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 (1.2)§§</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 (1.4)§§</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>161 (7.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>160 (7.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42 (1.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130 (5.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>140 (6.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (0.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (0.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (2.6) &#8224;&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (2.7) &#8224;&#8224;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56 (2.5) &#8225;&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 (2.7) &#8225;&#8225;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (0.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (0.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.04)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13 (5.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 (2.0)§§</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (2.5)§§</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>98 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sakamoto 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (7.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 (9.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (2.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 (6.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 (3.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Macin 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (6.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (10.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (6.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (6.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (6.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (18.2)¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (17.4)¶</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (1.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (9.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (21.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sato 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (4.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (0.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (12.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (20.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (2.9)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (2.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Shal'nev 2007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (3.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (5.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (7.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 (12.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACS 2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (7.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 (10.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 (15.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 (12.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (5.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 (2.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 (6.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (7.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15 (19.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 (7.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16 (20.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ren 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (2.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Combined primary endpoint; unique patients.</P>
<P>&#8224; Patients with &#8220;recurrent angina pectoris&#8221;.</P>
<P>&#8225; All 164 individuals were followed-up for 1 month, a subgroup of 77 individuals with additional coronary angioplasty were followed-up for 6 months.</P>
<P>§ These 824 individuals represent just the subgroup with unstable angina; the LIPS [Lescol Intervention Prevention Study]-trial originally included another 853 individuals with stable angina.</P>
<P>|| Fatal strokes only; non-fatal strokes were not recorded.</P>
<P>¶ Patients with &#8220;recurrent ischemia necessitating hospitalization&#8221;.</P>
<P># Patients with &#8220;recurrent symptomatic myocardial ischemia with objective evidence and emergency hospitalization&#8221;.</P>
<P>** Individuals enrolled into the trial were not amenable for direct revascularization by coronary artery bypass grafting or percutaneous coronary intervention.</P>
<P>&#8224;&#8224; Revascularization procedures had to be urgent, occur more than 14 days after randomization, and were not allowed to be planned prior to enrollment.</P>
<P>&#8225;&#8225; Patients with &#8220;readmission for acute coronary syndrome&#8221;.</P>
<P>§§ Patients with &#8220;new onset congestive heart failure requiring admission or initiation of heart failure medications&#8221;.</P>
<P>ALT: aminotransferase<BR/>CABG: coronary artery bypass grafting</P>
<P>CK: creatin kinase<BR/>MI: myocardial infarction<BR/>NA: not applicable<BR/>PCI: percutaneous coronary intervention<BR/>QOL: quality of life</P>
<P>ULN: upper limit of normal values<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-07-10 16:45:48 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-07-10 16:28:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Statins versus control at 1 month</NAME>
<DICH_OUTCOME CHI2="9.428485866998036" CI_END="1.0804631440421568" CI_START="0.7969043635710611" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9279147558719512" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="331" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03360995714048953" LOG_CI_START="-0.09859379512274062" LOG_EFFECT_SIZE="-0.03249191899112554" METHOD="IV" MODIFIED="2014-07-10 16:25:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6659616728024197" P_Q="1.0" P_Z="0.3353434723662887" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6762" TOTAL_2="6722" WEIGHT="100.00000000000003" Z="0.9634067100364935">
<NAME>Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.745504920919437" CI_START="0.007800322538545951" EFFECT_SIZE="0.14634146341463414" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4386222264559737" LOG_CI_START="-2.1078874391281572" LOG_EFFECT_SIZE="-0.8346326063360919" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="1.495832382990261" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.237514518002323" WEIGHT="0.26952366616003437"/>
<DICH_DATA CI_END="0.8945683125246789" CI_START="0.10564138094045955" EFFECT_SIZE="0.3074141048824593" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.04838648950721212" LOG_CI_START="-0.9761659303456366" LOG_EFFECT_SIZE="-0.5122762099264243" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.5449822361307909" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.29700563769811716" WEIGHT="2.0304769991984273"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-RECIFE-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.231755660272648"/>
<DICH_DATA CI_END="8.173197916704522" CI_START="0.013748614878411313" EFFECT_SIZE="0.3352165725047081" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.912392015631383" LOG_CI_START="-1.8617410531765335" LOG_EFFECT_SIZE="-0.4746745187725751" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.6295394967979304" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.6553989716244524" WEIGHT="0.22710828859339421"/>
<DICH_DATA CI_END="2.7117572548397275" CI_START="0.1007626332206649" EFFECT_SIZE="0.5227272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43325081071051913" LOG_CI_START="-0.9967004916477082" LOG_EFFECT_SIZE="-0.2817248404685946" MODIFIED="2009-12-16 11:11:11 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.8399604733783279" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="0.7055335968379447" WEIGHT="0.8547617274090024"/>
<DICH_DATA CI_END="3.7419560841068282" CI_START="0.11406987010279905" EFFECT_SIZE="0.6533333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5730986862794402" LOG_CI_START="-0.9428290530058129" LOG_EFFECT_SIZE="-0.18486518336318639" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.8904634580194895" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.7929251700680271" WEIGHT="0.7605548906040529"/>
<DICH_DATA CI_END="1.1807004478222947" CI_START="0.6701898705284302" EFFECT_SIZE="0.889546783625731" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="96" LOG_CI_END="0.07213972796127366" LOG_CI_START="-0.17380214052171492" LOG_EFFECT_SIZE="-0.05083120628022064" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.14446747097879098" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.020870850171007815" WEIGHT="28.894995222380416"/>
<DICH_DATA CI_END="1.2150152269526056" CI_START="0.710496655955772" EFFECT_SIZE="0.929120151371807" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="105" LOG_CI_END="0.08458172068334716" LOG_CI_START="-0.14843796179474247" LOG_EFFECT_SIZE="-0.03192812055569768" MODIFIED="2009-11-22 15:15:56 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.13687691495366097" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.018735289847231742" WEIGHT="32.18861949271603"/>
<DICH_DATA CI_END="6.9217807275946726" CI_START="0.14447149358738806" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8402178373296765" LOG_CI_START="-0.8402178373296765" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.9870962335856491" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.9743589743589745" WEIGHT="0.6189331979777168"/>
<DICH_DATA CI_END="3.543433034101941" CI_START="0.30391309276997863" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5494242296205172" LOG_CI_START="-0.5172505898336076" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.6265700690728659" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.392590051457976" WEIGHT="1.5361141061488206"/>
<DICH_DATA CI_END="1.3875896776078802" CI_START="0.8081062446958313" EFFECT_SIZE="1.0589239271781534" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="96" LOG_CI_END="0.14226106043017486" LOG_CI_START="-0.09253153718110343" LOG_EFFECT_SIZE="0.024864761624535707" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.13791833407896745" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01902146687511767" WEIGHT="31.704343305256142"/>
<DICH_DATA CI_END="58.00645065177381" CI_START="0.09999982294221291" EFFECT_SIZE="2.408450704225352" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7634762922990368" LOG_CI_START="-1.0000007689528798" LOG_EFFECT_SIZE="0.38173776167307855" MODIFIED="2009-11-22 15:24:16 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="1.623280105211448" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="2.63503829997529" WEIGHT="0.22886313112941983"/>
<DICH_DATA CI_END="28.03311541712967" CI_START="0.305835470361058" EFFECT_SIZE="2.9280575539568345" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4476713650911175" LOG_CI_START="-0.5145121471488675" LOG_EFFECT_SIZE="0.46657960897112494" MODIFIED="2009-11-22 15:24:23 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="1.1525963080548014" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="1.3284782493415586" WEIGHT="0.45395031215391596"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.191633589407266" CI_END="1.0265875621692409" CI_START="0.5939705046272256" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7808730577665599" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.011395998173343172" LOG_CI_START="-0.22623512066810558" LOG_EFFECT_SIZE="-0.10741956124738124" METHOD="IV" MODIFIED="2014-07-10 16:25:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6864811725278671" P_Q="1.0" P_Z="0.07639832949245344" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6592" TOTAL_2="6563" WEIGHT="99.99999999999997" Z="1.7719772755893661">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.141999536245619" CI_START="0.01432047042186095" EFFECT_SIZE="0.34146341463414637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9107310733067098" LOG_CI_START="-1.8440427153897048" LOG_EFFECT_SIZE="-0.46665582104149744" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="0.7441058886835576"/>
<DICH_DATA CI_END="1.1977372976043639" CI_START="0.3856154177678797" EFFECT_SIZE="0.67960721625942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="0.07836157371963472" LOG_CI_START="-0.41384561035620354" LOG_EFFECT_SIZE="-0.1677420183182844" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.2891249363910034" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.08359322884310177" WEIGHT="23.308306974147406"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-11-22 15:27:33 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.7376593345110786"/>
<DICH_DATA CI_END="3.30455871971681" CI_START="0.036209093886369774" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5191134733867832" LOG_CI_START="-1.4411823430391983" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="1.1514874661894108" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="1.3259233847913092" WEIGHT="1.469479052246926"/>
<DICH_DATA CI_END="58.00645065177381" CI_START="0.09999982294221291" EFFECT_SIZE="2.408450704225352" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7634762922990368" LOG_CI_START="-1.0000007689528798" LOG_EFFECT_SIZE="0.38173776167307855" MODIFIED="2009-11-22 15:27:18 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.623280105211448" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="2.63503829997529" WEIGHT="0.7394263069547947"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2009-11-22 15:27:33 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.7464546132335732"/>
<DICH_DATA CI_END="3.22506396074258" CI_START="0.03765559105238507" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5085383321564366" LOG_CI_START="-1.4241705312049882" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2009-12-17 14:38:16 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.1352827534016703" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="1.2888669301712778" WEIGHT="1.511728319832245"/>
<DICH_DATA CI_END="1.7578409316180683" CI_START="0.6557029175897114" EFFECT_SIZE="1.0736020806241873" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.24497957287308345" LOG_CI_START="-0.18329288390967327" LOG_EFFECT_SIZE="0.0308433444817051" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.25156936109704303" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.06328714344277442" WEIGHT="30.786926583232013"/>
<DICH_DATA CI_END="8.173197916704522" CI_START="0.013748614878411313" EFFECT_SIZE="0.3352165725047081" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.912392015631383" LOG_CI_START="-1.8617410531765335" LOG_EFFECT_SIZE="-0.4746745187725751" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.6295394967979304" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.6553989716244524" WEIGHT="0.7337566443520978"/>
<DICH_DATA CI_END="1.1177361507902306" CI_START="0.4228069989565423" EFFECT_SIZE="0.6874493927125506" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" LOG_CI_END="0.04833929748648558" LOG_CI_START="-0.37385783218994934" LOG_EFFECT_SIZE="-0.16275926735173188" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.24800068388143537" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.06150433920565964" WEIGHT="31.679336189923255"/>
<DICH_DATA CI_END="5.230738882847126" CI_START="0.04590173690132892" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7185630406986137" LOG_CI_START="-1.3381708806415866" LOG_EFFECT_SIZE="-0.3098039199714863" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="1.2081356863923414" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="1.4595918367346938" WEIGHT="1.334905135667272"/>
<DICH_DATA CI_END="1.2773983602220056" CI_START="0.10069659957021976" EFFECT_SIZE="0.35864978902953587" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.10632635432471271" LOG_CI_START="-0.9969851949163349" LOG_EFFECT_SIZE="-0.44532942029581113" MODIFIED="2009-11-22 15:27:58 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.6480906655044417" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.4200215107139902" WEIGHT="4.63884965206443"/>
<DICH_DATA CI_END="36.11959108747166" CI_START="0.45779942329677187" EFFECT_SIZE="4.066390041493776" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.557742824989755" LOG_CI_START="-0.3393247587545022" LOG_EFFECT_SIZE="0.6092090331176264" MODIFIED="2010-03-09 11:09:15 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.1143468893273665" STUDY_ID="STD-Sakamoto-2005" TOTAL_1="241" TOTAL_2="245" VAR="1.2417689897535777" WEIGHT="1.5690653051513406"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.184418268631846" CI_END="1.0737515365153552" CI_START="0.5967126334621354" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.800450565018285" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.03090379830580643" LOG_CI_START="-0.2242347672760438" LOG_EFFECT_SIZE="-0.09666548448511872" METHOD="IV" MODIFIED="2014-07-10 16:26:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.721328537720954" P_Q="1.0" P_Z="0.1375012954794619" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6203" TOTAL_2="6184" WEIGHT="100.0" Z="1.4851605652550215">
<NAME>Death from cardiovascular causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.141999536245619" CI_START="0.01432047042186095" EFFECT_SIZE="0.34146341463414637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9107310733067098" LOG_CI_START="-1.8440427153897048" LOG_EFFECT_SIZE="-0.46665582104149744" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="0.8577887279056345"/>
<DICH_DATA CI_END="1.1977372976043639" CI_START="0.3856154177678797" EFFECT_SIZE="0.67960721625942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="0.07836157371963472" LOG_CI_START="-0.41384561035620354" LOG_EFFECT_SIZE="-0.1677420183182844" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.2891249363910034" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.08359322884310177" WEIGHT="26.869298164485453"/>
<DICH_DATA CI_END="3.30455871971681" CI_START="0.036209093886369774" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5191134733867832" LOG_CI_START="-1.4411823430391983" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="1.1514874661894108" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="1.3259233847913092" WEIGHT="1.6939827866984076"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2009-11-22 15:29:43 +0000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.8604962853576027"/>
<DICH_DATA CI_END="3.22506396074258" CI_START="0.03765559105238507" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5085383321564366" LOG_CI_START="-1.4241705312049882" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="1.1352827534016703" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="1.2888669301712778" WEIGHT="1.7426868032209373"/>
<DICH_DATA CI_END="2.2788669366500294" CI_START="0.7348508708911416" EFFECT_SIZE="1.2940739364666543" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.3577189674069015" LOG_CI_START="-0.13380078679384236" LOG_EFFECT_SIZE="0.11195909030652959" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.2887211366795402" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.08335989476552574" WEIGHT="26.94450846699316"/>
<DICH_DATA CI_END="8.173197916704522" CI_START="0.013748614878411313" EFFECT_SIZE="0.3352165725047081" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.912392015631383" LOG_CI_START="-1.8617410531765335" LOG_EFFECT_SIZE="-0.4746745187725751" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="1.6295394967979304" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.6553989716244524" WEIGHT="0.8458583490914401"/>
<DICH_DATA CI_END="1.2597070072583931" CI_START="0.45772271753343585" EFFECT_SIZE="0.7593395252837978" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.10026954517501044" LOG_CI_START="-0.3393975322863247" LOG_EFFECT_SIZE="-0.1195639935556571" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.258262617687922" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.06669957969501779" WEIGHT="33.674745786818534"/>
<DICH_DATA CI_END="5.230738882847126" CI_START="0.04590173690132892" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7185630406986137" LOG_CI_START="-1.3381708806415866" LOG_EFFECT_SIZE="-0.3098039199714863" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.2081356863923414" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="1.4595918367346938" WEIGHT="1.5388489670798517"/>
<DICH_DATA CI_END="1.721625624896843" CI_START="0.1235069452130622" EFFECT_SIZE="0.46112115732368897" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.23593871812923017" LOG_CI_START="-0.9083086198707163" LOG_EFFECT_SIZE="-0.33618495087074307" MODIFIED="2009-11-22 15:29:50 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.6721365504568413" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.45176754246002193" WEIGHT="4.971785662348971"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.984555121170747" CI_END="1.1608944820084122" CI_START="0.8225697176439792" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9771983658808038" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="254" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0647927469013069" LOG_CI_START="-0.08482728279450356" LOG_EFFECT_SIZE="-0.010017267946598303" METHOD="IV" MODIFIED="2014-07-10 16:26:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7146868026960097" P_Q="1.0" P_Z="0.7929786920048859" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6552" TOTAL_2="6522" WEIGHT="99.99999999999999" Z="0.26244459968009154">
<NAME>Fatal and non-fatal myocardial infarction or reinfarction</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.745504920919437" CI_START="0.007800322538545951" EFFECT_SIZE="0.14634146341463414" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4386222264559737" LOG_CI_START="-2.1078874391281572" LOG_EFFECT_SIZE="-0.8346326063360919" MODIFIED="2010-02-07 14:47:07 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="1.495832382990261" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.237514518002323" WEIGHT="0.34521433013440084"/>
<DICH_DATA CI_END="1.1483653290329698" CI_START="0.6512033813583862" EFFECT_SIZE="0.8647655088525477" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="98" LOG_CI_END="0.060080071984547914" LOG_CI_START="-0.18628335304902124" LOG_EFFECT_SIZE="-0.06310164053223667" MODIFIED="2010-02-07 14:47:07 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.14471509538334057" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.020942458831809358" WEIGHT="36.883065245659786"/>
<DICH_DATA CI_END="5.401644829719638" CI_START="0.04628219882664439" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7325260249525283" LOG_CI_START="-1.3345860162804908" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-11-22 15:33:11 +0000" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.214231845389905" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="1.4743589743589745" WEIGHT="0.5239036685987578"/>
<DICH_DATA CI_END="11.23643077760827" CI_START="0.3833586353998623" EFFECT_SIZE="2.0754716981132075" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0506283806498655" LOG_CI_START="-0.41639474953499367" LOG_EFFECT_SIZE="0.317116815557436" MODIFIED="2010-02-07 14:47:07 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.8617366485521989" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.742590051457976" WEIGHT="1.0401729379239886"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2010-02-07 14:48:22 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.2959213189452937"/>
<DICH_DATA CI_END="28.03311541712967" CI_START="0.305835470361058" EFFECT_SIZE="2.9280575539568345" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4476713650911175" LOG_CI_START="-0.5145121471488675" LOG_EFFECT_SIZE="0.46657960897112494" MODIFIED="2009-11-22 15:33:11 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.1525963080548014" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="1.3284782493415586" WEIGHT="0.5814337388519599"/>
<DICH_DATA CI_END="3.22506396074258" CI_START="0.03765559105238507" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5085383321564366" LOG_CI_START="-1.4241705312049882" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2010-02-07 14:47:07 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.1352827534016703" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="1.2888669301712778" WEIGHT="0.5993031999009558"/>
<DICH_DATA CI_END="1.649766505021963" CI_START="0.875461654114372" EFFECT_SIZE="1.2017933738330455" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="67" LOG_CI_END="0.21742248193739155" LOG_CI_START="-0.05776287159223411" LOG_EFFECT_SIZE="0.07982980517257873" MODIFIED="2010-02-07 14:47:07 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.1616452388527712" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02612918324376946" WEIGHT="29.56166169803083"/>
<DICH_DATA CI_END="1.3196130478511896" CI_START="0.6845262001705454" EFFECT_SIZE="0.9504260651629073" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="70" LOG_CI_END="0.12044660103953661" LOG_CI_START="-0.16460992463483728" LOG_EFFECT_SIZE="-0.022081661797650358" MODIFIED="2010-03-09 11:22:36 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.16744361423368648" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.02803736394763961" WEIGHT="27.5497395882396"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 11:22:41 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="0.8049485686816306"/>
<DICH_DATA CI_END="2.613201320370725" CI_START="0.15948259758826805" EFFECT_SIZE="0.6455696202531646" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.417172868953553" LOG_CI_START="-0.7972866993385631" LOG_EFFECT_SIZE="-0.19005691519250506" MODIFIED="2010-03-09 11:23:05 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.713379562086607" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.5089103996028792" WEIGHT="1.5177958165148855"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 11:23:43 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-RECIFE-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.2968398885178913"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.337675370980901" CI_END="1.291345824829022" CI_START="0.4712336688668625" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7800805284136278" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.11104256271769616" LOG_CI_START="-0.32676368748939333" LOG_EFFECT_SIZE="-0.10786056238584854" METHOD="IV" MODIFIED="2014-07-10 16:27:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6310810876789705" P_Q="1.0" P_Z="0.3341758801655641" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6083" TOTAL_2="6064" WEIGHT="100.0" Z="0.9657368643252667">
<NAME>Fatal and non-fatal stroke</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.511277911770247" CI_START="0.597929368189249" EFFECT_SIZE="1.6423841059602649" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6542995821033737" LOG_CI_START="-0.2233501150372801" LOG_EFFECT_SIZE="0.2154747335330468" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.5155357765364871" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.2657771368890788" WEIGHT="24.884074912408877"/>
<DICH_DATA CI_END="8.452536623426301" CI_START="0.01415224441022766" EFFECT_SIZE="0.3458646616541353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9269870611671758" LOG_CI_START="-1.8491746797381994" LOG_EFFECT_SIZE="-0.46109380928551175" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.6307311488300666" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="2.659284079764629" WEIGHT="2.4869919820445627"/>
<DICH_DATA CI_END="1.8461561735987544" CI_START="0.2688790003788978" EFFECT_SIZE="0.7045513654096229" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.26626843691918445" LOG_CI_START="-0.5704431151277477" LOG_EFFECT_SIZE="-0.15208733910428157" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.4914885074613485" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.24156095296658397" WEIGHT="27.37867235218381"/>
<DICH_DATA CI_END="8.173197916704522" CI_START="0.013748614878411313" EFFECT_SIZE="0.3352165725047081" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.912392015631383" LOG_CI_START="-1.8617410531765335" LOG_EFFECT_SIZE="-0.4746745187725751" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.6295394967979304" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.6553989716244524" WEIGHT="2.4906306943048464"/>
<DICH_DATA CI_END="2.007878416792242" CI_START="0.3142864906420829" EFFECT_SIZE="0.7943859649122808" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3027374114038191" LOG_CI_START="-0.5026742863883719" LOG_EFFECT_SIZE="-0.09996843749227635" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.47310281813533617" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.22382627652759696" WEIGHT="29.547997165283455"/>
<DICH_DATA CI_END="7.832914996698886" CI_START="0.013634327870744605" EFFECT_SIZE="0.32679738562091504" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8939234135763198" LOG_CI_START="-1.86536626653948" LOG_EFFECT_SIZE="-0.48572142648158" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.620820416804222" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="2.6270588235294117" WEIGHT="2.5174990849531476"/>
<DICH_DATA CI_END="1.4358652638761082" CI_START="0.06581636470929891" EFFECT_SIZE="0.3074141048824593" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.15711368927922517" LOG_CI_START="-1.181666109132074" LOG_EFFECT_SIZE="-0.5122762099264243" MODIFIED="2009-11-22 15:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.7864058806536791" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.6184342091266887" WEIGHT="10.694133808821302"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.888302525359849" CI_END="1.1642273488234882" CI_START="0.8626241328962583" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0021430073961357" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="300" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.06603779706501028" LOG_CI_START="-0.06417839613549954" LOG_EFFECT_SIZE="9.29700464755407E-4" METHOD="IV" MODIFIED="2014-07-10 16:27:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7510433825275692" P_Q="1.0" P_Z="0.9776725302665242" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4849" TOTAL_2="4819" WEIGHT="100.0" Z="0.027986986603499027">
<NAME>Revascularization procedures (bypass grafts, angioplasty)</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5679443082561206" CI_START="0.46193745270581005" EFFECT_SIZE="0.85105358217941" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.19533063293605293" LOG_CI_START="-0.33541682484142654" LOG_EFFECT_SIZE="-0.07004309595268683" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.3117636839407791" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.09719659462432599" WEIGHT="6.019413035400582"/>
<DICH_DATA CI_END="3.2413681185644685" CI_START="0.17353783323108607" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5107283561734184" LOG_CI_START="-0.7606058293900183" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.7467879938056768" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.5576923076923077" WEIGHT="1.0490846665954183"/>
<DICH_DATA CI_END="2.868914378058799" CI_START="0.6673190547636229" EFFECT_SIZE="1.3836477987421383" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4577175870429737" LOG_CI_START="-0.17566647403946425" LOG_EFFECT_SIZE="0.14102555650175472" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.3720529327814919" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.1384233847913093" WEIGHT="4.226644577144789"/>
<DICH_DATA CI_END="3.2779654408839587" CI_START="0.007864817232646131" EFFECT_SIZE="0.16056338028169015" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5156043705546408" LOG_CI_START="-2.1043113653198464" LOG_EFFECT_SIZE="-0.7943534973826026" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="1.5389514720447242" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="2.3683716333086235" WEIGHT="0.24703321068783202"/>
<DICH_DATA CI_END="1.136783102081453" CI_START="0.6564203619895888" EFFECT_SIZE="0.8638330714738554" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="87" LOG_CI_END="0.05567760931831914" LOG_CI_START="-0.1828179557076674" LOG_EFFECT_SIZE="-0.06357017319467416" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.14009347546835138" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.01962618186880157" WEIGHT="29.810507850651028"/>
<DICH_DATA CI_END="2.5421682929772613" CI_START="0.42993817900683984" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4052042977097507" LOG_CI_START="-0.3665939873189774" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2009-12-06 14:10:05 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.45335813308900136" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="0.20553359683794464" WEIGHT="2.846573298376695"/>
<DICH_DATA CI_END="1.3708900347365505" CI_START="0.8974742191455859" EFFECT_SIZE="1.1092062312571322" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="147" LOG_CI_END="0.1370026194704169" LOG_CI_START="-0.04697801811858408" LOG_EFFECT_SIZE="0.045012300675916404" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.10807113723862313" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.011679370704049315" WEIGHT="50.09400450619892"/>
<DICH_DATA CI_END="10.216097979108612" CI_START="0.3760339816489496" EFFECT_SIZE="1.96" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0092850494454686" LOG_CI_START="-0.4247729067325167" LOG_EFFECT_SIZE="0.292256071356476" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.8423727421603181" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.7095918367346938" WEIGHT="0.8245112449017109"/>
<DICH_DATA CI_END="1.723934950460714" CI_START="0.42977660250263855" EFFECT_SIZE="0.8607594936708861" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.23652087448814352" LOG_CI_START="-0.3667572316565537" LOG_EFFECT_SIZE="-0.06511817858420509" MODIFIED="2009-11-22 15:37:00 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3543685458241826" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.1255770662695458" WEIGHT="4.659023068928796"/>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-02-25 16:07:18 +0000" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Ren-2009" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.223204541114232"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.579115923359893" CI_END="1.0466306201262463" CI_START="0.7607806685722909" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.892331969015947" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="300" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.019793436267718022" LOG_CI_START="-0.11874053134804216" LOG_EFFECT_SIZE="-0.04947354754016207" METHOD="IV" MODIFIED="2014-07-10 16:27:56 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4769959345384125" P_Q="1.0" P_Z="0.16154533832502266" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6099" TOTAL_2="6082" WEIGHT="100.00000000000001" Z="1.3998930808810044">
<NAME>Unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.832443951481025" CI_START="0.06635899064096924" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1995479592538743" LOG_CI_START="-1.1781002284703284" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="1.3966423150175427" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="1.950609756097561" WEIGHT="0.3394824730099561"/>
<DICH_DATA CI_END="1.4867521286669676" CI_START="0.5290520697124016" EFFECT_SIZE="0.886887417218543" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.17223856897569106" LOG_CI_START="-0.2765015822636604" LOG_EFFECT_SIZE="-0.05213150664398467" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.26359218613756835" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.06948084059278248" WEIGHT="9.530653605047705"/>
<DICH_DATA CI_END="1.6009781451569205" CI_START="0.0694020161656988" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.20438540343551742" LOG_CI_START="-1.1586279128748425" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.8006407690254357" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.6410256410256411" WEIGHT="1.0330286052486617"/>
<DICH_DATA CI_END="4.031451912644482" CI_START="0.38465789266070904" EFFECT_SIZE="1.2452830188679245" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6054614838804534" LOG_CI_START="-0.4149253519982943" LOG_EFFECT_SIZE="0.0952680659410796" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.5993802783914755" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.35925671812464266" WEIGHT="1.8432440939005639"/>
<DICH_DATA CI_END="2.3100802105448532" CI_START="0.36224246186006437" EFFECT_SIZE="0.9147727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.36362705971562626" LOG_CI_START="-0.4410006432802265" LOG_EFFECT_SIZE="-0.038686791782300105" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.47264229571113026" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="0.2233907396950875" WEIGHT="2.964302928497396"/>
<DICH_DATA CI_END="1.129104407080697" CI_START="0.6144996316013963" EFFECT_SIZE="0.832967131518766" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="87" LOG_CI_END="0.05273410252950721" LOG_CI_START="-0.21147837314128412" LOG_EFFECT_SIZE="-0.07937213530588849" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.1551997160818705" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02408695187189321" WEIGHT="27.491972724454953"/>
<DICH_DATA CI_END="1.2312710093611325" CI_START="0.7631301808038616" EFFECT_SIZE="0.9693400167084377" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="126" LOG_CI_END="0.09035365400050145" LOG_CI_START="-0.11740137032527138" LOG_EFFECT_SIZE="-0.013523858162384954" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.12203632969291527" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.014892865764917912" WEIGHT="44.464096724570005"/>
<DICH_DATA CI_END="2.754799334724696" CI_START="0.7375929838316472" EFFECT_SIZE="1.4254545454545455" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.44008996943255496" LOG_CI_START="-0.13218322305216568" LOG_EFFECT_SIZE="0.15395337319019461" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.3361561060635145" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.1130009276437848" WEIGHT="5.860109626398886"/>
<DICH_DATA CI_END="0.8974503756899375" CI_START="0.2497345202802197" EFFECT_SIZE="0.47341772151898737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.04698955629823577" LOG_CI_START="-0.6025214218816867" LOG_EFFECT_SIZE="-0.3247554890899612" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.3263221677708039" STUDY_ID="STD-PTT-2002" TOTAL_1="79" TOTAL_2="85" VAR="0.10648615717863671" WEIGHT="6.218628236968605"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 15:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-RECIFE-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.25448098190327806"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3319605643933943" CI_END="1.1442643429349233" CI_START="0.6332300765819459" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8512241758236614" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.058526364855904185" LOG_CI_START="-0.19843846559843248" LOG_EFFECT_SIZE="-0.0699560503712641" METHOD="IV" MODIFIED="2014-07-10 16:28:24 +0100" MODIFIED_BY="[Empty name]" NO="8" NOTES="&lt;p&gt;We used 6 weeks data from RECIFE.&lt;/p&gt;&lt;p&gt;Email request about A-to Z for heart failure data.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:28:24 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.6749564102024044" P_Q="1.0" P_Z="0.2858994495679028" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5587" TOTAL_2="5554" WEIGHT="100.0" Z="1.0671603501998508">
<NAME>Acute heart failure</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4330297666938463" CI_START="0.5140447131658568" EFFECT_SIZE="0.8582781456953642" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.15625521159526268" LOG_CI_START="-0.2889991031124525" LOG_EFFECT_SIZE="-0.06637194575859492" MODIFIED="2010-03-26 08:39:56 +0000" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.2615445885037161" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.06840557177557818" WEIGHT="33.30666139209344"/>
<DICH_DATA CI_END="1.235570685597685" CI_START="0.14153462452312723" EFFECT_SIZE="0.41818181818181815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09186759594360085" LOG_CI_START="-0.8491373028969028" LOG_EFFECT_SIZE="-0.378634853476651" MODIFIED="2009-12-06 15:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.5527509356282851" STUDY_ID="STD-Macin-2005" TOTAL_1="44" TOTAL_2="46" VAR="0.3055335968379447" WEIGHT="7.456990786090774"/>
<DICH_DATA CI_END="1.8353014819948095" CI_START="0.5519780736136454" EFFECT_SIZE="1.0065019505851756" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.26370741529773173" LOG_CI_START="-0.2580781735348085" LOG_EFFECT_SIZE="0.002814620881461557" MODIFIED="2010-05-17 20:10:30 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.306499437760555" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.09394190534753633" WEIGHT="24.252874242149673"/>
<DICH_DATA CI_END="1.4884512482431118" CI_START="0.5404321927814385" EFFECT_SIZE="0.8968873797396718" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.17273461461879805" LOG_CI_START="-0.2672587885713449" LOG_EFFECT_SIZE="-0.047262086976273404" MODIFIED="2009-12-06 15:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.25845430303636213" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.06679862675801171" WEIGHT="34.10790501300933"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-12-06 15:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-RECIFE-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.8755685666567792"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-07-10 16:32:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Statins versus control at 4 months (3 to 6 months)</NAME>
<DICH_OUTCOME CHI2="7.476958384532077" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9254005289054059" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449815" METHOD="IV" MODIFIED="2014-07-10 16:28:52 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Email request for OACIS-LIPID 4 months data, sent Dec 16 2009.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:28:52 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.6797793638370655" P_Q="1.0" P_Z="0.2703666163462425" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="100.00000000000003" Z="1.102218711966399">
<NAME>Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.8903852512724566"/>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642889"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.18947997471887645"/>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.6830222097535901"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.568945091275746"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-05-25 12:28:21 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303503"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797439"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318297"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005298"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.0765057770317064"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2009-11-22 15:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238446"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.5560014406038665" CI_END="1.1419483048326748" CI_START="0.7042691091359169" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8967936860414318" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.057646444160204695" LOG_CI_START="-0.15226136034546606" LOG_EFFECT_SIZE="-0.04730745809263072" METHOD="IV" MODIFIED="2014-07-10 16:29:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9507519723827982" P_Q="1.0" P_Z="0.37699633914417474" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4889" TOTAL_2="4844" WEIGHT="99.99999999999999" Z="0.8834441795058575">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.9393126948692887"/>
<DICH_DATA CI_END="1.3541598816153073" CI_START="0.6025663885114637" EFFECT_SIZE="0.9033112582781457" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13166994322954745" LOG_CI_START="-0.21999509717496601" LOG_EFFECT_SIZE="-0.044162576972709304" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.206569785503636" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.04267107628301818" WEIGHT="35.62860180288965"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.5822466837657638"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-11-22 15:55:45 +0000" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.5755809203467203"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="2.306098282491746"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.7725717239723181"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2009-11-22 15:55:45 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.582443701558802"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2009-11-22 15:55:45 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.5711539009848411"/>
<DICH_DATA CI_END="1.3228992178114711" CI_START="0.6783355915704159" EFFECT_SIZE="0.94729595349193" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" LOG_CI_END="0.12152675967084309" LOG_CI_START="-0.16855539535261824" LOG_EFFECT_SIZE="-0.023514317840887575" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.17039569379060693" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02903469246238228" WEIGHT="52.361869765216824"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.5843306780950828"/>
<DICH_DATA CI_END="2.834891059887564" CI_START="0.03353548423416844" EFFECT_SIZE="0.30833333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45253637434048116" LOG_CI_START="-1.4744954183017407" LOG_EFFECT_SIZE="-0.5109795219806298" MODIFIED="2009-11-22 15:55:50 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.131948013959257" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.2813063063063064" WEIGHT="1.1865318838327337"/>
<DICH_DATA CI_END="3.6930846804714745" CI_START="0.11175181263422147" EFFECT_SIZE="0.6424242424242425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5673892659070993" LOG_CI_START="-0.9517454238053712" LOG_EFFECT_SIZE="-0.19217807894913602" MODIFIED="2010-03-16 16:53:37 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.7962835906232132" WEIGHT="1.9092579619762209"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.064745585514029" CI_END="1.0857877668968774" CI_START="0.6427565702902249" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8354024306367076" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="121" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.03574494433834684" LOG_CI_START="-0.19195347528221554" LOG_EFFECT_SIZE="-0.07810426547193437" METHOD="IV" MODIFIED="2014-07-10 16:29:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7722906131161672" P_Q="1.0" P_Z="0.17875472759438749" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4651" TOTAL_2="4622" WEIGHT="99.99999999999999" Z="1.3445991203543919">
<NAME>Death from cardiovascular causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.431149398907067" CI_START="0.04836107989459014" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7348917494375433" LOG_CI_START="-1.3155040099819597" LOG_EFFECT_SIZE="-0.29030613027220814" MODIFIED="2009-11-22 15:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.2044126187057163" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="1.450609756097561" WEIGHT="1.2332315950581607"/>
<DICH_DATA CI_END="1.2992190613147767" CI_START="0.5722498536026793" EFFECT_SIZE="0.8622516556291391" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" LOG_CI_END="0.11368238363593833" LOG_CI_START="-0.2424143097579309" LOG_EFFECT_SIZE="-0.06436596306099629" MODIFIED="2009-11-22 15:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.20917296040661962" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.043753327365269254" WEIGHT="40.8868968612238"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2009-11-22 15:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="2.7135677713046813"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2009-11-22 15:56:56 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.6853569377978254"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2009-11-22 15:56:56 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.672072317964166"/>
<DICH_DATA CI_END="1.2343247727766224" CI_START="0.592976725969557" EFFECT_SIZE="0.8555266579973992" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="60" LOG_CI_END="0.09142944532699826" LOG_CI_START="-0.22696235213548965" LOG_EFFECT_SIZE="-0.0677664534042457" MODIFIED="2009-11-22 15:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.1870249178942813" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.034978319913362664" WEIGHT="51.14418839298517"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2009-11-22 15:57:02 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.864269489209637"/>
<DICH_DATA CI_END="2.4799517953643764" CI_START="0.007069035465911892" EFFECT_SIZE="0.13240418118466898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39444323920899177" LOG_CI_START="-2.150639839443356" LOG_EFFECT_SIZE="-0.8780983001171822" MODIFIED="2009-11-22 15:57:08 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.4949943987648122" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="2.2350082523381625" WEIGHT="0.8004166344565488"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.782739251158134" CI_END="1.059666147635048" CI_START="0.7732293451081271" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9051878044743533" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="308" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.025169060474799224" LOG_CI_START="-0.11169167226286719" LOG_EFFECT_SIZE="-0.043261305894033986" METHOD="IV" MODIFIED="2014-07-10 16:30:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4575664264665056" P_Q="1.0" P_Z="0.21531642086309577" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4784" TOTAL_2="4753" WEIGHT="100.0" Z="1.2390785841984773">
<NAME>Fatal and non-fatal myocardial infarction or reinfarction</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5806532906912742" CI_START="0.12208365990945234" EFFECT_SIZE="0.4392857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19883661980427694" LOG_CI_START="-0.9133424596099194" LOG_EFFECT_SIZE="-0.3572529199028213" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.6532994966231316" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.4268002322880371" WEIGHT="1.5142872949305899"/>
<DICH_DATA CI_END="1.1533499081765424" CI_START="0.7259747497731955" EFFECT_SIZE="0.915042573320719" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="140" LOG_CI_END="0.0619610853834204" LOG_CI_START="-0.139078484292842" LOG_EFFECT_SIZE="-0.038558699454710785" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.11809163838975623" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.013945635057576948" WEIGHT="46.34411889876984"/>
<DICH_DATA CI_END="3.1351978297218888" CI_START="0.03543990432047708" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49626494983846475" LOG_CI_START="-1.4505074592777896" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 16:00:13 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.1435437497937313" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="1.3076923076923077" WEIGHT="0.4942280117619757"/>
<DICH_DATA CI_END="3.9341406491010775" CI_START="0.48663263510962934" EFFECT_SIZE="1.3836477987421383" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5948498822830081" LOG_CI_START="-0.31279876927949857" LOG_EFFECT_SIZE="0.14102555650175472" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.5331573108611027" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.2842567181246426" WEIGHT="2.2736425492107677"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-09 12:04:57 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="1.061967116240543"/>
<DICH_DATA CI_END="8.746170592640663" CI_START="0.5929967800350141" EFFECT_SIZE="2.2773780975219826" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9418179439349709" LOG_CI_START="-0.22694766484285708" LOG_EFFECT_SIZE="0.35743513954605693" MODIFIED="2009-11-22 16:00:13 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.6865387040791666" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.4713353921987015" WEIGHT="1.3712065334460142"/>
<DICH_DATA CI_END="1.1508543185830848" CI_START="0.7142172140146967" EFFECT_SIZE="0.9066200776263413" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="131" LOG_CI_END="0.06102035174468526" LOG_CI_START="-0.14616968668103997" LOG_EFFECT_SIZE="-0.04257466746817732" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.12170445417850197" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.014811974166887084" WEIGHT="43.63349287173558"/>
<DICH_DATA CI_END="10.216097979108612" CI_START="0.3760339816489496" EFFECT_SIZE="1.96" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0092850494454686" LOG_CI_START="-0.4247729067325167" LOG_EFFECT_SIZE="0.292256071356476" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.8423727421603181" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.7095918367346938" WEIGHT="0.9108027118818739"/>
<DICH_DATA CI_END="1.220841379922235" CI_START="0.019468017305102354" EFFECT_SIZE="0.15416666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.08665924109517922" LOG_CI_START="-1.7106782763844013" LOG_EFFECT_SIZE="-0.812009517644611" MODIFIED="2010-02-07 14:56:51 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="1.0557649547317054" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.1146396396396399" WEIGHT="0.5798270097734418"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:54:13 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="1.8164270022493711"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.0143167449934225" CI_END="1.156867402445644" CI_START="0.44778740959241925" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7197434663705157" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.06328358394202095" LOG_CI_START="-0.3489281216131909" LOG_EFFECT_SIZE="-0.14282226883558502" METHOD="IV" MODIFIED="2014-07-10 16:31:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.541978272048546" P_Q="1.0" P_Z="0.1744101830735183" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4276" TOTAL_2="4260" WEIGHT="100.00000000000001" Z="1.3581686271184772">
<NAME>Fatal and non-fatal stroke</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.832443951481025" CI_START="0.06635899064096924" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1995479592538743" LOG_CI_START="-1.1781002284703284" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.3966423150175427" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="1.950609756097561" WEIGHT="3.005698762429501"/>
<DICH_DATA CI_END="2.7709570592052306" CI_START="0.6230166386851658" EFFECT_SIZE="1.3139072847682118" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4426297956867012" LOG_CI_START="-0.2055003546367205" LOG_EFFECT_SIZE="0.11856472052499038" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.38071485859596477" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.14494380355574543" WEIGHT="40.44978250919474"/>
<DICH_DATA CI_END="8.058814861166631" CI_START="0.013787524968035585" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9062711786413306" LOG_CI_START="-1.8605136880806552" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="2.2196773852760834"/>
<DICH_DATA CI_END="8.452536623426301" CI_START="0.01415224441022766" EFFECT_SIZE="0.3458646616541353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9269870611671758" LOG_CI_START="-1.8491746797381994" LOG_EFFECT_SIZE="-0.46109380928551175" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="1.6307311488300666" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="2.659284079764629" WEIGHT="2.204708167321588"/>
<DICH_DATA CI_END="1.0026870879334753" CI_START="0.25258283185326486" EFFECT_SIZE="0.5032509752925878" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="0.0011654223660067036" LOG_CI_START="-0.597596171931046" LOG_EFFECT_SIZE="-0.29821537478251964" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.351715524407782" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.12370381010944109" WEIGHT="47.39502627039852"/>
<DICH_DATA CI_END="3.9827136850633797" CI_START="0.009653405765447983" EFFECT_SIZE="0.19607843137254902" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6001790863574832" LOG_CI_START="-2.015319438553356" LOG_EFFECT_SIZE="-0.7075701760979364" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.5363567804591305" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="2.360392156862745" WEIGHT="2.483886125802898"/>
<DICH_DATA CI_END="7.355395653031318" CI_START="0.012976301617136022" EFFECT_SIZE="0.3089430894308943" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8666060387639877" LOG_CI_START="-1.8868490684091632" LOG_EFFECT_SIZE="-0.5101215148225877" MODIFIED="2009-11-22 16:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.6173931597761082" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="2.6159606332905434" WEIGHT="2.241220779576685"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.091290588092383" CI_END="1.0812122228303944" CI_START="0.7772254649826955" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9167036994767324" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="473" I2="20.723717841998166" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.03391094664358466" LOG_CI_START="-0.10945297863286857" LOG_EFFECT_SIZE="-0.03777101599464192" METHOD="IV" MODIFIED="2014-07-10 16:31:21 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2586770029444281" P_Q="1.0" P_Z="0.3017190674805791" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01211590907335446" TOTALS="YES" TOTAL_1="4759" TOTAL_2="4715" WEIGHT="100.0" Z="1.0327539632614053">
<NAME>Revascularization procedures (bypass grafts, angioplasty)</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4026386376374198" CI_START="0.6923188713663145" EFFECT_SIZE="0.9854304635761589" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="60" LOG_CI_END="0.14694579797471813" LOG_CI_START="-0.15969383014133723" LOG_EFFECT_SIZE="-0.006374016083309542" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.18012163544601034" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03244380355574545" WEIGHT="15.915217913877624"/>
<DICH_DATA CI_END="1.3612757950724064" CI_START="0.10330382756311343" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.13394612237004996" LOG_CI_START="-0.9858835869146123" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.6577935144802719" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.43269230769230765" WEIGHT="1.5943445061076853"/>
<DICH_DATA CI_END="1.5544921322648246" CI_START="0.6088743294471279" EFFECT_SIZE="0.972877358490566" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.19158852829454112" LOG_CI_START="-0.21547233570811866" LOG_EFFECT_SIZE="-0.011941903706788754" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.23910956649893644" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.05717338479130931" WEIGHT="10.235023293166465"/>
<DICH_DATA CI_END="0.7898714499205608" CI_START="0.04001276191813683" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.10244358356133171" LOG_CI_START="-1.3978014700054684" LOG_EFFECT_SIZE="-0.7501225267834001" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.7608996346222372" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.578968253968254" WEIGHT="1.1997911313045422"/>
<DICH_DATA CI_END="14.072922267905014" CI_START="0.05970883387128004" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1483842888383442" LOG_CI_START="-1.2239614106171437" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="1.3935276071607594" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="1.941919191919192" WEIGHT="0.362929783764716"/>
<DICH_DATA CI_END="1.1360880490206315" CI_START="0.6587620589249333" EFFECT_SIZE="0.8651079136690647" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="88" LOG_CI_END="0.05541199134150787" LOG_CI_START="-0.18127142175795938" LOG_EFFECT_SIZE="-0.06292971520822573" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.13902900845641727" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.019329065192374546" WEIGHT="22.55296921787602"/>
<DICH_DATA CI_END="1.1997030862200455" CI_START="0.8716514994528977" EFFECT_SIZE="1.0226059817945383" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="250" LOG_CI_END="0.07907377607133172" LOG_CI_START="-0.059657118412607735" LOG_EFFECT_SIZE="0.00970832882936199" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.08149121414886913" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.006640817983456849" WEIGHT="37.80923689532281"/>
<DICH_DATA CI_END="2.6337089669011635" CI_START="0.5447342978925701" EFFECT_SIZE="1.1977777777777778" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4205677823751617" LOG_CI_START="-0.26381527955237166" LOG_EFFECT_SIZE="0.07837625141139504" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.40200999832702655" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.1616120387548959" WEIGHT="4.082115431266083"/>
<DICH_DATA CI_END="1.1869753230122075" CI_START="0.3407118042521351" EFFECT_SIZE="0.6359375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.07444169015001624" LOG_CI_START="-0.4676128196673504" LOG_EFFECT_SIZE="-0.1965855647586671" MODIFIED="2009-11-22 16:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.3184055022798191" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.10138206388206389" WEIGHT="6.248371827314067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.90037565073514" CI_END="0.9624700743330633" CI_START="0.5948990254323787" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7566852114509497" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="275" I2="32.775231347375126" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.016612764940567043" LOG_CI_START="-0.22555674253862013" LOG_EFFECT_SIZE="-0.12108475373959358" METHOD="IV" MODIFIED="2014-07-10 16:31:53 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15570462248564676" P_Q="1.0" P_Z="0.023108836969517408" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03814867339809172" TOTALS="YES" TOTAL_1="4401" TOTAL_2="4369" WEIGHT="100.00000000000001" Z="2.2716305024406354">
<NAME>Unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.8323761198828423"/>
<DICH_DATA CI_END="1.294065369337752" CI_START="0.6324295248354761" EFFECT_SIZE="0.904657474758441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" LOG_CI_END="0.11195621514691226" LOG_CI_START="-0.19898786332266455" LOG_EFFECT_SIZE="-0.04351582408787613" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.1826500908910417" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03336105570250579" WEIGHT="21.065403736058013"/>
<DICH_DATA CI_END="0.8515570019046186" CI_START="0.07339496928592049" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06978627572949034" LOG_CI_START="-1.1343337069264343" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.6253204306798563" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.39102564102564097" WEIGHT="3.5099521661329938"/>
<DICH_DATA CI_END="3.011213824096463" CI_START="0.5342350720757487" EFFECT_SIZE="1.2683438155136268" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4787415955420055" LOG_CI_START="-0.2722676043172956" LOG_EFFECT_SIZE="0.10323699561235497" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.4411465215528487" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.194610253478178" WEIGHT="6.471851949038188"/>
<DICH_DATA CI_END="1.2401042982048704" CI_START="0.1857908244762304" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09345821276706777" LOG_CI_START="-0.7309757380158933" LOG_EFFECT_SIZE="-0.3187587626244128" MODIFIED="2009-12-17 14:53:05 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.48427658370378546" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.23452380952380952" WEIGHT="5.5245080046881005"/>
<DICH_DATA CI_END="0.949127363553169" CI_START="0.569987397336219" EFFECT_SIZE="0.735520656196859" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="130" LOG_CI_END="-0.02267550561599359" LOG_CI_START="-0.24413474665706136" LOG_EFFECT_SIZE="-0.13340512613652747" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.13008625442844635" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.016922433591222478" WEIGHT="27.353387228125197"/>
<DICH_DATA CI_END="1.7274438526504503" CI_START="0.7261596364335374" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.23740394034124918" LOG_CI_START="-0.13896789500088588" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.22108267915060228" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.04887755102040815" WEIGHT="17.309510146231272"/>
<DICH_DATA CI_END="0.868424484390695" CI_START="0.2931355809032587" EFFECT_SIZE="0.5045454545454545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.061267940530986456" LOG_CI_START="-0.5329314635401112" LOG_EFFECT_SIZE="-0.2970997020355488" MODIFIED="2009-11-22 16:04:06 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.2770574881876535" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.07676085176085176" WEIGHT="13.109281519322167"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:54:53 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="3.823729130521242"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.258488138692914" CI_END="1.1503641840643364" CI_START="0.6478229695631054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8632684065802462" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.06083535173720516" LOG_CI_START="-0.18854365747178667" LOG_EFFECT_SIZE="-0.06385415286729074" METHOD="IV" MODIFIED="2014-07-10 16:32:17 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6111607716882304" P_Q="1.0" P_Z="0.3155194452474265" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3803" TOTAL_2="3780" WEIGHT="100.0" Z="1.003707892498053">
<NAME>Acute heart failure</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1903641521180197" CI_START="0.5460994973549264" EFFECT_SIZE="0.8062612883804937" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="55" LOG_CI_END="0.07567983959649999" LOG_CI_START="-0.2627282232009194" LOG_EFFECT_SIZE="-0.09352419180220968" MODIFIED="2010-03-26 08:40:37 +0000" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.19878257123413137" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03951451062645252" WEIGHT="54.304821009900856"/>
<DICH_DATA CI_END="1.4317360910470598" CI_START="0.6122789665792954" EFFECT_SIZE="0.9362808842652796" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.15586297274513478" LOG_CI_START="-0.21305065948546" LOG_EFFECT_SIZE="-0.028593843370162592" MODIFIED="2009-12-17 13:43:14 +0000" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.2167016937241827" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.04695962406292947" WEIGHT="45.69517899009915"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-07-10 16:35:56 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Statins versus control at 12 months</NAME>
<DICH_OUTCOME CHI2="3.2405317807484506" CI_END="1.1091168518428107" CI_START="0.580602015966542" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8024683670540543" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.044977303982466015" LOG_CI_START="-0.23612146054426084" LOG_EFFECT_SIZE="-0.0955720782808974" METHOD="IV" MODIFIED="2014-07-10 16:32:41 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;9 month data used for OACIS-LIPID.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:32:41 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.662957861855599" P_Q="1.0" P_Z="0.1826123591351029" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1046" TOTAL_2="1034" WEIGHT="100.00000000000001" Z="1.3327545688333435">
<NAME>Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.356160560324898" CI_START="0.2933795850764814" EFFECT_SIZE="0.6307692307692307" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.1323111101321825" LOG_CI_START="-0.5325701099784227" LOG_EFFECT_SIZE="-0.2001294999231201" MODIFIED="2009-12-17 11:16:44 +0000" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.39055451990808904" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.15253283302063791" WEIGHT="17.874328739926593"/>
<DICH_DATA CI_END="1.2213516855603503" CI_START="0.1310023983195248" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.086840736103969" LOG_CI_START="-0.8827207534480442" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-11-22 16:07:58 +0000" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.5695252183696297" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.3243589743589743" WEIGHT="8.405569805587769"/>
<DICH_DATA CI_END="1.7039505910183086" CI_START="0.6319993655295251" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.23145699749687346" LOG_CI_START="-0.1992833577099639" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2009-12-17 11:15:09 +0000" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="0.25301901684764216" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.06401862288654742" WEIGHT="42.58795141337116"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-12-17 11:13:07 +0000" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="1.3854776048858428"/>
<DICH_DATA CI_END="1.70115868708775" CI_START="0.43596995081736933" EFFECT_SIZE="0.8611933982225984" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.2307448272587259" LOG_CI_START="-0.3605434434009862" LOG_EFFECT_SIZE="-0.06489930807113015" MODIFIED="2009-12-17 11:14:05 +0000" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.34732565710965946" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.12063511208665673" WEIGHT="22.600567561828278"/>
<DICH_DATA CI_END="1.9283713434921756" CI_START="0.17125940494045194" EFFECT_SIZE="0.5746753246753247" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.28519066903805385" LOG_CI_START="-0.766345569315329" LOG_EFFECT_SIZE="-0.24057745013863763" MODIFIED="2010-03-10 13:26:42 +0000" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.6176775915971052" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="0.3815256071612004" WEIGHT="7.146104874400364"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.672385706314915" CI_END="1.198203818680973" CI_START="0.38563821683186916" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6797596516690783" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.07853069935502387" LOG_CI_START="-0.4138199339580853" LOG_EFFECT_SIZE="-0.16764461730153074" METHOD="IV" MODIFIED="2014-07-10 16:33:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8923602354006234" P_Q="1.0" P_Z="0.1819649549288958" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1046" TOTAL_2="1034" WEIGHT="100.00000000000001" Z="1.3347293163896174">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.219364083338482" CI_START="0.18356934698953253" EFFECT_SIZE="0.76875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5077700945618248" LOG_CI_START="-0.7361998369948783" LOG_EFFECT_SIZE="-0.11421487121652682" MODIFIED="2009-12-17 11:24:57 +0000" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="0.7307140955468795" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.5339430894308942" WEIGHT="15.664958035370006"/>
<DICH_DATA CI_END="2.186759132956353" CI_START="0.028581108480614487" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3398009490235297" LOG_CI_START="-1.5439209316794544" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2009-11-22 16:08:48 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.1065075572986272" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="1.2243589743589745" WEIGHT="6.831489999564819"/>
<DICH_DATA CI_END="1.677905935936947" CI_START="0.25990625950283625" EFFECT_SIZE="0.660377358490566" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.22476761045657687" LOG_CI_START="-0.5851832609576038" LOG_EFFECT_SIZE="-0.18020782525051343" MODIFIED="2009-12-17 11:24:30 +0000" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.47576915119016466" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.22635628522420975" WEIGHT="36.9514638434974"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-12-17 11:23:26 +0000" MODIFIED_BY="[Empty name]" ORDER="399" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="4.2504081760054735"/>
<DICH_DATA CI_END="1.8490970059271439" CI_START="0.20124126925107008" EFFECT_SIZE="0.6100119904076738" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.26695969538512093" LOG_CI_START="-0.6962829521940456" LOG_EFFECT_SIZE="-0.21466162840446226" MODIFIED="2009-12-17 11:23:53 +0000" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="0.5658134993160073" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.32014491600822537" WEIGHT="26.126281165107972"/>
<DICH_DATA CI_END="8.91841965667481" CI_START="0.2551618903686809" EFFECT_SIZE="1.5085227272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9502879042425745" LOG_CI_START="-0.5931841890358984" LOG_EFFECT_SIZE="0.17855185760333805" MODIFIED="2009-11-22 16:09:58 +0000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.9066431479018582" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="0.8220017976373908" WEIGHT="10.175398780454328"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5071155782609286" CI_END="1.0910536950447534" CI_START="0.2788904086576291" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5516198064595284" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.03784612445434673" LOG_CI_START="-0.5545664213334208" LOG_EFFECT_SIZE="-0.25836014843953703" METHOD="IV" MODIFIED="2014-07-10 16:33:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9728046007948739" P_Q="1.0" P_Z="0.08735089754895324" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="976" TOTAL_2="978" WEIGHT="100.0" Z="1.709540385605962">
<NAME>Death from cardiovascular causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2009-12-17 11:28:51 +0000" MODIFIED_BY="[Empty name]" ORDER="406" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="15.446822722071689"/>
<DICH_DATA CI_END="4.099513080334857" CI_START="0.009757256341461098" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127322764559129" LOG_CI_START="-2.0106722851279506" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-11-22 16:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="1.5410008255363776" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.3746835443037972" WEIGHT="5.099386802792885"/>
<DICH_DATA CI_END="1.5086457381420795" CI_START="0.21237505287338185" EFFECT_SIZE="0.5660377358490566" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.17858727023767768" LOG_CI_START="-0.672896499999931" LOG_EFFECT_SIZE="-0.2471546148811266" MODIFIED="2009-12-17 11:28:23 +0000" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="0.5001657815502112" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.25016580903373353" WEIGHT="48.40561535329284"/>
<DICH_DATA CI_END="2.4344643286180325" CI_START="0.14086911750562545" EFFECT_SIZE="0.5856115107913669" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38640341535845923" LOG_CI_START="-0.851184206088247" LOG_EFFECT_SIZE="-0.2323903953648939" MODIFIED="2009-12-17 11:27:46 +0000" MODIFIED_BY="[Empty name]" ORDER="404" O_E="0.0" SE="0.7269650949953228" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.5284782493415587" WEIGHT="22.913771648539154"/>
<DICH_DATA CI_END="5.495283924243156" CI_START="0.046011995620443905" EFFECT_SIZE="0.5028409090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7399901359854582" LOG_CI_START="-1.3371289302181069" LOG_EFFECT_SIZE="-0.2985693971163244" MODIFIED="2009-11-22 16:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.2201100213931764" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="1.4886684643040575" WEIGHT="8.134403473303434"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.144272637350258" CI_END="1.4532513178947344" CI_START="0.6133769794707971" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9441350029430258" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="44" I2="3.481253526855369" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.16234072547267234" LOG_CI_START="-0.21227252746734424" LOG_EFFECT_SIZE="-0.02496590099733595" METHOD="IV" MODIFIED="2014-07-10 16:34:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.38683294931559187" P_Q="1.0" P_Z="0.7939062655807138" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009474417590787978" TOTALS="YES" TOTAL_1="976" TOTAL_2="978" WEIGHT="99.99999999999999" Z="0.26124151461457346">
<NAME>Fatal and non-fatal myocardial infarction or reinfarction</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5333630812551742" CI_START="0.24666369278331265" EFFECT_SIZE="0.615" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1856450025486391" LOG_CI_START="-0.6078947709978056" LOG_EFFECT_SIZE="-0.21112488422458328" MODIFIED="2010-03-09 14:06:49 +0000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.46612919106641204" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.21727642276422765" WEIGHT="21.354655715892235"/>
<DICH_DATA CI_END="2.00014405000963" CI_START="0.07999423841459302" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30106127459971216" LOG_CI_START="-1.0969412919437873" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-03-09 14:07:59 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.8211936278119639" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.6743589743589744" WEIGHT="7.08094425641375"/>
<DICH_DATA CI_END="2.552592086742511" CI_START="0.7267597140865665" EFFECT_SIZE="1.3620283018867925" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.4069814185523799" LOG_CI_START="-0.13860915460948134" LOG_EFFECT_SIZE="0.1341861319714493" MODIFIED="2010-03-09 14:11:31 +0000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.32048260339217105" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.10270909907702361" WEIGHT="43.16308021800456"/>
<DICH_DATA CI_END="2.5003921507235747" CI_START="0.46099259779138557" EFFECT_SIZE="1.073621103117506" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3980081268877849" LOG_CI_START="-0.3363060480684098" LOG_EFFECT_SIZE="0.030851039409687572" MODIFIED="2010-03-09 14:15:54 +0000" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.43133978128305794" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.18605400691731627" WEIGHT="24.764614869946463"/>
<DICH_DATA CI_END="3.1918077332924604" CI_START="0.03520804940974443" EFFECT_SIZE="0.3352272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5040367226269948" LOG_CI_START="-1.453358034971006" LOG_EFFECT_SIZE="-0.47466065617200565" MODIFIED="2009-11-22 16:13:13 +0000" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="1.1497833698733821" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="1.3220017976373908" WEIGHT="3.6367049397429785"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.25520656211994225" CI_END="1.1037986880126707" CI_START="0.1282596979356824" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37626172580573175" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.04288987352232674" LOG_CI_START="-0.8919097872241811" LOG_EFFECT_SIZE="-0.42450995685092724" METHOD="IV" MODIFIED="2014-07-10 16:34:42 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9682203246415967" P_Q="1.0" P_Z="0.0750575702089572" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="559" TOTAL_2="571" WEIGHT="100.0" Z="1.7801123843841276">
<NAME>Fatal and non-fatal stroke</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.431149398907067" CI_START="0.04836107989459014" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7348917494375433" LOG_CI_START="-1.3155040099819597" LOG_EFFECT_SIZE="-0.29030613027220814" MODIFIED="2009-12-17 11:33:39 +0000" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="1.2044126187057163" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="1.450609756097561" WEIGHT="20.785558688162702"/>
<DICH_DATA CI_END="3.1351978297218888" CI_START="0.03543990432047708" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49626494983846475" LOG_CI_START="-1.4505074592777896" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-11-22 16:15:47 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="1.1435437497937313" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="1.3076923076923077" WEIGHT="23.057208520402007"/>
<DICH_DATA CI_END="2.1209660660411496" CI_START="0.08123812707120129" EFFECT_SIZE="0.41509433962264153" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32653372016721216" LOG_CI_START="-1.0902400977243778" LOG_EFFECT_SIZE="-0.38185318877858276" MODIFIED="2009-12-17 11:33:01 +0000" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.832219953773025" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6925900514579759" WEIGHT="43.53474924381981"/>
<DICH_DATA CI_END="4.159616983024261" CI_START="0.009725235361462992" EFFECT_SIZE="0.20112994350282487" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6190533426899193" LOG_CI_START="-2.012099879467782" LOG_EFFECT_SIZE="-0.6965232683889314" MODIFIED="2009-11-22 16:15:47 +0000" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="1.5455524271139385" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.3887323049577858" WEIGHT="12.622483547615474"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.964740962471004" CI_END="0.9319116839057238" CI_START="0.5221855071501619" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6975892597219884" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="215" I2="49.77865546604006" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.03062524323591842" LOG_CI_START="-0.28217518584906776" LOG_EFFECT_SIZE="-0.15640021454249306" METHOD="IV" MODIFIED="2014-07-10 16:35:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.09287839854327473" P_Q="1.0" P_Z="0.014801481327432581" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05064829203866758" TOTALS="YES" TOTAL_1="1006" TOTAL_2="993" WEIGHT="100.00000000000003" Z="2.437200219512992">
<NAME>Revascularization procedures (bypass grafts, angioplasty)</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.97719307760699" CI_START="0.1637342749007369" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.01001961821081355" LOG_CI_START="-0.7858603991332616" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-11-22 16:16:33 +0000" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.45573271518764996" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.20769230769230768" WEIGHT="8.451445315795302"/>
<DICH_DATA CI_END="1.3430211814278092" CI_START="0.652328102946832" EFFECT_SIZE="0.9359970403255642" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="51" LOG_CI_END="0.1280828621882055" LOG_CI_START="-0.1855339112340205" LOG_EFFECT_SIZE="-0.02872552452290749" MODIFIED="2009-12-17 11:37:42 +0000" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.18422004513628124" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.033937025030013494" WEIGHT="25.812416707066017"/>
<DICH_DATA CI_END="0.8025428613251435" CI_START="0.23726237228761735" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.09553176398238207" LOG_CI_START="-0.6247711315828935" LOG_EFFECT_SIZE="-0.36015144778263786" MODIFIED="2009-12-17 11:35:59 +0000" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.31087782430566135" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.09664502164502164" WEIGHT="14.823153861313916"/>
<DICH_DATA CI_END="1.1212467268379827" CI_START="0.6566178875626014" EFFECT_SIZE="0.8580388436503544" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="91" LOG_CI_END="0.04970118825435375" LOG_CI_START="-0.18268729040972875" LOG_EFFECT_SIZE="-0.06649305107768749" MODIFIED="2009-12-17 11:36:46 +0000" MODIFIED_BY="[Empty name]" ORDER="412" O_E="0.0" SE="0.13650614270880396" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.01863392699723635" WEIGHT="31.513878768008684"/>
<DICH_DATA CI_END="1.000826062840674" CI_START="0.3774009167377578" EFFECT_SIZE="0.6145833333333334" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" LOG_CI_END="3.5860643806731395E-4" LOG_CI_START="-0.42319704923291573" LOG_EFFECT_SIZE="-0.2114192213974242" MODIFIED="2009-11-22 16:16:33 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.24879868877544503" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="0.06190078753638076" WEIGHT="19.399105347816096"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.589218526276694" CI_END="1.1186006964368116" CI_START="0.331735870851284" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6091633411223285" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="47" I2="34.62939315653056" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.048675085382512015" LOG_CI_START="-0.47920756534972103" LOG_EFFECT_SIZE="-0.21526623998360456" METHOD="IV" MODIFIED="2014-07-10 16:35:32 +0100" MODIFIED_BY="[Empty name]" NO="7" NOTES="&lt;p&gt;Email request sent Dec 16 2009 for FLORIDA and L-CAD.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:35:32 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.20446898432053873" P_Q="1.0" P_Z="0.10992848587701504" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13311505245253627" TOTALS="YES" TOTAL_1="559" TOTAL_2="571" WEIGHT="100.00000000000001" Z="1.5985146580209768">
<NAME>Unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1336044616648497" CI_START="0.05792502122262605" EFFECT_SIZE="0.25625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05446154654834115" LOG_CI_START="-1.2371337984207198" LOG_EFFECT_SIZE="-0.5913361259361893" MODIFIED="2009-12-17 13:16:01 +0000" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.758689499134897" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.5756097560975609" WEIGHT="13.56664142200294"/>
<DICH_DATA CI_END="0.9079057513448915" CI_START="0.1548894252423124" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.04195923275127373" LOG_CI_START="-0.8099782317932884" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-11-22 16:17:21 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.45113816179263866" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.203525641025641" WEIGHT="28.56165499522459"/>
<DICH_DATA CI_END="1.7704071898479625" CI_START="0.4806129075696799" EFFECT_SIZE="0.9224318658280922" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.24807316464771226" LOG_CI_START="-0.31820456975556527" LOG_EFFECT_SIZE="-0.0350657025539265" MODIFIED="2010-03-11 17:32:16 +0000" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.33263434430847866" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.11064560701353154" WEIGHT="39.44449184514653"/>
<DICH_DATA CI_END="3.412931451481809" CI_START="0.2963422892605606" EFFECT_SIZE="1.0056818181818181" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5331275655882909" LOG_CI_START="-0.5282063684929774" LOG_EFFECT_SIZE="0.0024605985476567798" MODIFIED="2009-11-22 16:17:21 +0000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.623432806567041" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="0.38866846430405755" WEIGHT="18.42721173762595"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6410101130763977" CI_START="0.005093271698823517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09142270159219312" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.21511125749412982" LOG_CI_START="-2.293003155916405" LOG_EFFECT_SIZE="-1.0389459492111377" METHOD="IV" MODIFIED="2014-07-10 16:35:56 +0100" MODIFIED_BY="[Empty name]" NO="8" NOTES="&lt;p&gt;9 month data used for OACIS-LIPID.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:35:56 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="1.0" P_Q="1.0" P_Z="0.10442555674519283" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="177" WEIGHT="100.0" Z="1.623766947352815">
<NAME>Acute heart failure</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6410101130763977" CI_START="0.005093271698823517" EFFECT_SIZE="0.09142270159219312" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.21511125749412982" LOG_CI_START="-2.293003155916405" LOG_EFFECT_SIZE="-1.0389459492111377" MODIFIED="2009-12-06 16:08:49 +0000" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.473278821803927" STUDY_ID="STD-OACIS_x002d_LIPID-2008" TOTAL_1="176" TOTAL_2="177" VAR="2.1705504867759675" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-07-10 16:37:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Statins versus control: adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="133.46651028146024" CI_START="0.35651795760249627" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.898058252427185" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="2.1253723052169495" LOG_CI_START="-0.4479185901003167" LOG_EFFECT_SIZE="0.8387268575583163" METHOD="IV" MODIFIED="2014-07-10 16:36:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.20137511495383842" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2265" TOTAL_2="2232" WEIGHT="100.0" Z="1.2776436870562817">
<NAME>Rhabdomyolysis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="133.46651028146024" CI_START="0.35651795760249627" EFFECT_SIZE="6.898058252427185" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1253723052169495" LOG_CI_START="-0.4479185901003167" LOG_EFFECT_SIZE="0.8387268575583163" MODIFIED="2010-03-09 14:41:46 +0000" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="1.5115638099047297" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="2.2848251514137017" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2814638971842427" CI_END="21.67119645421397" CI_START="1.0134791719409237" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.686502559199755" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.3358828891287213" LOG_CI_START="0.005814827914007973" LOG_EFFECT_SIZE="0.6708488585213646" METHOD="IV" MODIFIED="2014-07-10 16:37:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8687221522497186" P_Q="1.0" P_Z="0.04803018847006085" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2355" TOTAL_2="2322" WEIGHT="100.0" Z="1.9771012328058992">
<NAME>Elevated CK &gt; 10x upper-limit of normal</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.48758668839782743" MODIFIED="2010-02-07 15:12:17 +0000" MODIFIED_BY="[Empty name]" ORDER="488" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="23.31180199663755"/>
<DICH_DATA CI_END="56.0199281919614" CI_START="0.8493867854596813" EFFECT_SIZE="6.898013245033113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7483425477961017" LOG_CI_START="-0.07089449993420684" LOG_EFFECT_SIZE="0.8387240239309472" MODIFIED="2010-02-07 15:12:31 +0000" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="1.068628847205406" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="1.1419676130795549" WEIGHT="53.45263839713568"/>
<DICH_DATA CI_END="70.49623497028999" CI_START="0.12270895083670152" EFFECT_SIZE="2.9411764705882355" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8481659230156449" LOG_CI_START="-0.9111237571001548" LOG_EFFECT_SIZE="0.4685210829577449" MODIFIED="2010-02-07 15:13:37 +0000" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="1.620820416804222" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="2.6270588235294117" WEIGHT="23.235559606226765"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.708724490187185" CI_END="5.3236874027816885" CI_START="1.1645924440056687" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.489965084800933" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="24" I2="48.110741211574016" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.7262125465711085" LOG_CI_START="0.06617396803433792" LOG_EFFECT_SIZE="0.3961932573027232" METHOD="IV" MODIFIED="2014-07-10 16:37:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.10285005851016638" P_Q="1.0" P_Z="0.018624284091144406" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.32303953239210176" TOTALS="YES" TOTAL_1="5980" TOTAL_2="5934" WEIGHT="100.00000000000001" Z="2.352967055205814">
<NAME>Elevated ALT &gt; 3x upper-limit of normal</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="447.3012627594419" CI_START="1.5826505724978852" EFFECT_SIZE="26.606796116504853" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.650600124214874" LOG_CI_START="0.19938503919122" LOG_EFFECT_SIZE="1.4249925817030469" MODIFIED="2010-02-07 15:15:22 +0000" MODIFIED_BY="[Empty name]" ORDER="503" O_E="0.0" SE="1.439855874653255" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="2.07318493977349" WEIGHT="6.2731597239740715"/>
<DICH_DATA CI_END="4.752424511590993" CI_START="0.9051474872010965" EFFECT_SIZE="2.074040767386091" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.676915227176649" LOG_CI_START="-0.043280649901063215" LOG_EFFECT_SIZE="0.3168172886377929" MODIFIED="2010-02-07 15:16:01 +0000" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.42304662322253567" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.17896844541999007" WEIGHT="29.943545745834452"/>
<DICH_DATA CI_END="8.75818551612524" CI_START="2.062040903728153" EFFECT_SIZE="4.249674902470741" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="9" LOG_CI_END="0.942414140191136" LOG_CI_START="0.3142972759267578" LOG_EFFECT_SIZE="0.6283557080589468" MODIFIED="2010-02-07 15:15:36 +0000" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.36895895529751876" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.13613071069423643" WEIGHT="32.73709277707649"/>
<DICH_DATA CI_END="4.371478490135824" CI_START="0.44209018857985977" EFFECT_SIZE="1.3901754385964913" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6406283457832466" LOG_CI_START="-0.35448912339521044" LOG_EFFECT_SIZE="0.14306961119401806" MODIFIED="2010-02-07 15:15:15 +0000" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.5845369273063421" STUDY_ID="STD-PACT-2004" TOTAL_1="1710" TOTAL_2="1698" VAR="0.34168341938473984" WEIGHT="22.61378038505984"/>
<DICH_DATA CI_END="5.230738882847126" CI_START="0.04590173690132892" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7185630406986137" LOG_CI_START="-1.3381708806415866" LOG_EFFECT_SIZE="-0.3098039199714863" MODIFIED="2010-02-07 15:16:05 +0000" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="1.2081356863923414" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="1.4595918367346938" WEIGHT="8.43242136805516"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-07-10 16:45:48 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Statins versus control at 4 months: sensitivity analyses</NAME>
<DICH_OUTCOME CHI2="7.476958384532079" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.925400528905406" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="27.222957299589904" ID="CMP-005.01" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449766" METHOD="IV" MODIFIED="2014-07-10 16:38:04 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Email request for OACIS-LIPID 4 months data, sent Dec 16 2009.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:38:04 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.6797793638370653" P_Q="0.2411157842620566" P_Z="0.2703666163462425" Q="1.3740596799413025" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="100.00000000000001" Z="1.1022187119663989">
<NAME>Allocation concealment - combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.795698518118632" CI_END="1.15965238119267" CI_START="0.7917540703194271" DF="2" EFFECT_SIZE="0.9582063937194911" ESTIMABLE="YES" EVENTS_1="331" EVENTS_2="346" I2="28.461528056827024" ID="CMP-005.01.01" LOG_CI_END="0.06432782409339816" LOG_CI_START="-0.10140969529078621" LOG_EFFECT_SIZE="-0.018540935598694006" MODIFIED="2010-09-13 15:25:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24712817952674937" P_Z="0.6610097481227679" STUDIES="3" TAU2="0.008416280299853019" TOTAL_1="4220" TOTAL_2="4187" WEIGHT="91.6899021745137" Z="0.43851948729702767">
<NAME>Reported allocation concealment</NAME>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-03-09 16:10:23 +0000" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642889"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2010-03-09 16:10:30 +0000" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318297"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2010-03-09 16:10:07 +0000" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005298"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.314900003549585" CI_END="1.1360940130787736" CI_START="0.4365425086818724" DF="7" EFFECT_SIZE="0.7042395406165887" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.055414271227071654" LOG_CI_START="-0.35997346012084075" LOG_EFFECT_SIZE="-0.15227959444688452" MODIFIED="2010-09-13 15:25:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8544246564084865" P_Z="0.15070918910713632" STUDIES="8" TAU2="0.0" TOTAL_1="614" TOTAL_2="604" WEIGHT="8.310097825486313" Z="1.4370309865809632">
<NAME>No reported allocation concealment</NAME>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2010-03-09 16:10:45 +0000" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.8903852512724564"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:10:54 +0000" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.18947997471887643"/>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-03-09 16:10:59 +0000" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.68302220975359"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2010-03-09 16:11:03 +0000" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.5689450912757454"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:11:07 +0000" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303503"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-09 16:11:11 +0000" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797438"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:11:20 +0000" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.0765057770317064"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2010-03-09 16:11:24 +0000" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.476958384532077" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9254005289054059" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="68.56140499597328" ID="CMP-005.02" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449815" METHOD="IV" MODIFIED="2014-07-10 16:38:29 +0100" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;Email request for OACIS-LIPID 4 months data, sent Dec 16 2009.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:38:29 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.6797793638370655" P_Q="0.07450811716605443" P_Z="0.2703666163462425" Q="3.1808037218963436" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="100.00000000000003" Z="1.102218711966399">
<NAME>Blinded patients and caregivers - combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.407112039469833" CI_END="1.0890037195497488" CI_START="0.8228886545143225" DF="6" EFFECT_SIZE="0.9466408006954832" ESTIMABLE="YES" EVENTS_1="350" EVENTS_2="367" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.037029363114059966" LOG_CI_START="-0.08465892542133162" LOG_EFFECT_SIZE="-0.023814781153635802" MODIFIED="2014-06-26 17:02:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7562842379178432" P_Z="0.4429969542085368" STUDIES="7" TAU2="0.0" TOTAL_1="4649" TOTAL_2="4622" WEIGHT="96.8313308287545" Z="0.7671422438857671">
<NAME>Blinded patients and caregivers</NAME>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-03-09 16:24:35 +0000" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642889"/>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-03-09 16:25:06 +0000" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.68302220975359"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2010-03-09 16:25:15 +0000" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.5689450912757454"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-09 16:25:32 +0000" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797438"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2010-03-09 16:25:36 +0000" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318297"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2010-03-09 16:25:39 +0000" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005298"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:25:57 +0000" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.0765057770317064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8890426231658988" CI_END="1.0034689263974332" CI_START="0.21321060262518743" DF="3" EFFECT_SIZE="0.46254752676113897" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.0015039285892530108" LOG_CI_START="-0.6711912023325224" LOG_EFFECT_SIZE="-0.3348436368716347" MODIFIED="2014-06-26 17:02:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8280713492925311" P_Z="0.051033223998706204" STUDIES="4" TAU2="0.0" TOTAL_1="185" TOTAL_2="169" WEIGHT="3.1686691712455275" Z="1.9512002943191458">
<NAME>No blinded patients and caregivers</NAME>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2010-03-09 16:24:47 +0000" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.8903852512724564"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:24:57 +0000" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.18947997471887643"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:25:26 +0000" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303503"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2010-03-09 16:26:02 +0000" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.476958384532077" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.925400528905406" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="32.38604363927695" ID="CMP-005.03" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449766" METHOD="IV" MODIFIED="2014-07-10 16:38:52 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;Email request for OACIS-LIPID 4 months data, sent Dec 16 2009.&lt;/p&gt;" NOTES_MODIFIED="2014-07-10 16:38:52 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.6797793638370655" P_Q="0.22393379259795865" P_Z="0.2703666163462425" Q="1.4789845970038518" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="99.99999999999999" Z="1.1022187119663989">
<NAME>Blinded assessment - combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.821308281526137" CI_END="1.083487703883482" CI_START="0.8179086911430951" DF="4" EFFECT_SIZE="0.9413787812315381" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="365" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.03482398703022152" LOG_CI_START="-0.08729517694737972" LOG_EFFECT_SIZE="-0.026235594958579137" MODIFIED="2010-09-13 15:25:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4307290651372976" P_Z="0.39970864093951386" STUDIES="5" TAU2="0.0" TOTAL_1="4525" TOTAL_2="4503" WEIGHT="96.14923251706188" Z="0.8421417172693253">
<NAME>Blinded outcome assessors</NAME>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2010-03-09 16:34:58 +0000" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.890385251272456"/>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-03-09 16:34:49 +0000" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642887"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2010-03-09 16:35:28 +0000" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.568945091275745"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2010-03-09 16:35:43 +0000" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318292"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2010-03-09 16:35:46 +0000" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1766655060020876" CI_END="1.2184352159222183" CI_START="0.2989421492822465" DF="5" EFFECT_SIZE="0.6035243509660285" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.08580244274071859" LOG_CI_START="-0.5244128473890689" LOG_EFFECT_SIZE="-0.21930520232417516" MODIFIED="2010-09-13 15:25:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8241993332969442" P_Z="0.15889950374153447" STUDIES="6" TAU2="0.0" TOTAL_1="309" TOTAL_2="288" WEIGHT="3.85076748293811" Z="1.408782458027992">
<NAME>No blinded outcome assessors</NAME>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:35:07 +0000" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.1894799747188764"/>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-03-09 16:35:15 +0000" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.6830222097535898"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:35:34 +0000" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303502"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-09 16:35:39 +0000" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797437"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:35:59 +0000" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.076505777031706"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2010-03-09 16:36:02 +0000" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.5560014406038665" CI_END="1.1419483048326748" CI_START="0.7042691091359168" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8967936860414318" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.057646444160204695" LOG_CI_START="-0.1522613603454661" LOG_EFFECT_SIZE="-0.04730745809263072" METHOD="IV" MODIFIED="2014-07-10 16:39:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9507519723827982" P_Q="0.3325682562879294" P_Z="0.37699633914417474" Q="0.9388720361533187" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4889" TOTAL_2="4844" WEIGHT="100.0" Z="0.8834441795058575">
<NAME>Allocation concealment - death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5232670986952088" CI_END="1.2102236466320426" CI_START="0.7241254331674711" DF="2" EFFECT_SIZE="0.9361376620705655" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="116" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.0828656343851067" LOG_CI_START="-0.14018619870046636" LOG_EFFECT_SIZE="-0.028660282157679864" MODIFIED="2010-09-13 15:21:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7697930764468809" P_Z="0.6144878601505019" STUDIES="3" TAU2="0.0" TOTAL_1="4220" TOTAL_2="4187" WEIGHT="88.56162546909133" Z="0.5036777330070882">
<NAME>Reported allocation concealment</NAME>
<DICH_DATA CI_END="1.3541598816153073" CI_START="0.6025663885114637" EFFECT_SIZE="0.9033112582781457" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13166994322954745" LOG_CI_START="-0.21999509717496601" LOG_EFFECT_SIZE="-0.044162576972709304" MODIFIED="2010-03-09 16:14:51 +0000" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.206569785503636" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.04267107628301818" WEIGHT="35.628601802889655"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2010-03-09 16:15:32 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.5711539009848411"/>
<DICH_DATA CI_END="1.3228992178114711" CI_START="0.6783355915704159" EFFECT_SIZE="0.94729595349193" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" LOG_CI_END="0.12152675967084309" LOG_CI_START="-0.16855539535261824" LOG_EFFECT_SIZE="-0.023514317840887575" MODIFIED="2010-03-09 16:15:36 +0000" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.17039569379060693" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02903469246238228" WEIGHT="52.36186976521683"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0938623057553394" CI_END="1.3141396808556085" CI_START="0.3147690334902231" DF="8" EFFECT_SIZE="0.6431566506023787" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.1186415291512863" LOG_CI_START="-0.5020079994572682" LOG_EFFECT_SIZE="-0.19168323515299085" MODIFIED="2010-09-13 15:21:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.928329724785097" P_Z="0.226032608055325" STUDIES="9" TAU2="0.0" TOTAL_1="669" TOTAL_2="657" WEIGHT="11.438374530908678" Z="1.2106421418936886">
<NAME>No reported allocation concealment</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:14:56 +0000" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.939312694869289"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:15:04 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.5822466837657639"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-03-09 16:15:12 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.5755809203467204"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2010-03-09 16:15:17 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="2.3060982824917464"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:15:21 +0000" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.7725717239723182"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2010-03-09 16:15:27 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.5824437015588021"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:15:45 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.584330678095083"/>
<DICH_DATA CI_END="2.834891059887564" CI_START="0.03353548423416844" EFFECT_SIZE="0.30833333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45253637434048116" LOG_CI_START="-1.4744954183017407" LOG_EFFECT_SIZE="-0.5109795219806298" MODIFIED="2010-03-09 16:15:49 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="1.131948013959257" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.2813063063063064" WEIGHT="1.186531883832734"/>
<DICH_DATA CI_END="3.6930846804714745" CI_START="0.11175181263422147" EFFECT_SIZE="0.6424242424242425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5673892659070993" LOG_CI_START="-0.9517454238053712" LOG_EFFECT_SIZE="-0.19217807894913602" MODIFIED="2010-03-16 16:56:14 +0000" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.7962835906232132" WEIGHT="1.909257961976221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.556001440603867" CI_END="1.1419483048326746" CI_START="0.7042691091359168" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8967936860414318" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="135" I2="0.0" I2_Q="5.085566630853067" ID="CMP-005.05" LOG_CI_END="0.05764644416020461" LOG_CI_START="-0.1522613603454661" LOG_EFFECT_SIZE="-0.04730745809263072" METHOD="IV" MODIFIED="2014-07-10 16:40:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9507519723827982" P_Q="0.3046842614066695" P_Z="0.3769963391441745" Q="1.0535805403913014" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4889" TOTAL_2="4844" WEIGHT="100.00000000000001" Z="0.8834441795058577">
<NAME>Blinded patients and caregivers - death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.983314811106669" CI_END="1.1899534919962096" CI_START="0.7220648071584671" DF="6" EFFECT_SIZE="0.9269431151509717" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="124" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.07552998780923931" LOG_CI_START="-0.1414238216433637" LOG_EFFECT_SIZE="-0.03294691691706219" MODIFIED="2014-06-26 17:03:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8109381341283519" P_Z="0.551652390433058" STUDIES="7" TAU2="0.0" TOTAL_1="4649" TOTAL_2="4622" WEIGHT="93.61007905158368" Z="0.5952858880146349">
<NAME>Blinded patients and caregivers</NAME>
<DICH_DATA CI_END="1.3541598816153073" CI_START="0.6025663885114637" EFFECT_SIZE="0.9033112582781457" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13166994322954745" LOG_CI_START="-0.21999509717496601" LOG_EFFECT_SIZE="-0.044162576972709304" MODIFIED="2010-03-09 16:27:45 +0000" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.206569785503636" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.04267107628301818" WEIGHT="35.628601802889655"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-03-09 16:28:12 +0000" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.5755809203467204"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2010-03-09 16:28:19 +0000" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="2.3060982824917464"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2010-03-09 16:28:35 +0000" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.5824437015588021"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2010-03-09 16:28:40 +0000" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.5711539009848411"/>
<DICH_DATA CI_END="1.3228992178114711" CI_START="0.6783355915704159" EFFECT_SIZE="0.94729595349193" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" LOG_CI_END="0.12152675967084309" LOG_CI_START="-0.16855539535261824" LOG_EFFECT_SIZE="-0.023514317840887575" MODIFIED="2010-03-09 16:28:44 +0000" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.17039569379060693" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02903469246238228" WEIGHT="52.36186976521683"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:29:04 +0000" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.584330678095083"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5191060891058971" CI_END="1.4371744503808093" CI_START="0.21238405597476118" DF="4" EFFECT_SIZE="0.5524789035928652" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="0.1575094878554203" LOG_CI_START="-0.6728780895777967" LOG_EFFECT_SIZE="-0.25768430086118815" MODIFIED="2014-06-26 17:03:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9716145563358162" P_Z="0.2238232303986718" STUDIES="5" TAU2="0.0" TOTAL_1="240" TOTAL_2="222" WEIGHT="6.389920948416327" Z="1.216424625788506">
<NAME>No blinded patients and caregivers</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:27:54 +0000" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.939312694869289"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:28:04 +0000" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.5822466837657639"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:28:27 +0000" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.7725717239723182"/>
<DICH_DATA CI_END="2.834891059887564" CI_START="0.03353548423416844" EFFECT_SIZE="0.30833333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45253637434048116" LOG_CI_START="-1.4744954183017407" LOG_EFFECT_SIZE="-0.5109795219806298" MODIFIED="2010-03-09 16:29:08 +0000" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="1.131948013959257" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.2813063063063064" WEIGHT="1.186531883832734"/>
<DICH_DATA CI_END="3.6930846804714745" CI_START="0.11175181263422147" EFFECT_SIZE="0.6424242424242425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5673892659070993" LOG_CI_START="-0.9517454238053712" LOG_EFFECT_SIZE="-0.19217807894913602" MODIFIED="2010-03-16 16:56:37 +0000" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.7962835906232132" WEIGHT="1.909257961976221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.556001440603867" CI_END="1.1419483048326748" CI_START="0.7042691091359168" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8967936860414318" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.057646444160204695" LOG_CI_START="-0.1522613603454661" LOG_EFFECT_SIZE="-0.04730745809263072" METHOD="IV" MODIFIED="2014-07-10 16:41:52 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9507519723827982" P_Q="0.7349634335106316" P_Z="0.37699633914417463" Q="0.11460295360583095" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4889" TOTAL_2="4844" WEIGHT="100.00000000000001" Z="0.8834441795058576">
<NAME>Blinded assessment - death from all causes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0932703917775455" CI_END="1.1659622843026753" CI_START="0.7059827400721006" DF="4" EFFECT_SIZE="0.907275728922982" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="125" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.06668450240914796" LOG_CI_START="-0.15120591648796128" LOG_EFFECT_SIZE="-0.042260707039406646" MODIFIED="2010-09-13 15:23:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7186089967185725" P_Z="0.4470839495410378" STUDIES="5" TAU2="0.0" TOTAL_1="4525" TOTAL_2="4503" WEIGHT="92.80703644645237" Z="0.7602855066109958">
<NAME>Blinded outcome assessors</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:38:29 +0000" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.9393126948692891"/>
<DICH_DATA CI_END="1.3541598816153073" CI_START="0.6025663885114637" EFFECT_SIZE="0.9033112582781457" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13166994322954745" LOG_CI_START="-0.21999509717496601" LOG_EFFECT_SIZE="-0.044162576972709304" MODIFIED="2010-03-09 16:38:22 +0000" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.206569785503636" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.04267107628301818" WEIGHT="35.62860180288966"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2010-03-09 16:38:55 +0000" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="2.3060982824917464"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2010-03-09 16:39:08 +0000" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.5711539009848412"/>
<DICH_DATA CI_END="1.3228992178114711" CI_START="0.6783355915704159" EFFECT_SIZE="0.94729595349193" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" LOG_CI_END="0.12152675967084309" LOG_CI_START="-0.16855539535261824" LOG_EFFECT_SIZE="-0.023514317840887575" MODIFIED="2010-03-09 16:39:11 +0000" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.17039569379060693" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02903469246238228" WEIGHT="52.36186976521684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.348128095220491" CI_END="1.9006770352334106" CI_START="0.3135058088594844" DF="6" EFFECT_SIZE="0.7719282941514044" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="0.27890832742198624" LOG_CI_START="-0.5037544078404469" LOG_EFFECT_SIZE="-0.11242304020923037" MODIFIED="2010-09-13 15:23:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.885062395085741" P_Z="0.5733904288612719" STUDIES="7" TAU2="0.0" TOTAL_1="364" TOTAL_2="341" WEIGHT="7.192963553547643" Z="0.5630652895942627">
<NAME>No blinded outcome assessors</NAME>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 16:38:34 +0000" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.5822466837657639"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-03-09 16:38:46 +0000" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.5755809203467204"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 16:38:58 +0000" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.7725717239723184"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2010-03-09 16:39:05 +0000" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.5824437015588022"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 16:39:19 +0000" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.5843306780950832"/>
<DICH_DATA CI_END="2.834891059887564" CI_START="0.03353548423416844" EFFECT_SIZE="0.30833333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45253637434048116" LOG_CI_START="-1.4744954183017407" LOG_EFFECT_SIZE="-0.5109795219806298" MODIFIED="2010-03-09 16:39:22 +0000" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="1.131948013959257" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.2813063063063064" WEIGHT="1.1865318838327341"/>
<DICH_DATA CI_END="3.6930846804714745" CI_START="0.11175181263422147" EFFECT_SIZE="0.6424242424242425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5673892659070993" LOG_CI_START="-0.9517454238053712" LOG_EFFECT_SIZE="-0.19217807894913602" MODIFIED="2010-03-16 16:56:52 +0000" MODIFIED_BY="[Empty name]" ORDER="664" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.7962835906232132" WEIGHT="1.9092579619762213"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.90037565073514" CI_END="0.9624700743330633" CI_START="0.5948990254323787" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7566852114509497" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="275" I2="32.775231347375126" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-0.016612764940567043" LOG_CI_START="-0.22555674253862013" LOG_EFFECT_SIZE="-0.12108475373959358" METHOD="IV" MODIFIED="2014-07-10 16:42:17 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15570462248564676" P_Q="0.5319773197868612" P_Z="0.023108836969517408" Q="0.3906137789131745" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03814867339809172" TOTALS="YES" TOTAL_1="4401" TOTAL_2="4369" WEIGHT="100.00000000000003" Z="2.2716305024406354">
<NAME>Allocation concealment - unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8519654582371008" CI_END="0.9705968765290037" CI_START="0.6406984159464093" DF="1" EFFECT_SIZE="0.7885809288301774" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="191" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-0.012961110618508602" LOG_CI_START="-0.19334634975027135" LOG_EFFECT_SIZE="-0.10315373018438997" MODIFIED="2010-09-13 15:23:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35599699455827183" P_Z="0.02498593065859811" STUDIES="2" TAU2="0.0" TOTAL_1="3803" TOTAL_2="3780" WEIGHT="48.41879096418321" Z="2.2416201791842365">
<NAME>Reported allocation concealment</NAME>
<DICH_DATA CI_END="1.294065369337752" CI_START="0.6324295248354761" EFFECT_SIZE="0.904657474758441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" LOG_CI_END="0.11195621514691226" LOG_CI_START="-0.19898786332266455" LOG_EFFECT_SIZE="-0.04351582408787613" MODIFIED="2010-03-09 16:19:53 +0000" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.1826500908910417" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03336105570250579" WEIGHT="21.065403736058013"/>
<DICH_DATA CI_END="0.949127363553169" CI_START="0.569987397336219" EFFECT_SIZE="0.735520656196859" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="130" LOG_CI_END="-0.02267550561599359" LOG_CI_START="-0.24413474665706136" LOG_EFFECT_SIZE="-0.13340512613652747" MODIFIED="2010-03-09 16:20:36 +0000" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.13008625442844635" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.016922433591222478" WEIGHT="27.353387228125197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.970887199186514" CI_END="1.040716258494293" CI_START="0.4407602490851714" DF="6" EFFECT_SIZE="0.6772786408273423" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="84" I2="45.30980137645661" ID="CMP-005.07.02" LOG_CI_END="0.01733233934042941" LOG_CI_START="-0.3557975801758152" LOG_EFFECT_SIZE="-0.1692326204176929" MODIFIED="2010-09-13 15:23:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08928046514170607" P_Z="0.07542380306807406" STUDIES="7" TAU2="0.13644567671745353" TOTAL_1="598" TOTAL_2="589" WEIGHT="51.58120903581681" Z="1.7778785547835192">
<NAME>No reported allocation concealment</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:20:01 +0000" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.8323761198828423"/>
<DICH_DATA CI_END="0.8515570019046186" CI_START="0.07339496928592049" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06978627572949034" LOG_CI_START="-1.1343337069264343" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-03-09 16:20:13 +0000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="0.6253204306798563" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.39102564102564097" WEIGHT="3.5099521661329938"/>
<DICH_DATA CI_END="3.011213824096463" CI_START="0.5342350720757487" EFFECT_SIZE="1.2683438155136268" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4787415955420055" LOG_CI_START="-0.2722676043172956" LOG_EFFECT_SIZE="0.10323699561235497" MODIFIED="2010-03-09 16:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.4411465215528487" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.194610253478178" WEIGHT="6.471851949038188"/>
<DICH_DATA CI_END="1.2401042982048704" CI_START="0.1857908244762304" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09345821276706777" LOG_CI_START="-0.7309757380158933" LOG_EFFECT_SIZE="-0.3187587626244128" MODIFIED="2010-03-09 16:20:22 +0000" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.48427658370378546" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.23452380952380952" WEIGHT="5.5245080046881005"/>
<DICH_DATA CI_END="1.7274438526504503" CI_START="0.7261596364335374" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.23740394034124918" LOG_CI_START="-0.13896789500088588" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-09 16:20:46 +0000" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.22108267915060228" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.04887755102040815" WEIGHT="17.309510146231272"/>
<DICH_DATA CI_END="0.868424484390695" CI_START="0.2931355809032587" EFFECT_SIZE="0.5045454545454545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.061267940530986456" LOG_CI_START="-0.5329314635401112" LOG_EFFECT_SIZE="-0.2970997020355488" MODIFIED="2010-03-09 16:20:50 +0000" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.2770574881876535" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.07676085176085176" WEIGHT="13.109281519322167"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:57:10 +0000" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="3.823729130521242"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.900375650735139" CI_END="0.9624700743330633" CI_START="0.5948990254323788" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7566852114509497" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="275" I2="32.77523134737512" I2_Q="73.26292351686965" ID="CMP-005.08" LOG_CI_END="-0.016612764940567043" LOG_CI_START="-0.22555674253862004" LOG_EFFECT_SIZE="-0.12108475373959358" METHOD="IV" MODIFIED="2014-07-10 16:42:38 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.15570462248564698" P_Q="0.05312074201520045" P_Z="0.023108836969517384" Q="3.7401246940028985" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03814867339809171" TOTALS="YES" TOTAL_1="4401" TOTAL_2="4369" WEIGHT="99.99999999999999" Z="2.271630502440636">
<NAME>Blinded patients and caregivers - unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.524911199404735" CI_END="1.1439649816163187" CI_START="0.6387317611707336" DF="4" EFFECT_SIZE="0.8548021802881864" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="233" I2="46.843226531145994" ID="CMP-005.08.01" LOG_CI_END="0.05841273029304628" LOG_CI_START="-0.19468148785292108" LOG_EFFECT_SIZE="-0.06813437877993737" MODIFIED="2014-06-26 17:03:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11061592075309201" P_Z="0.2913034601507213" STUDIES="5" TAU2="0.04643091393478321" TOTAL_1="4196" TOTAL_2="4182" WEIGHT="75.71010522558564" Z="1.0552665287728553">
<NAME>Blinded patients and caregivers</NAME>
<DICH_DATA CI_END="1.294065369337752" CI_START="0.6324295248354761" EFFECT_SIZE="0.904657474758441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" LOG_CI_END="0.11195621514691226" LOG_CI_START="-0.19898786332266455" LOG_EFFECT_SIZE="-0.04351582408787613" MODIFIED="2010-03-09 16:30:47 +0000" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.1826500908910417" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03336105570250579" WEIGHT="21.065403736058013"/>
<DICH_DATA CI_END="0.8515570019046186" CI_START="0.07339496928592049" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06978627572949034" LOG_CI_START="-1.1343337069264343" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-03-09 16:31:04 +0000" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="0.6253204306798563" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.39102564102564097" WEIGHT="3.509952166132993"/>
<DICH_DATA CI_END="3.011213824096463" CI_START="0.5342350720757487" EFFECT_SIZE="1.2683438155136268" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4787415955420055" LOG_CI_START="-0.2722676043172956" LOG_EFFECT_SIZE="0.10323699561235497" MODIFIED="2010-03-09 16:31:08 +0000" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="0.4411465215528487" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.194610253478178" WEIGHT="6.471851949038186"/>
<DICH_DATA CI_END="0.949127363553169" CI_START="0.569987397336219" EFFECT_SIZE="0.735520656196859" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="130" LOG_CI_END="-0.02267550561599359" LOG_CI_START="-0.24413474665706136" LOG_EFFECT_SIZE="-0.13340512613652747" MODIFIED="2010-03-09 16:31:27 +0000" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.13008625442844635" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.016922433591222478" WEIGHT="27.353387228125186"/>
<DICH_DATA CI_END="1.7274438526504503" CI_START="0.7261596364335374" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.23740394034124918" LOG_CI_START="-0.13896789500088588" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-09 16:31:36 +0000" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.22108267915060228" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.04887755102040815" WEIGHT="17.30951014623127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14120445953083421" CI_END="0.7862001295462663" CI_START="0.33676997919899265" DF="3" EFFECT_SIZE="0.51455670365232" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="42" I2="0.0" ID="CMP-005.08.02" LOG_CI_END="-0.10446688895497316" LOG_CI_START="-0.47266662990790503" LOG_EFFECT_SIZE="-0.2885667594314391" MODIFIED="2014-06-26 17:04:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.986470914003536" P_Z="0.0021253048624841945" STUDIES="4" TAU2="0.0" TOTAL_1="205" TOTAL_2="187" WEIGHT="24.289894774414346" Z="3.0721393456567077">
<NAME>No blinded patients and caregivers</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:30:53 +0000" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.8323761198828419"/>
<DICH_DATA CI_END="1.2401042982048704" CI_START="0.1857908244762304" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09345821276706777" LOG_CI_START="-0.7309757380158933" LOG_EFFECT_SIZE="-0.3187587626244128" MODIFIED="2010-03-09 16:31:12 +0000" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="0.48427658370378546" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.23452380952380952" WEIGHT="5.5245080046881005"/>
<DICH_DATA CI_END="0.868424484390695" CI_START="0.2931355809032587" EFFECT_SIZE="0.5045454545454545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.061267940530986456" LOG_CI_START="-0.5329314635401112" LOG_EFFECT_SIZE="-0.2970997020355488" MODIFIED="2010-03-09 16:31:39 +0000" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.2770574881876535" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.07676085176085176" WEIGHT="13.109281519322161"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:57:21 +0000" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="3.8237291305212415"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.90037565073514" CI_END="0.9624700743330633" CI_START="0.5948990254323787" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7566852114509497" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="275" I2="32.775231347375126" I2_Q="15.820231387091766" ID="CMP-005.09" LOG_CI_END="-0.016612764940567043" LOG_CI_START="-0.22555674253862013" LOG_EFFECT_SIZE="-0.12108475373959358" METHOD="IV" MODIFIED="2014-07-10 16:42:57 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.15570462248564676" P_Q="0.27574677052698393" P_Z="0.023108836969517408" Q="1.1879338901469239" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.038148673398091734" TOTALS="YES" TOTAL_1="4401" TOTAL_2="4369" WEIGHT="100.0" Z="2.2716305024406354">
<NAME>Blinded assessment - unstable angina</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9851882205847455" CI_END="0.9868083934434024" CI_START="0.6607111778896084" DF="3" EFFECT_SIZE="0.8074622814617055" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="203" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="-0.005767165211232164" LOG_CI_START="-0.17998834575001124" LOG_EFFECT_SIZE="-0.09287775548062172" MODIFIED="2010-09-13 15:23:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5754866610807943" P_Z="0.036642636370731306" STUDIES="4" TAU2="0.0" TOTAL_1="4108" TOTAL_2="4096" WEIGHT="56.72301903310423" Z="2.0897235932391975">
<NAME>Blinded outcome assessors</NAME>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 16:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.8323761198828423"/>
<DICH_DATA CI_END="1.294065369337752" CI_START="0.6324295248354761" EFFECT_SIZE="0.904657474758441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" LOG_CI_END="0.11195621514691226" LOG_CI_START="-0.19898786332266455" LOG_EFFECT_SIZE="-0.04351582408787613" MODIFIED="2010-03-09 16:45:34 +0000" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.1826500908910417" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03336105570250579" WEIGHT="21.065403736058006"/>
<DICH_DATA CI_END="3.011213824096463" CI_START="0.5342350720757487" EFFECT_SIZE="1.2683438155136268" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4787415955420055" LOG_CI_START="-0.2722676043172956" LOG_EFFECT_SIZE="0.10323699561235497" MODIFIED="2010-03-09 16:45:59 +0000" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="0.4411465215528487" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.194610253478178" WEIGHT="6.471851949038187"/>
<DICH_DATA CI_END="0.949127363553169" CI_START="0.569987397336219" EFFECT_SIZE="0.735520656196859" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="130" LOG_CI_END="-0.02267550561599359" LOG_CI_START="-0.24413474665706136" LOG_EFFECT_SIZE="-0.13340512613652747" MODIFIED="2010-03-09 16:46:14 +0000" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.13008625442844635" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.016922433591222478" WEIGHT="27.35338722812519"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.391729328916213" CI_END="0.9985636403117865" CI_START="0.349503821972114" DF="4" EFFECT_SIZE="0.5907637503870364" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="72" I2="57.40933474643064" ID="CMP-005.09.02" LOG_CI_END="-6.242515188810376E-4" LOG_CI_START="-0.4565480706984903" LOG_EFFECT_SIZE="-0.22858616110868565" MODIFIED="2010-09-13 15:23:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.052020172944831966" P_Z="0.04937592190489966" STUDIES="5" TAU2="0.1877449326726511" TOTAL_1="293" TOTAL_2="273" WEIGHT="43.27698096689576" Z="1.965331155294602">
<NAME>No blinded outcome assessors</NAME>
<DICH_DATA CI_END="0.8515570019046186" CI_START="0.07339496928592049" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06978627572949034" LOG_CI_START="-1.1343337069264343" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-03-09 16:45:53 +0000" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.6253204306798563" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.39102564102564097" WEIGHT="3.5099521661329938"/>
<DICH_DATA CI_END="1.2401042982048704" CI_START="0.1857908244762304" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09345821276706777" LOG_CI_START="-0.7309757380158933" LOG_EFFECT_SIZE="-0.3187587626244128" MODIFIED="2010-03-09 16:46:03 +0000" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="0.48427658370378546" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.23452380952380952" WEIGHT="5.5245080046881005"/>
<DICH_DATA CI_END="1.7274438526504503" CI_START="0.7261596364335374" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.23740394034124918" LOG_CI_START="-0.13896789500088588" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-09 16:46:24 +0000" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.22108267915060228" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.04887755102040815" WEIGHT="17.30951014623127"/>
<DICH_DATA CI_END="0.868424484390695" CI_START="0.2931355809032587" EFFECT_SIZE="0.5045454545454545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.061267940530986456" LOG_CI_START="-0.5329314635401112" LOG_EFFECT_SIZE="-0.2970997020355488" MODIFIED="2010-03-09 16:46:27 +0000" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.2770574881876535" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.07676085176085176" WEIGHT="13.109281519322163"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:57:33 +0000" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="3.823729130521242"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.426047553437908" CI_END="1.1698774879210956" CI_START="0.7768751151694564" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9533355695466604" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="0.06814038387806132" LOG_CI_START="-0.10964878963139256" LOG_EFFECT_SIZE="-0.020754202876665635" METHOD="IV" MODIFIED="2014-07-10 16:43:22 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9422159625443307" P_Q="1.0" P_Z="0.6472452829333686" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6684" TOTAL_2="6654" WEIGHT="100.0" Z="0.45759243224041707">
<NAME>Death from all causes including PRINCESS</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.3912375470442937"/>
<DICH_DATA CI_END="1.3541598816153073" CI_START="0.6025663885114637" EFFECT_SIZE="0.9033112582781457" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" LOG_CI_END="0.13166994322954745" LOG_CI_START="-0.21999509717496601" LOG_EFFECT_SIZE="-0.044162576972709304" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.206569785503636" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.04267107628301818" WEIGHT="25.55949265325209"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.41769615093018997"/>
<DICH_DATA CI_END="72.52933375049966" CI_START="0.12408772471232023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8605136880806552" LOG_CI_START="-0.9062711786413304" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="0.41291421948982837"/>
<DICH_DATA CI_END="1.6986170104599623" CI_START="0.070442646104696" EFFECT_SIZE="0.34591194968553457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2300954689256603" LOG_CI_START="-1.1521643385780755" LOG_EFFECT_SIZE="-0.46103443482620765" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.8119462532240928" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.6592567181246426" WEIGHT="1.6543647273928248"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.5542328439444747"/>
<DICH_DATA CI_END="65.40585934911009" CI_START="0.11619307339667935" EFFECT_SIZE="2.7567567567567566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8156166561071514" LOG_CI_START="-0.934819760717306" LOG_EFFECT_SIZE="0.44039844769492253" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="1.6156199661225275" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="2.610227874933757" WEIGHT="0.417837488916496"/>
<DICH_DATA CI_END="71.6718417240772" CI_START="0.11963595137427359" EFFECT_SIZE="2.9282296650717705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8553485645131722" LOG_CI_START="-0.9221382924441578" LOG_EFFECT_SIZE="0.4666051360345072" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="1.6315095285584151" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="2.661823341776902" WEIGHT="0.40973833373709084"/>
<DICH_DATA CI_END="1.3228992178114711" CI_START="0.6783355915704159" EFFECT_SIZE="0.94729595349193" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="68" LOG_CI_END="0.12152675967084309" LOG_CI_START="-0.16855539535261824" LOG_EFFECT_SIZE="-0.023514317840887575" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="0.17039569379060693" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.02903469246238228" WEIGHT="37.56372009709503"/>
<DICH_DATA CI_END="6.684247769112593" CI_START="0.14368108920766465" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8250525397797073" LOG_CI_START="-0.8426003883947175" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="0.9795875850247867" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.9595918367346938" WEIGHT="1.1365780939461076"/>
<DICH_DATA CI_END="1.6363088304706925" CI_START="0.7575865125876674" EFFECT_SIZE="1.113393686165274" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" LOG_CI_END="0.21386527409784167" LOG_CI_START="-0.12056776573774483" LOG_EFFECT_SIZE="0.04664875418004842" MODIFIED="2010-03-09 15:11:31 +0000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.19644762306966979" STUDY_ID="STD-PRINCESS-2004" TOTAL_1="1795" TOTAL_2="1810" VAR="0.03859166860972306" WEIGHT="28.26130872421972"/>
<DICH_DATA CI_END="2.834891059887564" CI_START="0.03353548423416844" EFFECT_SIZE="0.30833333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45253637434048116" LOG_CI_START="-1.4744954183017407" LOG_EFFECT_SIZE="-0.5109795219806298" MODIFIED="2010-03-09 14:59:12 +0000" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="1.131948013959257" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.2813063063063064" WEIGHT="0.8512024450314647"/>
<DICH_DATA CI_END="3.6930846804714745" CI_START="0.11175181263422147" EFFECT_SIZE="0.6424242424242425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5673892659070993" LOG_CI_START="-0.9517454238053712" LOG_EFFECT_SIZE="-0.19217807894913602" MODIFIED="2010-03-16 16:58:03 +0000" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.8923472365750976" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.7962835906232132" WEIGHT="1.3696766750003753"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.887818144499123" CI_END="1.0348266548945904" CI_START="0.775393012002124" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.895766351700486" ESTIMABLE="YES" EVENTS_1="332" EVENTS_2="371" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.014867606674335464" LOG_CI_START="-0.11047811726044718" LOG_EFFECT_SIZE="-0.04780525529305588" METHOD="IV" MODIFIED="2014-07-10 16:44:00 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.5427822474440458" P_Q="1.0" P_Z="0.1349117354128781" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6579" TOTAL_2="6563" WEIGHT="100.0" Z="1.4950103713930065">
<NAME>Fatal and non-fatal myocardial infarction or reinfarction including PRINCESS</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5806532906912742" CI_START="0.12208365990945234" EFFECT_SIZE="0.4392857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19883661980427694" LOG_CI_START="-0.9133424596099194" LOG_EFFECT_SIZE="-0.3572529199028213" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.6532994966231316" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.4268002322880371" WEIGHT="1.2701926718170908"/>
<DICH_DATA CI_END="1.1533499081765424" CI_START="0.7259747497731955" EFFECT_SIZE="0.915042573320719" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="140" LOG_CI_END="0.0619610853834204" LOG_CI_START="-0.139078484292842" LOG_EFFECT_SIZE="-0.038558699454710785" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.11809163838975623" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.013945635057576948" WEIGHT="38.87370672930042"/>
<DICH_DATA CI_END="3.1351978297218888" CI_START="0.03543990432047708" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49626494983846475" LOG_CI_START="-1.4505074592777896" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="1.1435437497937313" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="1.3076923076923077" WEIGHT="0.41456122682160346"/>
<DICH_DATA CI_END="3.9341406491010775" CI_START="0.48663263510962934" EFFECT_SIZE="1.3836477987421383" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5948498822830081" LOG_CI_START="-0.31279876927949857" LOG_EFFECT_SIZE="0.14102555650175472" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.5331573108611027" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.2842567181246426" WEIGHT="1.9071441159198406"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8907839703041924"/>
<DICH_DATA CI_END="8.746170592640663" CI_START="0.5929967800350141" EFFECT_SIZE="2.2773780975219826" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9418179439349709" LOG_CI_START="-0.22694766484285708" LOG_EFFECT_SIZE="0.35743513954605693" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="0.6865387040791666" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.4713353921987015" WEIGHT="1.150175726998144"/>
<DICH_DATA CI_END="1.1508543185830848" CI_START="0.7142172140146967" EFFECT_SIZE="0.9066200776263413" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="131" LOG_CI_END="0.06102035174468526" LOG_CI_START="-0.14616968668103997" LOG_EFFECT_SIZE="-0.04257466746817732" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="403" O_E="0.0" SE="0.12170445417850197" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.014811974166887084" WEIGHT="36.6000184225294"/>
<DICH_DATA CI_END="10.216097979108612" CI_START="0.3760339816489496" EFFECT_SIZE="1.96" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0092850494454686" LOG_CI_START="-0.4247729067325167" LOG_EFFECT_SIZE="0.292256071356476" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="404" O_E="0.0" SE="0.8423727421603181" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.7095918367346938" WEIGHT="0.7639864205269701"/>
<DICH_DATA CI_END="1.2152063708626637" CI_START="0.5921733334670961" EFFECT_SIZE="0.8482999513640183" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="63" LOG_CI_END="0.08465003770071995" LOG_CI_START="-0.22755115349661206" LOG_EFFECT_SIZE="-0.07145055789794608" MODIFIED="2010-03-09 15:12:59 +0000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.18338852513013348" STUDY_ID="STD-PRINCESS-2004" TOTAL_1="1795" TOTAL_2="1810" VAR="0.033631351149405596" WEIGHT="16.119439417517377"/>
<DICH_DATA CI_END="1.220841379922235" CI_START="0.019468017305102354" EFFECT_SIZE="0.15416666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.08665924109517922" LOG_CI_START="-1.7106782763844013" LOG_EFFECT_SIZE="-0.812009517644611" MODIFIED="2010-03-09 15:00:01 +0000" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="1.0557649547317054" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="1.1146396396396399" WEIGHT="0.48636214620660934"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:58:27 +0000" MODIFIED_BY="[Empty name]" ORDER="406" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="1.5236291520583571"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.521447435201839" CI_END="1.1819267796679545" CI_START="0.5228260638890728" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7860929499867583" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="0.07259057284715743" LOG_CI_START="-0.28164277013309713" LOG_EFFECT_SIZE="-0.10452609864296986" METHOD="IV" MODIFIED="2014-07-10 16:44:30 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5965982795881034" P_Q="1.0" P_Z="0.24740296549040497" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6071" TOTAL_2="6070" WEIGHT="100.00000000000001" Z="1.1566804359019447">
<NAME>Fatal and non-fatal stroke including PRINCESS</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.832443951481025" CI_START="0.06635899064096924" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1995479592538743" LOG_CI_START="-1.1781002284703284" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="1.3966423150175427" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="1.950609756097561" WEIGHT="2.2196458507699623"/>
<DICH_DATA CI_END="2.7709570592052306" CI_START="0.6230166386851658" EFFECT_SIZE="1.3139072847682118" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4426297956867012" LOG_CI_START="-0.2055003546367205" LOG_EFFECT_SIZE="0.11856472052499038" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.38071485859596477" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.14494380355574543" WEIGHT="29.871320783493648"/>
<DICH_DATA CI_END="8.058814861166631" CI_START="0.013787524968035585" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9062711786413306" LOG_CI_START="-1.8605136880806552" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="1.6252231265184678" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="2.641350210970464" WEIGHT="1.6391854565936521"/>
<DICH_DATA CI_END="8.452536623426301" CI_START="0.01415224441022766" EFFECT_SIZE="0.3458646616541353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9269870611671758" LOG_CI_START="-1.8491746797381994" LOG_EFFECT_SIZE="-0.46109380928551175" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="1.6307311488300666" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="2.659284079764629" WEIGHT="1.6281310013244519"/>
<DICH_DATA CI_END="1.0026870879334753" CI_START="0.25258283185326486" EFFECT_SIZE="0.5032509752925878" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="0.0011654223660067036" LOG_CI_START="-0.597596171931046" LOG_EFFECT_SIZE="-0.29821537478251964" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.351715524407782" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.12370381010944109" WEIGHT="35.00023845476461"/>
<DICH_DATA CI_END="3.9827136850633797" CI_START="0.009653405765447983" EFFECT_SIZE="0.19607843137254902" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6001790863574832" LOG_CI_START="-2.015319438553356" LOG_EFFECT_SIZE="-0.7075701760979364" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="1.5363567804591305" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="2.360392156862745" WEIGHT="1.834298101273146"/>
<DICH_DATA CI_END="2.2384995584824154" CI_START="0.454225206312629" EFFECT_SIZE="1.0083565459610029" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.34995701306001803" LOG_CI_START="-0.3427287691503248" LOG_EFFECT_SIZE="0.003614121954846599" MODIFIED="2010-03-09 15:14:34 +0000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.40688705732027713" STUDY_ID="STD-PRINCESS-2004" TOTAL_1="1795" TOTAL_2="1810" VAR="0.16555707741475448" WEIGHT="26.152085547793675"/>
<DICH_DATA CI_END="7.355395653031318" CI_START="0.012976301617136022" EFFECT_SIZE="0.3089430894308943" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8666060387639877" LOG_CI_START="-1.8868490684091632" LOG_EFFECT_SIZE="-0.5101215148225877" MODIFIED="2010-03-09 15:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="1.6173931597761082" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="2.6159606332905434" WEIGHT="1.655094803986862"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.232303786562507" CI_END="0.9456693873188238" CI_START="0.6499511045128273" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7839890705818788" ESTIMABLE="YES" EVENTS_1="309" EVENTS_2="389" I2="26.42432564594475" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-0.024260669474547532" LOG_CI_START="-0.18711931387868228" LOG_EFFECT_SIZE="-0.10568999167661491" METHOD="IV" MODIFIED="2014-07-10 16:44:55 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.20052778733412158" P_Q="1.0" P_Z="0.010962044185670056" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021244485278950516" TOTALS="YES" TOTAL_1="6196" TOTAL_2="6179" WEIGHT="100.0" Z="2.543906440710176">
<NAME>Unstable angina including PRINCESS</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8751741606990042" CI_START="0.12049637644162477" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5882912256373874" LOG_CI_START="-0.9190260129652037" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="1.1365793744411345"/>
<DICH_DATA CI_END="1.294065369337752" CI_START="0.6324295248354761" EFFECT_SIZE="0.904657474758441" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="61" LOG_CI_END="0.11195621514691226" LOG_CI_START="-0.19898786332266455" LOG_EFFECT_SIZE="-0.04351582408787613" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.1826500908910417" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.03336105570250579" WEIGHT="16.759463847858807"/>
<DICH_DATA CI_END="0.8515570019046186" CI_START="0.07339496928592049" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06978627572949034" LOG_CI_START="-1.1343337069264343" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.6253204306798563" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.39102564102564097" WEIGHT="2.219805733135647"/>
<DICH_DATA CI_END="3.011213824096463" CI_START="0.5342350720757487" EFFECT_SIZE="1.2683438155136268" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4787415955420055" LOG_CI_START="-0.2722676043172956" LOG_EFFECT_SIZE="0.10323699561235497" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.4411465215528487" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.194610253478178" WEIGHT="4.239701177008636"/>
<DICH_DATA CI_END="1.2401042982048704" CI_START="0.1857908244762304" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09345821276706777" LOG_CI_START="-0.7309757380158933" LOG_EFFECT_SIZE="-0.3187587626244128" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.48427658370378546" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="0.23452380952380952" WEIGHT="3.578080663505342"/>
<DICH_DATA CI_END="0.949127363553169" CI_START="0.569987397336219" EFFECT_SIZE="0.735520656196859" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="130" LOG_CI_END="-0.02267550561599359" LOG_CI_START="-0.24413474665706136" LOG_EFFECT_SIZE="-0.13340512613652747" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.13008625442844635" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.016922433591222478" WEIGHT="23.977822078969965"/>
<DICH_DATA CI_END="1.7274438526504503" CI_START="0.7261596364335374" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.23740394034124918" LOG_CI_START="-0.13896789500088588" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.22108267915060228" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.04887755102040815" WEIGHT="13.050955709052324"/>
<DICH_DATA CI_END="1.105176215827535" CI_START="0.6524233220625555" EFFECT_SIZE="0.8491423544934761" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="114" LOG_CI_END="0.04343153002116148" LOG_CI_START="-0.18547052270527672" LOG_EFFECT_SIZE="-0.07101949634205759" MODIFIED="2010-03-09 15:17:51 +0000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.13445819885494492" STUDY_ID="STD-PRINCESS-2004" TOTAL_1="1795" TOTAL_2="1810" VAR="0.018079007239315912" WEIGHT="23.272591811278772"/>
<DICH_DATA CI_END="0.868424484390695" CI_START="0.2931355809032587" EFFECT_SIZE="0.5045454545454545" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.061267940530986456" LOG_CI_START="-0.5329314635401112" LOG_EFFECT_SIZE="-0.2970997020355488" MODIFIED="2010-03-09 15:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.2770574881876535" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.07676085176085176" WEIGHT="9.337854627241592"/>
<DICH_DATA CI_END="1.7726108023521314" CI_START="0.1710554324548889" EFFECT_SIZE="0.5506493506493506" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24861339158210682" LOG_CI_START="-0.7668631287416054" LOG_EFFECT_SIZE="-0.25912486857974926" MODIFIED="2010-03-16 16:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.5964959347279936" STUDY_ID="STD-Shal_x0027_nev-2007" TOTAL_1="55" TOTAL_2="53" VAR="0.3558074001470228" WEIGHT="2.427144977507779"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.476958384532077" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9254005289054059" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449815" METHOD="IV" MODIFIED="2014-07-10 16:45:26 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.6797793638370655" P_Q="0.7226536256213005" P_Z="0.2703666163462425" Q="0.12596438885931563" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="100.00000000000001" Z="1.102218711966399">
<NAME>Initiation of statins</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.846223511105141" CI_END="1.6415541349881146" CI_START="0.4073351049198417" DF="5" EFFECT_SIZE="0.8177179378043407" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="14.47470336188318" ID="CMP-005.14.01" LOG_CI_END="0.21525520941622583" LOG_CI_START="-0.3900481599704797" LOG_EFFECT_SIZE="-0.08739647527712698" MODIFIED="2010-09-13 15:13:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32147102967566354" P_Z="0.5714093031047691" STUDIES="6" TAU2="0.11040949033003052" TOTAL_1="656" TOTAL_2="639" WEIGHT="4.690368952639591" Z="0.5659771697371166">
<NAME>Statin initiated within 3 days</NAME>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-05-25 12:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.18947997471887643"/>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-05-25 12:49:07 +0100" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.68302220975359"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-05-25 12:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797438"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2010-05-25 12:50:52 +0100" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318297"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-05-25 12:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.0765057770317064"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2010-05-25 12:51:59 +0100" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5260603124989214" CI_END="1.071149654498029" CI_START="0.8075962273374175" DF="4" EFFECT_SIZE="0.930084092911166" ESTIMABLE="YES" EVENTS_1="339" EVENTS_2="363" I2="0.0" ID="CMP-005.14.02" LOG_CI_END="0.029850152047713047" LOG_CI_START="-0.09280571851785922" LOG_EFFECT_SIZE="-0.03147778323507309" MODIFIED="2010-09-13 15:13:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8220155230369401" P_Z="0.3144201443468978" STUDIES="5" TAU2="0.0" TOTAL_1="4178" TOTAL_2="4152" WEIGHT="95.30963104736043" Z="1.0059905191561032">
<NAME>Initiation of statins up to 14 days</NAME>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2010-05-25 12:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.8903852512724564"/>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-05-25 12:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642889"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2010-05-25 12:49:27 +0100" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.5689450912757454"/>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-05-25 12:50:14 +0100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303503"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2010-05-25 12:51:05 +0100" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005298"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.476958384532077" CI_END="1.0621898646704724" CI_START="0.8062269914089975" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.925400528905406" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="385" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="0.02620215310017123" LOG_CI_START="-0.09354266633707081" LOG_EFFECT_SIZE="-0.033670256618449766" METHOD="IV" MODIFIED="2014-07-10 16:45:48 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6797793638370655" P_Q="0.6067552535959319" P_Z="0.2703666163462425" Q="1.8377485529039166" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4834" TOTAL_2="4791" WEIGHT="99.99999999999997" Z="1.1022187119663989">
<NAME>Types of statins</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors early statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.953391671532398" CI_END="1.4546959981043648" CI_START="0.29437921702894715" DF="3" EFFECT_SIZE="0.6543945819894185" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="0.1627722440846663" LOG_CI_START="-0.5310928541451724" LOG_EFFECT_SIZE="-0.18416030503025302" MODIFIED="2010-09-13 15:14:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5821368625862904" P_Z="0.2981555340106522" STUDIES="4" TAU2="0.0" TOTAL_1="196" TOTAL_2="175" WEIGHT="2.978265298465644" Z="1.0403969479428832">
<NAME>Pravastatin</NAME>
<DICH_DATA CI_END="12.507149303287491" CI_START="0.05117073319271696" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0971583342392488" LOG_CI_START="-1.2909783602553615" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-05-25 12:27:22 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="1.402803315813426" STUDY_ID="STD-L_x002d_CAD-2000" TOTAL_1="70" TOTAL_2="56" VAR="1.967857142857143" WEIGHT="0.2514172683303502"/>
<DICH_DATA CI_END="4.229120380084079" CI_START="0.19868854566893931" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6262500473275979" LOG_CI_START="-0.7018271691063976" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-05-25 12:28:35 +0100" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.7801191310215758" STUDY_ID="STD-LAMIL-1997" TOTAL_1="36" TOTAL_2="33" VAR="0.6085858585858586" WEIGHT="0.8129555761797437"/>
<DICH_DATA CI_END="3.700691354013606" CI_START="0.2595190757960381" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5682828654684294" LOG_CI_START="-0.5858307140834398" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2010-05-25 12:28:57 +0100" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.677932029583124" STUDY_ID="STD-PAIS-2001" TOTAL_1="50" TOTAL_2="49" VAR="0.45959183673469384" WEIGHT="1.076505777031706"/>
<DICH_DATA CI_END="1.1922128346641898" CI_START="0.058585964472680725" EFFECT_SIZE="0.2642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.07635379287831977" LOG_CI_START="-1.232206416100806" LOG_EFFECT_SIZE="-0.577926311611243" MODIFIED="2010-05-25 12:29:23 +0100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.7686547442318402" STUDY_ID="STD-PTT-2002" TOTAL_1="40" TOTAL_2="37" VAR="0.5908301158301157" WEIGHT="0.8373866769238443"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.482119270576997" CI_END="2.528657999310259" CI_START="0.5418896455681608" DF="2" EFFECT_SIZE="1.1705783130612537" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="19.423694755205016" ID="CMP-005.15.02" LOG_CI_END="0.40289009503986767" LOG_CI_START="-0.26608914741088624" LOG_EFFECT_SIZE="0.06840047381449066" MODIFIED="2010-05-28 13:42:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28907782542470484" P_Z="0.6885695260755272" STUDIES="3" TAU2="0.09768152238222348" TOTAL_1="760" TOTAL_2="760" WEIGHT="4.342986039061164" Z="0.40079708515543555">
<NAME>Fluvastatin</NAME>
<DICH_DATA CI_END="2.6510719778346834" CI_START="0.09430147581439585" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42342151918992577" LOG_CI_START="-1.0254815105178883" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-05-25 12:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.8510928118360385" STUDY_ID="STD-FACS-2010" TOTAL_1="78" TOTAL_2="78" VAR="0.7243589743589745" WEIGHT="0.6830222097535898"/>
<DICH_DATA CI_END="2.452659863205972" CI_START="0.4390725793545526" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.38963732408278384" LOG_CI_START="-0.3574636842958743" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2010-05-25 12:31:04 +0100" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.43885083053125923" STUDY_ID="STD-FLORIDA-2002" TOTAL_1="265" TOTAL_2="275" VAR="0.192590051457976" WEIGHT="2.568945091275745"/>
<DICH_DATA CI_END="9.74165985716198" CI_START="0.6953784241852161" EFFECT_SIZE="2.6027178257394086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9886329615387138" LOG_CI_START="-0.1577787884912264" LOG_EFFECT_SIZE="0.41542708652374366" MODIFIED="2010-05-25 12:31:23 +0100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.673407936797272" STUDY_ID="STD-LIPS-2002" TOTAL_1="417" TOTAL_2="407" VAR="0.45347824934155867" WEIGHT="1.0910187380318292"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.092837785371271" CI_END="1.0607994348331728" CI_START="0.718055771705254" DF="2" EFFECT_SIZE="0.8727617984327861" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="193" I2="0.0" ID="CMP-005.15.03" LOG_CI_END="0.02563327967975922" LOG_CI_START="-0.14384182260564865" LOG_EFFECT_SIZE="-0.05910427146294473" MODIFIED="2010-05-25 12:31:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5790197549353231" P_Z="0.17160307199364402" STUDIES="3" TAU2="0.0" TOTAL_1="1613" TOTAL_2="1624" WEIGHT="49.9231129060443" Z="1.3670709365292344">
<NAME>Atorvastatin</NAME>
<DICH_DATA CI_END="1.5520820582821222" CI_START="0.20892386042239777" EFFECT_SIZE="0.5694444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19091467859551414" LOG_CI_START="-0.6800119580185802" LOG_EFFECT_SIZE="-0.24454863971153298" MODIFIED="2010-05-25 12:29:57 +0100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.5115866175034997" STUDY_ID="STD-Colivicchi-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.26172086720867205" WEIGHT="1.890385251272456"/>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-05-25 12:30:13 +0100" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-ESTABLISH-2004" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.1894799747188764"/>
<DICH_DATA CI_END="1.0875228207181067" CI_START="0.729993028139742" EFFECT_SIZE="0.8910017267475324" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="183" LOG_CI_END="0.03643837901330497" LOG_CI_START="-0.13668128762597895" LOG_EFFECT_SIZE="-0.050121454306336986" MODIFIED="2010-05-25 12:31:42 +0100" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.10169134914008605" STUDY_ID="STD-MIRACL-2001" TOTAL_1="1538" TOTAL_2="1548" VAR="0.01034113048993088" WEIGHT="47.84324768005297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2243257792684232" CI_START="0.8030947013629542" DF="0" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" I2="0.0" ID="CMP-005.15.04" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-09-13 15:14:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9374170674484346" STUDIES="1" TAU2="0.0" TOTAL_1="2265" TOTAL_2="2232" WEIGHT="42.75563575642887" Z="0.0785166737320002">
<NAME>Simvastatin</NAME>
<DICH_DATA CI_END="1.2243257792684232" CI_START="0.8030947013629542" EFFECT_SIZE="0.9915894039735099" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="160" LOG_CI_END="0.08789699404586497" LOG_CI_START="-0.09523323946063424" LOG_EFFECT_SIZE="-0.0036681227073846164" MODIFIED="2010-05-25 12:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.10757160567099348" STUDY_ID="STD-de-Lemos-2004" TOTAL_1="2265" TOTAL_2="2232" VAR="0.011571650346635716" WEIGHT="42.75563575642887"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-11 11:50:33 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow chart.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeIAAANSCAYAAAC5vM3/AAB72UlEQVR42uydf2TW3///37y85CVJ
ZJIkMZNkJpIkSUyS/pjIJHnJSCaTiUwySSQzMzOSyUwiySQZmckkkclMMiZJMpEkycv5fO/H91zO
dfb8eV3Xtuu6drtx2a7r+Xye5znP83ic+/Oc53mex/9MDfG///2Pzxr6AACsBWqmtaNhXoPGSZ0D
AEJMgwzUPQDAmhZiGmLABgAAIaYRBmwAAAAhBoQYAAAhphEGbAAAACEGhBgAACGmEQZsAAAAIa4H
3r17V9XpYQMAAAhxET9//jQXLlww69evN+vWrTOnTp0y3759K9rnypUrZsOGDeaff/6x2798+ZLr
eMfDhw+XXQyUh+VML0/+/X2rQQQRYgBAiKuwEb506ZIZHBw0//33n/1IdCWmjtu3b5uBgYHC9hs3
bpjDhw9nPt7x8eNHe9xyi0Gl0y8nPYQYAAAhTm2EN23aZAXU8efPn6Je4M6dO22v1+fvv//OfLyj
tbXVvH//PlUMtH1kZMRs3rzZ9rI7OzvNr1+/lvTQtU09dIn7p0+fCsdGrbHc29trNm7caI/p6upa
cr579+6Z7du3m7/++suW7dmzZ7Hp+enOz8+bEydO2HzouKamJvP48eNYIf7w4YNpbm5eUmZds23b
tpkfP34gxAAAa02IQ37//m0aGhoit33//t2KWnt7e67j1YtWrzpLPrS9paXFiqsEXudTr9tx586d
oh760NCQOXv2bGw5tV1Cq30leGNjY+bWrVtF+0tMnZhLhP0bjTA9/7tEdXR0tJAX5csve1SP+MiR
I2ZycrIoTeWvo6ODHjEAAEJszP379821a9eW/H769Gnbo9Tn7du3mY9//fq1OXr0aOZ8aPv09HTh
u3rj6i06du/ebcXeF371nuPSl6j7PXbXy/f3dyKcJKBZ869edVI64+PjdnTAZ+/evYnXFCEGAFgj
Qry4uGgFVz3HODQsvGfPnkzHa6hVIuNP7soixKFw+j1UX+iitofpa1s4xBwnlqUI8atXr+yNh0YJ
dJMQd6z/v4bB5+bm7P9v3ryx16iabsYAABDiVWiEJZ5nzpwxX79+Td3PF76k48+dO2cePXqUKx9R
2/3zRZ07STijhDvtfFmFWM+yd+3aZe7evWsmJibM58+fMwmxhuo101xoWH14eBghBgBYy0KsnqyE
YWFhYck2PfP0xTUcCk46vpRg9do2MzNT+K5XofTqlEO98XBo2p8cFqat/fVsezmEWPny01b5swix
rqcmeGmkQJPIwsloCDEAwBoS4pcvX5pDhw4VDR/7aCj6+vXrhQlJV69etZ+sx+cVA23XTGiJlTtf
W1tbYbsma/X39xfyo1enGhsbC9slcHrm68Ra+9+8ebOwv777r1+lCXGYXjjE7GZJz87Omn379mUS
YtcTPnnypJ0VXi2jIgAACPEqNMKaCJXUY9WQs8RCvU5N1JIw5zm+FCGWuG3ZssX2xi9fvhy5wIib
OCZB02tBDs2IVl79XnJPT4/tveo3zZDWEHJWIQ7T87dNTU3ZiV8aLtcQdbhgSZIQa0KaflvJlbsQ
YgBAiKtQiMnn6qCbAfWoubYAAAgx+VxhNESuXrqG/Lm2AAAIcVVR6bWiqxE9d9a71Ss1SQshBgCE
GCEGbAAAACEGhBgAACGmEQZsAAAAIQaEGAAAIaYRBmwAAAAhBoQYAAAhphEGbAAAACEGhBgAACGm
EQZsAAAAIQaEGAAAIaYRBmwAAAAhBoQYAAAhphEGbAAAoDaFmIYYEQYAQIhpkIE6BwBY20LsGmY+
a+cDAIAQAz1DAABAiBFiqgkAACEGhBgAABBihBgAABBiQIgBAAAhRogBAAAhBoQYAAAQYoQYAAAQ
YkCIAQAAIUaIAQAAIQaEGAAAEGKEGAAAEGJAiAEAACFGiAEAACEGhBgAABBihBgAABBiQIgBABBi
QIgBAAAhBoQYAAAhBoQYAAAQYkCIAQAQYkCIAQAAIQaEGAAAIQaEGAAAEGKEGAAAEGJAiAEAACFG
iAEAACEGhBgAABBihBgAABBiQIgBAAAhRogBAAAhBoQYAAAQYoQYAAAQYkCIAQAAIUaIAQAAIQaE
GAAAEGKEGAAAEGJAiAEAgBYeIQYAAIQYEGIAAIQYEGKAkuyTDx8+2T4IMUIMgG0CVJnP4EU0dgDY
JcAq+g6eRIMHgE0CrKIP4U00egDYJABCDDR6gE0CIMRAoweATQIgxECjB9gkAEIMNHoA2CQAQgw0
eoBNJvPu3TsqpA6p93pFiGn0AJbFJn/+/GkuXLhg1q9fb9atW2dOnTplvn37Vtj+48cPc/bsWbtt
8+bNpqurq2h7iPa/dOmS3ffvv/82O3fuNL29vUX7KK2KNoo15G/l5nW1j09KL6zXemsHEWKEGGBZ
bFKiOTg4aP777z/7uXLlihVjR0dHh7l161Zhe39/v2lra4s9T3t7u7l//77dV/z+/dumqU8l/aNW
fazehDgpbYQYEGKADDa5adOmgmiKP3/+FPVs9L+/Xf9v2LAh9jzqBUf1knUel49wHd/IJQS933TO
ixcv2vNu3brVjI2NJfaI1QPfuHGj7eWrB+/z9OlTm8e//vrL7Nmzx0xOTiZet7i0Tp8+bV68eFGU
7rFjxwo3HxpF+Oeff0xTU5OZnp7O3JPPU+60smY5Po4dO3aYxcVF+//CwoI97vXr1/b7ly9f7HY/
v3H1qhu37du32+ut6/7s2TOEGBBiwCaTkIg0NDTECrG2Jw0t79q1y/agtV85PSf/t76+PnPz5k2b
j69fv5qDBw/GCtrQ0JC5d++e3Vc3FRIf5ce/UXBi8Pz5czt0HkdSWp8/fzb79u2z2379+mXTmZub
s9uuXbtmHj58aP8fHx+316QUIU4rd1pZ045P4syZM+bRo0f2/wcPHtg61/ncd91opJVH348fP24+
ffpkv+u6R92oIcSAEAM26aFhZQmJQw2uejVOcDSUrd5NHG/evLGipAZXjfDw8LCZmpoqS4j37t1b
JOw6R5wAtLS0FN04CF9sdZPhRDKNtLQkTBI7iZ+ui38zEh5XihCnlTstf2nHJzEyMmLnDojz58/b
Rw76iHPnzlnRzyLEToTroW1EiBFigGW3SQ1FashVvSuHJmbpNwlrY2Oj7UVmmWz16tUrK1InTpyw
x96+fbtkIQ57URKfOAHQvuEwqX/joPzrN4nY9evXE8uQlpYTQ01Mc8O4UfktVYjTyp2Wv7Tjk1Dv
vrm52f6vIfyZmRmzbds2+13D7RquziLE9dQ2IsQIMcCy2qTEV8ORGsJMYnZ21j5vzINea/F7auUK
cZIAJPXW/ZsEDRm3traa7u7u2P2ypKVev3rAKyHEecuadnwaeq4ve3ACrGe9qn/3HSEGhBigQjYp
EdEwpOvlJKHnhm6IMq7xjhqW1WSirA22mxzk2L9/f9EQq8QgTgDUe/v+/Xuma6JeXtJ1SUtLs831
jPbu3btFQ9MaOShlaDpvudPyl3Z8Gpod/++//xbq2w1P+/WPEANCDFCmTb58+dIcOnTIzoSNQr09
N2lnfn7e9iL1rDEOvaZ0584d8/HjR/tdz5X1jLmzs7Owj2YT69mhEwl/ApWO03C2n9/R0VFz48aN
wqSjI0eOxAqAzu0mKOmj74cPHy4qj2Y4i7TJQ0lpabLWgQMHikTx/fv39n89Y9cQuNDM6rjJWuWW
O62sacenoXrTsLtuOISe96vudPMRVZ6wXhFiQIgBMtikhhnD54z+vhJdTfpxz4izTHTSKzXaV0On
asglzn7PTJOb9JzZPWt2gqj9dZyEMsyvnjErLb2qo0lSST2xnp4e+8qO0pe4STQdGpbevXt34XUa
J8pxxKWld63915f0v7a7mw9tV/o6l3/j4ue13HKnlTXL8UltlW7S/NeW3GQvd8MRHh/WK0IMCDEA
NgkpaEY0IMQ0egDYJKwS/qtqgBDT6AFgkwAIMdDoATYJAAgxjR4ANgmAEAONHmCTAIAQ0+gBYJMA
CDHQ6AE2CYAPIcQ0egDYJABCDDR6gE0CIMRAoweATQIgxECjB7Vtk/pd6y83NDTYNaUdWi9a6xMr
alJXV1fRMQr+oHWNtci/1kpWfNrHjx8XtmvNZLeGsoIhTE5OFh2vtaeVro5XkAI/eLzyo6ACCrnn
1oN2gRHS0sbvACEGGgSoSSFWZCRF6HEBAxQcQGKo3xSneGxszC7o71DAeEX2cVF/BgYGrJA7fPFU
FCI/FrEiBGl/d6zOdfbs2aL8SOSdOIcRkpLSBkCIASGGmhRiv0cqWlpalsTTTRM8P0i9RDkuSpOi
EfmRmPS/ogMl5cfPe1LaAAgxIMRQk0Icol5nGBbRF1qh4WwFDFCQeImrn456qvouQb9+/XqsYPvn
S8pP1rQBEGJAiKEuhDhKLH1GRkZssPu7d++aiYkJO6QdpiOhHh8fN62traa7uztSdCMbuAwxbOPS
BkCIASGGuhBiTYL6/v17bFoKRO9vX1hYiE1/ZmamaJvSDoemXSD5rEIclzYAQgwIMdSFEGtC1c2b
NwsTqvRds5sdmtHsZknPzs6affv2FaWj3rJmN4twspXS6u/vL6Q9ODhoGhsbMwtxUtoACDEgxFAX
Qix6enpsz1e9Vc1idjOqxdTUlJ28JRGUMGrylJ+Oho713Ni9fuSE0+FeX9JHM6Y/fPiQWYiT0sbv
ACEGGgTAJgEQYqDRA8AmARBiKoyLANgkAEIMNHoA2CQAQkyjB4BNAiDEQKMH2CQAIMQ0egDYJABC
DDR6gE0CAEJMoweATQIgxECjB9gkACDENHoA2CQAQgw0eoBNAgBCTKMHgE0CIMRAowfYJAAgxDR6
ANgkAEIMNHqATQLgQwgxjR4ANgmAEAONHmCTAAgx0OgBYJMACDHQ6EE92OTY2JjZsWOHWbdundm3
b5+ZmZmpivz6n7///tts2LDBXLhwwfz48aNo38XFRdPV1WUaGhrsfrt377ZlSkrP/5TCw4cPSz72
6dOnNp8tLS35BaCO25Zfv36ZxsZGhBgQYlhbNvn69Wuzf/9+s7CwYP777z8zOjpqdu3aVZX5lQB3
d3ebixcvFv22d+9ec+/ePfP79+9CmXRjMTIysiz++fHjR3P48OGS05EIP3v2rDQBqNO25c+fP6at
ra2qy4cQI8QAy2KT7e3t5vbt25HbTp8+bV68eFHUkzt27Fhs+hLD7du3m7/++itSbK5cuWLWr19v
/vnnHytknz59yp1f3SwoDce1a9fMnTt3Im8wJNDL4Z+tra3m/fv3RelkvVZxvfGka5MkxHHH6UZE
IwVCN1k6TtdEfPnyxW7Pc+3DPOgmZ/PmzfbcnZ2dtjeblenpaZtXH33XDQ5CDAgxrDmblHC+e/cu
ctvnz5/tULXETw3tzp07zdzcXGz6J06cKAiBRFhi7JBYDgwM2LT0GRoaMmfPni3Jh3whVu9dDfhK
+eeNGzdsOcJ08l4rn7RrEyfEScedOXPGPHr0yP7/4MED+9hB2933vNc+zIOG1VXXOm9vb6+5dOlS
ZgE+cuSI/d9nYmKi6ttOhBghBlgWm5RYPn/+3DQ1Ndle1alTp8y3b98K29V49/X1mVu3biU2tko/
7OH659RzWzd0LPS/elR58ivBVV7UA/Pzv1L+qR7l0aNHY9PJc6180q5NnBAnHaceq56ni/Pnz9uR
D33EuXPnljxDzyvEvpD+/PnTbNu2rSQBrqW2EyFGiAGWxSb1uxrs79+/F3pVrsF2qPejBt4NdZbS
eGu4OuomICm98LN161Y7FKvniQ7dPKyEf7pn0RrWTUqnlGuVdm3ihDjpOPXGm5ub7f979uyxE/Cc
WOqmS8PV5QixbCVPXUY9PkCIASEGbPL/oZnIfq9KDayGMX2OHz9uh4DLEeKohjrJT/xtEj89b42a
zS2x+fr165LfJdaPHz+umH+qF+mGepPSKeVapV2buP/Tjtu0aZO9Nk6A9Rhidna28D3ueXUWIc5z
U6VesHrD6hXTIwaEGLDJgHBCkYTY72UODg7aSVh3797NNdwa/qZeWTiMGgp+UnoSVj2DfvLkSdHv
169ft/kLuX//vjlw4EDF/DPL60+lXqu0axMngmnHaRbyv//+WxjhcMPT4YhHWv7cZC9/u39TpEcZ
uqFLI4sgI8SAEMOas0m9D6uPm/DT399vJx0JTUDyxUwNv2YLlyLEGppU2u48Eq2kd0aj0lPPWJOg
/GFViYCelSo9PatU2uq5qjc4NTW1rP4ZTtYq9VqlXZukyVpJx2mbhsn1uxgeHrY3WVE3LmHv1s14
13N53QCFeZCYqret8169etWKflacICPEgBADNuk12FoMQ70pNbpOQDRxy38lR/9reylCLNyrNvpo
1u6HDx9y51d5OHToUNFvEgvNEla6em6qZ7l+vvNcizy+6+9b7rVKujZZXl+KOu7ly5dFry29efPG
fo+7QXC4Ge+6lhJ2vYoV5kHD/lu2bLF2c/ny5aIJfvXadiLECDEANrkCaIYxYEsIMYYKgE2uElog
BLAlhBhDBcAmoWpJmmSHEAONHgA2CYAQA40eYJMACDHQ6AFgkwAIMRUGgE0CIMRAowfYJDYJgBDT
6AGsbZuMC7e4FvK1mmWv1uuOEANCDNjkChO+9lJunrSkpSJHaVUppR2GcCw1XytR9tW87vXWnin+
c9JyqQgxjR4ANhmTh3LzpMAKWkfZrbWs5R4lxtV4bVbz+tdze6RgIFrneqXrkBaeRg+gYjap3xUt
SMEBFCjhwYMHNpiAoun4i/873NrGCh6ghf8/ffpUlJYCCijcntYp9o+Pilikv1rnOmr/LCi/flxc
Ncqu93f69OmitZ+1XnIYaSopX69evbLrKGvdakdvb6/ZuHGjLX9XV1dROvPz83ZtaV0XlUMxf10Y
xrhz5LnuSefOe92jUPo6t/IyMDCwZG1pxWNW+ET1Pn0U8UkBLsrNZxYULEI256PvWmscIQaEGGpa
iBVrVyKmEINqjDs6Oux3t/i/Q0KhRtr1QIeGhmygAT8tiZET5/D4qB6x4vfG7Z8XiYLEUygakqJI
KZ8SD0Vtmpuby9xT7+zstMcqHaGySkT0m67N2NiYuXXrVuEYxUUeHR0tXBtdJ5eXuHNkve5p5857
3UOUdnd3t01fEZUURSoq0IQeA8gGfPr6+qz4ViKfaQKsiE1h+MSJiYlVGdWghUeIASoqxGGv9vv3
75HHKdxgGP9WPbq4tJY0XhFilLR/XhSD2F8rWsIgoZAY5IkPHJWvlpaWot63kLgnoV5f1nMkXfe0
c+e97iH79++3ISYdLkpTeLxuZNQrdnnR3x07dhTOXW4+8wjwarS5CDFCDLBsQpz1uy8sjrSeV5oQ
V8p3FhcX7XC0emKhgOpmQdvzCHFUOcNh3vB6aDhbNwLt7e32piVP2ZO+p50773UPCSdzSUzjjlcI
ShfPWCMAfqjHcvMZtS3sgSPEgBDDmhbiqGHEtAZ/JYRY4qt4xBpWDdHQ965du8oW4qibEJ+RkRF7
Hj331XCphrQrJcRp5y5XiMN6TRLi8fFx+/xb6NmwGxquRD6jesTqDatXTI8YEGJAiP9/wxsOTfu9
qdUQYgmsnl0uLCws2aYZ1eq9SRzzDk2HqOz+0HGInvH625WfSglx2rnLFWI9S/dvYt6+fZt4vCZb
achfw9J5rlGp9Z1FkBFiQIhhTQixhgk1y9lNSJLQ+e9vpjW0mlGsZ4ROzMsV4pcvX9qhUv/5pkM9
Uk068kXi/fv3kelkyZfKfvPmzULZ9d2fwStxcrOkZ2dnrbjlKXvadU86d97rHhJO1lLaSUKsZ+5b
t24tmohViXxmFWSEGBBiWLNCLNzrS/poxvSHDx8yN7RquNWDdr3oLA1zki9p4lD4TNLtr/eJ/deX
9L//PDMUlrR8iZ6eHtvz1X5Ky82oFlNTU3ZikoZ5NUT98OHDXGVP+5507rzXPYobN27Y144ksJrk
ljTSoVEIbY96FFBOPqu9zUWIEWKANWmT58+fp/JWGL3upZscQIhp9ACwyaLXkWB50KxyTcJy7/9q
1END1YAQ0+gBYJOwAmjms1YQ03CyVta6fPnyktfAACGm0QPAJgEQYqDRA2wSAB9CiGn0ALBJAIQY
aPQAmwRAiIFGDwCbBECIgUYPsMksvHv3jorgWiLEgBADNrlahCs7VSpPWoDCX2rT8fPnT7sOtVYB
07m12ta3b99q4trljZhUKzZRy20jQkyjB1DzNpln+cqs6H3Xtra2yLQU6EHrYbu1j7VQhcS4HgSr
EnlCiBFiGj2AKrBJ/a7oRFpdSYs5PHjwwC7Wr/WCtW7ys2fPivZ3a00rkIAW9A+D2yuAgAIgKCSe
f3zUetD6qyASUftnRXn4+PFjZPlUHj9QvUTb9SQVu9hfi/rp06fm2LFjsdcoLZ+9vb12rWZdm66u
rqJt8/Pzdt1lXTMdqzCCLkCEUB4vXrxor7nWeh4bG0uN0xtey7S6qYVyIcSAEMOaFeJz585ZkXry
5IltNDs6Oux3Ncp+rFoJ9MDAQKGHqeAACvzgp6WG2QlAeHxUj1jxguP2z4KLh5vF5xR9qKGhwf6v
YASKkKRyaGhbARvm5uZir1FSPnUddAPiloiU4PiRiZqbm83o6GjhuukaunwIhRR0UYsUSOHgwYO5
e8RpdVMr5UKIASGGNSnEYa/WjynrH7d79+4l8YjVk45La0njFSHESftX2ufu379ftHa1hEZiIXFJ
i1eclM+WlpainreQsCehHqhDy0v61/XNmze5hTitbmqlXAgxIMSwJoU463e/kXUk9XizCHGlfCft
OIXu03B0uIayxEaCpe150vZ/0zUIh4vDa/Xq1St7E9De3m5FMzzeR+KXV4jT6qZWyoUQA0IMCHHC
96iGPUloq0WIJb5nzpyJjJ+roVnFDy5HiKNE0GdkZMSeQ8/iNZSuYfGs1zXueXCYp0qksZLlQogB
IQZssgQh3rNnz5Lhz6QA8tUgxBJYvcK0sLCwZJtmVOsZqIQkbWg66TddF384P0TP3f3tyot//P79
+4uu6+zsbO4ecVrd1Eq5EGJAiAEhTviuCUGaZesm50jI/Pd30xp2za7VM0nXOC+3EL98+dIcOnTI
fPnyZck29d4OHDhQJDrv378vSbB0XdykJH30XbOWHZqV7GYTS4w0Scw/XhOebty4UZjUdOTIkdTr
EF7LtLqplXIhxIAQA0Kc8t29IqOPZuV++PAhc8OuSVHqpbmeWhYhzupLUftt27ZtybCs20/vE/uv
L+l/zfguRbBET0+P7SGqbEpHQu+Ympqyk5w0VKuh3IcPHy45/vbt2/ZZtV4V0iSytHKH1zKtbmql
XAgxIMSATVYZ58+fp/IAIQaEGLDJ1cJ/3QgAIQaEGLBJAHwIIabRA8AmARBioNEDbBIAIQYaPQBs
EgAhBho9wCYBEGKg0QPAJgEQYqDRA2wSSubdu3fLuj8gxDR6ANhk3Zfp6dOndrUpRXbKS9r60Gn7
r9Q10RrTcauWIcSw6hW1lgwTEC1YikT42bNnK1JPq1Wv4+PjdplQesSAEAOU2WAraIDWJVYQgaam
JjM9PV203a1frO1a8N8PJK80FblIawlv2rTJPHjwwAYG0NrEoRhpX4XN075Kr7Oz0/z69auwfX5+
3q5lrPPoWOXFBRRwxyv2bUNDgw04H5bJ9UIVuk8BHCYnJ3OVQ1GYFMRAx2cR0rj0svh/XF6jjk26
LlH7h9GuksqVds2SUDAHBZmIQnGf/XW8dZ5jx44hxLA6YgxQ7UKsJSS1WL/r5WjxfodEdWBgoBB9
R4v2S7T9NM+dO2fj/T558sQKcEdHh/2uBt+PR6t9NVQrwVJavb29RaEHm5ubbbQedy6dV6LrHy/x
1jYXeCCMfetE5vnz5zYYQZ5ySOycmIZ5D8mSXtYec5jX8Ngs1yVWLFLKlZSPNNra2szRo0dtMAfV
u25MHKofRWJSfnWzpXTn5uYQYkCIAbuMQsKrBjOK3bt3L4lxqx6tn2bYs/Tj04ai4Pe2f/78aaMj
JeEHpg/PFaYvcXI3FOWWI01Ms6SXRFJes7Qb4XVJEuJSr1kaW7ZsMffv37f/y36Gh4eL1gXXzUlf
X5+NEpUU6xkhBoQY1rwQJ/X8/AY/av88IRT1fyj44bk19KzGvL293YpdeHxSmdSjc73u69evl1WO
NEEsJT2fpLxGHZvnulTqmuVFdStx9lG6ukFZXFxEiAEhBihFiKO2ZRWBLKLgp6/nx+qd65nzxMSE
Hd7MIypOsDS83traarq7u0suR5qYlpJelLhG5TU8Nu91qdQ1K4XwBuX48eM27wgxVFWjB1BtNtnY
2Bg7NK0JPOEQrP+6TF4hnpmZKXz/9u2bfbbo0P/+sPbCwkLJYqnz+NvyliPNh0tJL44wr+Gxea9L
pa5ZGurp/vjxo+gaaCKZY3Bw0E4U0w0EQ9OAEAOY5MlaGqIUmukaTtbSzFg3UUiNq4S7VCHW7OKv
X7/atK5evWon/Dg0s9fNBp6dnbWTffKIivKt2bkinJSUtxxpPlxKej5JedXsaD3XdUKfdl3C/St1
zdK4fPmynXDnroGeBes6CPXaDxw4UHTj8v79+/oV4qjXZfjw4fM/XiXLKCya1ar3QdUI6/njmzdv
ira713T00czgDx8+lCzEEhQ9R9QkITXk6hU7pqam7Oxa5UMCoUlEeURFQ6zKv3tNxwlMKeXIIqZ5
0wuHg+PyKkFT79r1sNOuS7h/Ja9ZUjlkN5ohr/Pq1bWbN28Wtsme/NeX9L9mb9elENPrAmCkolbK
TntVe5w/f56LkCTEGDUAgoAQw3Liv44ES0YbMGgARKG2ypx3DWUAhBgAUaLMAIAQAyBKlBkAIQZA
lCgzAO0GQgyAKFFmAIQYAFGizAAIcW071Lt376oqneVOs1avL6JEmZfLzurFRvOWo5Llxs+rWIjH
xsbMjh077KsCWgrNX9tVaDUYrV2qZdG0+smXL19i03JBoxVBo4RMxu5XqdcYluN1iDDNrI1XNTXs
Wa7LauY36dx5bQ4hLr/Mea6Fv2+pvlLusZWmHJvL2wZVstzVdA1XEq3o5S8nGkW4+tiKCvHr16/N
/v377aLgWvtTwaT9dWNv375dFMz6xo0bdu3XOPyg0ZUU4kpdoOW+0LXasFe7Q6ZFtcljcwjx6pW5
nPSq6fqXY3N5y1HJcqctL1qP/Pnzx65PnlTWjx8/Wl1bNSFWrEqJbRxar1TBuEMjjDthuEZv2rql
WYQ4bu1fLR6+ceNGu25rV1dX4ffTp08XrVmqu9djx45lWkN4fn7erm+q3r/KqcggbvF0lxettap1
b/fu3ZtaZi2qrjVllZ7S8oOch3mIK49/B671XbUY+uTkZGLF+3lMSz+uDGEaWfKryCoK3K47UB9d
B+U7S1l1w3fx4kU7CrN161Y7YpPXNtyavrrucrAwEH3U9UGIS+sR639FzFGgAbf+sC9Svk0l+UqS
72VpW9LqPCmPUcSll6UdifPXqGPLKXeecsWlpUAUSccn+WqUL2VpQxWmUZGYlGZnZ6dtL7TudnNz
c6SQqk3xozY5VC9+mxqF9pHQJvmvwjkqwMSqCbEqIOtzA4XVUqVIvMu548orxFHbhoaGrAGq0VZF
qbHWQuZCUTw0xK5tqmDdTMzNzWVqTGUIGhVwIwAaDZCR+fmQ4WibzpNWZi33piEPofid/miDv19S
ecI7cEW9UZmSrlWYx7T0o8qQVM6k9C5cuGAjzfj09fVZ28mSF+2rxeC1XVF3Dh48mMs2dG5/FEfn
081QUtkQ4vKEWA2vE6owIk/W8HtZfC/u2Cx1npTHkCzpZe0xh/4aHltOufOWKyotxf+NOz5LuxH6
UpbyaEhf59R2tQsu5OGRI0eWdDJ0fgWKiEIirGOSBFnxmJPqTKO8yuNKjJj+LynAtwxFdy3uGbAf
3cTvZbqoIW/fvl11IVZFhvFQfWOXAalBl9H4cS1LudB+4God799pp5VZwhsXt9XfL608MmQn6Fkq
PsxjWvpRZUgqZ1J6uunRHazbrr+ag+DSS8uL7qz9uK2K7JPHNhQZJoz7qrvvpLIhxOUJcZKtZBXi
LL4Xd2wpdZ507izpJZHkr1nsKGu585arkn6ex5fC8viiqRFXtReus6LeqY/agyTNySrIUddFj2aP
Hj26rD6eSYj1u3ow6u26O7+kHq+Ga/whxtUSYt1AhEMtfmU7I5LzLC4u5rrQGmpRT1bXQQ6ZN2i2
/z3r3WlaeXSz5O4kr1+/nrvxTEs/b72lpXfo0CF7Jyt0d+yHM0s7Nrxmsss8thHaQZhmPTzTrzYh
LtXHw+95fM//XkqdJ9VnuTaU5K9Rx5Za7rzlqrSfx50rrTyhuPvXVqO0bgRTN+F5Hh9pJCPrBEMN
dSttf/LxqgmxnsP5d366QEmz+jQ8kXfoYzmEOMpRQjTkoh5pHiHWswsdc/fuXTukoeGWlRDiLOWR
cbs7xu7u7lyNZ1r6eestLT3lU6MsQjdubngoy7FR1yzvTVpe4UCIV1+I8/pemp+VI1iVsKE4fw2P
Lafcyy3EeduNUttQ/3prqFidQ6HHAcPDw6nXWr1g9YbVK87aIz537px59OjRsvt4JiHWJKaw96Eh
an+IRc/p4oZo8la0ZmdXQojVuKsXH8fg4KDtkckY8gxN68bETzcpv1nKrCnzWYam08rjo9fL8s4w
T0s/r4Nmya/ubPV4QMPSefKiWfz+zeHs7Gxu2wiHFf2bS4S4OoU4r++F9pi3zpPqs5I2FPpreGw5
5V5uIc7bbmQtj/+KrB6F6hiH9EYapJ6qJomFEz/zCnBS2eM+Ky7Eeo6hj3uwrhl0mujkD0VraMVt
v3r1qv3k6Z24SQuauaYhylKEWBWjZxHOOTQE4Sb06KPv7rUq3YEdOHCgyJg0Iy4qnSjxcDP8JAC6
Fml5DNMMJ2tpmEpoJnfcZK2k8ggdp5mYIu+EjCzpJ5WhlPwKPZ/XrGd/ckeWYzWUrbtiN1lLTpZ3
spbs2KWvmzL/HUKEePWEOMnO0nwv6dhS6jypPsu1oSR/DctRTrnzlqvSfh51fJY2VGnIt52m6PUi
H/WET548aSeCJZFFgPP476r1iIUMTj1f3fFJKJ1ouaFoXQxt00QtCXOegjgj1BCHDFnGWYoQqzFX
Hvy70p6eHnsn5fLtZu1pwpn/+pL+d88oo9LxmZqaspMRlGc5U/iSd1QewzT9fXQ3p/woPT0r0TOP
uLTiyuOGuXS8e8XAOXkeY0pKP6kMpeRX6JGAtvkjKlmP1St1GnnRHbHmLeQdAXCvnugjp9arEQjx
6gtxkp2l+V6ajeat87T6LMeGkvw1LEc55c5brkr7edTxWdpQCfWWLVus7ly+fHnJBGGJq/ar5Epg
VS/EAIAQU2aoFpuS2KtnXW/lRYgBECXKDFVvUxquVi887e0QhBiABoQyA5RA2lrbeo6td3uTJmkh
xAAIMWUGAIQYAFGizAAIMQCiRJkBACEGQJQoMwBCDIAo1WSZViIOOADtxhoS4kq+AL4W4fqtTSGO
W+IPIQZAiHM3BmlT41MuUk021JU8b3j9aIiXXoukNWrr8bOWb1QAEOISHLycciLENKb0iEvvEWM7
ACUKsX5XhCKt67tp0ybz4MEDu7C31hb1AzY43PqreulaC3f7QaGVltZY1fqhfgzJ3t5eu2awjuvq
6krMtFZVuXjxoj2/AgaMjY0tcfC49KIak/n5ebs+qvKr8ig0n1uQPK1HnJTvLPkMiUpPMTEVFDt8
eV2Lsru4z+WUIfwtKa2o6xe3nm9c/SvilZamc2vshvaDEFenEOctc5r9x9mZ1mtubm5ekp7WtJcf
yB+0LrNbn14+MDk5SWsO9S/EissoR3jy5Il1rI6ODvs9jBoigR4YGChE4tBi/FoM3U9LASK0zS0M
rn3UOOs3pSmHDaPx+Chsnov2oWABBw8eLCpIWnphOeX0iubj8qz860YhTcTSzpOWz5Ck9BR7U9c2
vA4S7nLKEPVbnrTC71nqX42vE+e0KFEIce2WOc3+k+xMEXNCcZVvqN0R/g2cIpcpgABA3Qtx2Kvx
Y0n6xymaSBij049NHKYlWlpalsTjTXIs9aT9cyhakZ+HtPSyNJZ+sOs4EUs7T1o+Q5LSm5ubs70B
t11/FcM3vJZ5y5D1msSlVYn6ryfxQohNyfbv29n4+LhpbW1dkt7bt2/t/xJsRewBWFNCnPW732A7
/B5P1Dm0PRzyjEonKj0nSn66aelF5UHD5YoL3N7ebsUkSxjGtPOk5TPvdTh06JDtFQj1JFzYxnLK
EPdb1rQqUf8IcX2WOYv9J9mZHl/oBtSJuP8oS71g7aub13pZ+B8Q4ooJcdQwY5oIJIluFgfPIgZJ
+R8ZGbExMfUcfGJiwg6ZZxGxtPOk5TPvdVAvQc/RhJ6LKa/lliHqtzxpVaL+EeK1IcR57ezGjRv2
kYzQ443h4eElIu56zt3d3bTmgBA7JBDh0KT/ukvUOXSMP9Sdxv79+4vOMTs7uyQPSemFedAzb3//
hYWFTCKWdp60fJZyHdRL0LM3DUtXogxR++ZJqxL1jxDXZ5nT7D/NzvRcWRO5vnz5YicwxkXamZmZ
YTY2IMThZJ3+/v7CBIzBwUHT2NiY6LQ6xk3q0EffNds2Dg3L6m7ZTQLRxI4wD0npybn1nNI1EhI3
NytYjcW+ffsyiVjaedLyWcp10OQtzUANJ7PlKYM/0eXjx492iDscEkxKK7x+5dY/QlyfZU6z/zQ7
cz3hkydP2gmePupJa+a0qLcJf4AQly3Ewr2+oo8cSa8jpDmtgjzrDlm9JwmDm1Edx+3bt+0kIN0p
a2ZumG5SehIx/e56alNTU3ZSlJxZDq5JIFl7k2n5Tstn3uuwuLhot6lh88lTBtdwaShcIqkGzd+e
llZ4/cqtf4S4fsucZP9pdiamp6ftb+FqbhqW1jNl9wqcE2WAuhViAECIV6PMuhFVzxkAIQYAhHiF
y6whbY0QMSsaEGIAQIhXocyai3D06NHYSVoACDEAIMSG9aMBEGIARIkyAyDEAIAQAwBCDIAoUWYA
hBgAh6LMAIAQAyBKlBkAIQZAlCgzACDEAIgSZQZAiAEQJcoMAAgxAKJEmQEQYgBEiTIDAEIMgChR
ZgCEGABRoswAtBv2f5wKAEGi7ACr5zv/w6kAECKuAcDq+cz/wh348OGT7QO0G3z4VKLdoDXhrh4A
AFZTg7gECDEAACDECDEAACDECDEAAABCjBADAABCjBADAAAgxAgxAAAgxAgxAAAAQowQAwAAQowQ
AwAAIMQIMQAAIMQIMQAAAEKMEAMAAEKMEAMAACDECDEAACDECDEAAABCjBADAABCjBADAAAgxAgx
AAAgxAgxAAAAQowQAwAAQowQAwAAIMQIMQAAIMQIMQAAIMQIMQAAAEKMEAMAAEKMEAMAACDECDEA
ACDECDEAAABCjBADAABCjBADAAAgxAgxAAAgxAgxAAAAQowQAwAAQowQAwAAIMQIMQAAIMQIMQAA
AEKMEAMAAEKMEAMAACDECDEAACDECDFUcf3zWTsfAIQYIQbqHqhzAIQYxwTqnboHQIhxSqDOARsA
hBhwSOocsAEAhBiHBOocsAFAiHFIoM4BGwBAiHFIoM4BGwCEGIcE6hywAQCEGIcE6hywAUCIcUhY
W3X+69cv09jYuOT3b9++mRMnTph//vnHrF+/3pw+fdp8/fo18Tz+5++//zYbNmwwFy5cMD9+/Cja
d3Fx0XR1dZmGhga73+7du83Y2FhieqwYhd8DQoxDQt3V+Z8/f0xbW1vkPr29veb69evmv//+s5/7
9++bnp6eXOeRAHd3d5uLFy8W/bZ3715z79498/v3b/vb69evzY4dO8zIyAh2i98DQoxDwtqp88OH
D5uPHz9G7nP06FEzOztbJNrHjh3LfR6JuHrUjmvXrpk7d+4s2U9iLIHOk/bTp09tj/qvv/4ye/bs
MZOTk1Q4fg8IMQ4JtVPnExMTsftoWFkiGv5Wynl8Id61a5cV/0qUQSL87Nkz+//z58/Nzp07qXD8
HhBiHBJqr86j9pHIZfktKQ0Jbl9fn+ns7MyURt4y6Bnzw4cPqWT8HhBiHBLqT4g13JtXiMPP1q1b
zZUrV+ywtkOTvypVBvWCta2lpcU+zwb8HhBiHBLqRoijhqGzDk1/+fLFPk+emZlZsl9zc3Pk7GuJ
9ePHj3OX4dWrV2Z8fNy0trbaiWGA3wNCjENCXQixhO3nz5+F73rNSZO7sqYhYdXrT0+ePCn6XT1X
zZgO0azsAwcOlFwGiT72jd8DQoxDQt0IsV5funnzZuH1pbt37yYO/0aloZ6xJlAtLCwUftP7yXpv
eHBw0Aq90n706JHZtGmTmZqaylUGTfzSzGmhSVulPH/GBgAQYhwSqlKIP3/+bI4cOWLWrVtnP8eP
H7cimvc8L168MIcOHSr6TZO4zpw5Y2dT61m0XlvSfnnT1rC0RF1pSISdKAN+DwgxDgnUOWADAAgx
DgnUOWADgBDjkECdAzYAgBDjkNQ5YAMACDEOCdQ5YAOAEOOQQJ0DNgCAEOOQQJ0DNgAIMQ4J1Dlg
AwAIMQ4J1HmV8+7dO2wAACHGIaG667zcc6328UnpaXWxWvUl/B4QYhwSEOKaFOKktBFiAIQYh4Sy
61yBHTZu3GjXfO7q6ir8fvr06aK1n7WGs8Iait+/f5uzZ8/auMJNTU1meno68lxR5/V/U7CHixcv
2tCKils8Nja25Ji4/GU9Po4dO3aYxcVF+78CUui4169f2+8KVKHtfn7DOMvut/7+frN9+/bCWtcK
PIHfAyDEOCRkqvOhoSEbjlCCppCFErJbt27ZbQr4sG/fPrtN4Q8VQWlubs5uu3btmnn48KH9X3GA
FQGpFCHu6+srRHdSfOKDBw8WbU/KX5bjk1DACUV8Eg8ePLDDzjqf+64bjbTy6LsCYXz69Ml+r+bo
T/g9IMQ4JFRhnbe0tFgR85Hg+kIosZP4Xbp0qfC7hDc8rhQhVsQl9a4db968Kdqelr+045MYGRkx
Fy5csP+fP3/etLe32484d+6cFf0sQuxEuNr9C78HhBiHhCqsc/XewiFXDbGGYr158+bCMK47Lsu5
0oQ4TEeiG25Pyl/a8Umod9/c3Gz/37Nnj5mZmTHbtm2z3zXc7uInpwlxrfgXfg8IMQ4JVVjnoehG
oaFX9YBXQojD7Wn5Szs+jU2bNtkhbSfAetY7Oztb+I4QAyDEOCQsa52rJ/j9+/fY4wYHB+0z2rt3
7xYNTTc2NpY0NO0mRTn2799fNLQsEfS3p+Uv7fg02trazL///lsYknbD0+47QgyAEOOQsKx1fufO
ncJkJ330/fDhw3abJmsdOHCgSBTfv39v/9dkrefPn9v/NbM6brKWP4v448eP5sSJE0XbR0dHzY0b
NwqTrY4cOVK0PSl/WY5PQzOeNeyuGw4xPDxsZ4Lr5iOqPNqmZ8JO/BFiAIQYh4Sy67ynp8e+/qNZ
wxJKCbA4depU0etL+l/bhWZRa7uEdvfu3XaSVNS53CxiDTGrF61XoMK83L5924qhXlHS5LBwe1z+
sh6fVPaXL18WvbbkJnu5G47weE1aUz7cwh4IMQBCjEMCdZ6CZkQDfg8IMQ4J1PkqoWF0wO8BIcYh
gToHbAAAIcYhqXPABgAQYhwSqHPABgAhxiGBOgdsAAAhxiGBOgdsABBiHBKoc8AGABBiHBKoc8AG
ACHGIYE6B2wAACHGIYE6B2wAEGIcEuq9zvX7q1evTENDg9m7d2/h997eXrt28/r1601XV1fRMfPz
83bNZwVA0DrSit37+PHjwnatJ+3Wl1agiMnJyaLjr1y5YtPV8QrgoCAKfn4UcEHhCHW8HzQiLW3s
Gr8HhBiHhJoU4s7OThu9yAVTUOAEiaF++/PnjxkbG7PBDhzNzc026pGLiDQwMGCF3OGLpyI07dy5
s7BN0ZO0vztW5zp79mxRfiTyTpxd0IgsaQN+DwgxDgk1KcR+j1S0tLQsiTWcJnjqoTokyg8fPozc
T5Ga/PjB+l+Rk5Ly4+c9KW3A7wEhxiGhJoU4RL1O/e5/fKEVGs5WMIX29nYrrn466qnquwT9+vXr
sYLtny8pP1nTBvweEGIcEupCiKPE0mdkZMTs2rXL3L1710xMTNgh7TAdCfX4+LhpbW013d3dkaIb
lYcs8X3j0gb8HhBiHBLqQog1Cer79++xaW3YsKFo+8LCQmz6MzMzRduUdjg0vW7dulxCHJc24PeA
EOOQUBdCrAlVN2/eLEyo0nfNbnZoRrObJT07O2v27dtXlI56y5rdLMLJVkqrv7+/kPbg4KBpbGzM
LMRJaQN+DwgxDgl1IcSip6fH9nzVW9UsZjejWkxNTdnJWxJBCaMmT/npaOhYz43d60dOOB3u9SV9
NGP6w4cPmYU4KW3sGr8HhBiHBOocsAEAhBiHBOocsAFAiHFIoM4BGwBAiHFIoM4BGwCEGIcE6hyw
AQCEGIekzgEbAECIcUigzgEbAIQYh+QyUOeADQAgxDgkUOeADQBCjEMCdQ7YAABCjEMCdQ7YACDE
OCRQ54ANACDEOCRQ54ANAEKMQwJ1DtgAAEKMQwJ1DtgAIMQ4JFDngA0AIMQ4JFDngA0AQoxDAnUO
2AAAQoxDAnUO2AAgxDgk1Hqd//jxw5w9e9asW7fObN682XR1dZlv377VTFny2HKl7L5W/Qe/B4S4
Shwx/MDaFuKOjg5z69Yt899//9lPf3+/aWtrQ1AQYgCEGCGGlWiE1ROWADv0/4YNG+z/p0+fNi9e
vChse/r0qTl27Fhs+vfu3TPbt283f/31l/n777/Ns2fPiva5cuWKWb9+vfnnn3/M4cOHzadPn2Lz
+/v3b9tT175NTU1meno6tUeclgd/36T05+fnzYkTJ+w2paHtjx8/RogBEOLKizEgxKEQS6D0m/j8
+bPZt2+f3f7r1y+zc+dOMzc3F5u+xMuJqwRQIua4c+eOGRgYKPS8h4aGrBDGce3aNfPw4UP7//j4
uNm1a1cmIU7Kg79vUvrNzc1mdHS0kFflu6GhASEGQIgRYqh8Iywx1HC0E9tLly7Z3qRDgtnX12eH
r7UtKf2wh+ufc/fu3VbkfcHXM+k4JIz+DUJcuuH/SXnw/09KPwr/miDEAAgxQgwVa4Q1MUtD0Oo5
NjY2mufPnxd6xI6WlhYrmouLi7nS93/zhczh91bzbEsS4qz7JqUvXr16ZXvN7e3t9iai1AliCDEA
QowQQ65GeHZ21mzdurXot+PHj9seZDlCHCV8SXlaTSEeGRmx5b17966ZmJiwQ/QIMQBCjEPCitT5
o0ePbC/QMTg4aCdASZTShqaTftuzZ8+Soemw5+2j3nkpQ9NZ901KX5PVvn//Xvi+sLCAEAMgxDgk
LE+dq+cn8RWaLdza2mrevHljv6sneODAgSIxff/+fUlCrMla7lm0PhJ4iWEcGhbWMLnQzO2sk7Wy
CnFS+pp17WZJa4RAE9YQYoBlEuKo13n41O8HIV6KRHfv3r2FZ8RuJrE4depU0etL+l+zkksRYuFe
X9JHk8Q+fPgQm19NHNP5lS89o3U3B5US4qT0p6am7AxxbZNA65ogxADLIMQYJWJE2QEbAFglIcYg
aYwoN2ADAKtmixgjRvA/ygzYAABCDDRIlBmwAUCIgQaJMgM2AIAQAw0SZQZsABBioEGizIANACDE
QINEmQEbAIS4Knj37l1Vp0eDRJnXik3VQzkRYqh6If7586e5cOGCXfVHa+Bq1R1FpnH8+PHDrgak
bYpE09XVVbQ9yujdR5FnFGRcaX79+jVzZpPW4i2FML08jlkPKwshxJWn0jZarddkucqpFb6SlvrE
7mFNCbEWtNf6t24tXC3HJ+F0dHR02JisbrvWzW1ra8ts9DpGa/oq5NxqOU456SHECHG9XctSb0Qr
xZ8/f2wbslLXECGGqhfiTZs2FUVjkZP4d8H639+u/xWlJa/Rh3fWbv1d9ZgPHz5cCGwet05yb2+v
2bhxoz1GvfLwnIqUo0Xr1QvXWrnPnj2LTc9PVwv+ax1h5UPHNTU1FRa+jxJirRPc3Nwc2bhs27bN
jiAgxLVR5jgbjDvOt5/QphRVSSNHSks2ND09netcivKkESf544MHD2ywCPmZb8tZfCFE/nrx4kWb
lsI8jo2NZbb/qHKm+UsWVP6PHz8uuca6WffX+H769Kk5duwYdg/1L8QhalAaGhpihTgtjFvUeXS8
Gg2HGpmBgYFCL3toaMg2YnFpaLuEVvtK8NSYqJfu76/GwTVuarj8uKthev53iero6GghL8qXX/6o
HvGRI0fM5ORkUZrKn0YP6BHXRpnz2mDa6IiiGrnAEePj40VRjbKc69y5c9a2nzx5YkVTtqTvoS2n
+UJIX1+fuXnzpt1fj4cOHjxYsv1n2T8LinUclbaiXinik9LV0LUCUMzNzWH3sPaE+P79+7ZRcajB
cGHc5BwaylavM6vRO2fVXblDUV/CGK3qDcSl0dLSsiSGqpzU39/vYaQ1mmnXwi9fVDpqaBU2z0eR
fN6+fYsQ10iZ89pgmk1JeOPi/GY5V9hD9uMC++dK84UQ2aV/bkVbKtX+s+xfbt3oRkM3D7q5SIoD
jd1D3Qrx4uKiHR7SnbZDE7P0mwsXp1imaT1i/6OhNk0G84dsoxw3qQerbWG6aY1FHiF+9eqVvflQ
YHg1mlnCzWkY3N2tu5B6tSpKa1GI89pgmk35x5Z7rqTvab6QdB53Y1yq/WfZvxJ1o5sN3aioPcLu
YU0JscT3zJkzqbObFTBcz5rKMfqoRivJ+dPuuMsR4pGREdub0TM6DZlpeCyLEN+4ccPeYLhRg+Hh
YYS4hsqc1wbLEeK850r6nrf3mXbuPPafZf9K1M3x48ftORBiWFNCLIOXqCwsLKQmpBnQuhMux+j3
7NmzZKjO72WHaWh/f6iukkKs53F+2roGWYRYNyyasPLlyxc7cUbD9ghx7ZQ5rw0m2YXQaFHc0HTe
cyV9T/OFkP379xedWzfSpdp/lv3LrRu9waFn4BJ6hqZhzQjxy5cvzaFDh6ygRKE7U4mv0IxJPRvV
UGw5Rq/JK+65sz5yPv+dQgmcnpm5BkT7uwkn+ui7Zl5mFeIwvXCI2c36VCOlySJZhNj1hE+ePGk6
OztrWpTWohCn2aA/W1kzfDUZMMmmNFSrxzZCM3/DyVpJ58ojxGm+EKKJVRq9cZO1NNEwj/2H5Uzb
v5y6Ue/6wIEDRTcd79+/x+6h/oVYr9yEz5z8fd3zT/eM2M0MLdfo3esc+kjQ9FqQQxM11GPwew09
PT32bly/qVGU02YV4jA9f9vU1JSd7KLyqfFU+bIKsV5R0W+1svoQQpzdBt1sZQ0Fy+71Kk2STWlE
RO/f6xg9Nw1vVpPOlUeI03whitu3b9tnrhq50WSoPPYfljNt/zx2Fu6n6+e/vqT/VT7sHupeiKF0
1ACqh1APorQWhRiWh/Pnz2MDAAjx8qOhPvVMrl+/jihRZvDwX3/EBgAQ4mVDz86OHj1aE5O0EGJY
440fFwEQYqBBosyADQC2iDFiBAgxYPcACDHQIFFmwAYAIQYaJMoM2AAAQgw0SJQZsAFAiNcgtbIA
Bw0SZcYfsAFAiOvS2ZKiR2U9l//RKkNa6SiMMiW0jreCtytmq1t1STFkk9KLWuGMBql2ylxr17lc
f8AGABDiFXfMqOMlwN3d3UVxl/WblgfVIvZurd7Xr1+bHTt22Cg2K91oIMQ0/GvRLmj7oOqFWIEc
tJ6rFqhQj62pqamwqLszYomG1qrVOrkKcOAvYpFlu+KXqkfox+x1a+/qvFq0PgyMnjdNv3xJZYrr
cfb29tq1eHU+9WBLcWyttqXjHVphSIvyh0iM4+IXx6WttY7d2sdaDH9ycpIGqYwyZ4nYpRsoLWGq
a+4HgRC6sdKa0bIx2ZfWHY9LO8m2svhflP+EpPlTXFmj/CGpbFnOpchJ8l3FIn/w4IH1AY0Yhdcw
r98hxFC3Qtzc3GwjtLhoLgMDA9bpfSNWoG45m7bLcfzwZFm2S0i1zS1OL8fUedw5tRC9HL+cNP3y
ZSmTj86vRlf7Ki6zho612H0pju0LsRbFV+SeSjQafiOmKD9aeJ8GaXmFWALpRMYFgfBvslwAlPHx
8aJoS346abaVxVZDWw/J4k9pZfVJKluWc507d86W9cmTJ1aAOzo67PfwGub1O4QY6laIo/CDj+s4
/47458+fNmJTnu3+HbPQc9IwPqvuoMtJM618YZl8JPphLNkkoYs6lwS3r6+vKCRiUrD4vI2GGue0
yFc0SJUV4iQbkzjFxR/298trW1G2GuYjJIs/5RHipLJlOVfYQ/bjF5d7bbB7qFsh1tCX7oLb29ut
o4VOGjqLLzBZtic1NJVKM/wtrUxh2uEQXVQe/ePDz9atW+2Qne7sHRq6q1SjoV6wGykoNdAEQpxP
iJO2J91khful2VYeW00T7lL8JcofKnWupO95/Q4hhroVYj2L1R2wnutMTEzY4a+0hiDNyfNsz9oI
5mlY8pYpr/P7x3/58sUcO3bMzMzMLNlPw44Kxh4isfafA2ZtNNRga6iwtbXVTgyjQap+IU6zrVL8
rxL+VKoQ5z1X0vflEF3sHmpSiPUMxx86WlhYWOJYvsh8+/bNHpNne4gmG4XDW/4rFKWk6f+WpUxh
fvz98zq2hFXPE/VMzEc9Vz0DC7l//745cOBAyY2Grk0pjQtCHP97mo2EvzU2NmYamk6zrby2GkUW
f8pT1qSy5T1X0ve8focQQ90KsWaFut7Z7Oys2bdv3xIn1cxI9ezknFevXjVtbW25todowkd/f39h
wsfg4KB1/nLS9H9LK5OGjPUcyzUoys/NmzcL+dF3nT+PY6tnrOdbauT8GwgNNap8es6ttB89emRn
k05NTeVqNNRr0sxpEU56oUHKX2Z/8pue7+tGKo8QayhZjwvEixcvYidrpdlWFv9LI82f0soa+kNS
2bL4blYhzut3CDHUrRBLECQgclY5nCYEhQ2BGootW7bYCUOXL1+2ApNnexTuFQh9NOvyw4cPZaXp
/5ZWJs3M1F28fyff09Njeyf6TQ1V3AzVpDKp0Tp06FDRb2r4zpw5Y8upoTi9gqL98qatYWmJunuV
xokyDVJpZXY3M7qeEhJdzzxCrNfpTp06VVik5c2bN7HHJtlWFv/LQpI/pZU19IeksmXx3axCnNfv
EGKoWyEu14iXw8hxHIboKDNgA4AQI8Q0SJQZsAGA1RfitHVol2Od2npf+5YGiTIDNgAIMdAgUWbA
BgAQYqBBosyADQBCDDRIlBmwAQCEGGiQKDNgA4AQAw0SZQZsAAAhNubdu3fkkQapasu83HVfa7aF
3QOUKcRazu748eNFv2n1HK14o+XvtMqOlnCMIlwJqFKErzBlPUel8qJVfpJWwIrKY7U3EAhx5fZd
7lfseIUPu4c1JsQKrTc3N1f4fvv27aLg3zdu3IhcA1bLN+r3alrUo1J50fXQcpTLeS6EuHaFeLmv
JeLBtYQ1JMQvX740R48eLfpNa98qSIFPVJABheN7//59qqHPz8/bHqZ610qnqampKAygjtdaylpX
WuIXxigNnUmL02uNW6WntKanp2Odrre312zcuNGui9vV1VW0TWvuujV4FQlmcnKyaLuui65PnHOH
eXQjCTqX8qablKSg7i6IuiuLwimG6/om5Z8GqfQy6wbz4sWLdtRHsaTHxsaK9k2y2ai6T7PxPD4R
Z1uA3UOdCvGlS5dsTNQ4FKZMYqCg5T7qJavXnMXQFZd3dHS00MPWcRJd31E6OzvtNrfoe9Ji8YoO
oyFxofi8cZFvhoaGbBhCpatQhWpstcC9f3PhotJoeF43ID6KEavrk9XBFT3GH0nQ+SWyScfv37/f
Dvu7yEznzp3LnH8apNLL3NfXV4j8oyhfBw8eLNo3i83msfFSfAIQYlgjQqywawq/FsXp06cLUVbe
vn1b+P3169dFvehSDN0PCu56hknO43+X8GaJBash93A/X2zV8DlBj8KFpcvq4IpUE8Zq3bx5c+Lx
fg9YeVWes+afBqn0Mmvkxa8r1UPa9QltNo+Nl+ITgBDDGhFiDY3FiZpDw60auhU/fvywjZg/eSuL
oWvoWT1Z9awlWHlCzoXfk2LxhvuFw3x+Y6desH6T4F2/fn1JWrouugnJ6uBRDW/WvEbtn5Z/GqTS
yxzWi+o63DevzSbtXwmfAOwe6lSIszTsGhZ1DZeGTjWEmsfQNfStXqyGeicmJuzw80oIcZayqTHU
8Laed3d3d5clpFH7Jl2bqG3+bNlyRJcGKZ8Qh/vmtdm0/SvhE4DdwxrqEWvIVs/NHP4Qa9hDyzKp
RBNi9KzZsbCwUJYQK7h5lqFp9eL98yYxMzOz5Jy6AcnTI9b5wqHppNdQdLw/W137b9u2raT8r9UG
Kc324rbp2bxfV3oM4e+b12bT9q+ETwB2D3UqxHoGGs7U1VC0hmrdRJKrV6/aT6mGvn379sKMUPfc
Na3R0Q2Cnhu7xjKcrKVhZaF3feMma2nylJuQo4+++69h6TjNnBaatBX2kvRcPOkZcZhHpd/f3184
3+DgoL1pSLpueta+uLho91de/claafmnQTKpN4VxZdZEKU04dJO1jhw5UrRvms2GdZ+2f16fCNMH
hBjqWIg1K1izc8OeoGYxqzenHqGEuRxDn5qaspOMJHQSv3ARkKjjNTtY53c9Sn+fX79+2UVGlJ6e
rfk3EmFaPT09tvehdPS6iJuVLTQsreM1BKy0nCg7hoeHE2dNh3l0NzFugptmTH/48CHxuuna6/Uk
pSFRDietJeW/1AYpaVSjHj9x6H15jfTo+qse/H3TbDas+7T98/pElG0BQgx1KsR6B7ecXlY9o1da
JNY0SPXXIwaEGKBqhFho1jBr2xaj4UL/VSIapOoWYhphwAagpoVYz0dPnjzJVfLQ9Uhba5oGiTID
NgBQESEGGiTKDNgAAEIMNEiUGbABQIiBBokyAzYAgBADDRJlBmwAEGKgQaLMgA0AIMSrSj291oUQ
w1r0F2wAql6IK2Wk5aaznMeXk3a4slEtOzVCvDbLrRXjtIKXey9+OX2tGv0FIYY10yOuZiGuZLoI
MWWuNSTCWitgJa5pNV5vbABqqkes/+/du2cXpHfrL/sOrAXotX6yFqRvamqyy2PGpZN0Hi20f/Hi
RbuG8tatW83Y2NiSY3p7e+0awFqzuaurq2hbluNLLWN4XLhsov4qsEPS8Ul5p0GqjjLrd4Ui1FrT
qietra41zP3tWt5UkcgUf7vUunW9UdmKomlNTk5mzkPa+bL4Y5wNL4evpZ1L/yvso8q7adMm8+DB
AxvIRGkvpx8hxFBzQqzAAi7wQBiRSFGPtDi9UAzfuKhHaULc19dXiCqkyDda09nfrgX4JZbargAU
cn4tgp/1+HLKmKVHfPz48djj0/KOEFePEGuoVvWoulKj7wf40HYJo7a5QBul1K0vMIoYpkAPWfOQ
dr5S/XGlfC0qH4oupvM8efLECnBHR4f9vpx+hBBDzQlxGP3H3y5HzxIHOE2I1cPww7spepK/XY1T
eB6/AUs7vpwyZmlYko5PyztCXD1C7Pcgf/78WRQLOqqeS6lb9aidWObNQ9r5SvXHlfK1NN/Tdz8m
83L5EUIMNSfESduz9hzzpiOHC7eHw1wa2st6fDl5y9OwxJUtKe8IcfUIcdjQ+3YVdVwpdatesOv5
KsZ3njzk9YNShHg5fS1PPpbTjxBiQIgzpuNvT3O4tONXU4irRXRpkNKFOMmuorYn1W1SDGQ9a9bQ
cWtrq+nu7s6ch1L8IK8ALqevlSPElfQjhBjqSogbGxtLGgpbWFgo+m3//v1Fw10KOehv16QWf8gq
JO341RTitLwjxNUjxDMzM4Xv3759s88sk44rt251vtAWk/KQdr5S/XGlfK0cIa6kHyHEUFdCrMkh
GmoTChEYNznEn6Dy8eNHOznK3z46Ompu3LhRmABy5MiRou2aSekmiOij74cPH858fCWFWDNS9VzL
NUZpx6flHSGuHiFWvch+VE9Xr141bW1ticeVUrfyEc2cFuGEpLQ8pJ0vqz8mCV6lfS3JX/IIcSX9
CCGGuhJivVpx6tQp25js3r3bTtyI2s81OBpe0l27GqIw7du3b9vXGPR6gmZIhtt7enps70ALBEjI
3czVrMdXSog1U1N5cAsVZDk+Le8IcXUI8ePHj82WLVvshKrLly/bHmnacXnrVsPS8hX3qpsT5Sx5
SDtfVn9ME8BK+lqSv+QR4kr6EUIMVS/EgCitVSGmPrB7AIQYaJAQYuA6A0IMNEhrr8zhmsirQTXk
AbsHQIiBBokyAzYACDHQIFFmwAYAEGKgQaLMgA0AQgw0SJQZsAEAhBhokCgzYAOAEOfl3bt3XGka
JMqMX2ADAKslxLXwOkYlrkOtOjZCvDrp8poSdg+wYkJcCwa/lp0SIea6Y/cAVSjE+v3u3bt2LdlN
mzaZBw8e2AXWtcarH7zB0dvba9ecXb9+venq6ipKJwwDNz8/b9eI1ULwSqupqcmurZtE2jFK+969
e2b79u2F9Xv9PGY5/sOHD6a5uXnJuf/8+WMDs//48cOuCezWy1YkmMnJyUjHTtqPBql6y6zfR0ZG
rN3Lljs7O+3azT5Xrlyx22RLCjgQBrXPYpNRflFLNoMQA6yQEJ87d86K0JMnT6wAd3R02O9htBgt
+K4GR9FQtH1sbMwu8h5n8BI7RW9xEVQGBgbs4vZJpB2jc0hoXaMY5jHL8UJRZMIGUGVT2YXfmCrC
zc6dOyPLmbQfDVJ1C3FLS4u1I9mJbjAvXbpU2K6bUdmOsyPZ/tmzZ2OFOMkmwzzUks0gxAArJMTh
nb4fB9Q/Tg1XGP80TqDiKCXgt39MmN8s5w2PFy5Qu8/evXvN27dv7f8S74cPH6Y6dtJ+NEjVLcTT
09OF7z9//rSjIQ5FM/Lj8Op/9Z7jhDjJJsM81JLNIMQAKyTEWb/rTj4caosSOR+FgVPc1Pb2dtu4
ZXGKpGOyhCHMeryGEufm5uz/CiEnIXaop+J6TdevX489X9J+NEjVLcThTaXfi426YYzr5abZZLi9
lmwGIQaoMiFO682Gx+oZnIKV6xn0xMSEjSfq9ol6dpZ2TJZGL8/xCnh+4cIF+7+GHYeHh5cIuus5
d3d3Jwp/1H40SNUtxElC6/+fJq55hbiWbAYhBqgyIdbEEn/YOi0tPW/2919YWEh1irRj0hq9PMd/
/frVTsT58uWLnYAWTtZxzMzMpOYhaj8apOoWYtWX49u3b9Z2fFsPh6b915DKFeJasRmEGKDKhFgT
WG7evFmYwKLvmk3qkKjpWZlrwDT062Ysz87Omn379qU6RdoxaY1e3uPVEz558qSdNeujXrVmt4qk
yTdJ+9EgVbcQy3Z1MyZbvnr1qmlrayuy9f7+/oKtDw4OmsbGxpKEOPSLWrIZhBigyoRY9PT02J6D
egeaKaqhX4dmUOt313OYmpqyk7nU0Kjx0QSVNKdIOyat0ct7vCbs6Ldw9SMNHer5snsdxTWcYRpJ
+9EgVbcQ64Zty5YtdvLU5cuXba/Yx72+pI9u2PTaWylCHPpFLdkMQgywAkK81tGNhHrRNEhrT4gB
IQZAiFcZDTmqh79WZq4ixDTOCDEAQlxV6Nnd0aNHYydp0SDVb5lZ/xkbAECIgQaJMgM2AAgx0CBR
ZsAGABBioEGizIANAEIMNEiUGbABAIQYaJAoM2ADgBADDRJlBmwAACEGGiTKDNgAIMRAg0SZARsA
QIiBBokyAzYACDHQIFFmwAYAEGKgQaLMgA0AQgw0SJQZsAEAhBhokCgzYANQC7aIQdIYUXag7gFW
WYgxTBojrgFQ5wCrLMTOQPmsnQ9g99g9QJUJMXfIAAAACDFCDAAACDFCDAAAgBAjxAAAgBAjxAAA
AAgxQgwAAAgxQgwAAIAQI8QAAIAQI8QAAAAIMUIMAAAIMUIMAACAECPEAACAECPEAAAACDFCDAAA
CDFCDAAAgBAjxAAAgBAjxAAAAAgxQgwAAAgxQgwAAIAQI8QAAIAQI8QAAIAQI8QAAAAIMUIMAAAI
MUIMAACAECPEAACAECPEAAAACDFCDAAACDFCDAAAgBAjxAAAgBAjxAAAAAgxQgwAAAgxQgwAAIAQ
I8QAAIAQI8QAAAAIMUIMAAAIMUIMAACAECPEAACAECPEAAAACDFCDAAACDFCDAAAgBAjxODqn8/a
+QAgxAgxUPdAnQMgxDgmUO/UPQBCjFMCdQ7YACDEgENS54ANACDEOCRQ54ANAEKMQwJ1DtgAAEKM
QwJ1DtgAIMQ4JFDngA0AIMQ4JFDngA0AQoxDwtqq81+/fpnGxsZM6fifv//+22zYsMFcuHDB/Pjx
o2jfxcVF09XVZRoaGux+u3fvNmNjY4npZVkRqlL2W246q308fg8IMUIMdVLnf/78MW1tbZnsImof
CXB3d7e5ePFi0W979+419+7dM79//7a/vX792uzYscOMjIzUhTAhxAAIMQ4JFanzw4cPm48fP5Ys
xOK///4z69evL3y/du2auXPnzpL9JMYS6HLs0t9P/0vst2/fbv766y/b83727Flhu24Czp49a/75
5x/T1NRkpqenY9NJOo/KpxsN9f63bt1qe/bhMb29vWbjxo32OmgkILw+acfj94AQ0yjDGq3ziYmJ
zHaRtI8vxLt27bLivhx2GQroiRMnzKdPn+x3ibDE2L8hePjwof1/fHzc5qsUIe7r6zM3b960gvr1
61dz8ODBou1DQ0P2hkDbNcIgob1161bm4/F7QIhplIE6L3kfCa6EprOzs/CbL4bLLcROhKO2S3gl
flnSSdquXrwbYhdv3rwp2t7S0rLkPDt37sx8PH4PCDGNMlDnmfcJPxpqvXLliu0JOjQUvFJCnLQ9
6YagnHQkuuH28LpoqDzr8fg9IMQ0ykCd597ny5cv5tixY2ZmZmbJfs3NzXYINkRi/fjx45oX4nC7
L7pRpB2P3wNCTKMM1HlJ+0hY9Yz2yZMnRb9fv37dPjMNuX//vjlw4MCKCbFeySplaHphYaHot/37
9xcNLc/OzhZt37Nnj/n+/XtsntOOx+8BIaZRBuq85H3UM9bzUImX49u3b/a94cHBQfPz508rho8e
PTKbNm0yU1NTKybEmqz1/Plz+/+LFy9iJ2v5s631zFs3F/720dFRc+PGjcJkqyNHjhRt1wxxNxlL
H33XbPSsx+P3gBDTKAN1XtY+ErlDhw4V/SZBO3PmjJ1NraFbTVjSfuXaZR4h1kIlp06dKiwooklS
Ufu52dbKp3rRT58+XZL27du3zebNm+0rSpolHW7v6emxryetW7fOCvnnz59zHY/fA0JMowzUOWAD
AAgxDgnUOWADgBDjkECdAzYAgBDjkECdAzYACDEOCdQ5YAMACDEOCdQ5YAOAEOOQQJ0DNgCAEOOQ
QJ0DNgAIMQ4J1DlgAwAIMQ4Jq1nnpaaLDeL3gBDjkECdY0vYAABCjEPC6te5YglrPWjFEFaggk+f
PhUdpyhK27dvt+sw+8ER3PYPHz7YsIchisy0bds28+PHj8T8pJ0jZH5+3q7lrPxq36amptjQioDf
A0KMQ0JV17miBA0MDBSiBikYwdmzZ4uOk+g5cXbBEcJ0FU1ocnKyKG2Ja0dHR2p+0s4RItFXNCOX
Z+W/oaGBSsbvASHGIaH26lwRifw4ufpfEYL84/wecpSIivHxcdPa2lq0n6ItvX37NpMQJ50jC+pJ
A34PCDEOCTVX51ECFtXjTRNioaHlubk5+7/CDUqIs+Qn7RxRvHr1ysYabm9vtzcT2DR+DwgxDgk1
WedRQ8B5RNL/X4HvL1y4YP/X8Pbw8PCyCPHIyIjZtWuXuXv3rpmYmLBxf7Fp/B4QYhwSarLO9+zZ
s2RoWoHtSxHir1+/2glUX758MRs3bjS/fv1aFiHesGGD+f79e+H7wsICNo3fA0KMQ0Jt1rkma/X3
9xcmPg0ODprGxsaShNj1hE+ePGk6Ozsz5yevEGsI3M2Snp2dNfv27cOm8XtAiHFIqN06d68v6SMh
1etIpQrx9PS0/e3du3fLJsRTU1Nm586ddlhdQ9QPHz7EpvF7QIhxSKDOhZ7XqscK+D0AQoxDwgrX
uYa2e3p6zPXr17ng+D0AQoxDwkrXuSZqHT16NHGSFuD3AFgiDkmdAzYAgBDjkECdAzYACDEOCdQ5
YAMACDEOCdQ5YAOAEOOQQJ0DNgCAEOOQsPbqPG3xj5VKAxsAQIhxSFgzde7nx1/bOk9ek9IA/B4Q
YhwSqPMVzBs2zTUChBiHhJqs86dPn9o1mxWXWJGYJicni7b39vbaSEpah7qrq2tJmvfu3bNLWup4
pfPs2bNMabv86K//cb/9+PHDbNu2bcniIIoOpbSS0mhubl5Szj9//tj0lC42AIAQ45BQNXXui+fz
589tMAXH0NCQFVotXSkhGxsbM7du3SpK88SJE+bTp0/2u9Lx4xsnpZ0U9MF9V2xjRYfy6evrszcH
SWkcOXJkyQ2FytHR0YENACDEOCRUV503NDTY6EVRtLS0WBH2CcXUiXDUeZLSziLEc3Nzthfr8qC/
O3bsKJwzLo3x8XHT2tpalObevXvN27dvsQEAhBiHhOqqc/VUtU2iGwZrUI82HPbVMHNSmv5vSWln
EWJx6NAh25sVo6OjtgeeJQ0Nl0vIxZs3b6wQYwP4PSDEOCRUZZ2/evWq0Ivs7u4u/O6LbtY0w9/i
0s4qxDq2qanJ/q9nwxMTE5nSuHHjhh3aFoqxPDw8jA3g94AQ45BQ3XU+MzNTtJ+E7/v372UJcVza
WYXY9W71bFjD0ll71V+/frXRoL58+WInmxERCr8HhBiHhKqs8127dtnZzSKcbKWJUjdv3rTPZvXR
98OHD2cW4qS0/f0kmHruqxnRUelqgtjWrVuLJoqlpeF6widPnjSdnZ0YAH4PCDEOCdVZ5xo63r17
d+H1Iyecjp6eHrNhwwa7YIaez37+/DmzECel7e8ngVX6blGOMN3FxUW7Tb3cuHOFaYjp6Wm7D6tu
4feAEOOQQJ2vArpp0LA24PeAEOOQQJ2vMBpKV28+nK2NDQAgxDgkUOcrgJ4ZHz16lEla+D0gxDgk
UOeADQAgxDgkdU6dYwPYACDEOCRQ54ANAGCJOCR1DtgAAEKMQwJ1DtgAIMQ4JFDnEEu9LQSCDQBC
jEPCGqzzSpx3JfPun8tfpase/Aa/B4S4Shwx/ABCTOOfLe8IMQBCjBBDxRvh+fl5u4a0FsDQetAK
Ofj48eOi4xQPWEtFujWjFcAhz/EfPnwwzc3NS879588fs23bNvPjxw+7DrWO1zkU9WlycjIy70n7
JaHITVqzWiwsLNg0X79+bb8rQpOL7OTOFeUn+tvf3x97LRBiAIQ4txgDQiyBHB0dLURYGhgYMA0N
DUXHSWgV2UiEUZSyHC+OHDmyRDQl8B0dHfZ/X9SeP39udu7cGZn3pP2SOHPmjHn06JH9/8GDB3bY
eWhoqPBdkZrCc0X1iI8fPx57LRBiAIQYIYaKNMLq7fnHOeHJmlZ4vBgfHzetra1F++3du9e8ffvW
/i/xfvjwYWrek/ZLYmRkxFy4cMH+f/78edPe3m4/4ty5c2ZsbCyTEOe9FggxAEKMEENqI6xwhdeu
XbPCpLCFSWIU9VvW4zWkOzc3Z/9/8+aNFWKHerfat6WlZUmgBj+NpP2S0Hnd8LiGtGdmZuywuNBw
uoarswhxLYsbPg8IMUIMVdgIq6e4a9cuc/fuXTMxMWFDB+YR4jzH37hxo9Ar1VDw8PDwEkF3Pefu
7u5E4Y/aL41NmzbZmMZOgHVjMDs7W/iOEAMgxDgkrHidb9iwwXz//r3w3U1kyio+eY6XCGpSlyZH
bdy4MTYyknqraXmI2i+NtrY28++//xaGpN3wtPuOEAMgxDgkrHidq1foZjmrd7hv375cQpz3ePWE
T548aTo7O4t+V69aM6JFOAnKTyNpvzQ043nz5s1mcHDQflePXDcGmjQWdS5t0zPh379/I8QAyyXE
Ua/z8KnfD0K8lKmpKTvzWIImkdNEqDxCnPf46elp+1u4apWGm/V82b0W5MQ2TCNpvzSxefnyZdFr
S3pOre/v37+PPP7WrVt2drVb2AMhBqiwEGOUiBFlX3n0DFm96OVCM6IB+4caEGIMksaIcq88es+4
p6cn12znvGj2NmD7UPW2iDFiBP+jzKuAnrkePXo0dpIWYPeAEAMNEmUGbAAAIQYaJMoM2AAgxECD
RJkBGwBAiIEGiTIDNgAIMdAgUWbABgAQYqBBosyADcAaEGK9WtHY2LjkdwUv1/J8WmVHy+R1dXWZ
b9++JRq9/9EqQFqXV4veKy0fBSxXegrxpv20cpALyxaXXiVWjFIkG8VXdfz8+dPmb/369bacp06d
ii1juIISDRJlBmwAoGwh/vPnj10YPmofBTDXkncuALrWrdW+eYxeAqxoMRcvXiz6TeHgtN6tW9NW
S/Dt2LHDRrZZTodSKDkXlk5cunTJrsPrynjlyhUrxiEfP340hw8fRogpM2ADAJUVYomLRCZqH/UQ
JU4O/a8ebl6j13HqcTq0EtCdO3eW7Ccx9uO1Zklb6+6qR611eBVzdXJyMjZ/WndXiyv4KEycX0bd
mLh1dn0Ufk7r8yLEtV9m/a71mzUa49tbb2+vjZAkW9Vojc/8/Lw5ceKEXaBD9qZ4vi7wQxY71A2e
0tXx8jkFVvDzo5tSLYPp1pNWcAfEBLuHNSLEiqcaZ7ChEKv3GiVSWYzeF2ItlC/xr4RD+Y2Whp21
GH8c6v3G9bj9MqqB9lFM2YGBgZp2bIS4+HdFQpJtax1oMTQ0ZMVQv+lmTI9JNBrkaG5uNqOjo4WR
E9mDbydJdqibTu3vjtW59MjHz49E3olz3ghLgN1DjQtxksGqsdBwtBoPPUeWkOmOPU8aEty+vr6i
EHClNDJxZVBjqGe3WVC4OoWtS+L+/ftFa/eql+73ohHi+hBiv0cq9MjCv+kUSTd1wveFJDvU/Af3
CMbd7GnORVJ+EBDsHhBiiyYtnT592gqnJnPpTj+tRxx+tm7daofl1MtwaHiuUg6lPGmbGtK0hfV1
3rCx9dEEMpXX5dU9y1ZQd4S4voQ4amQltN3wplPD2bpJa29vt+Lqp5Nkh1E3r3GxhxEQ7B4Q4kTU
m5SwZklD4nXs2DEzMzOzZD8N8339+nXJ7xJA/7lb1vypgRwfH7fPcTUxLEsPJurcZ86cKcrXuXPn
zKNHj+rCsRHi5N+TbEPokYYeqdy9e9c+ztGQdphOnB1GjQDliX8M2D0gxAUkSuoNZE1D4qZnX0+e
PCn6XT0GPY8L0bDwgQMHSs6fRD9pv7gesXrCeoVpYWEhtYdf7utTNEjVKcSaYPX9+/fYtDRJ0d8u
W4lLP7RDpR0OTfsjSwgxdg8IcazBqgfgeoSaNao7/Tdv3uRKQz1jPWvzRU5D3hra02tDeo9X4qjz
aAbz1NRULodSHjVjVaRNctEz4jD/mkl96NChouHnenRshDj5d02ounnzZmFClb5rdrNDM5rdaI1G
hmRLfjpJdqi03FwLfWT3/nv7CDF2DwhxrMFKtPSM1D0jTpsUFXeeFy9eWLHz0SQuDQVrNrWGBXUe
7Zc3bQ0HStTdax+uMYxCk800Y9Vn27ZtuXq8CHF9CrHo6emxPV/1VjWS42ZUC90g6oZSNibRDRd3
SbND9/qSPpoE+eHDh8xCjJhg97BGhHgtMD09XdTLoUGizIANACDEK4xmtb57944GiTIDNgCAEK8G
en538uRJGiTKDNgAAEIMNEiUGbABQIiBBokyAzYAgBADDRJlBmwAEGKgQaLMgA0AIMRAg0SZARsA
hBhokChz1ZD3lbu1+Ioedg9rRohdAHS9j1tvaDWlpNW9aJAo82qdJynqWZb916ogIcRQl0LsB0Cv
N+bm5uxSmzRIlLnWy4IAcR2gRoRYv2uNXAU19wWot7fXbNy40a6L29XVVbR/1HrMcfuXcg53jKIz
aaF9t3avL/6KXqP1ehVNqampyS5d6ZOUtuvRK11FxZmcnCzafvToURsIggapfstcjv1E2bN+U+xq
rVv+69evJeeSnQkFTtGoi84rG9S5/bCfcbYZ5XdJaUXtH65dneRf2D3ACgtxZ2enjQjjFrhXUAQ5
qX5TGMOxsTFz69atWMPOsn8p51Aj8+nTJ/s9jGaj4OwuAIXiv2oR/qz58RsdBXPXQv4+ijer4BA0
SPVb5nLsJ8qe3XkUSlORlnz6+vqssAvF4R4dHS1EYRoYGLCCnsU2w7KkpRXuHwpxkn9h9wArLMTO
GR169hvG7E1qELLsX8o5wmPCkHNRcYWzpK3GKimKlAtxR4NUv2Uux36SbFOPNtQrdsfr744dO5bs
76MeaRbbzFJ/flppQpzkX9g9wAoLcYjujMOhrSQHz7t/qcf4vyXdvaelrZ6GflODe/369SXHq/HU
kCQNUv2WuRz7SbNNhftUj1qox6qep4+GtdUjb29vt2ET/WOTbDPqvElppQnxWrEPhBhqUoj9RifL
MXn3L/WYrEKclrZrwDQk2draarq7u3M11DRI9S3E5dqm7ErPa4We805MTBS2jYyM2N64Hn/odw1t
h+nF2Wa4X1paCDFCDDUsxGo8vn//ntmw8+5f6jH+b42NjbFDi2lp+8zMzCw5l54L0iOu7zKXYz9Z
REyToPRsWMPSPhs2bChKe2FhITaPoW2G+6WlhRAjxFDDQqzJJjdv3ixMAtH3w4cPxx6Td/9Sj/F/
03CchvGE3vv1J9ukpa19NTtVRE1Sefv2Lc+I67zM5dhPFhHT5K6tW7cWTfJyAu1mNru5COHchzjb
1OxoPdfVLOwsaYX7I8QANSTEoqenx95xa1EAPeNys0Pjjsm7fynH+L/pFZFTp07ZhkrPxt68eZM5
bQ396Rj32oZr+BzDw8PMmq7zMpdjP1lEbHFx0R779evXot+npqbsxC+dV6KriVn+sUm2KVFXmm6h
jrS0wv0RYoAqFWJYysGDB22DSINEmQEbAECIVxgN8dXj0p0IMSDEAAhxTXDy5EnWmqbMgA0AIMRA
g0SZARsAhBhokCgzYAMACDHQIFFmwAYAIQYaJMoM2AAAQgw0SGGZksqF3QM2AAhxjfPu3TsapBoQ
4rg42ZUqcz3ZAUIMUGVCXCkjLTed5Ty+nLTdqkT14NR+gPi19KmETVXCDqrRdrRyl1bmqtd35xFi
WFM94moW4kqmWw9CTI94deygGq+/RFhrWtMjBqiSHrH+VxxVLSbv1rr1nVSLx589e9YuJq8wb9PT
07HpJJ1HC+lfvHjRruWrhfHHxsaWHNPb22s2btxooyB1dXUVbctyfKllTGrk3W/9/f2JxyflnQZp
eYQ4T5kVEUlrQQsXsej169f2+5cvXwoRk+JGELLYQZqN6n8to9rQ0GD27t1rf5ufn7frWsu/lJ58
zAV1yJPncu07zJe4cuWKtWflTQEwFEzCT0ehGDdv3mw2bdpkHjx4YANlqOzVIPQIMdScEKshcE4W
Rn9RxBotLC8UL9WPWJNHiBUezkW30aL4WtvZ3z40NGQbE21XSEI1Yn4Um7Tjyyljlp7Q8ePHY49P
yzsN0uqX+cyZM+bRo0f2f4mGhp1Vb+67bjbTbDrNDtJsVP93dnba7S6gRHNzsxkdHS1EfRoYGLCC
mDfP5dp3mC+JqvLi8qXzuvO5Y86dO2ft/cmTJ1aAOzo67Pe082P3gBBHNDb+nW64XcIbF8M1jxDr
TtuFZhOKfONv1/Oq8DyKMpP1+HLKmKWhSjo+Le80SKtf5pGREXPhwgX7//nz5017e7v9CAmKbp6y
CHGSHaTZaNTxUahXmzfPlbZvRYPyy6L/1fuNO0bf/TjJq213CDHUnBAnbc96Z503HQlXuD0cNnMN
Upbjy8lbloYqrWxJeadBWv0yz83N2d6n2LNnj5mZmTHbtm2z3zUcrKHfLEJcjo3H1YWGhTXyJJGV
ALr9Sslzpew7yn798qWlgRAD1IAQh9vThCvt+NUU4moRXRqk5DLrWaaGjJ2Y6ZmqIm+575UW4ix2
qF6vRp30vHViYsIODfv75c1zpez7/9q738i4sgeM4y9qraqqEHmxqlYZURUVIWJfrIgQVVWr8iZW
RFWIlRd5EX0TEVFRqlZEVKiIVRGhVkRVhIqoWhUqIqIijFgVEcuKioh1fr/ncMaZmzv3zp2ZNjOZ
74fRuTP3z9zm3PPMuffMPUn3hSAGvmIQp1Kpgk5Nu84lTktLS9apLlUm/vv6xu+f2gqKW/4sgzju
s1Mhlcc+379/3zx48CBzeted6nXTxQZxXBkNW17XVv2yEzxukn7mUpVvlengqWn/51wEMfANg1in
zJaWluxzDRWYq7OW31Nyd3fXdh7x31eHlMePH2c6srS1tWW9r84hrqOLHppWT818ly9lEKuXqK5/
uYoobvm4z06FVB77rB7Pus45OTlpp6empuzfWh3twpZNWg7iymjY8mrhul7SCu7m5uas+ZJ+5lIF
scqwtu3KtLavL+UEMXAGQXx0dGQ6Oztt0Or6lTqghM3nekrqNK0OWN00ILjup0+f2kpFP/NRL8zg
+0NDQ7aFoG/eCnLXgzPf5UsVxOrxrM/gWgD5LB/32amQzn6f3717l/UTINeZ6tOnT6HLFlIOospo
2PKrq6u2Y5+OHX3J1S8U/PmSfuZSBbG4ny/poR7T29vbBDFQqiAGocQ+gzIAEMSgQmKfQRkAQQwq
JPYZlAGAIAYVEvsMygAIYlAhsc+gDAAEMaiQ2GdQBkAQgwqJfQZlACCIQYXEPoMyAII4ysbGBv/T
VEgVsc/VXFarbd8JYlRVEPv3nz3PB2WlHtgEce6yWmn/N8V83ko4Tin3IIjPcYGv5oOSIM79ejUF
cbWVA4IYZR/Eel3DrumeuBpmbW5uzt7kXfdK9gdvcEZHR+29c3XP2YGBgaz1+A/Z2dmx91rWjem1
Lo2b6m5qn0vcMlq3bnKvG+TrXtbBz5jP8rpPrhvb1XdycmKHlDs8PLT3x3b3y9boMysrK6EHdtR8
VEjluc9hZVX/amCDXOUqquwXe1zlU2Y1TnFdXZ1pamoK3S8NwqJBJgo5TglioAyCuKenx4bQwsKC
rSh6e3vttBu8wdGN6xWCGoFF78/Oztqb4ecq8Ao7jULjRm2ZmJiwlUmUuGW0DVVaGglHgp8xn+VF
o+EEQ1P7pn0Xv7LUiFO6GX/YfkbNR4VUWS3iO3fu5CxXcWW/mOMqnzLb399v33MDiPif//3791lh
m/Q4JYiBMghiV/m4aX9MVH+5xsbGU+MR5wqoXNTaSMpfJvh589lucHlZXFw0HR0dWfOptfHx40f7
XBWhRr+JO7Cj5qNCqqwgjipXcWW/mOOqmDKvlrLGKPaV4jgliIFvHMT5TutbfPDUVljI+VRRaBxj
DV6uoRPzOSiilslnmLd8l9dpyK2tLftcQ8q5036udat5VamNjIzk3F7UfFRIlRXEUfPElf1ijqtC
y7y+NKrcabhFXyHHKUEMVEgQx7Vmg8vOzMzYcVV1rWx5edmeVvOvyYVdq4paJp8KM8nyuqbW19dn
n2uMVQ20HqwcXct5cHAwshINm48K6fwEcdIzOUmOq0LLvE4/f/nyxS67t7dX8HFKEAMVFMTqjOSf
Xotbl66L+fOn0+nYgyJumbgKM8ny+/v7toOMKjF1bDk6Ogr9TOvr67GfIWw+KqTzE8RxZb+Y46rY
Mq8A909PJz1OCWKggoJYvT7HxsYynUo03dramnlfoaZrWcfHx3Zap35d78/NzU3T3Nwce1DELRNX
KSVdXi3he/fu2c4wPrUy1CNagp1r/HVEzUeFVL77HCyrceUqruwXc1wVW+Zd+H748KGg45QgBioo
iGVoaMh+g9dNAdR72fXiFPXM1OvuhgGrq6u2k4jCSYGlTk1xB0XcMnGVUtLl1eNUrwXvNqTTzbpW
537K4sI2uI6o+aiQynefg2U1n7CLKvvFHFfFlnnRz5f8n+QlOU4JYuCMg7jaqYJSi4QKiX0GZQAg
iL8xnbZTy6HceztTIbHPoAyAID6XdK2svb09ZyctKiT2GZQBgCAGFRL7DMoACGJQIbHPoAwABDGo
kNhnUAZAEIMKiX0GZQAgiEGFxD6DMgCCGFRI7DMoAwBBDCok9hmUARDEoEJin0EZAAhiUCFRCYMy
AIIYVEjsMygDAEEMgphyT7mnDIAgBhUS+wzKAEAQgyAG5R44y7JIgaQyYt/B3x444yCmYFIZ8X8A
/ubAGQexK6A8qucByj3lHiizIOYbMgAABDFBDAAgiAliAAAIYoIYAEAQE8QAABDEBDEAgCAmiAEA
IIgJYgAAQUwQAwBAEBPEAACCmCAGAIAgJogBAAQxQQwAAEFMEAMACGKCGAAAgpggBgAQxAQxAAAE
MUEMACCICWIAAAhighgAQBATxAAAgpggBgCAICaIAQAEMUEMAABBTBADAAhighgAAIKYIAYAEMQE
MQAABDFBDAAgiAliAAAIYoIYAEAQE8QAABDEhQRw8AEAAEFMEAMACOLqC2MAAAhighgAQBATxAAA
EMQEMQCAIK6OMAYAgCAmiAEA1RzEYT/n4XF+HwCAMgpiKmbOBAAAziiIqZAJYwDAmdXDVMQUAsoA
ABDEIIgBgCAGQQwAIIhBEAMAQQyCGABAEIMgBgCCGEEbGxsEMQDg6wfx0dGRSaVSp17f29szv/zy
i/n+++/NxYsXTWdnp9nf34+s7P3Hd999Zy5fvmz6+vrM4eFh1rwHBwdmYGDA1NXV2flu3rxpZmdn
I9f3Le4Y5a9b+31ewowgBoAyDeKTkxNz//790Iq6ra3NzM3Nmf/++88+9Ly9vT1RZa8AHhwcNL/9
9lvWa01NTWZ6etocHx/b1z58+GB+/PFHMzMzUzZBEtwmQQwAKHkQt7a2mt3d3dCKWi3VfF6Lq+wV
4pcuXcpMDw8Pm2fPnp2aT2GsgE6y7tevX9vPdOHCBdPQ0GBWVlZC51PIqxUu6XTark/bcy1/ve9v
J6wFrn/Hx8fNtWvX7Pa03Tdv3hDEAIDCg3h5eTlnRe1axM78/Lz5+eefC6rs/SC+ceOGDf9SBIkf
hktLS+b69euh8/3666/m1atX9rn2Saednz9/npnu7u4+tZ2wFvGdO3fM33//bae13agvJgQxACA2
iKMq6q2tLVNTU5NpFeq5XkuyDgXu77//bvr7+/NqVScNEl1j1heEODrlrWvV8vDhQ9PV1WUf0tPT
k7k+HRfELoQrLeAIYgCowCC+e/euPYXsrhE/ffrUXk+OWkfw8cMPP5hHjx7Za9GOOn6VKkjUCtZ7
jY2NZmRkJOfy+gJx69Yt+1ynsNfX183Vq1ftdH19vT1dnU8QV2rAEcQAUIFBrNO3CmBHz6NC1F+H
rrvevn3bBl6QAjGs97XC+s8//0wcJH/99ZdZXFw0HR0dtmNYLmrRa7sugHWtd3NzMzNNEAMAyiqI
g6Eb7HQVtw4Fq1rVCwsLWa+r5aoe00F//PGH+emnnwoOEoV+1HxqzT948CBzStqdnnbTBDEAoKyC
WNd1X7x4YQNVIaxrvf7PkPJZh1rG6kDlTv3KP//8Y383PDk5ab58+WLXrY5UarGurq4mChJ1/FLP
aYnrPKUez7W1tXa7MjU1Zb9s+F8K/O3oPV0Tdj+xIogBAN80iHWjD4WxTlHroRDWa0kr+7dv357q
ba1OXOrJrBa2fgqkny1pvqTr1mlphbr7OZEL5TDv3r3L+tnS2tqanf706VPodp48eZLZd4IYAPBV
gxjnvhDwnwAABDEIYgAgiEEQAwAIYhDEAEAQgyAGABDEIIgBgCAGQQwAIIhBEAMAQQyCGABQyUEc
t02CgSAGAIKYICaIAQBnF8Rx907WfZt1/2bdx1lj+K6srGTe29nZsSMraWAEzaMxff0hDLUeDZjQ
3d1t59GQiLq3c65tj46OmitXrth7Tw8MDPBXI4gBgCBWwGpEI1laWrKjKDkaU/jly5d25CQ9JiYm
TF1dXdZ6Wlpa7OhLbnSlnp6e0O08f/7cjoCk+TTS0+zsrB1wAQQxAFR1ECtY5+fn896QWs7+evwW
sEK2sbExdDt6Xe/7/NAHQQwAVRnEagVrWkE5MjJyal4NQTg8PGy6urrsUIT+smHr9scKDra8Ne0/
/FAHQQwAVRnELmwXFxdNR0eHGRwczLw+MzNjbty4YV68eGGWl5fN58+fY4PYjesbfJ/QJYgBgCD+
v3Q6nbPCXl9fz3rv8uXL5t9//825rJ5vbW1lpo+Pj83Vq1dDt62OYP66QBADQFUEsd8Za3d31/aC
9udVi1c9p0Xz+aeWr127luklvbm5aZqbm08FcXt7uzk4OLDXf8fGxnJ21nr27Jl933X80nRrayt/
OYIYAM53ELtw1anhVCplQ9efV6elde1X72s+F8qyurpqO1TpdQW2OnUFg1i9ofWTJJ2SVijr50y5
gmFoaMi2sjWvvhDoVDcIYgA410EMghgAQBCDIAYAghgEMQCAIAZBDAAEMQhiAABBDIIYAAhiEMQA
AIIYBDEAEMTlZGNjg78sQQwAlR3ESSpn3VVLd9HyhzI8S/4AEt86aCox1AhiAKjwFrF/X+pqDxaC
GABQ8haxnk9PT9vBHNy9pV3wBscKdh49emQuXbpkLl68aAdpCN5LWveqrqurM01NTZnXNGxibW2t
qampMXNzc3aAB91jOhj0Ozs79p7TWrfeq6+vzwwyEfZ5gvsY99ly7Wu+oab1dXd32/Xfvn3brK2t
me3tbXPr1q1T85+cnNiRpw4PDwliACCIcwexgs8FVnC0peA6FKATExOZEZM0wIOCyZ+/v7/fvucG
cNBrGoFJwbSwsGADuLe3104Ht6dAe/nyZWb92pZCPdfnCY7mFPfZovY1n1BraWkxe3t7dv2vXr3K
jCzV1tZmVlZWsuZX6Gs/aREDAEEcGcR+qzHsfZ9GZdIYw46eq6Ubt75gy9QfhzguLNR6zSeIC/1s
SUJNLWBHYeyunS8uLpqOjo6s+XVG4OPHjwQxABDEJu+gjXvfD0UnqgUdF55h0zq1PTw8bLq6umy4
Rn0ef7oUny1pqAXHat7a2rLPFdju1DxBDAAEccmCOOxUbpL1xU3PzMzYcY51TXl5edme3s43iEvx
2ZKGmt+L+/Hjx6avr88+1ynxqakpghgACOLSBnFDQ8Op079+GBUbxLp+7J+2TqfTeQdxKT5bXKi5
Fq9bvzpjOfv7+7YTl64hX7lyxRwdHRHEAEAQlzaI1SFqfHw80yFqcnLSpFKpkgWxTu+6XtKbm5um
ubk5630Fna7zusANdtYq9rPFhVp7e7s5ODiw6x8bG8t01nLUEr53757tsFYmhYAjAQDOUxCL+4mQ
Hgoe/XynVEG8urpqrl+/bk8z6xT1/Px81vtPnjyxrVzX0s3186VSfbbge+qJrdautq9QDnb+ev/+
vZ2vXO4ARhADQBkGMXJ7+PBhUcvrmrZa9WVUCPijAgBBXDnUW7tQOl09NDRkRkZGCGIAAEH8ren6
tU5Xl0MnLYIYAAhiEMQAQBCDIAYAEMQgiAGAIAZBDAAgiEEQAwBBXIxyuVkFCGIAqMog9u/fDIIY
APCNg5jKnSAGABQZxO6ezLoJRWtra9Y9k6Puyax//YdoAAbd11nrqq+vt/dbTrItDXlYW1trampq
zNzcnB28QaMw6X7Tb968yVrX6Oiovdez1jcwMMBfmSAGgMoLYgXdxMREZpQiDWSgIM0niMPe120h
NTiDLC4u2sEakmxLIxidnJyYhYUFG8C9vb12WiHsjzGsZaenp+169P7s7KwdBAIEMQBUVBDfvHnz
1Li9apEWGsQKXoVjodsKtpD98Yj9bTU2Np7ajkZqAkEMABUVxBcuXDj1mt/yTBrE/rLFbitqWssF
T42HrR8EMQCUdRCHBWcxYxRHBXHSbUVNE7oEMQCciyBuaGg4dbrY/0lScLl0Oh0ZnqlUKuep6aTb
iprWuvzT1iCIAaAig1gdqMbHxzMdqCYnJ22Y+q1Y11t5d3fX3L17N6tCV+9nXdd1AavOWktLS/b5
27dvT3XWitpWkiDWusbGxjLr0rR6YYMgBoCKCmJxPynSQ72Yt7e3M++53so6FazQfP36dVaFrp7K
atW6lq3G3+3s7LTLqHPW2tpa3ttKEsQyNDRke1Zr2/qC8PnzZ/7SBDEAVF4QgyAGABDEIIgBgCAG
QQwAIIhBEAMAQQyCGABAEIMgBgCCGAQxAIAgBkEMAAQxCGIAAEEMghgACGIQxAAAghgEMQAQxCCI
AQAEMQhiACCIQRADAAhiEMQAUB51MBUxIQwAOOMgpkImhAEAZxzErmLmUT0PAMDZ+x9ATfF28fzz
oAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATIAAANUCAIAAAC/ljb8AAAqeklEQVR42u3dv24dyfH2cQIGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Statins versus control at 1 month, outcome: 1.1 Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Statins versus control at 4 months (3 to 6 months), outcome: 2.1 Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-07-11 11:53:52 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 3 Statins versus control at 12 months, outcome: 3.1 Combined outcome of non-fatal myocardial infarction, non-fatal stroke, and total number of deaths.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-06-26 17:09:37 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-26 17:07:53 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-05-15 11:01:44 +0100" MODIFIED_BY="[Empty name]">Search strategies 2010</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-26 17:07:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Cochrane Central Register of Controlled Trials</HEADING>
<P>1 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/<BR/>2 exp Hydroxymethylglutaryl CoA Reductases/<BR/>3 (hydroxymethylglutaryl$ adj5 inhibitor$).mp.<BR/>4 (hmg coa$ adj5 inhibit$).mp.<BR/>5 statin$.mp.<BR/>6 simvastatin.mp.<BR/>7 fluvastatin.mp.<BR/>8 cerivastatin.mp.<BR/>9 lovastatin.mp.<BR/>10 pravastatin.mp.<BR/>11 atorvastatin.mp.<BR/>12 rosuvastatin.mp.<BR/>13 lipostat.mp.<BR/>14 lipitor.mp.<BR/>15 crestor.mp.<BR/>16 zocor.mp.<BR/>17 pravachol.mp.<BR/>18 baycol.mp.<BR/>19 lescol.mp.<BR/>20 mevacor.mp.<BR/>21 mevinolin.mp.<BR/>22 exp Anticholesteremic Agents/ or hypocholesterolemic agent:.mp.<BR/>23 or/1-22<BR/>24 exp Myocardial Infarction/<BR/>25 exp Coronary Thrombosis/ or coronary thrombosis.mp.<BR/>26 acute coronary.mp.<BR/>27 exp Angina, Unstable/<BR/>28 Myocardial infarct$.mp.<BR/>29 heart infarct:.mp.<BR/>30 acs.mp.<BR/>31 ami.mp.<BR/>32 (coronary adj3 syndrome$).mp.<BR/>33 acute angina.mp.<BR/>34 (unstable adj3 angina).mp.<BR/>35 unstable coronary.mp.<BR/>36 or/24-35<BR/>37 36 and 23 </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ovid MEDLINE</HEADING>
<P>1 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/<BR/>2 exp Hydroxymethylglutaryl CoA Reductases/<BR/>3 (hydroxymethylglutaryl$ adj5 inhibitor$).mp.<BR/>4 (hmg coa$ adj5 inhibit$).mp.<BR/>5 statin$.mp.<BR/>6 simvastatin.mp.<BR/>7 fluvastatin.mp.<BR/>8 cerivastatin.mp.<BR/>9 lovastatin.mp.<BR/>10 pravastatin.mp.<BR/>11 atorvastatin.mp.<BR/>12 rosuvastatin.mp.<BR/>13 lipostat.mp.<BR/>14 lipitor.mp.<BR/>15 crestor.mp.<BR/>16 zocor.mp.<BR/>17 pravachol.mp.<BR/>18 baycol.mp.<BR/>19 lescol.mp.<BR/>20 mevacor.mp.<BR/>21 mevinolin.mp.<BR/>22 exp Anticholesteremic Agents/<BR/>23 or/1-22<BR/>24 exp Myocardial Infarction/<BR/>25 exp Coronary Thrombosis/<BR/>26 acute coronary.mp.<BR/>27 exp Angina, Unstable/<BR/>28 Myocardial infarct$.mp.<BR/>29 heart infarct:.mp.<BR/>30 acs.mp.<BR/>31 ami.mp.<BR/>32 (coronary adj3 syndrome$).mp.<BR/>33 acute angina.mp.<BR/>34 (unstable adj3 angina).mp.<BR/>35 unstable coronary.mp.<BR/>36 or/24-35<BR/>37 36 and 23<BR/>38 randomized controlled trial$.mp.<BR/>39 randomized controlled trial.pt.<BR/>40 double-blind method/<BR/>41 single-blind method/<BR/>42 controlled clinical trial.pt.<BR/>43 ((singl$ or double$ or trebl$ or tripl$) adj (blind$ or mask$)).mp.<BR/>44 or/38-43<BR/>45 clinical trials.pt. or comparative study/ or follow-up studies/ or comparative study.pt.<BR/>46 prospective studies/ or 45<BR/>47 (random: adj5 (controlled or clinical)).mp.<BR/>48 random$.mp.<BR/>49 46 and (47 or 48)<BR/>50 49 or 44<BR/>51 50 and 37<BR/>52 animals/ not humans/<BR/>53 51 not 52</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>1 exp Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor/<BR/>2 exp Hydroxymethylglutaryl Coenzyme a Reductase/<BR/>3 (hydroxymethylglutaryl$ adj5 inhibitor$).mp.<BR/>4 (hmg coa$ adj5 inhibit$).mp.<BR/>5 statin$.mp.<BR/>6 simvastatin.mp.<BR/>7 fluvastatin.mp.<BR/>8 cerivastatin.mp.<BR/>9 lovastatin.mp.<BR/>10 pravastatin.mp.<BR/>11 atorvastatin.mp.<BR/>12 rosuvastatin.mp.<BR/>13 lipostat.mp.<BR/>14 lipitor.mp.<BR/>15 crestor.mp.<BR/>16 zocor.mp.<BR/>17 pravachol.mp.<BR/>18 baycol.mp.<BR/>19 lescol.mp.<BR/>20 mevacor.mp.<BR/>21 mevinolin.mp.<BR/>22 Anticholesteremic agents.mp. or Hypocholesterolemic Agent/<BR/>23 or/1-22<BR/>24 exp Heart Infarction/<BR/>25 coronary thrombosis.mp. or exp Coronary Artery Thrombosis/<BR/>26 acute coronary.mp.<BR/>27 exp Unstable Angina Pectoris/<BR/>28 Myocardial infarct$.mp.<BR/>29 heart infarct:.mp.<BR/>30 acs.mp.<BR/>31 ami.mp.<BR/>32 (coronary adj3 syndrome$).mp.<BR/>33 acute angina.mp.<BR/>34 (unstable adj3 angina).mp.<BR/>35 unstable coronary.mp.<BR/>36 or/24-35<BR/>37 Randomized Controlled Trial/<BR/>38 double-blind method/<BR/>39 single-blind method/<BR/>40 randomized controlled trial:.mp.<BR/>41 ((singl$ or double$ or trebl$ or tripl$) adj (blind$ or mask$)).mp.<BR/>42 controlled clinical trial/<BR/>43 or/37-42<BR/>44 Clinical Trial/<BR/>45 exp comparative study/<BR/>46 follow up/<BR/>47 prospective study/<BR/>48 or/44-47<BR/>49 random:.mp.<BR/>50 (random: adj5 (controlled or clinical)).mp.<BR/>51 50 or 49<BR/>52 51 and 48<BR/>53 52 or 43<BR/>54 53 and 36 and 23<BR/>55 nonhuman/ not human/<BR/>56 55 and 54<BR/>57 54 not 56</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EBSCO host CINAHL</HEADING>
<P>S58 S57 and S36<BR/>S57 S55 or S56<BR/>S56 S49 or S48 or S47 or S46 or S45 or S44 or S43 or S42 or S41 or S40 or S39 or S38 or S37<BR/>S55 S54 and S52<BR/>S54 S53 or S52 or S50<BR/>S53 PT clinical trial<BR/>S52 "random*"<BR/>S51 (MH "Prospective Studies+")<BR/>S50 (MH "Comparative Studies")<BR/>S49 "controlled clinical trial*"<BR/>S48 TX trebl* w1 mask*<BR/>S47 TX tripl* w1 mask*<BR/>S46 TX double* w1 mask*<BR/>S45 TX singl* w1 mask*<BR/>S44 "singl* w1 mask*"<BR/>S43 "doubl* w1 mask*"<BR/>S42 doubl* w1 blind*<BR/>S41 TX tripl* w1 blind*<BR/>S40 TX trebl* w1 blind*<BR/>S39 TX singl* w1 blind*<BR/>S38 TX randomized controlled trial*<BR/>S37 (MH "Clinical Trials+")<BR/>S36 S35 and S22<BR/>S35 S34 or S33 or S32 or S31 or S30 or S29 or S28 or S27 or S26 or<BR/>S25 or S24 or S23<BR/>S34 TX unstable coronary<BR/>S33 TX unstable n3 angina<BR/>S32 TX acute angina<BR/>S31 TX coronary n3 syndrome*<BR/>S30 TX ami<BR/>S29 TX acs<BR/>S28 TX Myocardial infarct*<BR/>S27 (MH "angina, unstable+")<BR/>S26 (MH "angina unstable+")<BR/>S25 TX acute coronary<BR/>S24 (MH "coronary thrombosis+")<BR/>S23 (MH "Myocardial Infarction+")<BR/>S22 S21 or S20 or S19 or S18 or S17 or S16 or S15 or S14 or S13 or<BR/>S12 or S11 or S10 or S9 or S8 or S7 or S6 or S5 or S4 or S3 or S2 or S1<BR/>S21 TX Anticholesteremic<BR/>S20 TX mevinolin<BR/>S19 TX mevacor<BR/>S18 TX lescol<BR/>S17 TX baycol<BR/>S16 TX Pravachol<BR/>S15 TX zocor<BR/>S14 TX crestor<BR/>S13 TX lipitor<BR/>S12 TX lipostat<BR/>S11 TX rosuvastatin<BR/>S10 TX atorvastatin<BR/>S9 TX pravastatin<BR/>S8 TX lovastatin<BR/>S7 TX cerivastatin<BR/>S6 TX fluvastatin<BR/>S5 TX simvastatin<BR/>S4 TX statin*<BR/>S3 TX hmg coa* N5 inhibit*<BR/>S2 TX hydroxymethylglutaryl* N5 inhibitor*<BR/>S1 (MH "Statins+")<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-26 17:09:37 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-05-15 11:01:55 +0100" MODIFIED_BY="[Empty name]">Search strategies 2013</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-26 17:09:37 +0100" MODIFIED_BY="[Empty name]">
<P>The RCT filter for MEDLINE is the Cochrane sensitivity-maximizing RCT filter and for EMBASE the terms as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> have been applied. For both the reference is <LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees<BR/>#2 hydroxymethylglutaryl*<BR/>#3 HMG-CoA*<BR/>#4 statin or statins<BR/>#5 atorvastatin<BR/>#6 cerivastatin<BR/>#7 fluvastatin<BR/>#8 lovastatin<BR/>#9 pravastatin<BR/>#10 simvastatin<BR/>#11 lipitor<BR/>#12 baycol<BR/>#13 lescol<BR/>#14 mevacor<BR/>#15 altocor<BR/>#16 pravachol<BR/>#17 lipostat<BR/>#18 zocor<BR/>#19 mevinolin<BR/>#20 compactin<BR/>#21 fluindostatin<BR/>#22 rosuvastatin<BR/>#23 dalvastatin<BR/>#24 cranoc<BR/>#25 canef<BR/>#26 locol<BR/>#27 lochol<BR/>#28 leucol<BR/>#29 lescol<BR/>#30 monacolin<BR/>#31 medostatin<BR/>#32 mevinacor<BR/>#33 livalo<BR/>#34 pitava<BR/>#35 pitavastatin<BR/>#36 pravasin<BR/>#37 mevalotin<BR/>#38 gerosim<BR/>#39 lipex<BR/>#40 zenas<BR/>#41 crestor<BR/>#42 meglutol<BR/>#43 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14<BR/>#44 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29<BR/>#45 #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42<BR/>#46 #43 or #44 or #45<BR/>#47 MeSH descriptor: [Myocardial Infarction] explode all trees<BR/>#48 MeSH descriptor: [Acute Coronary Syndrome] this term only<BR/>#49 MeSH descriptor: [Coronary Thrombosis] this term only<BR/>#50 coronary next thrombosis<BR/>#51 acute next coronary<BR/>#52 MeSH descriptor: [Angina, Unstable] explode all trees<BR/>#53 myocardial next infarct*<BR/>#54 heart next infarct*<BR/>#55 acs<BR/>#56 ami<BR/>#57 coronary near/3 syndrome*<BR/>#58 acute next angina<BR/>#59 unstable near/3 angina<BR/>#60 unstable next coronary<BR/>#61 #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60<BR/>#62 #46 and #61 from 2010 to 2013<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE OVID</HEADING>
<P>1. exp Anticholesteremic Agents/<BR/>2. exp Hydroxymethylglutaryl CoA Reductases/<BR/>3. (hydroxymethylglutaryl* adj5 inhibitor*).mp.<BR/>4. (hmg-coa* adj5 statin*).mp.<BR/>5. (hmg-coa* adj5 inhibit*).mp.<BR/>6. anticholesteremic agent*.mp.<BR/>7. hypocholesterolemic agent*.mp.<BR/>8. 3-hydroxy-3-methylpentanedioic acid.mp.<BR/>9. beta-hydroxy-beta-methylglutarate.mp.<BR/>10. 3-hydroxy-3-methylglutaric acid.mp.<BR/>11. statin*.mp.<BR/>12. (altoc?r or altoprev or artein or atorvastatin).mp.<BR/>13. (baycol or bristacol or "bay w 6228" or "bay w6228").mp.<BR/>14. (canef or cerivastatin or certa or compactin or cranoc or crestor or ci-981 or ci981 or cs-500 or cs500 or cs-514 or cs514).mp.<BR/>15. (dalvastatin or denan).mp.<BR/>16. (elisor or epatostantin or eptastatin* or epistatin or fluindostatin or fluvastatin or gerosim or itavastatin).mp.<BR/>17. (lescol or leucol or lipemol or lipitor or lipibec or liplat or lipex or lipobay or lipovas or lipostat or livalo or loc?ol or lodales or lovacol or lovastatin or l-654969 or l-644128 or l644128).mp.<BR/>18. (mevastatin or mevastin or mevinolin or mona?olin or methylcompactin or mk-803 or mk803 or mk-0803 or mk0803 or msd-803 or mevacor or mk-733 or mk733 or meglutol or mevalotin or mevinacor or medostatin or ml-236b or ml236b or medipo).mp.<BR/>19. (nk-104 or nk104 or nks-104 or nks104 or nisvastatin or neolipid).mp.<BR/>20. (pravastatin or prareduct or pravachol or pravacol or pravasin* or pitavastatin or pitava or pravachol).mp.<BR/>21. (rms-431 or rms431 or ribar or rivastatin or rosuvastatin or RG-12561).mp.<BR/>22. (sanaprav or selektine or simvastatin or sinvacor or s?nvinolin or sortis or sq-31000 or sq31000 sq-31,000 or sq31,000 or sri-62320 or sri62320 or s-4522 or s4522).mp.<BR/>23. (tahor or torvast).mp.<BR/>24. (vast?n or xu-62320 or xu62320 or ym-548 or ym548 or zarator or zenas or zocor? or zd-4522 or zd4522).mp.<BR/>25. or/1-24<BR/>26. Acute Coronary Syndrome/<BR/>27. exp Myocardial Infarction/<BR/>28. exp Coronary Thrombosis/<BR/>29. coronary thrombosis.tw.<BR/>30. acute coronary.tw.<BR/>31. exp Angina, Unstable/<BR/>32. myocardial infarct*.tw.<BR/>33. heart infarct*.tw.<BR/>34. acs.tw.<BR/>35. ami.tw.<BR/>36. (coronary adj3 syndrome*).tw.<BR/>37. acute angina.tw.<BR/>38. (unstable adj3 angina).tw.<BR/>39. unstable coronary.tw.<BR/>40. or/26-39<BR/>41. 25 and 40<BR/>42. randomized controlled trial.pt.<BR/>43. controlled clinical trial.pt.<BR/>44. randomized.ab.<BR/>45. placebo.ab.<BR/>46. clinical trials as topic.sh.<BR/>47. randomly.ab.<BR/>48. trial.ti.<BR/>49. 42 or 43 or 44 or 45 or 46 or 47 or 48<BR/>50. exp animals/ not humans.sh.<BR/>51. 49 not 50<BR/>52. 41 and 51<BR/>53. ((2010* or 2011* or 2012* or 2013*) not (201001* or "20100201")).ed.<BR/>54. 52 and 53<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE OVID</HEADING>
<P>1. (hydroxymethylglutaryl* adj5 inhibitor*).mp.<BR/>2. (hmg-coa* adj5 statin*).mp.<BR/>3. (hmg-coa* adj5 inhibit*).mp.<BR/>4. anticholesteremic agent*.mp.<BR/>5. hypocholesterolemic agent*.mp.<BR/>6. 3-hydroxy-3-methylpentanedioic acid.mp.<BR/>7. beta-hydroxy-beta-methylglutarate.mp.<BR/>8. 3-hydroxy-3-methylglutaric acid.mp.<BR/>9. statin*.mp.<BR/>10. (altoc?r or altoprev or artein or atorvastatin).mp.<BR/>11. (baycol or bristacol or "bay w 6228" or "bay w6228").mp.<BR/>12. (canef or cerivastatin or certa or compactin or cranoc or crestor or ci-981 or ci981 or cs-500 or cs500 or cs-514 or cs514).mp.<BR/>13. (dalvastatin or denan).mp.<BR/>14. (elisor or epatostantin or eptastatin* or epistatin or fluindostatin or fluvastatin or gerosim or itavastatin).mp.<BR/>15. (lescol or leucol or lipemol or lipitor or lipibec or liplat or lipex or lipobay or lipovas or lipostat or livalo or loc?ol or lodales or lovacol or lovastatin or l-654969 or l-644128 or l644128).mp.<BR/>16. (mevastatin or mevastin or mevinolin or mona?olin or methylcompactin or mk-803 or mk803 or mk-0803 or mk0803 or msd-803 or mevacor or mk-733 or mk733 or meglutol or mevalotin or mevinacor or medostatin or ml-236b or ml236b or medipo).mp.<BR/>17. (nk-104 or nk104 or nks-104 or nks104 or nisvastatin or neolipid).mp.<BR/>18. (pravastatin or prareduct or pravachol or pravacol or pravasin* or pitavastatin or pitava or pravachol).mp.<BR/>19. (rms-431 or rms431 or ribar or rivastatin or rosuvastatin or RG-12561).mp.<BR/>20. (tahor or torvast).mp.<BR/>21. exp hypocholesterolemic agent/<BR/>22. hydroxymethylglutaryl coenzyme A reductase/<BR/>23. or/1-22<BR/>24. exp heart infarction/<BR/>25. exp acute coronary syndrome/<BR/>26. exp coronary artery thrombosis/<BR/>27. coronary thrombosis.tw.<BR/>28. acute coronary.tw.<BR/>29. exp unstable angina pectoris/<BR/>30. Myocardial infarct*.tw.<BR/>31. heart infarct*.tw.<BR/>32. acs.tw.<BR/>33. ami.tw.<BR/>34. (coronary adj3 syndrome*).tw.<BR/>35. acute angina.tw.<BR/>36. (unstable adj3 angina).tw.<BR/>37. unstable coronary.tw.<BR/>38. or/24-37<BR/>39. 23 and 38<BR/>40. random$.tw.<BR/>41. factorial$.tw.<BR/>42. crossover$.tw.<BR/>43. cross over$.tw.<BR/>44. cross-over$.tw.<BR/>45. placebo$.tw.<BR/>46. (doubl$ adj blind$).tw.<BR/>47. (singl$ adj blind$).tw.<BR/>48. assign$.tw.<BR/>49. allocat$.tw.<BR/>50. volunteer$.tw.<BR/>51. crossover procedure/<BR/>52. double blind procedure/<BR/>53. randomized controlled trial/<BR/>54. single blind procedure/<BR/>55. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54<BR/>56. (animal/ or nonhuman/) not human/<BR/>57. 55 not 56<BR/>58. 39 and 57<BR/>59. ((2010* or 2011* or 2012* or 2013*) not ("201001" or "201002" or "201003" or "201004")).em.<BR/>60. 58 and 59<BR/>61. limit 60 to embase<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<P>S26 S24 AND S25<BR/>S25 EM 2010-2013<BR/>S24 S9 AND S23<BR/>S23 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22<BR/>S22 "unstable coronary"<BR/>S21 unstable N3 angina<BR/>S20 "acute angina"<BR/>S19 coronary N3 syndrome*<BR/>S18 acs or ami<BR/>S17 "myocardial infarct*"<BR/>S16 "myocardial infarct*"<BR/>S15 (MH "Angina, Unstable")<BR/>S14 "acute coronary"<BR/>S13 "coronary thrombosis"<BR/>S12 (MH "Coronary Thrombosis")<BR/>S11 (MH "Acute Coronary Syndrome")<BR/>S10 (MH "Myocardial Infarction+")<BR/>S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8<BR/>S8 livalo or pitava or pitavastatin or pravasin or mevalotin or gerosim or lipex or zenas or crestor or meglutol<BR/>S7 locol or lochol or leucol or lescol or monacolin or medostatin or mevinacor<BR/>S6 fluindostatin or rosuvastatin or dalvastatin or cranoc or canef<BR/>S5 pravachol or lipostat or zocor or mevinolin or compactin<BR/>S4 simvastatin or lipitor or baycol or lescol or mevacor or altocor<BR/>S3 atorvastatin or atorvastatin or fluvastatin or lovastatin or pravastatin<BR/>S2 statin* or hydroxymethylglutaryl* or HMG-CoA*<BR/>S1 (MH "Statins+")<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 RCTs with usable information, by outcome&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 RCTs (24 references) included in the meta-analysis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;29 Potentially appropriate RCTs (34 articles) to be included in the meta-analysis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;63 full text articles retrieved for more detailed evaluation&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2324 potentially &lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;29 Studies excluded, with reasons:&lt;/p&gt;&lt;p&gt;6x no RCT, 4x follow-up &amp;lt;1 month, 2x treatment given &amp;lt;1 month, 12x head-to-head comparison of statins, 5x initiation of statin therapy &amp;gt;14 days&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;10 RCTs excluded, with reasons:&lt;/p&gt;&lt;p&gt;9x no clinical outcome data, 1x unclear outcome data at pre-specified time points&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 RCT included only in a sensitivity analysis, with reason: cerivastatin withdrawn from the market&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>